<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="0" size="11" family="Times" color="#ffffff"/>
	<fontspec id="1" size="26" family="Times" color="#0e2a52"/>
	<fontspec id="2" size="9" family="Times" color="#000000"/>
	<fontspec id="3" size="9" family="Times" color="#4c4c4c"/>
	<fontspec id="4" size="9" family="Times" color="#327eb1"/>
	<fontspec id="5" size="6" family="Times" color="#000000"/>
	<fontspec id="6" size="6" family="Times" color="#327eb1"/>
	<fontspec id="7" size="5" family="Times" color="#000000"/>
	<fontspec id="8" size="5" family="Times" color="#327eb1"/>
<text top="142" left="166" width="246" height="17" font="0">CLINICAL PRACTICE GUIDELINE</text>
<text top="185" left="165" width="454" height="25" font="1">2016 AHA/ACC Guideline on the</text>
<text top="221" left="165" width="511" height="25" font="1">Management of Patients With Lower</text>
<text top="257" left="165" width="498" height="25" font="1">Extremity Peripheral Artery Disease</text>
<text top="307" left="167" width="421" height="12" font="2">A Report of the American College of Cardiology/American Heart Association</text>
<text top="324" left="167" width="232" height="12" font="2">Task Force on Clinical Practice Guidelines</text>
<text top="353" left="167" width="569" height="12" font="3">Developed in Collaboration With the American Association of Cardiovascular and Pulmonary Rehabilitation,</text>
<text top="372" left="167" width="405" height="12" font="3">Inter-Society Consensus for the Management of Peripheral Arterial Disease,</text>
<text top="392" left="167" width="512" height="12" font="3">Society for Cardiovascular Angiography and Interventions, Society for Clinical Vascular Surgery,</text>
<text top="411" left="167" width="515" height="12" font="3">Society of Interventional Radiology, Society for Vascular Medicine, Society for Vascular Nursing,</text>
<text top="431" left="167" width="411" height="12" font="3">Society for Vascular Surgery, and Vascular and Endovascular Surgery Society</text>
<text top="505" left="63" width="40" height="12" font="3">Writing</text>
<text top="523" left="63" width="60" height="12" font="3">Committee</text>
<text top="541" left="63" width="51" height="12" font="3"><a href="">Members</a></text>
<text top="541" left="113" width="6" height="12" font="4"><a href="">*</a></text>
<text top="505" left="167" width="285" height="12" font="2">Marie D. Gerhard-Herman, MD, FACC, FAHA, Chair</text>
<text top="523" left="167" width="305" height="12" font="2">Heather L. Gornik, MD, FACC, FAHA, FSVM, Vice <a href="">Chair</a></text>
<text top="523" left="471" width="5" height="12" font="4"><a href="">*</a></text>
<text top="559" left="167" width="105" height="12" font="2">Coletta Barrett, <a href="">RN</a></text>
<text top="557" left="271" width="5" height="15" font="4"><a href="">y</a></text>
<text top="577" left="167" width="147" height="12" font="2">Neal R. Barshes, MD, MPH</text>
<text top="575" left="314" width="5" height="15" font="4"><a href="">z</a></text>
<text top="595" left="167" width="203" height="12" font="2">Matthew A. Corriere, MD, MS, FAHA</text>
<text top="593" left="370" width="5" height="15" font="4"><a href="">x</a></text>
<text top="613" left="167" width="224" height="12" font="2">Douglas E. Drachman, MD, FACC, <a href="">FSCAI</a></text>
<text top="613" left="390" width="5" height="12" font="4"><a href="">*</a></text>
<text top="611" left="396" width="6" height="15" font="4"><a href="">k</a></text>
<text top="631" left="167" width="187" height="12" font="2">Lee A. Fleisher, MD, FACC, <a href="">FAHA</a></text>
<text top="629" left="353" width="7" height="15" font="4"><a href="">{</a></text>
<text top="649" left="167" width="201" height="12" font="2">Francis Gerry R. Fowkes, MD, FAHA</text>
<text top="649" left="368" width="12" height="12" font="4"><a href="">*#</a></text>
<text top="667" left="167" width="213" height="12" font="2">Naomi M. Hamburg, MD, FACC, FAHA</text>
<text top="665" left="380" width="5" height="15" font="4"><a href="">z</a></text>
<text top="685" left="167" width="120" height="12" font="2">Scott Kinlay, MBBS, P</text>
<text top="687" left="286" width="6" height="8" font="5">H</text>
<text top="685" left="292" width="165" height="12" font="2">D, FACC, FAHA, FSVM, <a href="">FSCAI</a></text>
<text top="685" left="457" width="19" height="12" font="4"><a href="">* **</a></text>
<text top="703" left="167" width="194" height="12" font="2">Robert Lookstein, MD, FAHA, <a href="">FSIR</a></text>
<text top="703" left="360" width="5" height="12" font="4"><a href="">*</a></text>
<text top="701" left="366" width="5" height="15" font="4"><a href="">z</a></text>
<text top="721" left="167" width="169" height="12" font="2">Sanjay Misra, MD, FAHA, FSIR</text>
<text top="721" left="336" width="5" height="12" font="4"><a href="">*</a></text>
<text top="719" left="341" width="10" height="15" font="4"><a href="">yy</a></text>
<text top="738" left="167" width="173" height="12" font="2">Leila Mureebe, MD, MPH, <a href="">RPVI</a></text>
<text top="737" left="340" width="10" height="15" font="4"><a href="">zz</a></text>
<text top="756" left="167" width="185" height="12" font="2">Jeffrey W. Olin, DO, FACC, FAHA</text>
<text top="756" left="352" width="5" height="12" font="4"><a href="">*</a></text>
<text top="755" left="357" width="5" height="15" font="4"><a href="">z</a></text>
<text top="774" left="167" width="234" height="12" font="2">Rajan A.G. Patel, MD, FACC, FAHA, FSCAI</text>
<text top="774" left="401" width="7" height="12" font="4"><a href="">#</a></text>
<text top="792" left="167" width="141" height="12" font="2">Judith G. Regensteiner, P</text>
<text top="795" left="307" width="6" height="8" font="5">H</text>
<text top="792" left="313" width="48" height="12" font="2">D, FAHA</text>
<text top="790" left="362" width="5" height="15" font="4"><a href="">z</a></text>
<text top="810" left="167" width="119" height="12" font="2">Andres Schanzer, <a href="">MD</a></text>
<text top="810" left="285" width="5" height="12" font="4"><a href="">*</a></text>
<text top="808" left="291" width="10" height="15" font="4"><a href="">xx</a></text>
<text top="505" left="494" width="189" height="12" font="2">Mehdi H. Shishehbor, DO, MPH, P</text>
<text top="508" left="683" width="6" height="8" font="5">H</text>
<text top="505" left="689" width="90" height="12" font="2">D, FACC, FAHA,</text>
<text top="523" left="494" width="33" height="12" font="2"><a href="">FSCAI</a></text>
<text top="523" left="527" width="5" height="12" font="4"><a href="">*</a></text>
<text top="521" left="533" width="5" height="15" font="4"><a href="">z</a></text>
<text top="541" left="494" width="103" height="12" font="2">Kerry J. Stewart, E</text>
<text top="544" left="597" width="6" height="8" font="5">D</text>
<text top="541" left="603" width="113" height="12" font="2">D, FAHA, MAACVPR</text>
<text top="539" left="716" width="17" height="15" font="4"><a href="">zkk</a></text>
<text top="559" left="494" width="133" height="12" font="2">Diane Treat-Jacobson, P</text>
<text top="562" left="627" width="6" height="8" font="5">H</text>
<text top="559" left="633" width="72" height="12" font="2">D, RN, <a href="">FAHA</a></text>
<text top="557" left="705" width="5" height="15" font="4"><a href="">z</a></text>
<text top="577" left="494" width="104" height="12" font="2">M. Eileen Walsh, P</text>
<text top="580" left="598" width="6" height="8" font="5">H</text>
<text top="577" left="605" width="123" height="12" font="2">D, APN, RN-BC, FAHA</text>
<text top="575" left="728" width="14" height="15" font="4"><a href="">{{</a></text>
<text top="628" left="494" width="298" height="9" font="5">*Writing committee members are required to recuse themselves from</text>
<text top="642" left="494" width="166" height="9" font="5">voting on sections to which their speci</text>
<text top="641" left="659" width="148" height="12" font="5">ﬁc relationships with industry and</text>
<text top="656" left="494" width="124" height="9" font="5">other entities may apply; see</text>
<text top="656" left="621" width="48" height="9" font="6"><a href="">Appendix 1</a></text>
<text top="656" left="672" width="101" height="9" font="5">for recusal information.</text>
<text top="669" left="494" width="292" height="12" font="5"><a href="">yFunctioning </a>as the lay volunteer/patient representative. <a href="">zACC/AHA</a></text>
<text top="685" left="494" width="67" height="9" font="5">Representative.</text>
<text top="683" left="563" width="189" height="12" font="5"><a href="">x</a>Vascular and Endovascular Surgery Society</text>
<text top="699" left="494" width="67" height="9" font="5">Representative.</text>
<text top="697" left="563" width="192" height="12" font="5"><a href="">kSociety </a>for Cardiovascular Angiography and</text>
<text top="713" left="494" width="127" height="9" font="5">Interventions Representative.</text>
<text top="712" left="624" width="180" height="12" font="5"><a href="">{</a>ACC/AHA Task Force on Clinical Practice</text>
<text top="727" left="494" width="294" height="9" font="5">Guidelines Liaison. #Inter-Society Consensus for the Management of</text>
<text top="741" left="494" width="278" height="9" font="5">Peripheral Arterial Disease Representative. **Society for Vascular</text>
<text top="756" left="494" width="109" height="9" font="5">Medicine Representative.</text>
<text top="754" left="605" width="159" height="12" font="5"><a href="">yy</a>Society of Interventional Radiology</text>
<text top="770" left="494" width="67" height="9" font="5">Representative.</text>
<text top="768" left="563" width="232" height="12" font="5"><a href="">zz</a>Society for Clinical Vascular Surgery Representative.</text>
<text top="783" left="494" width="313" height="12" font="5"><a href="">xxSociety </a>for Vascular Surgery Representative. <a href="">kk</a>American Association of</text>
<text top="798" left="494" width="263" height="9" font="5">Cardiovascular and Pulmonary Rehabilitation Representative.</text>
<text top="811" left="494" width="201" height="12" font="5"><a href="">{{Society </a>for Vascular Nursing Representative.</text>
<text top="911" left="176" width="631" height="9" font="5">This document was approved by the American College of Cardiology Board of Trustees in October 2016, the American Heart Association Science</text>
<text top="925" left="167" width="574" height="9" font="5">Advisory and Coordinating Committee in September 2016, and the American Heart Association Executive Committee in October 2016.</text>
<text top="939" left="176" width="631" height="9" font="5">The American College of Cardiology requests that this document be cited as follows: Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere</text>
<text top="953" left="167" width="640" height="9" font="5">MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RAG, Regensteiner JG, Schanzer A,</text>
<text top="967" left="167" width="640" height="9" font="5">Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral</text>
<text top="982" left="167" width="640" height="9" font="5">artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol</text>
<text top="996" left="167" width="48" height="9" font="5">2017;69:e71</text>
<text top="994" left="215" width="21" height="12" font="5">–126.</text>
<text top="1010" left="176" width="358" height="9" font="5">This article has been copublished in Circulation and reprinted in Vascular Medicine.</text>
<text top="1024" left="176" width="450" height="9" font="5">Copies: This document is available on the World Wide Web sites of the American College of Cardiology (</text>
<text top="1024" left="626" width="55" height="9" font="6"><a href="http://www.acc.org">www.acc.org</a></text>
<text top="1024" left="681" width="126" height="9" font="5">) and the American Heart As-</text>
<text top="1038" left="167" width="44" height="9" font="5">sociation (</text>
<text top="1038" left="211" width="93" height="9" font="6"><a href="http://professional.heart.org/">professional.heart.org</a></text>
<text top="1038" left="304" width="462" height="9" font="5"><a href="http://professional.heart.org/">). </a>For copies of this document, please contact Elsevier Reprint Department via fax (212-633-3820) or e-mail <a href="mailto:reprints@elsevier.com">(</a></text>
<text top="1038" left="765" width="42" height="9" font="6"><a href="mailto:reprints@elsevier.com">reprints@</a></text>
<text top="1053" left="167" width="54" height="9" font="6"><a href="mailto:reprints@elsevier.com">elsevier.com</a></text>
<text top="1053" left="220" width="6" height="9" font="5">).</text>
<text top="1067" left="176" width="152" height="9" font="5">Permissions: Multiple copies, modi</text>
<text top="1065" left="327" width="480" height="12" font="5">ﬁcation, alteration, enhancement, and/or distribution of this document are not permitted without the express</text>
<text top="1081" left="167" width="468" height="9" font="5">permission of the American College of Cardiology. Requests may be completed online via the Elsevier site <a href="http://www.elsevier.com/about/policies/author-agreement/obtaining-permission">(</a></text>
<text top="1081" left="634" width="173" height="9" font="6"><a href="http://www.elsevier.com/about/policies/author-agreement/obtaining-permission">http://www.elsevier.com/about/policies/</a></text>
<text top="1095" left="167" width="171" height="9" font="6"><a href="http://www.elsevier.com/about/policies/author-agreement/obtaining-permission">author-agreement/obtaining-permission</a></text>
<text top="1095" left="337" width="6" height="9" font="5">).</text>
<text top="54" left="167" width="256" height="7" font="7">J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y</text>
<text top="54" left="709" width="97" height="7" font="7">V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="66" left="167" width="268" height="10" font="7">ª 2 0 1 7 B Y T H E A M E R I C A N H E A R T A S S O C I A T I O N , I N C . A N D</text>
<text top="81" left="167" width="236" height="7" font="7">A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N</text>
<text top="94" left="167" width="113" height="7" font="7">P U B L I S H E D B Y E L S E V I E R</text>
<text top="67" left="699" width="107" height="7" font="7">I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0</text>
<text top="81" left="607" width="200" height="7" font="8"><a href="http://dx.doi.org/10.1016/j.jacc.2016.11.007">h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 6 . 1 1 . 0 0 7</a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="9" size="11" family="Times" color="#e3202b"/>
	<fontspec id="10" size="8" family="Times" color="#e3202b"/>
	<fontspec id="11" size="8" family="Times" color="#000000"/>
	<fontspec id="12" size="9" family="Times" color="#0e2a52"/>
	<fontspec id="13" size="7" family="Times" color="#000000"/>
<text top="143" left="108" width="80" height="12" font="3">ACC/AHA Task</text>
<text top="161" left="108" width="84" height="12" font="3">Force Members</text>
<text top="143" left="211" width="257" height="12" font="2">Jonathan L. Halperin, MD, FACC, FAHA, Chair</text>
<text top="161" left="211" width="261" height="12" font="2">Glenn N. Levine, MD, FACC, FAHA, Chair-Elect</text>
<text top="197" left="211" width="238" height="12" font="2">Sana M. Al-Khatib, MD, MHS, FACC, FAHA</text>
<text top="215" left="211" width="100" height="12" font="2">Kim K. Birtcher, P</text>
<text top="217" left="311" width="25" height="8" font="5">HARM</text>
<text top="215" left="337" width="71" height="12" font="2">D, MS, AACC</text>
<text top="233" left="211" width="129" height="12" font="2">Biykem Bozkurt, MD, P</text>
<text top="235" left="341" width="6" height="8" font="5">H</text>
<text top="233" left="347" width="86" height="12" font="2">D, FACC, FAHA</text>
<text top="250" left="211" width="192" height="12" font="2">Ralph G. Brindis, MD, MPH, MACC</text>
<text top="268" left="211" width="172" height="12" font="2">Joaquin E. Cigarroa, MD, FACC</text>
<text top="286" left="211" width="102" height="12" font="2">Lesley H. Curtis, P</text>
<text top="289" left="314" width="6" height="8" font="5">H</text>
<text top="286" left="320" width="48" height="12" font="2">D, FAHA</text>
<text top="143" left="513" width="187" height="12" font="2">Lee A. Fleisher, MD, FACC, FAHA</text>
<text top="161" left="513" width="155" height="12" font="2">Federico Gentile, MD, FACC</text>
<text top="178" left="513" width="154" height="12" font="2">Samuel Gidding, MD, FAHA</text>
<text top="196" left="513" width="148" height="12" font="2">Mark A. Hlatky, MD, FACC</text>
<text top="214" left="513" width="133" height="12" font="2">John Ikonomidis, MD, P</text>
<text top="217" left="646" width="6" height="8" font="5">H</text>
<text top="214" left="653" width="48" height="12" font="2">D, FAHA</text>
<text top="232" left="513" width="164" height="12" font="2">José Joglar, MD, FACC, FAHA</text>
<text top="250" left="513" width="106" height="12" font="2">Susan J. Pressler, P</text>
<text top="253" left="620" width="6" height="8" font="5">H</text>
<text top="250" left="626" width="72" height="12" font="2">D, RN, FAHA</text>
<text top="268" left="513" width="187" height="12" font="2">Duminda N. Wijeysundera, MD, P</text>
<text top="271" left="701" width="6" height="8" font="5">H</text>
<text top="268" left="707" width="8" height="12" font="2">D</text>
<text top="355" left="108" width="160" height="17" font="9">TABLE OF CONTENTS</text>
<text top="397" left="108" width="65" height="14" font="10">PREAMBLE</text>
<text top="397" left="176" width="242" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="398" left="423" width="18" height="11" font="2">e73</text>
<text top="433" left="110" width="106" height="14" font="10">1. INTRODUCTION</text>
<text top="433" left="223" width="195" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="434" left="423" width="18" height="11" font="2">e75</text>
<text top="458" left="123" width="218" height="12" font="12">1.1. Methodology and Evidence Review</text>
<text top="458" left="349" width="69" height="14" font="11">. . . . . . . . . . .</text>
<text top="459" left="423" width="18" height="11" font="2">e75</text>
<text top="483" left="122" width="240" height="12" font="12">1.2. Organization of the Writing Committee</text>
<text top="483" left="369" width="49" height="14" font="11">. . . . . . . .</text>
<text top="484" left="423" width="18" height="11" font="2">e76</text>
<text top="508" left="122" width="203" height="12" font="12">1.3. Document Review and Approval</text>
<text top="508" left="329" width="89" height="14" font="11">. . . . . . . . . . . . . .</text>
<text top="509" left="423" width="18" height="11" font="2">e76</text>
<text top="533" left="121" width="128" height="12" font="12">1.4. Scope of Guideline</text>
<text top="532" left="256" width="162" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="533" left="423" width="18" height="11" font="2">e76</text>
<text top="570" left="108" width="213" height="14" font="10">2. CLINICAL ASSESSMENT FOR PAD</text>
<text top="570" left="329" width="89" height="14" font="11">. . . . . . . . . . . . . .</text>
<text top="571" left="423" width="18" height="11" font="2">e79</text>
<text top="595" left="121" width="214" height="12" font="12">2.1. History and Physical Examination:</text>
<text top="610" left="144" width="103" height="12" font="12">Recommendations</text>
<text top="609" left="249" width="168" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="610" left="423" width="18" height="11" font="2">e79</text>
<text top="645" left="108" width="296" height="14" font="10">3. DIAGNOSTIC TESTING FOR THE PATIENT WITH</text>
<text top="663" left="121" width="223" height="14" font="10">SUSPECTED LOWER EXTREMITY PAD</text>
<text top="681" left="121" width="150" height="14" font="10">(CLAUDICATION OR CLI)</text>
<text top="681" left="276" width="142" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="682" left="421" width="20" height="11" font="2">e80</text>
<text top="707" left="122" width="203" height="12" font="12">3.1. Resting ABI for Diagnosing PAD:</text>
<text top="721" left="145" width="103" height="12" font="12">Recommendations</text>
<text top="721" left="256" width="162" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="722" left="421" width="20" height="11" font="2">e80</text>
<text top="746" left="121" width="251" height="12" font="12">3.2. Physiological Testing: Recommendations</text>
<text top="746" left="376" width="42" height="14" font="11">. . . . . . .</text>
<text top="747" left="423" width="18" height="11" font="2">e81</text>
<text top="771" left="121" width="217" height="12" font="12">3.3. Imaging for Anatomic Assessment:</text>
<text top="786" left="145" width="103" height="12" font="12">Recommendations</text>
<text top="786" left="256" width="162" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="787" left="422" width="19" height="11" font="2">e86</text>
<text top="821" left="108" width="293" height="14" font="10">4. SCREENING FOR ATHEROSCLEROTIC DISEASE</text>
<text top="839" left="122" width="221" height="14" font="10">IN OTHER VASCULAR BEDS FOR THE</text>
<text top="857" left="122" width="118" height="14" font="10">PATIENT WITH PAD</text>
<text top="857" left="249" width="169" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="858" left="422" width="19" height="11" font="2">e87</text>
<text top="883" left="123" width="185" height="12" font="12">4.1. Abdominal Aortic Aneurysm:</text>
<text top="898" left="147" width="97" height="12" font="12">Recommendation</text>
<text top="897" left="250" width="169" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="898" left="422" width="19" height="11" font="2">e87</text>
<text top="923" left="122" width="269" height="12" font="12">4.2. Screening for Asymptomatic Atherosclerosis</text>
<text top="938" left="147" width="255" height="12" font="12">in Other Arterial Beds (Coronary, Carotid, and</text>
<text top="952" left="147" width="82" height="12" font="12">Renal Arteries)</text>
<text top="952" left="237" width="182" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="953" left="422" width="19" height="11" font="2">e87</text>
<text top="991" left="108" width="275" height="14" font="10">5. MEDICAL THERAPY FOR THE PATIENT WITH PAD</text>
<text top="991" left="389" width="29" height="14" font="11">. . . . .</text>
<text top="992" left="422" width="19" height="11" font="2">e87</text>
<text top="1016" left="128" width="240" height="12" font="12">5.1. Antiplatelet Agents: Recommendations</text>
<text top="1015" left="376" width="42" height="14" font="11">. . . . . . .</text>
<text top="1016" left="421" width="20" height="11" font="2">e88</text>
<text top="1041" left="127" width="203" height="12" font="12">5.2. Statin Agents: Recommendation</text>
<text top="1040" left="336" width="82" height="14" font="11">. . . . . . . . . . . . .</text>
<text top="1041" left="422" width="19" height="11" font="2">e89</text>
<text top="1066" left="127" width="271" height="12" font="12">5.3. Antihypertensive Agents: Recommendations</text>
<text top="1065" left="402" width="16" height="14" font="11">. . .</text>
<text top="1066" left="422" width="19" height="11" font="2">e89</text>
<text top="1091" left="126" width="240" height="12" font="12">5.4. Smoking Cessation: Recommendations</text>
<text top="1090" left="369" width="49" height="14" font="11">. . . . . . . .</text>
<text top="1091" left="421" width="20" height="11" font="2">e90</text>
<text top="395" left="488" width="229" height="12" font="12">5.5. Glycemic Control: Recommendations</text>
<text top="394" left="723" width="56" height="14" font="11">. . . . . . . . .</text>
<text top="395" left="784" width="17" height="11" font="2">e91</text>
<text top="420" left="487" width="249" height="12" font="12">5.6. Oral Anticoagulation: Recommendations</text>
<text top="419" left="743" width="36" height="14" font="11">. . . . . .</text>
<text top="420" left="784" width="17" height="11" font="2">e91</text>
<text top="445" left="488" width="182" height="12" font="12">5.7. Cilostazol: Recommendation</text>
<text top="444" left="676" width="102" height="14" font="11">. . . . . . . . . . . . . . . .</text>
<text top="445" left="783" width="18" height="11" font="2">e92</text>
<text top="473" left="487" width="207" height="12" font="12">5.8. Pentoxifylline: Recommendation</text>
<text top="472" left="696" width="82" height="14" font="11">. . . . . . . . . . . . .</text>
<text top="473" left="783" width="18" height="11" font="2">e92</text>
<text top="498" left="487" width="232" height="12" font="12">5.9. Chelation Therapy: Recommendation</text>
<text top="497" left="723" width="56" height="14" font="11">. . . . . . . . .</text>
<text top="498" left="783" width="18" height="11" font="2">e92</text>
<text top="523" left="481" width="270" height="12" font="12">5.10. Homocysteine Lowering: Recommendation</text>
<text top="522" left="756" width="22" height="14" font="11">. . . .</text>
<text top="523" left="783" width="18" height="11" font="2">e92</text>
<text top="547" left="484" width="39" height="12" font="12">5.11. In</text>
<text top="546" left="523" width="214" height="15" font="12">ﬂuenza Vaccination: Recommendation</text>
<text top="547" left="743" width="36" height="14" font="11">. . . . . .</text>
<text top="548" left="783" width="18" height="11" font="2">e93</text>
<text top="586" left="468" width="223" height="14" font="10">6. STRUCTURED EXERCISE THERAPY:</text>
<text top="604" left="481" width="126" height="14" font="10">RECOMMENDATIONS</text>
<text top="604" left="616" width="162" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="605" left="783" width="18" height="11" font="2">e93</text>
<text top="640" left="468" width="247" height="14" font="10">7. MINIMIZING TISSUE LOSS IN PATIENTS</text>
<text top="657" left="481" width="195" height="14" font="10">WITH PAD: RECOMMENDATIONS</text>
<text top="657" left="683" width="95" height="14" font="11">. . . . . . . . . . . . . . .</text>
<text top="658" left="783" width="18" height="11" font="2">e95</text>
<text top="693" left="468" width="275" height="14" font="10">8. REVASCULARIZATION FOR CLAUDICATION</text>
<text top="693" left="749" width="29" height="14" font="11">. . . . .</text>
<text top="694" left="782" width="19" height="11" font="2">e96</text>
<text top="719" left="481" width="217" height="12" font="12">8.1. Revascularization for Claudication:</text>
<text top="734" left="505" width="97" height="12" font="12">Recommendation</text>
<text top="733" left="610" width="169" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="734" left="782" width="19" height="11" font="2">e96</text>
<text top="761" left="507" width="226" height="12" font="2">8.1.1. Endovascular Revascularization for</text>
<text top="776" left="538" width="179" height="12" font="2">Claudication: Recommendations</text>
<text top="776" left="720" width="56" height="14" font="11">. . . . . . . . .</text>
<text top="777" left="783" width="18" height="11" font="2">e97</text>
<text top="800" left="506" width="273" height="12" font="2">8.1.2. Surgical Revascularization for Claudication:</text>
<text top="815" left="538" width="103" height="12" font="2">Recommendations</text>
<text top="814" left="647" width="129" height="14" font="11">. . . . . . . . . . . . . . . . . . . .</text>
<text top="815" left="782" width="19" height="11" font="2">e98</text>
<text top="850" left="468" width="145" height="14" font="10">9. MANAGEMENT OF CLI</text>
<text top="850" left="616" width="162" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="851" left="782" width="19" height="11" font="2">e99</text>
<text top="875" left="483" width="273" height="12" font="12">9.1. Revascularization for CLI: Recommendations</text>
<text top="874" left="762" width="16" height="14" font="11">. . .</text>
<text top="875" left="782" width="19" height="11" font="2">e99</text>
<text top="895" left="508" width="252" height="12" font="2">9.1.1. Endovascular Revascularization for CLI:</text>
<text top="910" left="539" width="103" height="12" font="2">Recommendations</text>
<text top="910" left="648" width="122" height="14" font="11">. . . . . . . . . . . . . . . . . . .</text>
<text top="911" left="776" width="25" height="11" font="2">e100</text>
<text top="934" left="506" width="222" height="12" font="2">9.1.2. Surgical Revascularization for CLI:</text>
<text top="949" left="539" width="103" height="12" font="2">Recommendations</text>
<text top="948" left="648" width="122" height="14" font="11">. . . . . . . . . . . . . . . . . . .</text>
<text top="949" left="779" width="23" height="11" font="2">e101</text>
<text top="976" left="481" width="215" height="12" font="12">9.2. Wound Healing Therapies for CLI:</text>
<text top="991" left="506" width="103" height="12" font="12">Recommendations</text>
<text top="990" left="616" width="155" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="991" left="778" width="24" height="11" font="2">e102</text>
<text top="1026" left="469" width="151" height="14" font="10">10. MANAGEMENT OF ALI</text>
<text top="1026" left="629" width="142" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1027" left="778" width="24" height="11" font="2">e103</text>
<text top="1051" left="490" width="184" height="12" font="12">10.1. Clinical Presentation of ALI:</text>
<text top="1066" left="520" width="103" height="12" font="12">Recommendations</text>
<text top="1066" left="630" width="142" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1067" left="778" width="24" height="11" font="2">e103</text>
<text top="1091" left="489" width="265" height="12" font="12">10.2. Medical Therapy for ALI: Recommendations</text>
<text top="1090" left="756" width="16" height="14" font="11">. . .</text>
<text top="1091" left="776" width="25" height="11" font="2">e104</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="14" height="9" font="5">e72</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="14" size="9" family="Times" color="#e3202b"/>
<text top="143" left="84" width="270" height="12" font="12">10.3. Revascularization for ALI: Recommendations</text>
<text top="142" left="358" width="9" height="14" font="11">. .</text>
<text top="143" left="372" width="24" height="11" font="2">e105</text>
<text top="168" left="83" width="266" height="12" font="12">10.4. Diagnostic Evaluation of the Cause of ALI:</text>
<text top="182" left="114" width="103" height="12" font="12">Recommendations</text>
<text top="182" left="225" width="142" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="183" left="372" width="24" height="11" font="2">e106</text>
<text top="218" left="67" width="191" height="14" font="10">11. LONGITUDINAL FOLLOW-UP:</text>
<text top="236" left="83" width="126" height="14" font="10">RECOMMENDATIONS</text>
<text top="236" left="218" width="149" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="237" left="372" width="24" height="11" font="2">e106</text>
<text top="271" left="65" width="269" height="14" font="10">12. EVIDENCE GAPS AND FUTURE RESEARCH</text>
<text top="289" left="83" width="75" height="14" font="10">DIRECTIONS</text>
<text top="289" left="165" width="202" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="290" left="371" width="25" height="11" font="2">e108</text>
<text top="325" left="65" width="161" height="14" font="10">13. ADVOCACY PRIORITIES</text>
<text top="325" left="231" width="135" height="14" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="326" left="371" width="25" height="11" font="2">e108</text>
<text top="361" left="63" width="80" height="14" font="10">REFERENCES</text>
<text top="361" left="151" width="215" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="362" left="372" width="24" height="11" font="2">e109</text>
<text top="397" left="63" width="71" height="14" font="10">APPENDIX 1</text>
<text top="422" left="83" width="222" height="12" font="12">Author Relationships With Industry and</text>
<text top="437" left="83" width="137" height="12" font="12">Other Entities (Relevant)</text>
<text top="437" left="225" width="142" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="438" left="374" width="22" height="11" font="2">e119</text>
<text top="472" left="63" width="73" height="14" font="10">APPENDIX 2</text>
<text top="498" left="83" width="235" height="12" font="12">Reviewer Relationships With Industry and</text>
<text top="513" left="83" width="174" height="12" font="12">Other Entities (Comprehensive)</text>
<text top="512" left="264" width="102" height="14" font="11">. . . . . . . . . . . . . . . .</text>
<text top="513" left="375" width="21" height="11" font="2">e121</text>
<text top="548" left="63" width="73" height="14" font="10">APPENDIX 3</text>
<text top="573" left="83" width="76" height="12" font="12">Abbreviations</text>
<text top="573" left="165" width="202" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="574" left="373" width="23" height="11" font="2">e126</text>
<text top="608" left="63" width="73" height="16" font="14">PREAMBLE</text>
<text top="646" left="63" width="333" height="12" font="2">Since 1980, the American College of Cardiology (ACC) and</text>
<text top="664" left="63" width="333" height="12" font="2">American Heart Association (AHA) have translated scien-</text>
<text top="682" left="63" width="8" height="12" font="2">ti</text>
<text top="680" left="71" width="325" height="15" font="2">ﬁc evidence into clinical practice guidelines with rec-</text>
<text top="700" left="63" width="333" height="12" font="2">ommendations to improve cardiovascular health. These</text>
<text top="718" left="63" width="333" height="12" font="2">guidelines, based on systematic methods to evaluate and</text>
<text top="735" left="63" width="333" height="12" font="2">classify evidence, provide a cornerstone of quality car-</text>
<text top="753" left="63" width="98" height="12" font="2">diovascular care.</text>
<text top="771" left="78" width="318" height="12" font="2">In response to reports from the Institute of Medicine</text>
<text top="789" left="63" width="24" height="12" font="4"><a href="e71.full.html#39">(1,2)</a></text>
<text top="789" left="94" width="302" height="12" font="2">and a mandate to evaluate new knowledge and</text>
<text top="807" left="63" width="333" height="12" font="2">maintain relevance at the point of care, the ACC/AHA</text>
<text top="825" left="63" width="333" height="12" font="2">Task Force on Clinical Practice Guidelines (Task Force)</text>
<text top="843" left="63" width="29" height="12" font="2">modi</text>
<text top="841" left="93" width="120" height="15" font="2">ﬁed its methodology</text>
<text top="843" left="217" width="10" height="12" font="4"><a href="e71.full.html#39">(3</a></text>
<text top="841" left="228" width="16" height="15" font="4"><a href="e71.full.html#39">–5)</a></text>
<text top="843" left="244" width="152" height="12" font="2">. The relationships among</text>
<text top="861" left="63" width="333" height="12" font="2">guidelines, data standards, appropriate use criteria, and</text>
<text top="879" left="63" width="279" height="12" font="2">performance measures are addressed elsewhere</text>
<text top="879" left="346" width="15" height="12" font="4"><a href="e71.full.html#39">(5)</a></text>
<text top="879" left="361" width="3" height="12" font="2">.</text>
<text top="910" left="63" width="71" height="11" font="12">Intended Use</text>
<text top="932" left="63" width="333" height="12" font="2">Practice guidelines provide recommendations applicable</text>
<text top="950" left="63" width="333" height="12" font="2">to patients with or at risk of developing cardiovascular</text>
<text top="968" left="63" width="333" height="12" font="2">disease. The focus is on medical practice in the United</text>
<text top="985" left="63" width="333" height="12" font="2">States, but guidelines developed in collaboration with</text>
<text top="1003" left="63" width="333" height="12" font="2">other organizations may have a broader target. Although</text>
<text top="1021" left="63" width="333" height="12" font="2">guidelines may be used to inform regulatory or payer</text>
<text top="1039" left="63" width="333" height="12" font="2">decisions, the intent is to improve quality of care and</text>
<text top="1057" left="63" width="110" height="12" font="2">align with patients</text>
<text top="1055" left="173" width="223" height="15" font="2">’ interests. Guidelines are intended to</text>
<text top="1075" left="63" width="14" height="12" font="2">de</text>
<text top="1073" left="77" width="319" height="15" font="2">ﬁne practices meeting the needs of patients in most,</text>
<text top="1093" left="63" width="333" height="12" font="2">but not all, circumstances, and should not replace clinical</text>
<text top="143" left="423" width="333" height="12" font="2">judgment. Guidelines are reviewed annually by the Task</text>
<text top="161" left="423" width="99" height="12" font="2">Force and are of</text>
<text top="159" left="522" width="234" height="15" font="2">ﬁcial policy of the ACC and AHA. Each</text>
<text top="178" left="423" width="333" height="12" font="2">guideline is considered current until it is updated,</text>
<text top="196" left="423" width="333" height="12" font="2">revised, or superseded by published addenda, statements</text>
<text top="214" left="423" width="45" height="12" font="2">of clari</text>
<text top="213" left="468" width="288" height="15" font="2">ﬁcation, focused updates, or revised full-text</text>
<text top="232" left="423" width="333" height="12" font="2">guidelines. To ensure that guidelines remain current,</text>
<text top="250" left="423" width="333" height="12" font="2">new data are reviewed biannually to determine whether</text>
<text top="268" left="423" width="208" height="12" font="2">recommendations should be modi</text>
<text top="266" left="631" width="125" height="15" font="2">ﬁed. In general, full</text>
<text top="286" left="423" width="211" height="12" font="2">revisions are posted in 5-year cycles</text>
<text top="286" left="639" width="10" height="12" font="4"><a href="e71.full.html#39">(3</a></text>
<text top="284" left="649" width="17" height="15" font="4"><a href="e71.full.html#39">–6)</a></text>
<text top="286" left="666" width="3" height="12" font="2">.</text>
<text top="326" left="423" width="76" height="11" font="12">Modernization</text>
<text top="347" left="423" width="333" height="12" font="2">Processes have evolved to support the evolution of</text>
<text top="365" left="423" width="75" height="12" font="2">guidelines as</text>
<text top="364" left="502" width="255" height="15" font="2">“living documents” that can be dynamically</text>
<text top="383" left="423" width="333" height="12" font="2">updated. This process delineates a recommendation to</text>
<text top="401" left="423" width="90" height="12" font="2">address a speci</text>
<text top="399" left="514" width="242" height="15" font="2">ﬁc clinical question, followed by concise</text>
<text top="419" left="423" width="71" height="12" font="2">text (ideally</text>
<text top="417" left="499" width="258" height="15" font="2">&lt;250 words) and hyperlinked to supportive</text>
<text top="437" left="423" width="333" height="12" font="2">evidence. This approach accommodates time constraints</text>
<text top="455" left="423" width="333" height="12" font="2">on busy clinicians and facilitates easier access to recom-</text>
<text top="473" left="423" width="333" height="12" font="2">mendations via electronic search engines and other</text>
<text top="491" left="423" width="122" height="12" font="2">evolving technology.</text>
<text top="531" left="423" width="89" height="11" font="12">Evidence Review</text>
<text top="553" left="423" width="333" height="12" font="2">Writing committee members review the literature; weigh</text>
<text top="571" left="423" width="333" height="12" font="2">the quality of evidence for or against particular tests,</text>
<text top="589" left="423" width="333" height="12" font="2">treatments, or procedures; and estimate expected health</text>
<text top="607" left="423" width="333" height="12" font="2">outcomes. In developing recommendations, the writing</text>
<text top="625" left="423" width="333" height="12" font="2">committee uses evidence-based methodologies that are</text>
<text top="642" left="423" width="171" height="12" font="2">based on all available data</text>
<text top="642" left="602" width="10" height="12" font="4"><a href="e71.full.html#39">(3</a></text>
<text top="641" left="613" width="16" height="15" font="4"><a href="e71.full.html#39">–7)</a></text>
<text top="642" left="629" width="127" height="12" font="2">. Literature searches</text>
<text top="660" left="423" width="333" height="12" font="2">focus on randomized controlled trials (RCTs) but also</text>
<text top="678" left="423" width="43" height="12" font="2">include</text>
<text top="678" left="478" width="57" height="12" font="2">registries,</text>
<text top="678" left="547" width="92" height="12" font="2">nonrandomized</text>
<text top="678" left="651" width="72" height="12" font="2">comparative</text>
<text top="678" left="735" width="21" height="12" font="2">and</text>
<text top="696" left="423" width="333" height="12" font="2">descriptive studies, case series, cohort studies, system-</text>
<text top="714" left="423" width="333" height="12" font="2">atic reviews, and expert opinion. Only selected refer-</text>
<text top="732" left="423" width="92" height="12" font="2">ences are cited.</text>
<text top="750" left="438" width="319" height="12" font="2">The Task Force recognizes the need for objective, in-</text>
<text top="768" left="423" width="333" height="12" font="2">dependent Evidence Review Committees (ERCs) that</text>
<text top="786" left="423" width="333" height="12" font="2">include methodologists, epidemiologists, clinicians, and</text>
<text top="804" left="423" width="333" height="12" font="2">biostatisticians who systematically survey, abstract, and</text>
<text top="822" left="423" width="333" height="12" font="2">assess the evidence to address systematic review ques-</text>
<text top="840" left="423" width="29" height="12" font="2">tions</text>
<text top="840" left="464" width="34" height="12" font="2">posed</text>
<text top="840" left="510" width="11" height="12" font="2">in</text>
<text top="840" left="533" width="19" height="12" font="2">the</text>
<text top="840" left="563" width="43" height="12" font="2">PICOTS</text>
<text top="840" left="618" width="39" height="12" font="2">format</text>
<text top="840" left="669" width="11" height="12" font="2">(P</text>
<text top="838" left="680" width="76" height="15" font="2">¼population,</text>
<text top="858" left="423" width="4" height="12" font="2">I</text>
<text top="856" left="427" width="329" height="15" font="2">¼intervention, C¼comparator, O¼outcome, T¼timing,</text>
<text top="876" left="423" width="6" height="12" font="2">S</text>
<text top="874" left="430" width="53" height="15" font="2">¼setting)</text>
<text top="876" left="492" width="22" height="12" font="4"><a href="e71.full.html#39">(2,4</a></text>
<text top="874" left="514" width="17" height="15" font="4"><a href="e71.full.html#39">–6)</a></text>
<text top="876" left="531" width="225" height="12" font="2">. Practical considerations, including</text>
<text top="894" left="423" width="333" height="12" font="2">time and resource constraints, limit the ERCs to evidence</text>
<text top="912" left="423" width="333" height="12" font="2">that is relevant to key clinical questions and lends itself to</text>
<text top="929" left="423" width="333" height="12" font="2">systematic review and analysis that could affect the</text>
<text top="947" left="423" width="263" height="12" font="2">strength of corresponding recommendations.</text>
<text top="982" left="423" width="254" height="11" font="12">Guideline-Directed Management and Treatment</text>
<text top="1003" left="423" width="54" height="12" font="2">The term</text>
<text top="1002" left="481" width="275" height="15" font="2">“guideline-directed management and therapy”</text>
<text top="1021" left="423" width="142" height="12" font="2">(GDMT) refers to care de</text>
<text top="1020" left="566" width="191" height="15" font="2">ﬁned mainly by ACC/AHA Class I</text>
<text top="1039" left="423" width="333" height="12" font="2">recommendations. For these and all recommended drug</text>
<text top="1057" left="423" width="263" height="12" font="2">treatment regimens, the reader should con</text>
<text top="1055" left="686" width="70" height="15" font="2">ﬁrm dosage</text>
<text top="1075" left="423" width="333" height="12" font="2">with product insert material and carefully evaluate for</text>
<text top="1093" left="423" width="333" height="12" font="2">contraindications and interactions. Recommendations are</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="794" width="14" height="9" font="5">e73</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="15" size="8" family="Times" color="#ffffff"/>
	<fontspec id="16" size="8" family="Times" color="#0e2a52"/>
<text top="985" left="108" width="333" height="12" font="2">limited to treatments, drugs, and devices approved for</text>
<text top="1003" left="108" width="189" height="12" font="2">clinical use in the United States.</text>
<text top="1036" left="108" width="258" height="11" font="12">Class of Recommendation and Level of Evidence</text>
<text top="1057" left="108" width="333" height="12" font="2">The Class of Recommendation (COR; i.e., the strength of</text>
<text top="1075" left="108" width="19" height="12" font="2">the</text>
<text top="1075" left="139" width="103" height="12" font="2">recommendation)</text>
<text top="1075" left="255" width="76" height="12" font="2">encompasses</text>
<text top="1075" left="344" width="19" height="12" font="2">the</text>
<text top="1075" left="376" width="65" height="12" font="2">anticipated</text>
<text top="1093" left="108" width="193" height="12" font="2">magnitude and certainty of bene</text>
<text top="1091" left="301" width="140" height="15" font="2">ﬁt in proportion to risk.</text>
<text top="985" left="468" width="333" height="12" font="2">The Level of Evidence (LOE) rates evidence supporting</text>
<text top="1003" left="468" width="333" height="12" font="2">the effect of the intervention on the basis of the type,</text>
<text top="1021" left="468" width="333" height="12" font="2">quality, quantity, and consistency of data from clinical</text>
<text top="1039" left="468" width="147" height="12" font="2">trials and other reports (</text>
<text top="1040" left="615" width="41" height="11" font="4"><a href="e71.full.html#4">Table 1</a></text>
<text top="1039" left="656" width="4" height="12" font="2">)</text>
<text top="1039" left="665" width="10" height="12" font="4"><a href="e71.full.html#39">(3</a></text>
<text top="1037" left="676" width="16" height="15" font="4"><a href="e71.full.html#39">–5)</a></text>
<text top="1039" left="693" width="109" height="12" font="2"><a href="e71.full.html#39">. </a>Unless otherwise</text>
<text top="1057" left="468" width="333" height="12" font="2">stated, recommendations are sequenced by COR and</text>
<text top="1075" left="468" width="333" height="12" font="2">then by LOE. Where comparative data exist, preferred</text>
<text top="1093" left="468" width="202" height="12" font="2">strategies take precedence. When</text>
<text top="1091" left="676" width="125" height="15" font="2">&gt;1 drug, strategy, or</text>
<text top="156" left="116" width="46" height="10" font="15">T A B L E 1</text>
<text top="149" left="179" width="585" height="10" font="16">Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or</text>
<text top="163" left="179" width="313" height="10" font="16">Diagnostic Testing in Patient Care* (Updated August 2015)</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="15" height="9" font="5">e74</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="12" font="2">therapy exists within the same COR and LOE and no</text>
<text top="161" left="63" width="72" height="12" font="2">comparative</text>
<text top="161" left="146" width="54" height="12" font="2">data are</text>
<text top="161" left="213" width="55" height="12" font="2">available,</text>
<text top="161" left="280" width="73" height="12" font="2">options are</text>
<text top="161" left="364" width="32" height="12" font="2">listed</text>
<text top="178" left="63" width="85" height="12" font="2">alphabetically.</text>
<text top="218" left="63" width="248" height="11" font="12">Relationships With Industry and Other Entities</text>
<text top="240" left="63" width="333" height="12" font="2">The ACC and AHA sponsor the guidelines without com-</text>
<text top="257" left="63" width="333" height="12" font="2">mercial support, and members volunteer their time. The</text>
<text top="275" left="63" width="27" height="12" font="2">Task</text>
<text top="275" left="102" width="32" height="12" font="2">Force</text>
<text top="275" left="147" width="54" height="12" font="2">zealously</text>
<text top="275" left="214" width="37" height="12" font="2">avoids</text>
<text top="275" left="264" width="39" height="12" font="2">actual,</text>
<text top="275" left="316" width="56" height="12" font="2">potential,</text>
<text top="275" left="384" width="12" height="12" font="2">or</text>
<text top="293" left="63" width="83" height="12" font="2">perceived con</text>
<text top="292" left="146" width="250" height="15" font="2">ﬂicts of interest that might arise through</text>
<text top="311" left="63" width="333" height="12" font="2">relationships with industry or other entities (RWI). All</text>
<text top="329" left="63" width="333" height="12" font="2">writing committee members and reviewers are required to</text>
<text top="347" left="63" width="333" height="12" font="2">disclose current industry relationships or personal in-</text>
<text top="365" left="63" width="333" height="12" font="2">terests, from 12 months before initiation of the writing</text>
<text top="383" left="63" width="333" height="12" font="2">effort. Management of RWI involves selecting a balanced</text>
<text top="401" left="63" width="333" height="12" font="2">writing committee and assuring that the chair and</text>
<text top="419" left="63" width="333" height="12" font="2">a majority of committee members have no relevant</text>
<text top="437" left="63" width="24" height="12" font="2">RWI</text>
<text top="437" left="101" width="4" height="12" font="2"><a href="e71.full.html#49">(</a></text>
<text top="437" left="105" width="56" height="12" font="4"><a href="e71.full.html#49">Appendix</a></text>
<text top="437" left="175" width="5" height="12" font="4"><a href="e71.full.html#49">1</a></text>
<text top="437" left="181" width="8" height="12" font="2"><a href="e71.full.html#49">).</a></text>
<text top="437" left="202" width="53" height="12" font="2">Members</text>
<text top="437" left="269" width="18" height="12" font="2">are</text>
<text top="437" left="301" width="55" height="12" font="2">restricted</text>
<text top="437" left="370" width="26" height="12" font="2">with</text>
<text top="455" left="63" width="333" height="12" font="2">regard to writing or voting on sections to which their</text>
<text top="473" left="63" width="235" height="12" font="2">RWI apply. For transparency, members</text>
<text top="471" left="298" width="98" height="15" font="2">’ comprehensive</text>
<text top="491" left="63" width="221" height="12" font="2">disclosure information is available</text>
<text top="491" left="295" width="37" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Guideline_RWI.pdf">online</a></text>
<text top="491" left="332" width="64" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Guideline_RWI.pdf">. </a>Compre-</text>
<text top="509" left="63" width="333" height="12" font="2">hensive disclosure information for the Task Force is also</text>
<text top="526" left="63" width="52" height="12" font="2">available</text>
<text top="526" left="118" width="37" height="12" font="4"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces">online</a></text>
<text top="526" left="155" width="3" height="12" font="2">.</text>
<text top="544" left="78" width="318" height="12" font="2">The Task Force strives to avoid bias by selecting ex-</text>
<text top="562" left="63" width="333" height="12" font="2">perts from a broad array of backgrounds representing</text>
<text top="580" left="63" width="333" height="12" font="2">different geographic regions, sexes, ethnicities, intellec-</text>
<text top="598" left="63" width="333" height="12" font="2">tual perspectives/biases, and scopes of clinical practice,</text>
<text top="616" left="63" width="333" height="12" font="2">and by inviting organizations and professional societies</text>
<text top="634" left="63" width="333" height="12" font="2">with related interests and expertise to participate as</text>
<text top="652" left="63" width="147" height="12" font="2">partners or collaborators.</text>
<text top="692" left="63" width="193" height="11" font="12">Individualizing Care in Patients With</text>
<text top="710" left="63" width="216" height="11" font="12">Associated Conditions and Comorbidities</text>
<text top="731" left="63" width="333" height="12" font="2">Managing patients with multiple conditions can be</text>
<text top="749" left="63" width="333" height="12" font="2">complex, especially when recommendations applicable</text>
<text top="767" left="63" width="308" height="12" font="2">to coexisting illnesses are discordant or interacting</text>
<text top="767" left="377" width="16" height="12" font="4"><a href="e71.full.html#39">(8)</a></text>
<text top="767" left="393" width="3" height="12" font="2"><a href="e71.full.html#39">.</a></text>
<text top="785" left="63" width="202" height="12" font="2">The guidelines are intended to de</text>
<text top="783" left="265" width="131" height="15" font="2">ﬁne practices meeting</text>
<text top="803" left="63" width="333" height="12" font="2">the needs of patients in most, but not all, circumstances.</text>
<text top="821" left="63" width="22" height="12" font="2">The</text>
<text top="821" left="98" width="104" height="12" font="2">recommendations</text>
<text top="821" left="215" width="39" height="12" font="2">should</text>
<text top="821" left="268" width="19" height="12" font="2">not</text>
<text top="821" left="300" width="42" height="12" font="2">replace</text>
<text top="821" left="355" width="41" height="12" font="2">clinical</text>
<text top="839" left="63" width="60" height="12" font="2">judgment.</text>
<text top="878" left="63" width="126" height="11" font="12">Clinical Implementation</text>
<text top="900" left="63" width="333" height="12" font="2">Management in accordance with guideline recommenda-</text>
<text top="918" left="63" width="333" height="12" font="2">tions is effective only when followed. Adherence to rec-</text>
<text top="936" left="63" width="333" height="12" font="2">ommendations can be enhanced by shared decision</text>
<text top="954" left="63" width="333" height="12" font="2">making between clinicians and patients, with patient</text>
<text top="971" left="63" width="333" height="12" font="2">engagement in selecting interventions on the basis of</text>
<text top="989" left="63" width="333" height="12" font="2">individual values, preferences, and associated conditions</text>
<text top="1007" left="63" width="333" height="12" font="2">and comorbidities. Consequently, circumstances may</text>
<text top="1025" left="63" width="333" height="12" font="2">arise in which deviations from these guidelines are</text>
<text top="1043" left="63" width="71" height="12" font="2">appropriate.</text>
<text top="1061" left="166" width="230" height="12" font="2">Jonathan L. Halperin, MD, FACC, FAHA</text>
<text top="1079" left="63" width="333" height="12" font="2">Chair, ACC/AHA Task Force on Clinical Practice Guidelines</text>
<text top="141" left="423" width="120" height="16" font="14">1. INTRODUCTION</text>
<text top="179" left="423" width="207" height="11" font="12">1.1. Methodology and Evidence Review</text>
<text top="200" left="423" width="333" height="12" font="2">The recommendations listed in this guideline are, when-</text>
<text top="218" left="423" width="333" height="12" font="2">ever possible, evidence based. An initial extensive evi-</text>
<text top="236" left="423" width="333" height="12" font="2">dence review, which included literature derived from</text>
<text top="254" left="423" width="333" height="12" font="2">research involving human subjects, published in English,</text>
<text top="272" left="423" width="333" height="12" font="2">and indexed in MEDLINE (through PubMed), EMBASE,</text>
<text top="290" left="423" width="19" height="12" font="2">the</text>
<text top="290" left="454" width="54" height="12" font="2">Cochrane</text>
<text top="290" left="521" width="45" height="12" font="2">Library,</text>
<text top="290" left="579" width="19" height="12" font="2">the</text>
<text top="290" left="610" width="42" height="12" font="2">Agency</text>
<text top="290" left="665" width="16" height="12" font="2">for</text>
<text top="290" left="694" width="62" height="12" font="2">Healthcare</text>
<text top="308" left="423" width="333" height="12" font="2">Research and Quality, and other selected databases</text>
<text top="326" left="423" width="333" height="12" font="2">relevant to this guideline, was conducted from January</text>
<text top="344" left="423" width="333" height="12" font="2">through September 2015. Key search words included but</text>
<text top="362" left="423" width="333" height="12" font="2">were not limited to the following: acute limb ischemia,</text>
<text top="380" left="423" width="333" height="12" font="2">angioplasty, ankle-brachial index, anticoagulation, anti-</text>
<text top="398" left="423" width="333" height="12" font="2">platelet therapy, atypical leg symptoms, blood pressure</text>
<text top="415" left="423" width="130" height="12" font="2">lowering/hypertension,</text>
<text top="415" left="568" width="38" height="12" font="2">bypass</text>
<text top="415" left="622" width="70" height="12" font="2">graft/bypass</text>
<text top="415" left="707" width="49" height="12" font="2">grafting/</text>
<text top="433" left="423" width="44" height="12" font="2">surgical</text>
<text top="433" left="483" width="41" height="12" font="2">bypass,</text>
<text top="433" left="541" width="57" height="12" font="2">cilostazol,</text>
<text top="433" left="613" width="143" height="12" font="2">claudication/intermittent</text>
<text top="451" left="423" width="333" height="12" font="2">claudication, critical limb ischemia/severe limb ischemia,</text>
<text top="469" left="423" width="50" height="12" font="2">diabetes,</text>
<text top="469" left="489" width="57" height="12" font="2">diagnostic</text>
<text top="469" left="562" width="41" height="12" font="2">testing,</text>
<text top="469" left="618" width="75" height="12" font="2">endovascular</text>
<text top="469" left="709" width="48" height="12" font="2">therapy,</text>
<text top="487" left="423" width="333" height="12" font="2">exercise rehabilitation/exercise therapy/exercise training/</text>
<text top="505" left="423" width="333" height="12" font="2">supervised exercise, lower extremity/foot wound/ulcer,</text>
<text top="523" left="423" width="333" height="12" font="2">peripheral artery disease/peripheral arterial disease/pe-</text>
<text top="541" left="423" width="333" height="12" font="2">ripheral vascular disease/lower extremity arterial disease,</text>
<text top="559" left="423" width="333" height="12" font="2">smoking/smoking cessation, statin, stenting, and vascular</text>
<text top="577" left="423" width="333" height="12" font="2">surgery. Additional relevant studies published through</text>
<text top="595" left="423" width="333" height="12" font="2">September 2016, during the guideline writing process,</text>
<text top="613" left="423" width="333" height="12" font="2">were also considered by the writing committee, and</text>
<text top="631" left="423" width="304" height="12" font="2">added to the evidence tables when appropriate. The</text>
<text top="629" left="731" width="26" height="15" font="2">ﬁnal</text>
<text top="649" left="423" width="185" height="12" font="2">evidence tables included in the</text>
<text top="649" left="613" width="144" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement</a></text>
<text top="667" left="423" width="333" height="12" font="2">summarize the evidence utilized by the writing com-</text>
<text top="685" left="423" width="333" height="12" font="2">mittee to formulate recommendations. Additionally, the</text>
<text top="702" left="423" width="333" height="12" font="2">writing committee reviewed documents related to lower</text>
<text top="720" left="423" width="333" height="12" font="2">extremity peripheral artery disease (PAD) previously</text>
<text top="738" left="423" width="213" height="12" font="2">published by the ACC and AHA</text>
<text top="738" left="647" width="32" height="12" font="4"><a href="e71.full.html#39">(9,10)</a></text>
<text top="738" left="679" width="77" height="12" font="2">. References</text>
<text top="756" left="423" width="333" height="12" font="2">selected and published in this document are represen-</text>
<text top="774" left="423" width="163" height="12" font="2">tative and not all-inclusive.</text>
<text top="792" left="438" width="318" height="12" font="2">As stated in the Preamble, the ACC/AHA guideline</text>
<text top="810" left="423" width="333" height="12" font="2">methodology provides for commissioning an independent</text>
<text top="828" left="423" width="333" height="12" font="2">ERC to address systematic review questions (PICOTS</text>
<text top="846" left="423" width="333" height="12" font="2">format) to inform recommendations developed by the</text>
<text top="864" left="423" width="333" height="12" font="2">writing committee. All other guideline recommendations</text>
<text top="882" left="423" width="333" height="12" font="2">(not based on the systematic review questions) were also</text>
<text top="900" left="423" width="333" height="12" font="2">subjected to an extensive evidence review process. For</text>
<text top="918" left="423" width="333" height="12" font="2">this guideline, the writing committee in conjunction with</text>
<text top="936" left="423" width="225" height="12" font="2">the Task Force and ERC Chair identi</text>
<text top="934" left="649" width="108" height="15" font="2">ﬁed the following</text>
<text top="954" left="423" width="333" height="12" font="2">systematic review questions: 1) Is antiplatelet therapy</text>
<text top="971" left="423" width="28" height="12" font="2">bene</text>
<text top="970" left="451" width="305" height="15" font="2">ﬁcial for prevention of cardiovascular events in the</text>
<text top="989" left="423" width="333" height="12" font="2">patient with symptomatic or asymptomatic lower ex-</text>
<text top="1007" left="423" width="333" height="12" font="2">tremity PAD? 2) What is the effect of revascularization,</text>
<text top="1025" left="423" width="333" height="12" font="2">compared with optimal medical therapy and exercise</text>
<text top="1043" left="423" width="333" height="12" font="2">training, on functional outcome and quality of life (QoL)</text>
<text top="1061" left="423" width="333" height="12" font="2">among patients with claudication? Each question has</text>
<text top="1079" left="423" width="333" height="12" font="2">been the subject of recently published, systematic</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="793" width="14" height="9" font="5">e75</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="102" height="12" font="2">evidence reviews</text>
<text top="143" left="216" width="15" height="12" font="4"><a href="e71.full.html#39">(11</a></text>
<text top="141" left="231" width="21" height="15" font="4"><a href="e71.full.html#39">–13)</a></text>
<text top="143" left="252" width="189" height="12" font="2">. The quality of these evidence</text>
<text top="161" left="108" width="333" height="12" font="2">reviews was appraised by the ACC/AHA methodologist</text>
<text top="178" left="108" width="333" height="12" font="2">and a vendor contracted to support this process (Doctor</text>
<text top="196" left="108" width="333" height="12" font="2">Evidence [Santa Monica, CA]). Few substantive random-</text>
<text top="214" left="108" width="333" height="12" font="2">ized or nonrandomized studies had been published after</text>
<text top="232" left="108" width="333" height="12" font="2">the end date of the literature searches used for the</text>
<text top="250" left="108" width="333" height="12" font="2">existing evidence reviews, so the ERC concluded that no</text>
<text top="268" left="108" width="333" height="12" font="2">additional systematic review was necessary to address</text>
<text top="286" left="108" width="192" height="12" font="2">either of these critical questions.</text>
<text top="304" left="123" width="318" height="12" font="2">A third systematic review question was then identi-</text>
<text top="320" left="108" width="333" height="15" font="2">ﬁed: 3) Is one revascularization strategy (endovascular</text>
<text top="340" left="108" width="333" height="12" font="2">or surgical) associated with improved cardiovascular</text>
<text top="358" left="108" width="333" height="12" font="2">and limb-related outcomes in patients with critical</text>
<text top="376" left="108" width="333" height="12" font="2">limb ischemia (CLI)? This question had also been the</text>
<text top="394" left="108" width="333" height="12" font="2">subject of a high-quality systematic review that syn-</text>
<text top="412" left="108" width="333" height="12" font="2">thesized evidence from observational data and an RCT</text>
<text top="430" left="108" width="21" height="12" font="4"><a href="e71.full.html#39">(14)</a></text>
<text top="430" left="129" width="312" height="12" font="2">; additional RCTs addressing this question are</text>
<text top="447" left="108" width="47" height="12" font="2">ongoing</text>
<text top="447" left="162" width="16" height="12" font="4"><a href="e71.full.html#39">(15</a></text>
<text top="446" left="178" width="21" height="15" font="4"><a href="e71.full.html#39">–17)</a></text>
<text top="447" left="200" width="241" height="12" font="2"><a href="e71.full.html#39">. </a>The writing committee and the Task</text>
<text top="465" left="108" width="333" height="12" font="2">Force decided to expand the survey to include more</text>
<text top="483" left="108" width="333" height="12" font="2">relevant randomized and observational studies. Based</text>
<text top="501" left="108" width="333" height="12" font="2">on evaluation of this additional evidence the ERC</text>
<text top="519" left="108" width="333" height="12" font="2">decided that further systematic review was not needed</text>
<text top="537" left="108" width="333" height="12" font="2">to inform the writing committee on this question.</text>
<text top="555" left="108" width="333" height="12" font="2">Hence, the ERC and writing committee concluded</text>
<text top="573" left="108" width="333" height="12" font="2">that available systematic reviews could be used to</text>
<text top="591" left="108" width="333" height="12" font="2">inform the development of recommendations address-</text>
<text top="609" left="108" width="311" height="12" font="2">ing each of the 3 systematic review questions speci</text>
<text top="607" left="419" width="22" height="15" font="2">ﬁed</text>
<text top="627" left="108" width="333" height="12" font="2">above. The members of the Task Force and writing</text>
<text top="645" left="108" width="333" height="12" font="2">committee thank the members of the ERC that began</text>
<text top="663" left="108" width="333" height="12" font="2">this process and their willingness to participate in this</text>
<text top="681" left="108" width="333" height="12" font="2">volunteer effort. They include Aruna Pradhan, MD,</text>
<text top="698" left="108" width="333" height="12" font="2">MPH (ERC Chair); Natalie Evans, MD; Peter Henke, MD;</text>
<text top="716" left="108" width="333" height="12" font="2">Dharam J. Kumbhani, MD, SM, FACC; and Tamar</text>
<text top="734" left="108" width="86" height="12" font="2">Polonsky, MD.</text>
<text top="770" left="108" width="231" height="11" font="12">1.2. Organization of the Writing Committee</text>
<text top="791" left="108" width="333" height="12" font="2">The writing committee consisted of clinicians, including</text>
<text top="809" left="108" width="333" height="12" font="2">noninvasive and interventional cardiologists, exercise</text>
<text top="827" left="108" width="333" height="12" font="2">physiologists, internists, interventional radiologists, vas-</text>
<text top="845" left="108" width="333" height="12" font="2">cular nurses, vascular medicine specialists, and vascular</text>
<text top="863" left="108" width="284" height="12" font="2">surgeons, as well as clinical researchers in the</text>
<text top="861" left="398" width="43" height="15" font="2">ﬁeld of</text>
<text top="881" left="108" width="333" height="12" font="2">vascular disease, a nurse (in the role of patient repre-</text>
<text top="899" left="108" width="333" height="12" font="2">sentative), and members with experience in epidemiology</text>
<text top="917" left="108" width="333" height="12" font="2">and/or health services research. The writing committee</text>
<text top="935" left="108" width="333" height="12" font="2">included representatives from the ACC and AHA, Amer-</text>
<text top="953" left="108" width="333" height="12" font="2">ican Association of Cardiovascular and Pulmonary Reha-</text>
<text top="971" left="108" width="333" height="12" font="2">bilitation, Inter-Society Consensus for the Management of</text>
<text top="989" left="108" width="333" height="12" font="2">Peripheral Arterial Disease, Society for Cardiovascular</text>
<text top="1007" left="108" width="333" height="12" font="2">Angiography and Interventions, Society for Clinical</text>
<text top="1024" left="108" width="333" height="12" font="2">Vascular Surgery, Society of Interventional Radiology,</text>
<text top="1042" left="108" width="333" height="12" font="2">Society for Vascular Medicine, Society for Vascular</text>
<text top="1060" left="108" width="333" height="12" font="2">Nursing, Society for Vascular Surgery, and Vascular and</text>
<text top="1078" left="108" width="176" height="12" font="2">Endovascular Surgery Society.</text>
<text top="143" left="468" width="193" height="11" font="12">1.3. Document Review and Approval</text>
<text top="164" left="468" width="241" height="12" font="2">This document was reviewed by 2 of</text>
<text top="163" left="709" width="92" height="15" font="2">ﬁcial reviewers</text>
<text top="182" left="468" width="333" height="12" font="2">nominated by the ACC and AHA; 1 to 2 reviewers each</text>
<text top="200" left="468" width="333" height="12" font="2">from the American Association of Cardiovascular and</text>
<text top="218" left="468" width="333" height="12" font="2">Pulmonary Rehabilitation, Inter-Society Consensus for</text>
<text top="236" left="468" width="333" height="12" font="2">the Management of Peripheral Arterial Disease, Society</text>
<text top="254" left="468" width="333" height="12" font="2">for Cardiovascular Angiography and Interventions, Soci-</text>
<text top="272" left="468" width="333" height="12" font="2">ety for Clinical Vascular Surgery, Society of Interventional</text>
<text top="290" left="468" width="333" height="12" font="2">Radiology, Society for Vascular Medicine, Society for</text>
<text top="308" left="468" width="333" height="12" font="2">Vascular Nursing, Society for Vascular Surgery, and</text>
<text top="326" left="468" width="333" height="12" font="2">Vascular and Endovascular Surgery Society; and 16 addi-</text>
<text top="344" left="468" width="278" height="12" font="2">tional individual content reviewers. Reviewers</text>
<text top="342" left="747" width="55" height="15" font="2">’ RWI in-</text>
<text top="362" left="468" width="333" height="12" font="2">formation was distributed to the writing committee and is</text>
<text top="380" left="468" width="169" height="12" font="2">published in this document (</text>
<text top="380" left="637" width="66" height="12" font="4"><a href="e71.full.html#51">Appendix 2</a></text>
<text top="380" left="703" width="8" height="12" font="2">).</text>
<text top="398" left="483" width="318" height="12" font="2">This document was approved for publication by the</text>
<text top="415" left="468" width="333" height="12" font="2">governing bodies of the ACC and the AHA and endorsed</text>
<text top="433" left="468" width="333" height="12" font="2">by the American Association of Cardiovascular and Pul-</text>
<text top="451" left="468" width="333" height="12" font="2">monary Rehabilitation, Inter-Society Consensus for the</text>
<text top="469" left="468" width="333" height="12" font="2">Management of Peripheral Arterial Disease, Society for</text>
<text top="487" left="468" width="333" height="12" font="2">Cardiovascular Angiography and Interventions, Society</text>
<text top="505" left="468" width="333" height="12" font="2">for Clinical Vascular Surgery, Society of Interventional</text>
<text top="523" left="468" width="333" height="12" font="2">Radiology, Society for Vascular Medicine, Society for</text>
<text top="541" left="468" width="333" height="12" font="2">Vascular Nursing, Society for Vascular Surgery, and</text>
<text top="559" left="468" width="255" height="12" font="2">Vascular and Endovascular Surgery Society.</text>
<text top="591" left="468" width="123" height="11" font="12">1.4. Scope of Guideline</text>
<text top="613" left="468" width="333" height="12" font="2">Lower extremity PAD is a common cardiovascular disease</text>
<text top="631" left="468" width="333" height="12" font="2">that is estimated to affect approximately 8.5 million</text>
<text top="648" left="468" width="333" height="12" font="2">Americans above the age of 40 years and is associated</text>
<text top="666" left="468" width="60" height="12" font="2">with signi</text>
<text top="665" left="529" width="273" height="15" font="2">ﬁcant morbidity, mortality, and QoL impair-</text>
<text top="684" left="468" width="30" height="12" font="2">ment</text>
<text top="684" left="502" width="21" height="12" font="4"><a href="e71.full.html#39">(18)</a></text>
<text top="684" left="524" width="277" height="12" font="2"><a href="e71.full.html#39">. </a>It has been estimated that 202 million people</text>
<text top="702" left="468" width="119" height="12" font="2">worldwide have PAD</text>
<text top="702" left="590" width="21" height="12" font="4"><a href="e71.full.html#39">(19)</a></text>
<text top="702" left="611" width="190" height="12" font="2">. The purpose of this document is</text>
<text top="720" left="468" width="333" height="12" font="2">to provide a contemporary guideline for diagnosis and</text>
<text top="738" left="468" width="333" height="12" font="2">management of patients with lower extremity PAD. This</text>
<text top="756" left="468" width="333" height="12" font="2">document supersedes recommendations related to lower</text>
<text top="774" left="468" width="124" height="12" font="2">extremity PAD in the</text>
<text top="772" left="597" width="204" height="15" font="2">“ACC/AHA 2005 Guidelines for the</text>
<text top="792" left="468" width="327" height="12" font="2">Management of Patients With Peripheral Arterial Disease</text>
<text top="790" left="795" width="6" height="15" font="2">”</text>
<text top="810" left="468" width="15" height="12" font="4"><a href="e71.full.html#39">(9)</a></text>
<text top="810" left="491" width="48" height="12" font="2">and the</text>
<text top="808" left="548" width="253" height="15" font="2">“2011 ACCF/AHA Focused Update of the</text>
<text top="828" left="468" width="333" height="12" font="2">Guideline for the Management of Patients With Peripheral</text>
<text top="846" left="468" width="83" height="12" font="2">Artery Disease</text>
<text top="844" left="551" width="6" height="15" font="2">”</text>
<text top="846" left="561" width="21" height="12" font="4"><a href="e71.full.html#39">(10)</a></text>
<text top="846" left="582" width="219" height="12" font="2">. The scope of this guideline is limited</text>
<text top="864" left="468" width="333" height="12" font="2">to atherosclerotic disease of the lower extremity arteries</text>
<text top="882" left="468" width="333" height="12" font="2">(PAD) and includes disease of the aortoiliac, femo-</text>
<text top="900" left="468" width="333" height="12" font="2">ropopliteal, and infrapopliteal arterial segments. It does</text>
<text top="917" left="468" width="333" height="12" font="2">not address nonatherosclerotic causes of lower extremity</text>
<text top="935" left="468" width="41" height="12" font="2">arterial</text>
<text top="935" left="523" width="46" height="12" font="2">disease,</text>
<text top="935" left="583" width="27" height="12" font="2">such</text>
<text top="935" left="623" width="12" height="12" font="2">as</text>
<text top="935" left="649" width="58" height="12" font="2">vasculitis,</text>
<text top="934" left="721" width="80" height="15" font="2">ﬁbromuscular</text>
<text top="953" left="468" width="333" height="12" font="2">dysplasia, physiological entrapment syndromes, cystic</text>
<text top="971" left="468" width="333" height="12" font="2">adventitial disease, and other entities. Future guidelines</text>
<text top="989" left="468" width="333" height="12" font="2">will address aneurysmal disease of the abdominal aorta</text>
<text top="1007" left="468" width="333" height="12" font="2">and lower extremity arteries and diseases of the renal and</text>
<text top="1025" left="468" width="115" height="12" font="2">mesenteric arteries.</text>
<text top="1043" left="483" width="108" height="12" font="2">In developing the</text>
<text top="1041" left="598" width="203" height="15" font="2">“2016 AHA/ACC Guideline on the</text>
<text top="1061" left="468" width="333" height="12" font="2">Management of Patients With Lower Extremity Peripheral</text>
<text top="1079" left="468" width="92" height="12" font="2">Artery Disease,</text>
<text top="1077" left="560" width="241" height="15" font="2">” the writing committee reviewed the</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="15" height="9" font="5">e76</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="17" size="7" family="Times" color="#0e2a52"/>
	<fontspec id="18" size="7" family="Times" color="#327eb1"/>
	<fontspec id="19" size="4" family="Times" color="#000000"/>
<text top="668" left="63" width="333" height="12" font="2">evidence to support recommendations in the relevant</text>
<text top="686" left="63" width="181" height="12" font="2">ACC/AHA guidelines noted in</text>
<text top="686" left="251" width="44" height="11" font="4"><a href="e71.full.html#7">Table 2</a></text>
<text top="686" left="302" width="39" height="12" font="2">and af</text>
<text top="684" left="341" width="55" height="15" font="2">ﬁrms the</text>
<text top="704" left="63" width="333" height="12" font="2">ongoing validity of the related recommendations, thus</text>
<text top="722" left="63" width="54" height="12" font="2">obviating</text>
<text top="722" left="131" width="19" height="12" font="2">the</text>
<text top="722" left="164" width="28" height="12" font="2">need</text>
<text top="722" left="206" width="11" height="12" font="2">to</text>
<text top="722" left="232" width="36" height="12" font="2">repeat</text>
<text top="722" left="282" width="46" height="12" font="2">existing</text>
<text top="722" left="342" width="54" height="12" font="2">guideline</text>
<text top="668" left="423" width="257" height="12" font="2">recommendations in the current guideline.</text>
<text top="668" left="686" width="42" height="11" font="4"><a href="e71.full.html#7">Table 2</a></text>
<text top="668" left="734" width="23" height="12" font="2">also</text>
<text top="686" left="423" width="333" height="12" font="2">contains a list of other statements that may be of interest</text>
<text top="704" left="423" width="83" height="12" font="2">to the reader.</text>
<text top="704" left="512" width="43" height="11" font="4"><a href="e71.full.html#7">Table 3</a></text>
<text top="704" left="561" width="69" height="12" font="2">includes de</text>
<text top="702" left="630" width="127" height="15" font="2">ﬁnitions for PAD key</text>
<text top="722" left="423" width="219" height="12" font="2">terms used throughout the guideline.</text>
<text top="149" left="71" width="47" height="10" font="15">T A B L E 2</text>
<text top="149" left="135" width="142" height="10" font="16">Important Guideline Policy</text>
<text top="185" left="63" width="21" height="9" font="13">Title</text>
<text top="185" left="575" width="59" height="9" font="13">Organization</text>
<text top="173" left="678" width="76" height="9" font="13">Publication Year</text>
<text top="185" left="689" width="55" height="9" font="13">(Reference)</text>
<text top="204" left="63" width="347" height="9" font="17">ACC/AHA Guideline policy relevant to the management of lower extremity PAD</text>
<text top="224" left="63" width="324" height="9" font="13">Duration of dual antiplatelet therapy in patients with coronary artery disease</text>
<text top="224" left="575" width="39" height="9" font="13">ACC/AHA</text>
<text top="224" left="695" width="21" height="9" font="13">2016</text>
<text top="224" left="719" width="18" height="9" font="18"><a href="e71.full.html#39">(20)</a></text>
<text top="243" left="63" width="420" height="9" font="13">Perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery</text>
<text top="243" left="575" width="39" height="9" font="13">ACC/AHA</text>
<text top="243" left="696" width="21" height="9" font="13">2014</text>
<text top="243" left="720" width="16" height="9" font="18"><a href="e71.full.html#39">(21)</a></text>
<text top="262" left="63" width="215" height="9" font="13">Lifestyle management to reduce cardiovascular risk</text>
<text top="262" left="575" width="39" height="9" font="13">AHA/ACC</text>
<text top="262" left="696" width="20" height="9" font="13">2013</text>
<text top="262" left="719" width="17" height="9" font="18"><a href="e71.full.html#39">(22)</a></text>
<text top="281" left="63" width="140" height="9" font="13">Assessment of cardiovascular risk</text>
<text top="281" left="575" width="39" height="9" font="13">ACC/AHA</text>
<text top="281" left="696" width="20" height="9" font="13">2013</text>
<text top="281" left="719" width="17" height="9" font="18"><a href="e71.full.html#40">(23)</a></text>
<text top="300" left="63" width="300" height="9" font="13">Blood cholesterol to reduce atherosclerotic cardiovascular risk in adults</text>
<text top="300" left="575" width="39" height="9" font="13">ACC/AHA</text>
<text top="300" left="696" width="20" height="9" font="13">2013</text>
<text top="300" left="719" width="17" height="9" font="18"><a href="e71.full.html#40">(24)</a></text>
<text top="320" left="63" width="265" height="9" font="13">PAD (lower extremity, renal, mesenteric, and abdominal aortic)</text>
<text top="320" left="575" width="39" height="9" font="13">ACC/AHA</text>
<text top="320" left="693" width="23" height="9" font="13">2005</text>
<text top="320" left="718" width="12" height="9" font="18"><a href="e71.full.html#39">(9)</a></text>
<text top="320" left="734" width="15" height="9" font="13">and</text>
<text top="332" left="697" width="19" height="9" font="13">2011</text>
<text top="332" left="719" width="17" height="9" font="18"><a href="e71.full.html#39">(10)</a></text>
<text top="351" left="63" width="496" height="9" font="13">Secondary prevention and risk-reduction therapy for patients with coronary and other atherosclerotic vascular disease</text>
<text top="351" left="575" width="39" height="9" font="13">AHA/ACC</text>
<text top="351" left="697" width="19" height="9" font="13">2011</text>
<text top="351" left="719" width="17" height="9" font="18"><a href="e71.full.html#40">(25)</a></text>
<text top="374" left="63" width="114" height="9" font="17">Other related publications</text>
<text top="394" left="63" width="283" height="9" font="13">Atherosclerotic occlusive disease of the lower extremities guideline</text>
<text top="394" left="575" width="16" height="9" font="13">SVS</text>
<text top="394" left="696" width="20" height="9" font="13">2015</text>
<text top="394" left="719" width="18" height="9" font="18"><a href="e71.full.html#40">(26)</a></text>
<text top="413" left="63" width="251" height="9" font="13">Measurement and interpretation of the ankle-brachial index</text>
<text top="413" left="575" width="18" height="9" font="13">AHA</text>
<text top="413" left="696" width="20" height="9" font="13">2012</text>
<text top="413" left="720" width="16" height="9" font="18"><a href="e71.full.html#40">(27)</a></text>
<text top="432" left="63" width="400" height="9" font="13">Cardiac disease evaluation and management among kidney and liver transplantation candidates</text>
<text top="432" left="575" width="39" height="9" font="13">AHA/ACC</text>
<text top="432" left="696" width="20" height="9" font="13">2012</text>
<text top="432" left="719" width="18" height="9" font="18"><a href="e71.full.html#40">(28)</a></text>
<text top="451" left="63" width="298" height="9" font="13">Intensive glycemic control and the prevention of cardiovascular events</text>
<text top="451" left="575" width="61" height="9" font="13">ADA/ACC/AHA</text>
<text top="451" left="694" width="24" height="9" font="13">2009</text>
<text top="451" left="721" width="18" height="9" font="18"><a href="e71.full.html#40">(29)</a></text>
<text top="470" left="63" width="8" height="9" font="13">In</text>
<text top="469" left="71" width="295" height="12" font="13">ﬂuenza vaccination as secondary prevention for cardiovascular disease</text>
<text top="470" left="575" width="39" height="9" font="13">AHA/ACC</text>
<text top="470" left="694" width="24" height="9" font="13">2006</text>
<text top="470" left="720" width="18" height="9" font="18"><a href="e71.full.html#40">(30)</a></text>
<text top="490" left="63" width="303" height="9" font="13">Indications for renal arteriography at the time of coronary arteriography</text>
<text top="490" left="575" width="48" height="9" font="13">AHA/CLCD/</text>
<text top="502" left="590" width="47" height="9" font="13">CVRI/KCVD</text>
<text top="490" left="695" width="24" height="9" font="13">2006</text>
<text top="490" left="722" width="15" height="9" font="18"><a href="e71.full.html#40">(31)</a></text>
<text top="521" left="63" width="428" height="9" font="13">Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment</text>
<text top="533" left="78" width="131" height="9" font="13">of High Blood Pressure (JNC <a href="e71.full.html#7">7)</a></text>
<text top="533" left="208" width="4" height="9" font="18"><a href="e71.full.html#7">*</a></text>
<text top="521" left="575" width="26" height="9" font="13">NHLBI</text>
<text top="521" left="695" width="23" height="9" font="13">2003</text>
<text top="521" left="721" width="17" height="9" font="18"><a href="e71.full.html#40">(32)</a></text>
<text top="557" left="63" width="470" height="8" font="5">*A revision to the current document is being prepared, with publication expected in 2017. The new title is expected to be</text>
<text top="555" left="536" width="221" height="11" font="5">“ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/</text>
<text top="568" left="63" width="385" height="8" font="5">PCNA Guideline for the Detection, Evaluation, Prevention and Management of High Blood Pressure.</text>
<text top="567" left="448" width="4" height="11" font="5">”</text>
<text top="583" left="71" width="686" height="8" font="5">AAPA indicates American Academy of Physician Assistants; ABC, Association of Black Cardiologists; ACC, American College of Cardiology; ACPM, American College of Preventive</text>
<text top="595" left="63" width="694" height="8" font="5">Medicine; ADA, American Diabetes Association; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASH, American Society of</text>
<text top="607" left="63" width="694" height="8" font="5">Hypertension; ASPC, American Society for Preventive Cardiology; CLCD, Council on Clinical Cardiology; CVRI, Council on Cardiovascular Radiology and Intervention; KCVD, Council on</text>
<text top="619" left="63" width="694" height="8" font="5">the Kidney in Cardiovascular Disease; NHLBI, National Heart, Lung, and Blood Institute; NMA, National Medical Association; PAD, peripheral artery disease; PCNA, Preventive Car-</text>
<text top="630" left="63" width="271" height="8" font="5">diovascular Nurses Association; and SVS, Society for Vascular Surgery.</text>
<text top="762" left="71" width="47" height="10" font="15">T A B L E 3</text>
<text top="762" left="135" width="13" height="10" font="16">De</text>
<text top="761" left="148" width="138" height="14" font="16">ﬁnition of PAD Key Terms</text>
<text top="787" left="63" width="24" height="9" font="13">Term</text>
<text top="787" left="477" width="12" height="9" font="13">De</text>
<text top="785" left="489" width="33" height="12" font="13">ﬁnition</text>
<text top="806" left="63" width="51" height="9" font="13">Claudication</text>
<text top="806" left="243" width="513" height="9" font="13">Fatigue, discomfort, cramping, or pain of vascular origin in the muscles of the lower extremities that is consistently induced</text>
<text top="818" left="258" width="256" height="9" font="13">by exercise and consistently relieved by rest (within 10 min).</text>
<text top="837" left="63" width="107" height="9" font="13">Acute limb ischemia (ALI)</text>
<text top="837" left="243" width="30" height="9" font="13">Acute (</text>
<text top="835" left="273" width="484" height="12" font="13">&lt;2 wk), severe hypoperfusion of the limb characterized by these features: pain, pallor, pulselessness, poikilothermia</text>
<text top="849" left="258" width="144" height="9" font="13">(cold), paresthesias, and paralysis.</text>
<text top="860" left="243" width="6" height="10" font="7">n</text>
<text top="861" left="258" width="192" height="9" font="13">One of these categories of ALI is assigned <a href="e71.full.html#33">(</a></text>
<text top="861" left="450" width="46" height="9" font="18"><a href="e71.full.html#33">Section 10</a></text>
<text top="861" left="497" width="6" height="9" font="13"><a href="e71.full.html#33">):</a></text>
<text top="873" left="264" width="37" height="9" font="13">I. Viable</text>
<text top="871" left="301" width="455" height="12" font="13">—Limb is not immediately threatened; no sensory loss; no muscle weakness; audible arterial and venous</text>
<text top="885" left="274" width="38" height="9" font="13">Doppler.</text>
<text top="897" left="261" width="63" height="9" font="13">II. Threatened</text>
<text top="895" left="324" width="432" height="12" font="13">—Mild-to-moderate sensory or motor loss; inaudible arterial Doppler; audible venous Doppler; may</text>
<text top="909" left="274" width="368" height="9" font="13">be further divided into IIa (marginally threatened) or IIb (immediately threatened).</text>
<text top="921" left="258" width="66" height="9" font="13">III. Irreversible</text>
<text top="919" left="324" width="413" height="12" font="13">—Major tissue loss or permanent nerve damage inevitable; profound sensory loss, anesthetic;</text>
<text top="933" left="274" width="377" height="9" font="13">profound muscle weakness or paralysis (rigor); inaudible arterial and venous Doppler</text>
<text top="933" left="654" width="31" height="9" font="18"><a href="e71.full.html#40">(33,34)</a></text>
<text top="933" left="686" width="3" height="9" font="13">.</text>
<text top="952" left="63" width="45" height="9" font="13">Tissue loss</text>
<text top="952" left="243" width="81" height="9" font="13">Type of tissue loss:</text>
<text top="963" left="243" width="6" height="10" font="7">n</text>
<text top="964" left="258" width="25" height="9" font="13">Minor</text>
<text top="962" left="283" width="280" height="12" font="13">—nonhealing ulcer, focal gangrene with diffuse pedal ischemia.</text>
<text top="975" left="243" width="6" height="10" font="7">n</text>
<text top="976" left="258" width="24" height="9" font="13">Major</text>
<text top="974" left="282" width="350" height="12" font="13">—extending above transmetatarsal level; functional foot no longer salvageable</text>
<text top="976" left="636" width="17" height="9" font="18"><a href="e71.full.html#40">(33)</a></text>
<text top="976" left="653" width="3" height="9" font="13">.</text>
<text top="993" left="63" width="111" height="9" font="13">Critical limb ischemia (CLI)</text>
<text top="993" left="243" width="159" height="9" font="13">A condition characterized by chronic (</text>
<text top="992" left="402" width="348" height="12" font="13">$2 wk) ischemic rest pain, nonhealing wound/ulcers, or gangrene in 1 or both legs</text>
<text top="1005" left="258" width="251" height="9" font="13">attributable to objectively proven arterial occlusive disease.</text>
<text top="1017" left="243" width="6" height="10" font="7">n</text>
<text top="1017" left="258" width="499" height="9" font="13">The diagnosis of CLI is a constellation of both symptoms and signs. Arterial disease can be proved objectively with</text>
<text top="1029" left="258" width="64" height="9" font="13">ABI, TBI, TcPO</text>
<text top="1033" left="322" width="4" height="6" font="19">2</text>
<text top="1029" left="326" width="431" height="9" font="13">, or skin perfusion pressure. Supplementary parameters, such as absolute ankle and toe pressures</text>
<text top="1041" left="258" width="286" height="9" font="13">and pulse volume recordings, may also be used to assess for signi</text>
<text top="1040" left="544" width="212" height="12" font="13">ﬁcant arterial occlusive disease. However, a very</text>
<text top="1053" left="258" width="470" height="9" font="13">low ABI or TBI does not necessarily mean the patient has CLI. The term CLI implies chronicity and is to be</text>
<text top="1065" left="258" width="100" height="9" font="13">distinguished from ALI</text>
<text top="1065" left="361" width="17" height="9" font="18"><a href="e71.full.html#40">(35)</a></text>
<text top="1065" left="379" width="3" height="9" font="13"><a href="e71.full.html#40">.</a></text>
<text top="1086" left="651" width="105" height="8" font="5">Continued on the next page</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="794" width="14" height="9" font="5">e77</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="20" size="5" family="Times" color="#999999"/>
	<fontspec id="21" size="3" family="Times" color="#000000"/>
<text top="148" left="116" width="47" height="10" font="15">T A B L E 3</text>
<text top="148" left="179" width="53" height="10" font="16">Continued</text>
<text top="171" left="108" width="22" height="9" font="13">Term</text>
<text top="171" left="522" width="12" height="9" font="13">De</text>
<text top="170" left="534" width="33" height="12" font="13">ﬁnition</text>
<text top="191" left="108" width="54" height="9" font="13">In-line blood</text>
<text top="189" left="164" width="18" height="12" font="13">ﬂow</text>
<text top="191" left="288" width="57" height="9" font="13">Direct arterial</text>
<text top="189" left="348" width="162" height="12" font="13">ﬂow to the foot, excluding collaterals.</text>
<text top="210" left="108" width="72" height="9" font="13">Functional status</text>
<text top="210" left="288" width="30" height="9" font="13">Patient</text>
<text top="208" left="318" width="484" height="12" font="13">’s ability to perform normal daily activities required to meet basic needs, fulﬁll usual roles, and maintain health and</text>
<text top="222" left="303" width="267" height="9" font="13">well-being. Walking ability is a component of functional status.</text>
<text top="241" left="108" width="63" height="9" font="13">Nonviable limb</text>
<text top="241" left="288" width="513" height="9" font="13">Condition of extremity (or portion of extremity) in which loss of motor function, neurological function, and tissue integrity</text>
<text top="253" left="303" width="148" height="9" font="13">cannot be restored with treatment.</text>
<text top="272" left="108" width="71" height="9" font="13">Salvageable limb</text>
<text top="272" left="288" width="513" height="9" font="13">Condition of extremity with potential to secure viability and preserve motor function to the weight-bearing portion of the</text>
<text top="284" left="303" width="62" height="9" font="13">foot if treated.</text>
<text top="303" left="108" width="119" height="9" font="13">Structured exercise program</text>
<text top="303" left="288" width="502" height="9" font="13">Planned program that provides individualized recommendations for type, frequency, intensity, and duration of exercise.</text>
<text top="314" left="288" width="6" height="10" font="7">n</text>
<text top="315" left="302" width="499" height="9" font="13">Program provides recommendations for exercise progression to assure that the body is consistently challenged to</text>
<text top="327" left="302" width="345" height="9" font="13">increase exercise intensity and levels as functional status improves over time.</text>
<text top="338" left="288" width="6" height="10" font="7">n</text>
<text top="339" left="302" width="319" height="9" font="13">There are 2 types of structured exercise program for patients with PAD:</text>
<text top="351" left="304" width="138" height="9" font="13">1. Supervised exercise program</text>
<text top="363" left="303" width="264" height="9" font="13">2. Structured community- or home-based exercise program</text>
<text top="382" left="108" width="120" height="9" font="13">Supervised exercise program</text>
<text top="382" left="288" width="513" height="9" font="13">Structured exercise program that takes place in a hospital or outpatient facility in which intermittent walking exercise is used</text>
<text top="394" left="303" width="112" height="9" font="13">as the treatment modality.</text>
<text top="405" left="288" width="6" height="10" font="7">n</text>
<text top="406" left="302" width="412" height="9" font="13">Program can be standalone or can be made available within a cardiac rehabilitation program.</text>
<text top="417" left="288" width="6" height="10" font="7">n</text>
<text top="418" left="302" width="172" height="9" font="13">Program is directly supervised by quali</text>
<text top="416" left="475" width="120" height="12" font="13">ﬁed healthcare provider(s).</text>
<text top="429" left="288" width="6" height="10" font="7">n</text>
<text top="430" left="302" width="499" height="9" font="13">Training is performed for a minimum of 30 to 45 min per session, in sessions performed at least 3 times/wk for a</text>
<text top="442" left="302" width="79" height="9" font="13">minimum of 12 wk</text>
<text top="442" left="384" width="15" height="9" font="18"><a href="e71.full.html#40">(36</a></text>
<text top="440" left="399" width="20" height="12" font="18"><a href="e71.full.html#40">–46)</a></text>
<text top="442" left="419" width="382" height="9" font="13">. Patients may not initially achieve these targets, and a treatment goal is to progress to</text>
<text top="454" left="302" width="101" height="9" font="13">these levels over time.</text>
<text top="465" left="288" width="6" height="10" font="7">n</text>
<text top="466" left="302" width="499" height="9" font="13">Training involves intermittent bouts of walking to moderate-to-maximum claudication, alternating with periods of</text>
<text top="478" left="302" width="20" height="9" font="13">rest.</text>
<text top="489" left="288" width="6" height="10" font="7">n</text>
<text top="490" left="302" width="344" height="9" font="13">Warm-up and cool-down periods precede and follow each session of walking.</text>
<text top="509" left="108" width="163" height="9" font="13">Structured community- or home-based</text>
<text top="521" left="123" width="72" height="9" font="13">exercise program</text>
<text top="509" left="288" width="466" height="9" font="13">Structured exercise program that takes place in the personal setting of the patient rather than in a clinical setting</text>
<text top="509" left="756" width="26" height="9" font="18"><a href="e71.full.html#40">(41,47</a></text>
<text top="507" left="782" width="16" height="12" font="18"><a href="e71.full.html#40">–51)</a></text>
<text top="509" left="799" width="3" height="9" font="13"><a href="e71.full.html#40">.</a></text>
<text top="520" left="288" width="6" height="10" font="7">n</text>
<text top="521" left="302" width="496" height="9" font="13">Program is self-directed with the guidance of healthcare providers who prescribe an exercise regimen similar to</text>
<text top="533" left="302" width="131" height="9" font="13">that of a supervised program.</text>
<text top="544" left="288" width="6" height="10" font="7">n</text>
<text top="545" left="302" width="499" height="9" font="13">Patient counseling ensures that patients understand how to begin the program, how to maintain the program, and</text>
<text top="557" left="302" width="104" height="9" font="13">how to progress the dif</text>
<text top="555" left="407" width="247" height="12" font="13">ﬁculty of the walking (by increasing distance or speed).</text>
<text top="568" left="288" width="6" height="10" font="7">n</text>
<text top="569" left="302" width="471" height="9" font="13">Program may incorporate behavioral change techniques, such as health coaching and/or use of activity</text>
<text top="581" left="302" width="42" height="9" font="13">monitors.</text>
<text top="600" left="108" width="106" height="9" font="13">Emergency versus urgent</text>
<text top="599" left="288" width="6" height="10" font="7">n</text>
<text top="600" left="302" width="481" height="9" font="13">An emergency procedure is one in which life or limb is threatened if the patient is not in the operating room</text>
<text top="612" left="302" width="471" height="9" font="13">or interventional suite and/or where there is time for no or very limited clinical evaluation, typically within</text>
<text top="610" left="777" width="24" height="12" font="13">&lt;6 h.</text>
<text top="623" left="288" width="6" height="10" font="7">n</text>
<text top="624" left="302" width="491" height="9" font="13">An urgent procedure is one in which there may be time for a limited clinical evaluation, usually when life or</text>
<text top="636" left="302" width="467" height="9" font="13">limb is threatened if the patient is not in the operating room or interventional suite, typically between</text>
<text top="648" left="302" width="53" height="9" font="13">6 and 24 h.</text>
<text top="667" left="108" width="111" height="9" font="13">Interdisciplinary care team</text>
<text top="667" left="288" width="509" height="9" font="13">A team of professionals representing different disciplines to assist in the evaluation and management of the patient with</text>
<text top="679" left="303" width="20" height="9" font="13">PAD.</text>
<text top="690" left="288" width="6" height="10" font="7">n</text>
<text top="691" left="302" width="484" height="9" font="13">For the care of patients with CLI, the interdisciplinary care team should include individuals who are skilled in</text>
<text top="703" left="302" width="499" height="9" font="13">endovascular revascularization, surgical revascularization, wound healing therapies and foot surgery, and medical</text>
<text top="715" left="302" width="89" height="9" font="13">evaluation and care.</text>
<text top="726" left="288" width="6" height="10" font="7">n</text>
<text top="727" left="302" width="220" height="9" font="13">Interdisciplinary care team members may include:</text>
<text top="738" left="310" width="6" height="10" font="20">n</text>
<text top="739" left="325" width="477" height="9" font="13">Vascular medical and surgical specialists (i.e., vascular medicine, vascular surgery, interventional radiology,</text>
<text top="751" left="325" width="114" height="9" font="13">interventional cardiology)</text>
<text top="762" left="310" width="6" height="10" font="20">n</text>
<text top="763" left="325" width="30" height="9" font="13">Nurses</text>
<text top="774" left="310" width="6" height="10" font="20">n</text>
<text top="775" left="325" width="160" height="9" font="13">Orthopedic surgeons and podiatrists</text>
<text top="786" left="310" width="6" height="10" font="20">n</text>
<text top="787" left="325" width="73" height="9" font="13">Endocrinologists</text>
<text top="798" left="310" width="6" height="10" font="20">n</text>
<text top="799" left="325" width="125" height="9" font="13">Internal medicine specialists</text>
<text top="810" left="310" width="6" height="10" font="20">n</text>
<text top="810" left="325" width="127" height="9" font="13">Infectious disease specialists</text>
<text top="822" left="310" width="6" height="10" font="20">n</text>
<text top="822" left="325" width="188" height="9" font="13">Radiology and vascular imaging specialists</text>
<text top="834" left="310" width="6" height="10" font="20">n</text>
<text top="834" left="325" width="202" height="9" font="13">Physical medicine and rehabilitation clinicians</text>
<text top="846" left="310" width="6" height="10" font="20">n</text>
<text top="846" left="325" width="160" height="9" font="13">Orthotics and prosthetics specialists</text>
<text top="857" left="310" width="6" height="10" font="20">n</text>
<text top="858" left="325" width="63" height="9" font="13">Social workers</text>
<text top="869" left="310" width="6" height="10" font="20">n</text>
<text top="870" left="325" width="97" height="9" font="13">Exercise physiologists</text>
<text top="881" left="310" width="6" height="10" font="20">n</text>
<text top="882" left="325" width="161" height="9" font="13">Physical and occupational therapists</text>
<text top="893" left="310" width="6" height="10" font="20">n</text>
<text top="894" left="325" width="100" height="9" font="13">Nutritionists/dieticians</text>
<text top="913" left="108" width="129" height="9" font="13">Cardiovascular ischemic events</text>
<text top="913" left="288" width="362" height="9" font="13">Acute coronary syndrome (acute MI, unstable angina), stroke, or cardiovascular death.</text>
<text top="933" left="108" width="84" height="9" font="13">Limb-related events</text>
<text top="933" left="288" width="427" height="9" font="13">Worsening claudication, new CLI, new lower extremity revascularization, or new ischemic amputation.</text>
<text top="956" left="108" width="688" height="8" font="5">ABI indicates ankle-brachial index; ALI, acute limb ischemia; CLI, critical limb ischemia; MI, myocardial infarction; PAD, peripheral artery disease; TBI, toe-brachial index; and TcPO</text>
<text top="960" left="795" width="3" height="6" font="21">2</text>
<text top="956" left="799" width="2" height="8" font="5">,</text>
<text top="968" left="108" width="126" height="8" font="5">transcutaneous oxygen pressure.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="15" height="9" font="5">e78</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="22" size="9" family="Times" color="#ffffff"/>
	<fontspec id="23" size="6" family="Times" color="#0e2a52"/>
<text top="141" left="63" width="240" height="16" font="14">2. CLINICAL ASSESSMENT FOR PAD</text>
<text top="178" left="63" width="333" height="12" font="2">Evaluating the patient for PAD begins with the clinical</text>
<text top="196" left="63" width="329" height="12" font="2">history, review of symptoms, and physical examination.</text>
<text top="227" left="63" width="304" height="11" font="12">2.1. History and Physical Examination: Recommendations</text>
<text top="264" left="63" width="313" height="11" font="22">Recommendations for History and Physical Examination</text>
<text top="305" left="89" width="19" height="10" font="13">COR</text>
<text top="305" left="161" width="18" height="10" font="13">LOE</text>
<text top="305" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="342" left="97" width="3" height="9" font="5">I</text>
<text top="342" left="160" width="21" height="9" font="5">B-NR</text>
<text top="329" left="233" width="173" height="11" font="12">Patients at increased risk of PAD (</text>
<text top="329" left="406" width="38" height="11" font="4"><a href="e71.full.html#10">Table 4</a></text>
<text top="329" left="444" width="337" height="11" font="12"><a href="e71.full.html#10">) </a>should undergo a comprehensive medical history and a review of</text>
<text top="345" left="233" width="574" height="11" font="12">symptoms to assess for exertional leg symptoms, including claudication or other walking impairment, ischemic rest</text>
<text top="360" left="233" width="148" height="11" font="12">pain, and nonhealing wounds</text>
<text top="360" left="385" width="16" height="11" font="4"><a href="e71.full.html#40">(52</a></text>
<text top="358" left="401" width="21" height="15" font="4"><a href="e71.full.html#40">–57)</a></text>
<text top="360" left="422" width="3" height="11" font="12"><a href="e71.full.html#40">.</a></text>
<text top="385" left="75" width="13" height="8" font="23">See</text>
<text top="385" left="91" width="100" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 1</a></text>
<text top="385" left="192" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="383" left="233" width="574" height="11" font="2">The symptoms and signs of PAD are variable. Patients with PAD may experience the classic symptom of claudication</text>
<text top="399" left="233" width="574" height="11" font="2">or may present with advanced disease, including CLI. Studies have demonstrated that the majority of patients with</text>
<text top="415" left="233" width="18" height="11" font="2">con</text>
<text top="413" left="251" width="505" height="15" font="2">ﬁrmed PAD do not have typical claudication but have other non–joint-related limb symptoms or are</text>
<text top="430" left="233" width="70" height="11" font="2">asymptomatic</text>
<text top="430" left="307" width="35" height="11" font="4"><a href="e71.full.html#40">(53,55)</a></text>
<text top="430" left="342" width="449" height="11" font="2">. Atypical lower extremity symptoms related to PAD may include pain or discomfort that</text>
<text top="446" left="233" width="574" height="11" font="2">begins at rest but worsens with exertion, pain or discomfort that does not stop an individual from walking, and pain</text>
<text top="462" left="233" width="429" height="11" font="2">or discomfort that begins with exertion but is not alleviated within 10 minutes of rest</text>
<text top="462" left="665" width="21" height="11" font="4"><a href="e71.full.html#40">(54)</a></text>
<text top="462" left="686" width="121" height="11" font="2"><a href="e71.full.html#40">. </a>Patients with PAD who</text>
<text top="477" left="233" width="574" height="11" font="2">do not have typical claudication but have other leg symptoms, or who are asymptomatic, have been shown to have</text>
<text top="493" left="233" width="321" height="11" font="2">functional impairment comparable to patients with claudication</text>
<text top="493" left="558" width="21" height="11" font="4"><a href="e71.full.html#40">(54)</a></text>
<text top="493" left="578" width="218" height="11" font="2">. Thus, all patients at increased risk of PAD</text>
<text top="509" left="233" width="404" height="11" font="2">should be asked not only about claudication but also about other exertional non</text>
<text top="507" left="637" width="170" height="15" font="2">–joint-related limb symptoms and</text>
<text top="524" left="233" width="154" height="11" font="2">perceived walking impairment.</text>
<text top="569" left="97" width="3" height="9" font="5">I</text>
<text top="569" left="160" width="21" height="9" font="5">B-NR</text>
<text top="556" left="233" width="173" height="11" font="12">Patients at increased risk of PAD (</text>
<text top="556" left="406" width="38" height="11" font="4"><a href="e71.full.html#10">Table 4</a></text>
<text top="556" left="444" width="344" height="11" font="12"><a href="e71.full.html#10">) </a>should undergo vascular examination, including palpation of lower</text>
<text top="572" left="233" width="570" height="11" font="12">extremity pulses (i.e., femoral, popliteal, dorsalis pedis, and posterior tibial), auscultation for femoral bruits, and</text>
<text top="587" left="233" width="155" height="11" font="12">inspection of the legs and feet</text>
<text top="587" left="392" width="53" height="11" font="4"><a href="e71.full.html#40">(56,58,59)</a></text>
<text top="587" left="446" width="3" height="11" font="12"><a href="e71.full.html#40">.</a></text>
<text top="614" left="63" width="13" height="8" font="23">See</text>
<text top="614" left="78" width="125" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 1 and 2</a></text>
<text top="614" left="204" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="612" left="233" width="529" height="11" font="2">A thorough lower extremity vascular examination and careful inspection of the legs and feet are important</text>
<text top="627" left="233" width="574" height="11" font="2">components of the clinical assessment for PAD. To perform a thorough examination, legs and feet are examined with</text>
<text top="643" left="233" width="338" height="11" font="2">lower garments (pants/skirt, shoes, and socks) removed. Examination</text>
<text top="641" left="573" width="193" height="15" font="2">ﬁndings suggestive of PAD are shown in</text>
<text top="643" left="768" width="36" height="11" font="4"><a href="e71.full.html#10">Table 5</a></text>
<text top="643" left="804" width="3" height="11" font="2"><a href="e71.full.html#10">.</a></text>
<text top="659" left="233" width="574" height="11" font="2">Lower extremity pulses should be assessed and rated as follows: 0, absent; 1, diminished; 2, normal; or 3, bounding.</text>
<text top="674" left="233" width="557" height="11" font="2">Reproducibility of pulse assessment is better for detection of normal versus absent pulse than for normal versus</text>
<text top="690" left="233" width="83" height="11" font="2">diminished pulse</text>
<text top="690" left="319" width="21" height="11" font="4"><a href="e71.full.html#40">(56)</a></text>
<text top="690" left="340" width="467" height="11" font="2"><a href="e71.full.html#40">. </a>Absence of the dorsalis pedis pulse is less accurate for diagnosis of PAD than is absence of the</text>
<text top="706" left="233" width="462" height="11" font="2">posterior tibial pulse because the dorsalis pedis pulse can be absent on examination in a signi</text>
<text top="704" left="695" width="100" height="15" font="2">ﬁcant percentage of</text>
<text top="721" left="233" width="81" height="11" font="2">healthy patients</text>
<text top="721" left="317" width="37" height="11" font="4"><a href="e71.full.html#40">(56,58)</a></text>
<text top="721" left="354" width="223" height="11" font="2">. The presence of multiple abnormal physical</text>
<text top="719" left="580" width="212" height="15" font="2">ﬁndings (i.e., multiple pulse abnormalities,</text>
<text top="737" left="233" width="182" height="11" font="2">bruits) increases the likelihood of con</text>
<text top="735" left="415" width="56" height="15" font="2">ﬁrmed PAD</text>
<text top="737" left="473" width="53" height="11" font="4"><a href="e71.full.html#40">(56,58,59)</a></text>
<text top="737" left="527" width="96" height="11" font="2"><a href="e71.full.html#40">. </a>Abnormal physical</text>
<text top="735" left="625" width="182" height="15" font="2">ﬁndings, such as a pulse abnormality,</text>
<text top="753" left="233" width="55" height="11" font="2">require con</text>
<text top="751" left="288" width="519" height="15" font="2">ﬁrmation with the ankle-brachial index (ABI) to establish the diagnosis of PAD. Similarly, an entirely normal</text>
<text top="769" left="233" width="356" height="11" font="2">pulse examination and absence of bruits decreases the likelihood of con</text>
<text top="767" left="589" width="57" height="15" font="2">ﬁrmed PAD</text>
<text top="769" left="649" width="37" height="11" font="4"><a href="e71.full.html#40">(56,58)</a></text>
<text top="769" left="686" width="85" height="11" font="2">. The presence of</text>
<text top="784" left="233" width="561" height="11" font="2">nonhealing lower extremity wounds may be a sign of CLI. Findings of cool or discolored skin and delayed capillary re</text>
<text top="782" left="794" width="13" height="15" font="2">ﬁll</text>
<text top="800" left="233" width="163" height="11" font="2">are not reliable for PAD diagnosis</text>
<text top="800" left="398" width="21" height="11" font="4"><a href="e71.full.html#40">(56)</a></text>
<text top="800" left="419" width="38" height="11" font="2"><a href="e71.full.html#40">. </a>To con</text>
<text top="798" left="457" width="350" height="15" font="2">ﬁrm the diagnosis of PAD, abnormal physical examination ﬁndings must</text>
<text top="816" left="233" width="33" height="11" font="2">be con</text>
<text top="814" left="266" width="156" height="15" font="2">ﬁrmed with diagnostic testing (</text>
<text top="816" left="422" width="46" height="11" font="4"><a href="e71.full.html#10">Section 3</a></text>
<text top="816" left="468" width="210" height="11" font="2"><a href="e71.full.html#10">), </a>generally with the ABI as the initial test.</text>
<text top="860" left="97" width="3" height="9" font="5">I</text>
<text top="860" left="160" width="21" height="9" font="5">B-NR</text>
<text top="848" left="233" width="574" height="11" font="12">Patients with PAD should undergo noninvasive blood pressure measurement in both arms at least once during the</text>
<text top="863" left="233" width="88" height="11" font="12">initial assessment</text>
<text top="863" left="325" width="19" height="11" font="4"><a href="e71.full.html#40">(60</a></text>
<text top="861" left="344" width="22" height="15" font="4"><a href="e71.full.html#40">–62)</a></text>
<text top="863" left="366" width="3" height="11" font="12"><a href="e71.full.html#40">.</a></text>
<text top="890" left="76" width="13" height="8" font="23">See</text>
<text top="890" left="92" width="100" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 1</a></text>
<text top="888" left="233" width="211" height="11" font="2">An inter-arm blood pressure difference of</text>
<text top="885" left="448" width="321" height="15" font="2">&gt;15 to 20 mm Hg is abnormal and suggestive of subclavian (or</text>
<text top="903" left="233" width="487" height="11" font="2">innominate) artery stenosis. Patients with PAD are at increased risk of subclavian artery stenosis</text>
<text top="903" left="724" width="19" height="11" font="4"><a href="e71.full.html#40">(60</a></text>
<text top="901" left="742" width="22" height="15" font="4"><a href="e71.full.html#40">–62)</a></text>
<text top="903" left="764" width="3" height="11" font="2">.</text>
<text top="919" left="233" width="230" height="11" font="2">Measuring blood pressure in both arms identi</text>
<text top="917" left="463" width="329" height="15" font="2">ﬁes the arm with the highest systolic pressure, a requirement for</text>
<text top="935" left="233" width="169" height="11" font="2">accurate measurement of the ABI</text>
<text top="935" left="406" width="20" height="11" font="4"><a href="e71.full.html#40">(27)</a></text>
<text top="935" left="426" width="35" height="11" font="2"><a href="e71.full.html#40">. </a>Identi</text>
<text top="933" left="461" width="346" height="15" font="2">ﬁcation of unequal blood pressures in the arms also allows for more</text>
<text top="950" left="233" width="574" height="11" font="2">accurate measurement of blood pressure in the treatment of hypertension (i.e., blood pressure is taken at the arm</text>
<text top="966" left="233" width="396" height="11" font="2">with higher measurements). Although a difference in arm systolic pressures of</text>
<text top="964" left="633" width="139" height="15" font="2">&gt;15 to 20 mm Hg suggests</text>
<text top="982" left="233" width="560" height="11" font="2">subclavian (or innominate) artery stenosis, in the absence of symptoms (e.g., arm claudication or symptoms of</text>
<text top="997" left="233" width="360" height="11" font="2">vertebral artery steal), no further imaging or intervention is warranted.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="793" width="15" height="9" font="5">e79</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1160" width="864">
<text top="560" left="108" width="332" height="16" font="14">3. DIAGNOSTIC TESTING FOR THE PATIENT WITH</text>
<text top="578" left="108" width="249" height="16" font="14">SUSPECTED LOWER EXTREMITY PAD</text>
<text top="596" left="108" width="167" height="16" font="14">(CLAUDICATION OR CLI)</text>
<text top="634" left="108" width="297" height="11" font="12">3.1. Resting ABI for Diagnosing PAD: Recommendations</text>
<text top="313" left="116" width="47" height="10" font="15">T A B L E 5</text>
<text top="313" left="179" width="344" height="10" font="16">History and/or Physical Examination Findings Suggestive of PAD</text>
<text top="337" left="108" width="37" height="11" font="2">History</text>
<text top="350" left="108" width="6" height="10" font="7">n</text>
<text top="349" left="122" width="65" height="11" font="2">Claudication</text>
<text top="362" left="108" width="6" height="10" font="7">n</text>
<text top="361" left="122" width="53" height="11" font="2">Other non</text>
<text top="359" left="176" width="427" height="15" font="2">–joint-related exertional lower extremity symptoms (not typical of claudication)</text>
<text top="374" left="108" width="6" height="10" font="7">n</text>
<text top="373" left="122" width="138" height="11" font="2">Impaired walking function</text>
<text top="386" left="108" width="6" height="10" font="7">n</text>
<text top="385" left="122" width="96" height="11" font="2">Ischemic rest pain</text>
<text top="408" left="108" width="108" height="11" font="2">Physical Examination</text>
<text top="421" left="108" width="6" height="10" font="7">n</text>
<text top="420" left="122" width="239" height="11" font="2">Abnormal lower extremity pulse examination</text>
<text top="433" left="108" width="6" height="10" font="7">n</text>
<text top="432" left="122" width="73" height="11" font="2">Vascular bruit</text>
<text top="445" left="108" width="6" height="10" font="7">n</text>
<text top="444" left="122" width="187" height="11" font="2">Nonhealing lower extremity wound</text>
<text top="457" left="108" width="6" height="10" font="7">n</text>
<text top="456" left="122" width="140" height="11" font="2">Lower extremity gangrene</text>
<text top="469" left="108" width="6" height="10" font="7">n</text>
<text top="468" left="122" width="225" height="11" font="2">Other suggestive lower extremity physical</text>
<text top="466" left="351" width="259" height="15" font="2">ﬁndings (e.g., elevation pallor/dependent rubor)</text>
<text top="493" left="108" width="153" height="8" font="5">PAD indicates peripheral artery disease.</text>
<text top="149" left="115" width="48" height="10" font="15">T A B L E 4</text>
<text top="149" left="179" width="179" height="10" font="16">Patients at Increased Risk of PAD</text>
<text top="170" left="108" width="6" height="10" font="7">n</text>
<text top="170" left="122" width="20" height="11" font="2">Age</text>
<text top="168" left="146" width="32" height="15" font="2">$65 y</text>
<text top="182" left="108" width="6" height="10" font="7">n</text>
<text top="182" left="122" width="38" height="11" font="2">Age 50</text>
<text top="180" left="161" width="639" height="15" font="2">–64 y, with risk factors for atherosclerosis (e.g., diabetes mellitus, history of smoking, hyperlipidemia, hypertension) or</text>
<text top="197" left="122" width="114" height="11" font="2">family history of PAD</text>
<text top="197" left="240" width="22" height="11" font="4"><a href="e71.full.html#40">(63)</a></text>
<text top="210" left="108" width="6" height="10" font="7">n</text>
<text top="209" left="122" width="20" height="11" font="2">Age</text>
<text top="207" left="146" width="407" height="15" font="2">&lt;50 y, with diabetes mellitus and 1 additional risk factor for atherosclerosis</text>
<text top="222" left="108" width="6" height="10" font="7">n</text>
<text top="221" left="122" width="664" height="11" font="2">Individuals with known atherosclerotic disease in another vascular bed (e.g., coronary, carotid, subclavian, renal, mesenteric</text>
<text top="237" left="122" width="127" height="11" font="2">artery stenosis, or AAA)</text>
<text top="262" left="108" width="284" height="8" font="5">AAA indicates abdominal aortic aneurysm; PAD, peripheral artery disease.</text>
<text top="675" left="57" width="305" height="11" font="22">Recommendations for Resting ABI for Diagnosing PAD</text>
<text top="716" left="83" width="19" height="10" font="13">COR</text>
<text top="716" left="156" width="18" height="10" font="13">LOE</text>
<text top="716" left="227" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="753" left="92" width="3" height="9" font="5">I</text>
<text top="753" left="154" width="21" height="9" font="5">B-NR</text>
<text top="740" left="227" width="240" height="11" font="12">In patients with history or physical examination</text>
<text top="738" left="471" width="144" height="15" font="12">ﬁndings suggestive of PAD <a href="e71.full.html#10">(</a></text>
<text top="740" left="614" width="37" height="11" font="4"><a href="e71.full.html#10">Table 5</a></text>
<text top="740" left="652" width="129" height="11" font="12"><a href="e71.full.html#10">), </a>the resting ABI, with or</text>
<text top="755" left="227" width="448" height="11" font="12">without segmental pressures and waveforms, is recommended to establish the diagnosis</text>
<text top="755" left="679" width="18" height="11" font="4"><a href="e71.full.html#40">(64</a></text>
<text top="753" left="697" width="23" height="15" font="4"><a href="e71.full.html#40">–69)</a></text>
<text top="755" left="720" width="3" height="11" font="12"><a href="e71.full.html#40">.</a></text>
<text top="781" left="68" width="13" height="8" font="23">See</text>
<text top="781" left="85" width="102" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 4</a></text>
<text top="781" left="187" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="779" left="227" width="574" height="11" font="2">The resting ABI is obtained by measuring systolic blood pressures at the arms (brachial arteries) and ankles (dorsalis</text>
<text top="794" left="227" width="574" height="11" font="2">pedis and posterior tibial arteries) in the supine position by using a Doppler device. The ABI of each leg is calculated</text>
<text top="810" left="227" width="574" height="11" font="2">by dividing the higher of the dorsalis pedis or posterior tibial pressure by the higher of the right or left arm blood</text>
<text top="826" left="227" width="42" height="11" font="2">pressure</text>
<text top="826" left="273" width="20" height="11" font="4"><a href="e71.full.html#40">(27)</a></text>
<text top="826" left="293" width="508" height="11" font="2">. In patients with a history or physical examination suggestive of PAD, the ABI has good validity as a</text>
<text top="839" left="227" width="574" height="15" font="2">ﬁrst-line test in the diagnosis of PAD, as shown by vascular imaging, with sensitivities ranging from 68% to 84%</text>
<text top="857" left="227" width="47" height="11" font="2">and speci</text>
<text top="855" left="275" width="131" height="15" font="2">ﬁcities from 84% to 99%</text>
<text top="857" left="409" width="18" height="11" font="4"><a href="e71.full.html#40">(64</a></text>
<text top="855" left="427" width="23" height="15" font="4"><a href="e71.full.html#40">–69)</a></text>
<text top="857" left="450" width="307" height="11" font="2"><a href="e71.full.html#40">. </a>Segmental lower extremity blood pressures and Doppler or</text>
<text top="873" left="227" width="574" height="11" font="2">plethysmographic waveforms (pulse volume recordings) can be used to localize anatomic segments of disease (e.g.,</text>
<text top="888" left="227" width="211" height="11" font="2">aortoiliac, femoropopliteal, infrapopliteal)</text>
<text top="888" left="442" width="51" height="11" font="4"><a href="e71.full.html#40">(34,70,71)</a></text>
<text top="888" left="493" width="3" height="11" font="2"><a href="e71.full.html#40">.</a></text>
<text top="933" left="92" width="3" height="9" font="5">I</text>
<text top="933" left="155" width="20" height="9" font="5">C-LD</text>
<text top="920" left="227" width="277" height="11" font="12">Resting ABI results should be reported as abnormal (ABI</text>
<text top="918" left="507" width="294" height="15" font="12">£0.90), borderline (ABI 0.91–0.99), normal (1.00–1.40), or</text>
<text top="936" left="227" width="109" height="11" font="12">noncompressible (ABI</text>
<text top="934" left="340" width="32" height="15" font="12">&gt;1.40)</text>
<text top="936" left="376" width="32" height="11" font="4"><a href="e71.full.html#40">(27,67</a></text>
<text top="934" left="408" width="38" height="15" font="4"><a href="e71.full.html#40">–69,72)</a></text>
<text top="936" left="446" width="3" height="11" font="12"><a href="e71.full.html#40">.</a></text>
<text top="962" left="68" width="13" height="8" font="23">See</text>
<text top="962" left="85" width="102" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 4</a></text>
<text top="962" left="187" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="960" left="227" width="557" height="11" font="2">Standardized reporting improves communication among healthcare providers. Calculated ABI values should be</text>
<text top="976" left="227" width="240" height="11" font="2">recorded to 2 decimal places. Patients with ABI</text>
<text top="974" left="471" width="159" height="15" font="2">#0.90 are diagnosed with PAD</text>
<text top="976" left="634" width="17" height="11" font="4"><a href="e71.full.html#41">(67</a></text>
<text top="974" left="650" width="23" height="15" font="4"><a href="e71.full.html#41">–69)</a></text>
<text top="976" left="673" width="124" height="11" font="2">. Those with ABI 0.91 to</text>
<text top="992" left="227" width="496" height="11" font="2">0.99 may possibly have PAD and should undergo exercise ABI, if the clinical suspicion of PAD is signi</text>
<text top="990" left="724" width="35" height="15" font="2">ﬁcant <a href="e71.full.html#10">(</a></text>
<text top="992" left="758" width="43" height="11" font="4"><a href="e71.full.html#10">Tables 4</a></text>
<text top="1007" left="227" width="18" height="11" font="2">and</text>
<text top="1007" left="249" width="6" height="11" font="4"><a href="e71.full.html#10">5</a></text>
<text top="1007" left="256" width="4" height="11" font="2"><a href="e71.full.html#10">)</a></text>
<text top="1007" left="263" width="35" height="11" font="4"><a href="e71.full.html#41">(73,74)</a></text>
<text top="1007" left="298" width="40" height="11" font="2">. Values</text>
<text top="1005" left="342" width="450" height="15" font="2">&gt;1.40 indicate that the arteries were not able to be compressed, which is more common</text>
<text top="1023" left="227" width="574" height="11" font="2">among individuals with diabetes mellitus and/or advanced chronic kidney disease. In the setting of noncompressible</text>
<text top="1039" left="227" width="457" height="11" font="2">ABI values, additional imaging can be used to diagnose PAD if the clinical suspicion is signi</text>
<text top="1037" left="685" width="36" height="15" font="2">ﬁcant <a href="e71.full.html#14">(</a></text>
<text top="1039" left="720" width="46" height="11" font="4"><a href="e71.full.html#14">Figures 1</a></text>
<text top="1039" left="769" width="18" height="11" font="2">and</text>
<text top="1039" left="791" width="6" height="11" font="4"><a href="e71.full.html#15">2</a></text>
<text top="1039" left="797" width="4" height="11" font="2">)</text>
<text top="1054" left="227" width="20" height="11" font="4"><a href="e71.full.html#41">(72)</a></text>
<text top="1054" left="247" width="554" height="11" font="2">. These cutpoints for ABI interpretation have been previously proposed and represent a reasonable standardized</text>
<text top="1070" left="227" width="71" height="11" font="2">categorization</text>
<text top="1070" left="302" width="20" height="11" font="4"><a href="e71.full.html#40">(27)</a></text>
<text top="1070" left="322" width="3" height="11" font="2"><a href="e71.full.html#40">.</a></text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="16" height="9" font="5">e80</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1160" width="864">
<text top="685" left="63" width="240" height="11" font="12">3.2. Physiological Testing: Recommendations</text>
<text top="175" left="94" width="10" height="9" font="5">IIa</text>
<text top="175" left="160" width="21" height="9" font="5">B-NR</text>
<text top="162" left="233" width="179" height="11" font="12">In patients at increased risk of PAD <a href="e71.full.html#10">(</a></text>
<text top="162" left="412" width="37" height="11" font="4"><a href="e71.full.html#10">Table 4</a></text>
<text top="162" left="449" width="222" height="11" font="12">) but without history or physical examination</text>
<text top="160" left="674" width="133" height="15" font="12">ﬁndings suggestive of PAD</text>
<text top="178" left="233" width="4" height="11" font="12"><a href="e71.full.html#10">(</a></text>
<text top="178" left="237" width="37" height="11" font="4"><a href="e71.full.html#10">Table 5</a></text>
<text top="178" left="274" width="241" height="11" font="12">), measurement of the resting ABI is reasonable</text>
<text top="178" left="519" width="47" height="11" font="4"><a href="e71.full.html#40">(54,55,75</a></text>
<text top="176" left="567" width="22" height="15" font="4"><a href="e71.full.html#40">–97)</a></text>
<text top="178" left="588" width="3" height="11" font="12">.</text>
<text top="204" left="74" width="13" height="8" font="23">See</text>
<text top="204" left="90" width="105" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 3</a></text>
<text top="215" left="128" width="22" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 4</a></text>
<text top="215" left="151" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="202" left="233" width="574" height="11" font="2">The ABI test is noninvasive, is simple to perform, and has minimal risks, making it suitable for use in asymptomatic</text>
<text top="218" left="233" width="278" height="11" font="2">individuals. Previous studies have demonstrated a signi</text>
<text top="216" left="511" width="248" height="15" font="2">ﬁcant prevalence of abnormal resting ABI among</text>
<text top="234" left="233" width="242" height="11" font="2">asymptomatic patients with risk factors for PAD</text>
<text top="234" left="479" width="52" height="11" font="4"><a href="e71.full.html#40">(55,79,95)</a></text>
<text top="234" left="531" width="41" height="11" font="2">. A signi</text>
<text top="232" left="572" width="215" height="15" font="2">ﬁcant body of evidence demonstrates that</text>
<text top="249" left="233" width="574" height="11" font="2">patients with an abnormal ABI who are asymptomatic have poorer cardiovascular morbidity and mortality outcomes</text>
<text top="265" left="233" width="168" height="11" font="2">than do patients with normal ABI</text>
<text top="265" left="405" width="17" height="11" font="4"><a href="e71.full.html#41">(79</a></text>
<text top="263" left="422" width="22" height="15" font="4"><a href="e71.full.html#41">–87)</a></text>
<text top="265" left="444" width="355" height="11" font="2"><a href="e71.full.html#41">. </a>While there is no conclusive evidence that aspirin treatment changes</text>
<text top="281" left="233" width="567" height="11" font="2">cardiovascular or limb outcomes in this population, in 1 cohort study of 5,480 patients with asymptomatic PAD,</text>
<text top="296" left="233" width="260" height="11" font="2">statin treatment improved cardiovascular outcomes</text>
<text top="296" left="497" width="16" height="11" font="4"><a href="e71.full.html#41">(75</a></text>
<text top="294" left="513" width="39" height="15" font="4"><a href="e71.full.html#41">–78,96)</a></text>
<text top="296" left="551" width="3" height="11" font="2">.</text>
<text top="312" left="248" width="559" height="11" font="2">There is also evidence that asymptomatic patients with a low resting ABI have a poorer functional status and a</text>
<text top="328" left="233" width="360" height="11" font="2">more rapid rate of functional decline than do patients with a normal ABI</text>
<text top="328" left="596" width="34" height="11" font="4"><a href="e71.full.html#40">(54,88</a></text>
<text top="326" left="630" width="22" height="15" font="4"><a href="e71.full.html#40">–92)</a></text>
<text top="328" left="652" width="155" height="11" font="2"><a href="e71.full.html#40">. </a>Although physical activity has</text>
<text top="344" left="233" width="511" height="11" font="2">been shown to be associated with improvement in functional status in patients with asymptomatic PAD</text>
<text top="344" left="747" width="38" height="11" font="4"><a href="e71.full.html#41">(93,94)</a></text>
<text top="344" left="785" width="22" height="11" font="2"><a href="e71.full.html#41">, </a>the</text>
<text top="359" left="233" width="24" height="11" font="2">bene</text>
<text top="357" left="258" width="549" height="15" font="2">ﬁt of resting ABI testing to identify asymptomatic patients who are at increased risk of functional decline and</text>
<text top="375" left="233" width="49" height="11" font="2">may bene</text>
<text top="373" left="282" width="326" height="15" font="2">ﬁt from structured exercise programs remains to be determined.</text>
<text top="419" left="71" width="47" height="9" font="5">III: No Bene</text>
<text top="418" left="118" width="9" height="12" font="5">ﬁt</text>
<text top="419" left="160" width="21" height="9" font="5">B-NR</text>
<text top="407" left="233" width="200" height="11" font="12">In patients not at increased risk of PAD <a href="e71.full.html#10">(</a></text>
<text top="407" left="433" width="37" height="11" font="4"><a href="e71.full.html#10">Table 4</a></text>
<text top="407" left="470" width="224" height="11" font="12">) and without history or physical examination</text>
<text top="405" left="698" width="109" height="15" font="12">ﬁndings suggestive of</text>
<text top="422" left="233" width="29" height="11" font="12">PAD <a href="e71.full.html#10">(</a></text>
<text top="422" left="262" width="37" height="11" font="4"><a href="e71.full.html#10">Table 5</a></text>
<text top="422" left="299" width="155" height="11" font="12">), the ABI is not recommended</text>
<text top="422" left="458" width="38" height="11" font="4"><a href="e71.full.html#41">(95,98)</a></text>
<text top="422" left="496" width="3" height="11" font="12">.</text>
<text top="449" left="74" width="13" height="8" font="23">See</text>
<text top="449" left="90" width="102" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 4</a></text>
<text top="449" left="192" width="2" height="8" font="23">.</text>
<text top="447" left="233" width="472" height="11" font="2">The prevalence of PAD among individuals without risk factors for atherosclerosis and who are</text>
<text top="445" left="709" width="98" height="15" font="2">&lt;50 years of age is</text>
<text top="463" left="233" width="549" height="11" font="2">low. Data from population-based cohort studies have demonstrated a low prevalence (approximately 1%) of</text>
<text top="478" left="233" width="201" height="11" font="2">abnormal resting ABI among individuals</text>
<text top="476" left="437" width="88" height="15" font="2">&lt;50 years of age</text>
<text top="478" left="529" width="38" height="11" font="4"><a href="e71.full.html#41">(95,98)</a></text>
<text top="478" left="567" width="240" height="11" font="2">. In the NHANES (National Health and Nutrition</text>
<text top="494" left="233" width="574" height="11" font="2">Study), approximately 95% of participants with an abnormal resting ABI had at least 1 risk factor for atherosclerosis</text>
<text top="510" left="233" width="21" height="11" font="4"><a href="e71.full.html#41">(95)</a></text>
<text top="510" left="254" width="552" height="11" font="2">. The yield of ABI testing among younger, asymptomatic individuals without risk factors for atherosclerosis is</text>
<text top="525" left="233" width="319" height="11" font="2">low, and these patients should not be routinely tested for PAD</text>
<text top="525" left="556" width="38" height="11" font="4"><a href="e71.full.html#41">(95,98)</a></text>
<text top="525" left="594" width="3" height="11" font="2">.</text>
<text top="726" left="63" width="245" height="11" font="22">Recommendations for Physiological Testing</text>
<text top="766" left="89" width="19" height="10" font="13">COR</text>
<text top="766" left="161" width="18" height="10" font="13">LOE</text>
<text top="766" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="803" left="97" width="3" height="9" font="5">I</text>
<text top="803" left="160" width="21" height="9" font="5">B-NR</text>
<text top="791" left="233" width="574" height="11" font="12">Toe-brachial index (TBI) should be measured to diagnose patients with suspected PAD when the ABI is greater than</text>
<text top="806" left="233" width="22" height="11" font="12">1.40</text>
<text top="806" left="259" width="33" height="11" font="4"><a href="e71.full.html#41">(72,99</a></text>
<text top="804" left="292" width="27" height="15" font="4"><a href="e71.full.html#41">–102)</a></text>
<text top="806" left="319" width="3" height="11" font="12">.</text>
<text top="831" left="74" width="13" height="8" font="23">See</text>
<text top="831" left="91" width="101" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 5</a></text>
<text top="831" left="192" width="2" height="8" font="23">.</text>
<text top="829" left="233" width="574" height="11" font="2">TBI is a noninvasive test that is useful to evaluate for PAD in patents with noncompressible arteries, which cause an</text>
<text top="845" left="233" width="17" height="11" font="2">arti</text>
<text top="843" left="250" width="126" height="15" font="2">ﬁcial elevation of the ABI</text>
<text top="845" left="379" width="88" height="11" font="4"><a href="e71.full.html#41">(99,100,102,103)</a></text>
<text top="845" left="467" width="33" height="11" font="2"><a href="e71.full.html#41">. </a>A TBI</text>
<text top="843" left="502" width="305" height="15" font="2">#0.70 is abnormal and diagnostic of PAD because the digital</text>
<text top="861" left="233" width="177" height="11" font="2">arteries are rarely noncompressible</text>
<text top="861" left="414" width="18" height="11" font="4"><a href="e71.full.html#41">(99</a></text>
<text top="859" left="432" width="71" height="15" font="4"><a href="e71.full.html#41">–102,104,105)</a></text>
<text top="861" left="503" width="231" height="11" font="2"><a href="e71.full.html#41">. </a>Patients with longstanding diabetes mellitus</text>
<text top="861" left="738" width="40" height="11" font="4"><a href="e71.full.html#41">(72,101)</a></text>
<text top="861" left="782" width="10" height="11" font="2">or</text>
<text top="876" left="233" width="163" height="11" font="2">advanced chronic kidney disease</text>
<text top="876" left="400" width="27" height="11" font="4"><a href="e71.full.html#41">(106)</a></text>
<text top="876" left="431" width="331" height="11" font="2">have a high incidence of noncompressible arteries. Therefore, TBI</text>
<text top="892" left="233" width="567" height="11" font="2">assessment allows for the diagnosis of PAD in these patients with noncompressible arteries who have history or</text>
<text top="908" left="233" width="105" height="11" font="2">physical examination</text>
<text top="906" left="342" width="143" height="15" font="2">ﬁndings suggestive of PAD (</text>
<text top="908" left="485" width="41" height="11" font="4"><a href="e71.full.html#14">Figure 1</a></text>
<text top="908" left="526" width="7" height="11" font="2"><a href="e71.full.html#14">).</a></text>
<text top="952" left="97" width="3" height="9" font="5">I</text>
<text top="952" left="160" width="21" height="9" font="5">B-NR</text>
<text top="940" left="233" width="142" height="11" font="12">Patients with exertional non</text>
<text top="938" left="376" width="429" height="15" font="12">–joint-related leg symptoms and normal or borderline resting ABI (&gt;0.90 and £1.40)</text>
<text top="955" left="233" width="334" height="11" font="12">should undergo exercise treadmill ABI testing to evaluate for PAD</text>
<text top="955" left="571" width="51" height="11" font="4"><a href="e71.full.html#41">(71,74,107</a></text>
<text top="953" left="622" width="26" height="15" font="4"><a href="e71.full.html#41">–110)</a></text>
<text top="955" left="648" width="3" height="11" font="12">.</text>
<text top="982" left="74" width="13" height="8" font="23">See</text>
<text top="982" left="91" width="102" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 5</a></text>
<text top="982" left="192" width="2" height="8" font="23">.</text>
<text top="980" left="233" width="533" height="11" font="2">Exercise treadmill ABI testing is important to objectively measure symptom limitations and diagnose PAD</text>
<text top="995" left="233" width="51" height="11" font="4"><a href="e71.full.html#41">(71,74,107</a></text>
<text top="993" left="284" width="26" height="15" font="4"><a href="e71.full.html#41">–110)</a></text>
<text top="995" left="310" width="497" height="11" font="2">. It is useful in establishing the diagnosis of lower extremity PAD in the symptomatic patient when</text>
<text top="1011" left="233" width="574" height="11" font="2">resting ABIs are normal or borderline and to differentiate claudication from pseudoclaudication in individuals with</text>
<text top="1027" left="233" width="574" height="11" font="2">exertional leg symptoms. If the post-exercise treadmill ABI is normal, alternative causes of leg pain are considered</text>
<text top="1043" left="233" width="4" height="11" font="2"><a href="e71.full.html#13">(</a></text>
<text top="1043" left="237" width="39" height="11" font="4"><a href="e71.full.html#13">Table 6</a></text>
<text top="1043" left="276" width="250" height="11" font="2"><a href="e71.full.html#13">). </a>If a treadmill is not available, the pedal plantar</text>
<text top="1041" left="526" width="278" height="15" font="2">ﬂexion ABI test is a reasonable alternative because the</text>
<text top="1058" left="233" width="214" height="11" font="2">results correlate well with treadmill ABIs (</text>
<text top="1058" left="448" width="41" height="11" font="4"><a href="e71.full.html#14">Figure 1</a></text>
<text top="1058" left="488" width="4" height="11" font="2">)</text>
<text top="1058" left="496" width="22" height="11" font="4"><a href="e71.full.html#41">(111)</a></text>
<text top="1058" left="518" width="3" height="11" font="2">.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="794" width="14" height="9" font="5">e81</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="24" size="5" family="Times" color="#0e2a52"/>
<text top="175" left="88" width="10" height="9" font="5">IIa</text>
<text top="175" left="154" width="21" height="9" font="5">B-NR</text>
<text top="162" left="227" width="249" height="11" font="12">In patients with PAD and an abnormal resting ABI (</text>
<text top="160" left="477" width="324" height="15" font="12">£0.90), exercise treadmill ABI testing can be useful to objectively</text>
<text top="178" left="227" width="119" height="11" font="12">assess functional status</text>
<text top="178" left="350" width="51" height="11" font="4"><a href="e71.full.html#41">(71,74,107</a></text>
<text top="176" left="401" width="26" height="15" font="4"><a href="e71.full.html#41">–110)</a></text>
<text top="178" left="427" width="3" height="11" font="12">.</text>
<text top="204" left="69" width="13" height="8" font="23">See</text>
<text top="204" left="85" width="102" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 5</a></text>
<text top="204" left="186" width="2" height="8" font="23">.</text>
<text top="202" left="227" width="563" height="11" font="2">In patients with PAD, exercise treadmill ABI testing can objectively assess symptoms, measure change in ABI in</text>
<text top="218" left="227" width="246" height="11" font="2">response to exercise, and assess functional status</text>
<text top="218" left="477" width="51" height="11" font="4"><a href="e71.full.html#41">(71,74,107</a></text>
<text top="216" left="528" width="26" height="15" font="4"><a href="e71.full.html#41">–110)</a></text>
<text top="218" left="557" width="4" height="11" font="2">(</text>
<text top="218" left="561" width="40" height="11" font="4"><a href="e71.full.html#14">Figure 1</a></text>
<text top="218" left="601" width="200" height="11" font="2"><a href="e71.full.html#14">). </a>It can be useful to correlate exertional</text>
<text top="234" left="227" width="574" height="11" font="2">lower extremity symptoms to a decline in ABI after treadmill exercise. Exercise treadmill ABI testing can document</text>
<text top="249" left="227" width="567" height="11" font="2">the magnitude of symptom limitation in patients with PAD and provide objective data that can demonstrate the</text>
<text top="265" left="227" width="574" height="11" font="2">safety of exercise and help to individualize exercise prescriptions in patients with PAD before initiation of a formal</text>
<text top="281" left="227" width="550" height="11" font="2">program of structured exercise training. Exercise ABI may also be used to objectively measure the functional</text>
<text top="296" left="227" width="574" height="11" font="2">improvement obtained in response to claudication treatment (e.g., structured exercise program or revascularization).</text>
<text top="312" left="227" width="574" height="11" font="2">Administration of a 6-minute walk test in a corridor is a reasonable alternative to treadmill ABI testing for assessment</text>
<text top="328" left="227" width="97" height="11" font="2">of functional status</text>
<text top="328" left="327" width="21" height="11" font="4"><a href="e71.full.html#40">(54)</a></text>
<text top="328" left="348" width="3" height="11" font="2">.</text>
<text top="372" left="88" width="10" height="9" font="5">IIa</text>
<text top="372" left="154" width="21" height="9" font="5">B-NR</text>
<text top="360" left="227" width="145" height="11" font="12">In patients with normal (1.00</text>
<text top="358" left="372" width="429" height="15" font="12">–1.40) or borderline (0.91–0.99) ABI in the setting of nonhealing wounds or gangrene,</text>
<text top="375" left="227" width="511" height="11" font="12">it is reasonable to diagnose CLI by using TBI with waveforms, transcutaneous oxygen pressure (TcPO</text>
<text top="380" left="739" width="5" height="7" font="24">2</text>
<text top="375" left="743" width="44" height="11" font="12">), or skin</text>
<text top="390" left="227" width="123" height="11" font="12">perfusion pressure (SPP)</text>
<text top="390" left="355" width="19" height="11" font="4"><a href="e71.full.html#41">(112</a></text>
<text top="388" left="374" width="25" height="15" font="4"><a href="e71.full.html#41">–116)</a></text>
<text top="390" left="399" width="3" height="11" font="12">.</text>
<text top="417" left="69" width="13" height="8" font="23">See</text>
<text top="417" left="85" width="102" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 5</a></text>
<text top="417" left="186" width="2" height="8" font="23">.</text>
<text top="415" left="227" width="574" height="11" font="2">The toe pressure and TBI may be discordant with the ABI 0.90 to 1.40 in some patients with diabetes mellitus and a</text>
<text top="431" left="227" width="101" height="11" font="2">nonhealing wound <a href="e71.full.html#15">(</a></text>
<text top="431" left="328" width="42" height="11" font="4"><a href="e71.full.html#15">Figure 2</a></text>
<text top="431" left="370" width="4" height="11" font="2">)</text>
<text top="431" left="378" width="43" height="11" font="4"><a href="e71.full.html#42">(115,116)</a></text>
<text top="431" left="421" width="34" height="11" font="2"><a href="e71.full.html#42">. </a>A TBI</text>
<text top="429" left="459" width="196" height="15" font="2">#0.70 is considered diagnostic of PAD</text>
<text top="431" left="658" width="69" height="11" font="4"><a href="e71.full.html#41">(101,104,105)</a></text>
<text top="431" left="727" width="61" height="11" font="2"><a href="e71.full.html#41">. </a>Doppler or</text>
<text top="446" left="227" width="559" height="11" font="2">plethysmographic waveforms taken at the toe supplement the toe pressure and TBI measurement and may be</text>
<text top="462" left="227" width="509" height="11" font="2">severely dampened in the setting of CLI. The likelihood of wound healing decreases with toe pressure</text>
<text top="460" left="739" width="62" height="15" font="2">&lt;30 mm Hg</text>
<text top="478" left="227" width="28" height="11" font="4"><a href="e71.full.html#41">(100)</a></text>
<text top="478" left="255" width="328" height="11" font="2">. Perfusion assessment measures (i.e., TBI with waveforms, TcPO</text>
<text top="483" left="583" width="5" height="7" font="7">2</text>
<text top="478" left="588" width="194" height="11" font="2">, SPP) are obtained in a warm room to</text>
<text top="493" left="227" width="315" height="11" font="2">prevent arterial vasoconstriction in response to the cold. TcPO</text>
<text top="498" left="543" width="5" height="7" font="7">2</text>
<text top="493" left="551" width="250" height="11" font="2">measurements are performed with a standardized</text>
<text top="509" left="227" width="200" height="11" font="2">protocol and are taken at multiple sites</text>
<text top="509" left="431" width="23" height="11" font="4"><a href="e71.full.html#42">(117)</a></text>
<text top="509" left="454" width="162" height="11" font="2">. Correlation between TBI, TcPO</text>
<text top="514" left="616" width="5" height="7" font="7">2</text>
<text top="509" left="621" width="144" height="11" font="2">, and SPP has been reported</text>
<text top="509" left="768" width="23" height="11" font="4"><a href="e71.full.html#42">(113)</a></text>
<text top="509" left="792" width="3" height="11" font="2"><a href="e71.full.html#42">.</a></text>
<text top="525" left="227" width="26" height="11" font="2">TcPO</text>
<text top="530" left="253" width="5" height="7" font="7">2</text>
<text top="523" left="261" width="253" height="15" font="2">&gt;30 mm Hg has been used to predict ulcer healing</text>
<text top="525" left="517" width="24" height="11" font="4"><a href="e71.full.html#42">(118)</a></text>
<text top="525" left="541" width="25" height="11" font="2">. SPP</text>
<text top="523" left="569" width="232" height="15" font="2">$30 to 50 mm Hg is associated with increased</text>
<text top="541" left="227" width="140" height="11" font="2">likelihood of wound healing</text>
<text top="541" left="372" width="23" height="11" font="4"><a href="e71.full.html#42">(113)</a></text>
<text top="541" left="395" width="405" height="11" font="2"><a href="e71.full.html#42">. </a>If perfusion measures are normal or only mildly impaired, alternative causes of</text>
<text top="556" left="227" width="199" height="11" font="2">the nonhealing wounds are considered (</text>
<text top="556" left="426" width="37" height="11" font="4"><a href="e71.full.html#13">Table 7</a></text>
<text top="556" left="463" width="36" height="11" font="2"><a href="e71.full.html#13">). </a>TcPO</text>
<text top="561" left="499" width="5" height="7" font="7">2</text>
<text top="556" left="506" width="295" height="11" font="2">and SPP can be used in angiosome-targeted assessment for</text>
<text top="572" left="227" width="84" height="11" font="2">revascularization</text>
<text top="572" left="315" width="24" height="11" font="4"><a href="e71.full.html#42">(119)</a></text>
<text top="572" left="339" width="3" height="11" font="2">.</text>
<text top="616" left="88" width="10" height="9" font="5">IIa</text>
<text top="616" left="154" width="21" height="9" font="5">B-NR</text>
<text top="604" left="227" width="222" height="11" font="12">In patients with PAD with an abnormal ABI (</text>
<text top="602" left="450" width="352" height="15" font="12">£0.90) or with noncompressible arteries (ABI &gt;1.40 and TBI £0.70) in</text>
<text top="619" left="227" width="373" height="11" font="12">the setting of nonhealing wounds or gangrene, TBI with waveforms, TcPO</text>
<text top="624" left="600" width="5" height="7" font="24">2</text>
<text top="619" left="605" width="197" height="11" font="12">, or SPP can be useful to evaluate local</text>
<text top="634" left="227" width="47" height="11" font="12">perfusion</text>
<text top="634" left="278" width="19" height="11" font="4"><a href="e71.full.html#41">(112</a></text>
<text top="632" left="297" width="25" height="15" font="4"><a href="e71.full.html#41">–116)</a></text>
<text top="634" left="323" width="3" height="11" font="12"><a href="e71.full.html#41">.</a></text>
<text top="661" left="69" width="13" height="8" font="23">See</text>
<text top="661" left="85" width="102" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 5</a></text>
<text top="661" left="186" width="2" height="8" font="23">.</text>
<text top="659" left="227" width="325" height="11" font="2">Perfusion assessment measures (e.g., TBI with waveforms, TcPO</text>
<text top="664" left="552" width="5" height="7" font="7">2</text>
<text top="659" left="557" width="244" height="11" font="2">, SPP) can be useful when the ABI is only mildly</text>
<text top="675" left="227" width="115" height="11" font="2">reduced (e.g., ABI 0.70</text>
<text top="673" left="342" width="459" height="15" font="2">–0.90) to determine whether factors other than PAD may be contributing to impaired wound</text>
<text top="691" left="227" width="44" height="11" font="2">healing (</text>
<text top="691" left="272" width="42" height="11" font="4"><a href="e71.full.html#15">Figure 2</a></text>
<text top="691" left="314" width="448" height="11" font="2"><a href="e71.full.html#15">). </a>These perfusion assessment measures are obtained in a warm room to prevent arterial</text>
<text top="706" left="227" width="232" height="11" font="2">vasoconstriction in response to the cold. TcPO</text>
<text top="711" left="459" width="5" height="7" font="7">2</text>
<text top="706" left="467" width="334" height="11" font="2">measurements are performed with a standardized protocol and are</text>
<text top="722" left="227" width="111" height="11" font="2">taken at multiple sites</text>
<text top="722" left="341" width="23" height="11" font="4"><a href="e71.full.html#42">(117)</a></text>
<text top="722" left="364" width="307" height="11" font="2">. The likelihood of wound healing decreases with toe pressure</text>
<text top="720" left="675" width="61" height="15" font="2">&lt;30 mm Hg</text>
<text top="722" left="739" width="28" height="11" font="4"><a href="e71.full.html#41">(100)</a></text>
<text top="722" left="767" width="34" height="11" font="2"><a href="e71.full.html#41">. </a>There</text>
<text top="738" left="227" width="165" height="11" font="2">is correlation between TBI, TcPO</text>
<text top="742" left="393" width="5" height="7" font="7">2</text>
<text top="738" left="397" width="81" height="11" font="2">, and SPP. TcPO</text>
<text top="742" left="478" width="5" height="7" font="7">2</text>
<text top="736" left="486" width="260" height="15" font="2">&gt;30 mm Hg has been used to predict ulcer healing</text>
<text top="738" left="750" width="24" height="11" font="4"><a href="e71.full.html#42">(118)</a></text>
<text top="738" left="774" width="3" height="11" font="2">.</text>
<text top="753" left="227" width="19" height="11" font="2">SPP</text>
<text top="751" left="249" width="373" height="15" font="2">$30 to 50 mm Hg is associated with increased likelihood of wound healing</text>
<text top="753" left="625" width="23" height="11" font="4"><a href="e71.full.html#42">(113)</a></text>
<text top="753" left="648" width="32" height="11" font="2">. TcPO</text>
<text top="758" left="680" width="5" height="7" font="7">2</text>
<text top="753" left="688" width="114" height="11" font="2">and SPP can be used in</text>
<text top="769" left="227" width="266" height="11" font="2">angiosome-targeted assessment for revascularization</text>
<text top="769" left="496" width="24" height="11" font="4"><a href="e71.full.html#42">(119)</a></text>
<text top="769" left="521" width="281" height="11" font="2"><a href="e71.full.html#42">. </a>Additional perfusion assessment may also be useful for</text>
<text top="785" left="227" width="439" height="11" font="2">patients with nonhealing wounds or gangrene who have noncompressible arteries (ABI</text>
<text top="783" left="670" width="117" height="15" font="2">&gt;1.40) but who have a</text>
<text top="800" left="227" width="281" height="11" font="2">diagnosis of PAD that is based on an abnormal TBI (ABI</text>
<text top="798" left="513" width="40" height="15" font="2">#0.70).</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="15" height="9" font="5">e82</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1160" width="864">
<text top="149" left="70" width="48" height="10" font="15">T A B L E 6</text>
<text top="149" left="135" width="559" height="10" font="16">Alternative Diagnoses for Leg Pain or Claudication With Normal Physiological Testing (Not PAD-Related)</text>
<text top="173" left="63" width="44" height="9" font="13">Condition</text>
<text top="173" left="188" width="39" height="9" font="13">Location</text>
<text top="173" left="266" width="64" height="9" font="13">Characteristic</text>
<text top="173" left="347" width="82" height="9" font="13">Effect of Exercise</text>
<text top="173" left="455" width="65" height="9" font="13">Effect of Rest</text>
<text top="173" left="546" width="82" height="9" font="13">Effect of Position</text>
<text top="173" left="650" width="98" height="9" font="13">Other Characteristics</text>
<text top="192" left="63" width="55" height="9" font="13">Symptomatic</text>
<text top="204" left="78" width="23" height="9" font="13">Baker</text>
<text top="203" left="101" width="26" height="12" font="13">’s cyst</text>
<text top="192" left="162" width="54" height="9" font="13">Behind knee,</text>
<text top="204" left="177" width="41" height="9" font="13">down calf</text>
<text top="192" left="262" width="38" height="9" font="13">Swelling,</text>
<text top="204" left="277" width="46" height="9" font="13">tenderness</text>
<text top="192" left="343" width="56" height="9" font="13">With exercise</text>
<text top="192" left="443" width="83" height="9" font="13">Also present at rest</text>
<text top="192" left="542" width="22" height="9" font="13">None</text>
<text top="192" left="642" width="69" height="9" font="13">Not intermittent</text>
<text top="224" left="63" width="83" height="9" font="13">Venous claudication</text>
<text top="224" left="162" width="43" height="9" font="13">Entire leg,</text>
<text top="236" left="177" width="54" height="9" font="13">worse in calf</text>
<text top="224" left="262" width="62" height="9" font="13">Tight, bursting</text>
<text top="236" left="277" width="17" height="9" font="13">pain</text>
<text top="224" left="343" width="56" height="9" font="13">After walking</text>
<text top="224" left="443" width="66" height="9" font="13">Subsides slowly</text>
<text top="224" left="542" width="62" height="9" font="13">Relief speeded</text>
<text top="236" left="557" width="51" height="9" font="13">by elevation</text>
<text top="224" left="642" width="113" height="9" font="13">History of iliofemoral deep</text>
<text top="236" left="657" width="69" height="9" font="13">vein thrombosis;</text>
<text top="248" left="657" width="99" height="9" font="13">edema; signs of venous</text>
<text top="260" left="657" width="23" height="9" font="13">stasis</text>
<text top="279" left="63" width="90" height="9" font="13">Chronic compartment</text>
<text top="291" left="78" width="41" height="9" font="13">syndrome</text>
<text top="279" left="162" width="53" height="9" font="13">Calf muscles</text>
<text top="279" left="262" width="62" height="9" font="13">Tight, bursting</text>
<text top="291" left="277" width="17" height="9" font="13">pain</text>
<text top="279" left="343" width="83" height="9" font="13">After much exercise</text>
<text top="291" left="358" width="38" height="9" font="13">(jogging)</text>
<text top="279" left="443" width="87" height="9" font="13">Subsides very slowly</text>
<text top="279" left="542" width="64" height="9" font="13">Relief with rest</text>
<text top="279" left="642" width="102" height="9" font="13">Typically heavy muscled</text>
<text top="291" left="657" width="34" height="9" font="13">athletes</text>
<text top="310" left="63" width="62" height="9" font="13">Spinal stenosis</text>
<text top="310" left="162" width="61" height="9" font="13">Often bilateral</text>
<text top="322" left="177" width="39" height="9" font="13">buttocks,</text>
<text top="334" left="177" width="53" height="9" font="13">posterior leg</text>
<text top="310" left="262" width="36" height="9" font="13">Pain and</text>
<text top="322" left="277" width="40" height="9" font="13">weakness</text>
<text top="310" left="343" width="45" height="9" font="13">May mimic</text>
<text top="322" left="358" width="50" height="9" font="13">claudication</text>
<text top="310" left="443" width="75" height="9" font="13">Variable relief but</text>
<text top="322" left="458" width="64" height="9" font="13">can take a long</text>
<text top="334" left="458" width="64" height="9" font="13">time to recover</text>
<text top="310" left="542" width="69" height="9" font="13">Relief by lumbar</text>
<text top="322" left="557" width="22" height="9" font="13">spine</text>
<text top="320" left="582" width="28" height="12" font="13">ﬂexion</text>
<text top="310" left="642" width="104" height="9" font="13">Worse with standing and</text>
<text top="322" left="657" width="66" height="9" font="13">extending spine</text>
<text top="353" left="63" width="45" height="9" font="13">Nerve root</text>
<text top="365" left="78" width="52" height="9" font="13">compression</text>
<text top="353" left="162" width="77" height="9" font="13">Radiates down leg</text>
<text top="353" left="262" width="72" height="9" font="13">Sharp lancinating</text>
<text top="365" left="277" width="17" height="9" font="13">pain</text>
<text top="353" left="343" width="78" height="9" font="13">Induced by sitting,</text>
<text top="365" left="358" width="50" height="9" font="13">standing, or</text>
<text top="377" left="358" width="32" height="9" font="13">walking</text>
<text top="353" left="443" width="58" height="9" font="13">Often present</text>
<text top="365" left="458" width="27" height="9" font="13">at rest</text>
<text top="353" left="542" width="53" height="9" font="13">Improved by</text>
<text top="365" left="557" width="75" height="9" font="13">change in position</text>
<text top="353" left="642" width="108" height="9" font="13">History of back problems;</text>
<text top="365" left="657" width="78" height="9" font="13">worse with sitting;</text>
<text top="377" left="657" width="89" height="9" font="13">relief when supine or</text>
<text top="389" left="657" width="26" height="9" font="13">sitting</text>
<text top="408" left="63" width="50" height="9" font="13">Hip arthritis</text>
<text top="408" left="162" width="72" height="9" font="13">Lateral hip, thigh</text>
<text top="408" left="262" width="28" height="9" font="13">Aching</text>
<text top="420" left="277" width="45" height="9" font="13">discomfort</text>
<text top="408" left="343" width="89" height="9" font="13">After variable degree</text>
<text top="420" left="358" width="45" height="9" font="13">of exercise</text>
<text top="408" left="443" width="48" height="9" font="13">Not quickly</text>
<text top="420" left="458" width="33" height="9" font="13">relieved</text>
<text top="408" left="542" width="82" height="9" font="13">Improved when not</text>
<text top="420" left="557" width="63" height="9" font="13">weight bearing</text>
<text top="408" left="642" width="114" height="9" font="13">Symptoms variable; history</text>
<text top="420" left="657" width="100" height="9" font="13">of degenerative arthritis</text>
<text top="439" left="63" width="80" height="9" font="13">Foot/ankle arthritis</text>
<text top="439" left="162" width="70" height="9" font="13">Ankle, foot, arch</text>
<text top="439" left="262" width="49" height="9" font="13">Aching pain</text>
<text top="439" left="343" width="89" height="9" font="13">After variable degree</text>
<text top="451" left="358" width="45" height="9" font="13">of exercise</text>
<text top="439" left="443" width="48" height="9" font="13">Not quickly</text>
<text top="451" left="458" width="33" height="9" font="13">relieved</text>
<text top="439" left="542" width="67" height="9" font="13">May be relieved</text>
<text top="451" left="557" width="27" height="9" font="13">by not</text>
<text top="463" left="557" width="63" height="9" font="13">bearing weight</text>
<text top="439" left="642" width="115" height="9" font="13">Symptoms variable; may be</text>
<text top="451" left="657" width="98" height="9" font="13">related to activity level</text>
<text top="463" left="657" width="73" height="9" font="13">or present at rest</text>
<text top="493" left="69" width="19" height="8" font="5">Modi</text>
<text top="491" left="88" width="102" height="11" font="5">ﬁed from Norgren L, et al.</text>
<text top="493" left="193" width="15" height="8" font="6"><a href="e71.full.html#40">(35)</a></text>
<text top="493" left="208" width="2" height="8" font="5">.</text>
<text top="507" left="81" width="153" height="8" font="5">PAD indicates peripheral artery disease.</text>
<text top="540" left="71" width="47" height="10" font="15">T A B L E 7</text>
<text top="540" left="135" width="536" height="10" font="16">Alternative Diagnoses for Nonhealing Wounds With Normal Physiological Testing (Not PAD-Related)</text>
<text top="564" left="63" width="44" height="9" font="13">Condition</text>
<text top="564" left="251" width="39" height="9" font="13">Location</text>
<text top="564" left="486" width="123" height="9" font="13">Characteristics and Causes</text>
<text top="583" left="63" width="54" height="9" font="13">Venous ulcer</text>
<text top="583" left="208" width="86" height="9" font="13">Distal leg, especially</text>
<text top="595" left="223" width="94" height="9" font="13">above medial mellolus</text>
<text top="582" left="338" width="6" height="10" font="7">n</text>
<text top="583" left="352" width="338" height="9" font="13">Develops in regions of skin changes due to chronic venous disease and local</text>
<text top="595" left="352" width="91" height="9" font="13">venous hypertension</text>
<text top="606" left="338" width="6" height="10" font="7">n</text>
<text top="607" left="352" width="258" height="9" font="13">Typically wet (i.e., wound drainage) rather than dry lesion</text>
<text top="626" left="63" width="123" height="9" font="13">Distal small arterial occlusion</text>
<text top="638" left="78" width="76" height="9" font="13">(microangiopathy)</text>
<text top="626" left="208" width="61" height="9" font="13">Toes, foot, leg</text>
<text top="626" left="338" width="6" height="10" font="7">n</text>
<text top="626" left="352" width="112" height="9" font="13">Diabetic microangiopathy</text>
<text top="638" left="338" width="6" height="10" font="7">n</text>
<text top="638" left="352" width="105" height="9" font="13">End-stage renal disease</text>
<text top="649" left="338" width="6" height="10" font="7">n</text>
<text top="650" left="352" width="160" height="9" font="13">Thromboangiitis obliterans (Buerger</text>
<text top="649" left="512" width="10" height="12" font="13">’s)</text>
<text top="661" left="338" width="6" height="10" font="7">n</text>
<text top="662" left="352" width="78" height="9" font="13">Sickle cell anemia</text>
<text top="673" left="338" width="6" height="10" font="7">n</text>
<text top="674" left="352" width="380" height="9" font="13">Vasculitis (e.g., Churg-Strauss, Henoch-Schonlein purpura, leukocytoclastic vasculitis,</text>
<text top="686" left="352" width="204" height="9" font="13">microscopic polyangiitis, polyarteritis nodosa)</text>
<text top="697" left="338" width="6" height="10" font="7">n</text>
<text top="698" left="352" width="54" height="9" font="13">Scleroderma</text>
<text top="709" left="338" width="6" height="10" font="7">n</text>
<text top="710" left="352" width="79" height="9" font="13">Cryoagglutination</text>
<text top="721" left="338" width="6" height="10" font="7">n</text>
<text top="722" left="352" width="284" height="9" font="13">Embolic (e.g., cholesterol emboli, thromboemboli, endocarditis)</text>
<text top="733" left="338" width="6" height="10" font="7">n</text>
<text top="734" left="352" width="285" height="9" font="13">Thrombotic (e.g., antiphospholipid antibody syndrome, Sneddon</text>
<text top="732" left="638" width="116" height="12" font="13">’s syndrome, warfarin skin</text>
<text top="746" left="352" width="366" height="9" font="13">necrosis, disseminated intravascular coagulation, livedoid vasculitis, protein C or S</text>
<text top="758" left="352" width="11" height="9" font="13">de</text>
<text top="756" left="363" width="138" height="12" font="13">ﬁciency, prolonged vasospasm)</text>
<text top="777" left="63" width="48" height="9" font="13">Local injury</text>
<text top="777" left="208" width="61" height="9" font="13">Toes, foot, leg</text>
<text top="776" left="338" width="6" height="10" font="7">n</text>
<text top="777" left="352" width="32" height="9" font="13">Trauma</text>
<text top="788" left="338" width="6" height="10" font="7">n</text>
<text top="789" left="352" width="91" height="9" font="13">Insect or animal bite</text>
<text top="800" left="338" width="6" height="10" font="7">n</text>
<text top="801" left="352" width="20" height="9" font="13">Burn</text>
<text top="820" left="63" width="78" height="9" font="13">Medication related</text>
<text top="820" left="208" width="61" height="9" font="13">Toes, foot, leg</text>
<text top="819" left="338" width="6" height="10" font="7">n</text>
<text top="820" left="352" width="191" height="9" font="13">Drug reactions (e.g., erythema multiforme)</text>
<text top="831" left="338" width="6" height="10" font="7">n</text>
<text top="832" left="352" width="401" height="9" font="13">Medication direct toxicity (e.g., doxorubicin, hydroxyurea, some tyrosine kinase inhibitors)</text>
<text top="851" left="63" width="51" height="9" font="13">Neuropathic</text>
<text top="851" left="208" width="94" height="9" font="13">Pressure zones of foot</text>
<text top="851" left="338" width="6" height="10" font="7">n</text>
<text top="851" left="352" width="155" height="9" font="13">Hyperkeratosis surrounds the ulcer</text>
<text top="870" left="338" width="6" height="10" font="7">n</text>
<text top="871" left="352" width="200" height="9" font="13">Diabetes mellitus with peripheral neuropathy</text>
<text top="882" left="338" width="6" height="10" font="7">n</text>
<text top="883" left="352" width="214" height="9" font="13">Peripheral neuropathy without diabetes mellitus</text>
<text top="894" left="338" width="6" height="10" font="7">n</text>
<text top="895" left="352" width="34" height="9" font="13">Leprosy</text>
<text top="914" left="63" width="79" height="9" font="13">Autoimmune injury</text>
<text top="914" left="208" width="61" height="9" font="13">Toes, foot, leg</text>
<text top="913" left="338" width="6" height="10" font="7">n</text>
<text top="914" left="352" width="296" height="9" font="13">With blisters (e.g., pemphigoid, pemphigus, epidermolysis bullosa)</text>
<text top="925" left="338" width="6" height="10" font="7">n</text>
<text top="926" left="352" width="266" height="9" font="13">Without blisters (e.g., dermatomyositis, lupus, scleroderma)</text>
<text top="945" left="63" width="37" height="9" font="13">Infection</text>
<text top="945" left="208" width="61" height="9" font="13">Toes, foot, leg</text>
<text top="944" left="338" width="6" height="10" font="7">n</text>
<text top="945" left="352" width="251" height="9" font="13">Bacterial (e.g., pseudomonas, necrotizing streptococcus)</text>
<text top="956" left="338" width="6" height="10" font="7">n</text>
<text top="957" left="352" width="258" height="9" font="13">Fungal (e.g., blastomycosis, Madura foot, chromomycosis)</text>
<text top="968" left="338" width="6" height="10" font="7">n</text>
<text top="969" left="352" width="61" height="9" font="13">Mycobacterial</text>
<text top="980" left="338" width="6" height="10" font="7">n</text>
<text top="981" left="352" width="165" height="9" font="13">Parasitic (e.g., Chagas, leishmaniasis)</text>
<text top="992" left="338" width="6" height="10" font="7">n</text>
<text top="993" left="352" width="82" height="9" font="13">Viral (e.g., herpes)</text>
<text top="1012" left="63" width="47" height="9" font="13">Malignancy</text>
<text top="1012" left="208" width="61" height="9" font="13">Toes, foot, leg</text>
<text top="1011" left="338" width="6" height="10" font="7">n</text>
<text top="1012" left="352" width="107" height="9" font="13">Primary skin malignancy</text>
<text top="1023" left="338" width="6" height="10" font="7">n</text>
<text top="1024" left="352" width="99" height="9" font="13">Metastatic malignancy</text>
<text top="1035" left="338" width="6" height="10" font="7">n</text>
<text top="1036" left="352" width="150" height="9" font="13">Malignant transformation of ulcer</text>
<text top="1055" left="63" width="8" height="9" font="13">In</text>
<text top="1054" left="71" width="48" height="12" font="13">ﬂammatory</text>
<text top="1055" left="208" width="61" height="9" font="13">Toes, foot, leg</text>
<text top="1054" left="338" width="6" height="10" font="7">n</text>
<text top="1055" left="352" width="90" height="9" font="13">Necrobiosis lipoidica</text>
<text top="1066" left="338" width="6" height="10" font="7">n</text>
<text top="1067" left="352" width="106" height="9" font="13">Pyoderma gangrenosum</text>
<text top="1078" left="338" width="6" height="10" font="7">n</text>
<text top="1079" left="352" width="89" height="9" font="13">Granuloma annulare</text>
<text top="1103" left="63" width="153" height="8" font="5">PAD indicates peripheral artery disease.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="792" width="15" height="9" font="5">e83</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="25" size="6" family="Times" color="#e3202b"/>
<text top="153" left="125" width="44" height="11" font="25">FIGURE 1</text>
<text top="154" left="177" width="168" height="9" font="23">Diagnostic Testing for Suspected PAD</text>
<text top="810" left="125" width="213" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="810" left="342" width="31" height="9" font="18"><a href="e71.full.html#4">Table 1</a></text>
<text top="810" left="373" width="3" height="9" font="13"><a href="e71.full.html#4">.</a></text>
<text top="824" left="125" width="658" height="9" font="13">ABI indicates ankle-brachial index; CLI, critical limb ischemia; CTA, computed tomography angiography; GDMT, guideline-directed management and therapy;</text>
<text top="839" left="125" width="424" height="9" font="13">MRA, magnetic resonance angiography; PAD, peripheral artery disease; and TBI, toe-brachial index.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="16" height="9" font="5">e84</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1160" width="864">
<text top="153" left="80" width="45" height="11" font="25">FIGURE 2</text>
<text top="154" left="134" width="162" height="9" font="23">Diagnostic Testing for Suspected CLI</text>
<text top="770" left="80" width="213" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="770" left="297" width="31" height="9" font="18"><a href="e71.full.html#4">Table 1</a></text>
<text top="770" left="328" width="3" height="9" font="13"><a href="e71.full.html#4">.</a></text>
<text top="785" left="80" width="149" height="9" font="13">*Order based on expert consensus.</text>
<text top="783" left="233" width="200" height="12" font="13">†TBI with waveforms if not already performed.</text>
<text top="800" left="80" width="639" height="9" font="13">ABI indicates ankle-brachial index; CLI, critical limb ischemia; CTA, computed tomography angiography; MRA, magnetic resonance angiography; TcPO</text>
<text top="804" left="719" width="4" height="6" font="19">2</text>
<text top="800" left="723" width="3" height="9" font="13">,</text>
<text top="815" left="80" width="261" height="9" font="13">transcutaneous oxygen pressure; and TBI, toe-brachial index.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="792" width="15" height="9" font="5">e85</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="310" height="11" font="12">3.3. Imaging for Anatomic Assessment: Recommendations</text>
<text top="172" left="57" width="318" height="11" font="22">Recommendations for Imaging for Anatomic Assessment</text>
<text top="213" left="83" width="19" height="10" font="13">COR</text>
<text top="213" left="156" width="18" height="10" font="13">LOE</text>
<text top="213" left="227" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="250" left="92" width="3" height="9" font="5">I</text>
<text top="250" left="154" width="21" height="9" font="5">B-NR</text>
<text top="237" left="227" width="568" height="11" font="12">Duplex ultrasound, computed tomography angiography (CTA), or magnetic resonance angiography (MRA) of the</text>
<text top="253" left="227" width="568" height="11" font="12">lower extremities is useful to diagnose anatomic location and severity of stenosis for patients with symptomatic</text>
<text top="268" left="227" width="225" height="11" font="12">PAD in whom revascularization is considered</text>
<text top="268" left="456" width="42" height="11" font="4"><a href="e71.full.html#42">(118,120</a></text>
<text top="266" left="498" width="26" height="15" font="4"><a href="e71.full.html#42">–122)</a></text>
<text top="268" left="524" width="3" height="11" font="12"><a href="e71.full.html#42">.</a></text>
<text top="293" left="68" width="13" height="8" font="23">See</text>
<text top="293" left="85" width="102" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 6</a></text>
<text top="293" left="187" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="291" left="227" width="239" height="11" font="2">For symptomatic patients in whom ABI/TBI con</text>
<text top="289" left="466" width="332" height="15" font="2">ﬁrms PAD and in whom revascularization is considered, additional</text>
<text top="307" left="227" width="574" height="11" font="2">imaging with duplex ultrasonography, CTA, or MRA is useful to develop an individualized treatment plan, including</text>
<text top="323" left="227" width="267" height="11" font="2">assistance in selection of vascular access sites, identi</text>
<text top="321" left="495" width="277" height="15" font="2">ﬁcation of signiﬁcant lesions, and determination of the</text>
<text top="338" left="227" width="574" height="11" font="2">feasibility of and modality for invasive treatment. All 3 of these noninvasive imaging methods have good sensitivity</text>
<text top="354" left="227" width="47" height="11" font="2">and speci</text>
<text top="352" left="275" width="226" height="15" font="2">ﬁcity as compared with invasive angiography</text>
<text top="354" left="505" width="42" height="11" font="4"><a href="e71.full.html#42">(118,120</a></text>
<text top="352" left="546" width="26" height="15" font="4"><a href="e71.full.html#42">–122)</a></text>
<text top="354" left="572" width="229" height="11" font="2">. Renal function does not affect the safety of</text>
<text top="370" left="227" width="574" height="11" font="2">duplex ultrasonography, although duplex offers lower spatial resolution than CTA and MRA in the setting of arterial</text>
<text top="385" left="227" width="22" height="11" font="2">calci</text>
<text top="383" left="250" width="513" height="15" font="2">ﬁcation. The tomographic data from CTA and MRA afford 3-dimensional reconstruction of the vessels</text>
<text top="401" left="227" width="562" height="11" font="2">examined. The iodinated contrast used in CTA confers risk of contrast-induced nephropathy and (rarely) severe</text>
<text top="417" left="227" width="80" height="11" font="2">allergic reaction</text>
<text top="417" left="312" width="45" height="11" font="4"><a href="e71.full.html#42">(123,124)</a></text>
<text top="417" left="357" width="444" height="11" font="2"><a href="e71.full.html#42">; </a>CTA uses ionizing radiation. MRA does not use ionizing radiation; however, gadolinium</text>
<text top="432" left="227" width="574" height="11" font="2">contrast used frequently in MRA studies confers risk of nephrogenic systemic sclerosis for patients with advanced</text>
<text top="448" left="227" width="339" height="11" font="2">renal dysfunction and is therefore contraindicated in this population</text>
<text top="448" left="569" width="25" height="11" font="4"><a href="e71.full.html#42">(125)</a></text>
<text top="448" left="594" width="207" height="11" font="2"><a href="e71.full.html#42">. </a>The choice of the examination should be</text>
<text top="464" left="227" width="509" height="11" font="2">determined in an individualized approach to the anatomic assessment for each patient, including risk</text>
<text top="462" left="737" width="40" height="15" font="2">–beneﬁt</text>
<text top="480" left="227" width="563" height="11" font="2">assessment of each study type. If these noninvasive tests are nondiagnostic, then invasive angiography may be</text>
<text top="495" left="227" width="291" height="11" font="2">required to delineate anatomy and plan revascularization.</text>
<text top="540" left="92" width="3" height="9" font="5">I</text>
<text top="540" left="154" width="20" height="9" font="5">C-EO</text>
<text top="527" left="227" width="466" height="11" font="12">Invasive angiography is useful for patients with CLI in whom revascularization is considered.</text>
<text top="565" left="121" width="15" height="8" font="23">N/A</text>
<text top="564" left="227" width="29" height="11" font="2">By de</text>
<text top="562" left="256" width="545" height="15" font="2">ﬁnition, CLI results from extensive PAD that limits tissue perfusion. Because timely diagnosis and treatment</text>
<text top="580" left="227" width="542" height="11" font="2">are essential to preserve tissue viability in CLI, it is often most effective and expeditious to pursue invasive</text>
<text top="596" left="227" width="574" height="11" font="2">angiography with endovascular revascularization directly, without delay and potential risk of additional noninvasive</text>
<text top="611" left="227" width="43" height="11" font="2">imaging.</text>
<text top="656" left="88" width="10" height="9" font="5">IIa</text>
<text top="656" left="154" width="20" height="9" font="5">C-EO</text>
<text top="643" left="227" width="574" height="11" font="12">Invasive angiography is reasonable for patients with lifestyle-limiting claudication with an inadequate response to</text>
<text top="658" left="227" width="243" height="11" font="12">GDMT for whom revascularization is considered.</text>
<text top="685" left="121" width="15" height="8" font="23">N/A</text>
<text top="685" left="227" width="562" height="11" font="2">For patients with lifestyle-limiting claudication despite GDMT (including structured exercise therapy) for whom</text>
<text top="700" left="227" width="574" height="11" font="2">revascularization is being considered, proceeding directly to invasive angiography for anatomic assessment and to</text>
<text top="716" left="227" width="554" height="11" font="2">determine revascularization strategy is reasonable. In certain clinical settings, noninvasive imaging studies for</text>
<text top="732" left="227" width="574" height="11" font="2">anatomic assessment (i.e., duplex ultrasound, CTA, or MRA) may not be available because of lack of local resources</text>
<text top="747" left="227" width="574" height="11" font="2">or expertise. In addition, there are clinical scenarios in which noninvasive studies for anatomic assessment may be</text>
<text top="763" left="227" width="574" height="11" font="2">perceived to confer greater risk to the patient than invasive angiography (e.g., patient with advanced chronic kidney</text>
<text top="779" left="227" width="515" height="11" font="2">disease for whom contrast dose for invasive angiography would be lower than that required for CTA).</text>
<text top="823" left="76" width="35" height="9" font="5">III: Harm</text>
<text top="823" left="157" width="15" height="9" font="5">B-R</text>
<text top="811" left="227" width="567" height="11" font="12">Invasive and noninvasive angiography (i.e., CTA, MRA) should not be performed for the anatomic assessment of</text>
<text top="826" left="227" width="165" height="11" font="12">patients with asymptomatic PAD</text>
<text top="826" left="396" width="66" height="11" font="4"><a href="e71.full.html#42">(123,124,126)</a></text>
<text top="826" left="462" width="3" height="11" font="12">.</text>
<text top="853" left="68" width="13" height="8" font="23">See</text>
<text top="853" left="84" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 6</a></text>
<text top="863" left="123" width="21" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 7</a></text>
<text top="863" left="144" width="2" height="8" font="23">.</text>
<text top="851" left="227" width="574" height="11" font="2">Angiography, either noninvasive or invasive, should not be performed for the anatomic assessment of patients with</text>
<text top="867" left="227" width="574" height="11" font="2">PAD without leg symptoms because delineation of anatomy will not change treatment for this population. This lack</text>
<text top="882" left="227" width="38" height="11" font="2">of bene</text>
<text top="880" left="266" width="535" height="15" font="2">ﬁt occurs in the setting of risk of contrast-induced nephropathy, patient discomfort, and allergic reactions</text>
<text top="898" left="227" width="66" height="11" font="4"><a href="e71.full.html#42">(123,124,126)</a></text>
<text top="898" left="294" width="474" height="11" font="2"><a href="e71.full.html#42">.This </a>recommendation does not address assessment of lower extremity aneurysmal disease or</text>
<text top="914" left="227" width="457" height="11" font="2">nonatherosclerotic causes of arterial disease, which is beyond the scope of this document.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="16" height="9" font="5">e86</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1160" width="864">
<text top="141" left="63" width="329" height="16" font="14">4. SCREENING FOR ATHEROSCLEROTIC DISEASE</text>
<text top="159" left="63" width="247" height="16" font="14">IN OTHER VASCULAR BEDS FOR THE</text>
<text top="177" left="63" width="132" height="16" font="14">PATIENT WITH PAD</text>
<text top="215" left="63" width="272" height="11" font="12">4.1. Abdominal Aortic Aneurysm: Recommendation</text>
<text top="617" left="63" width="308" height="11" font="12">4.2. Screening for Asymptomatic Atherosclerosis in Other</text>
<text top="635" left="87" width="280" height="11" font="12">Arterial Beds (Coronary, Carotid, and Renal Arteries)</text>
<text top="656" left="63" width="333" height="12" font="2">The prevalence of atherosclerosis in the coronary, carotid,</text>
<text top="674" left="63" width="333" height="12" font="2">and renal arteries is higher in patients with PAD than in</text>
<text top="692" left="63" width="119" height="12" font="2">those without PAD</text>
<text top="692" left="191" width="46" height="12" font="4"><a href="e71.full.html#42">(128,130</a></text>
<text top="690" left="237" width="28" height="15" font="4"><a href="e71.full.html#42">–135)</a></text>
<text top="692" left="266" width="131" height="12" font="2"><a href="e71.full.html#42">. </a>However, intensive</text>
<text top="710" left="63" width="188" height="12" font="2">atherosclerosis risk factor modi</text>
<text top="708" left="251" width="145" height="15" font="2">ﬁcation in patients with</text>
<text top="728" left="63" width="69" height="12" font="2">PAD is justi</text>
<text top="726" left="132" width="264" height="15" font="2">ﬁed regardless of the presence of disease in</text>
<text top="746" left="63" width="264" height="12" font="2">other arterial beds. Thus, the only justi</text>
<text top="744" left="327" width="70" height="15" font="2">ﬁcation for</text>
<text top="764" left="63" width="333" height="12" font="2">screening for disease in other arterial beds is if revascu-</text>
<text top="782" left="63" width="333" height="12" font="2">larization results in a reduced risk of myocardial infarc-</text>
<text top="800" left="63" width="333" height="12" font="2">tion (MI), stroke, or death, and this has never been shown.</text>
<text top="818" left="63" width="333" height="12" font="2">Currently, there is no evidence to demonstrate that</text>
<text top="836" left="63" width="333" height="12" font="2">screening all patients with PAD for asymptomatic</text>
<text top="854" left="63" width="333" height="12" font="2">atherosclerosis in other arterial beds improves clinical</text>
<text top="871" left="63" width="333" height="12" font="2">outcome. Intensive treatment of risk factors through</text>
<text top="889" left="63" width="333" height="12" font="2">GDMT is the principle method for preventing adverse</text>
<text top="907" left="63" width="333" height="12" font="2">cardiovascular ischemic events from asymptomatic dis-</text>
<text top="925" left="63" width="156" height="12" font="2">ease in other arterial beds.</text>
<text top="615" left="423" width="272" height="16" font="14">5. MEDICAL THERAPY FOR THE PATIENT</text>
<text top="633" left="423" width="69" height="16" font="14">WITH PAD</text>
<text top="670" left="423" width="333" height="12" font="2">Patients with PAD should receive a comprehensive</text>
<text top="688" left="423" width="333" height="12" font="2">program of GDMT, including structured exercise and</text>
<text top="706" left="423" width="81" height="12" font="2">lifestyle modi</text>
<text top="704" left="504" width="252" height="15" font="2">ﬁcation, to reduce cardiovascular ischemic</text>
<text top="724" left="423" width="333" height="12" font="2">events and improve functional status. Smoking cessa-</text>
<text top="742" left="423" width="333" height="12" font="2">tion is a vital component of care for patients with PAD</text>
<text top="760" left="423" width="333" height="12" font="2">who continue to smoke. A guideline-based program of</text>
<text top="778" left="423" width="333" height="12" font="2">pharmacotherapy to reduce cardiovascular ischemic</text>
<text top="796" left="423" width="333" height="12" font="2">events and limb-related events should be prescribed for</text>
<text top="814" left="423" width="333" height="12" font="2">each patient with PAD and is customized to individual</text>
<text top="832" left="423" width="333" height="12" font="2">risk factors, such as whether the patient also has dia-</text>
<text top="850" left="423" width="333" height="12" font="2">betes mellitus. Previous studies have demonstrated</text>
<text top="868" left="423" width="333" height="12" font="2">that patients with PAD are less likely to receive GDMT</text>
<text top="885" left="423" width="333" height="12" font="2">than are patients with other forms of cardiovascular</text>
<text top="903" left="423" width="46" height="12" font="2">disease,</text>
<text top="903" left="483" width="55" height="12" font="2">including</text>
<text top="903" left="553" width="51" height="12" font="2">coronary</text>
<text top="903" left="618" width="34" height="12" font="2">artery</text>
<text top="903" left="667" width="42" height="12" font="2">disease</text>
<text top="903" left="723" width="33" height="12" font="2">(CAD)</text>
<text top="921" left="423" width="23" height="12" font="4"><a href="e71.full.html#42">(136</a></text>
<text top="920" left="446" width="29" height="15" font="4"><a href="e71.full.html#42">–138)</a></text>
<text top="921" left="475" width="3" height="12" font="2">.</text>
<text top="251" left="63" width="278" height="11" font="22">Recommendation for Abdominal Aortic Aneurysm</text>
<text top="292" left="89" width="19" height="10" font="13">COR</text>
<text top="292" left="161" width="18" height="10" font="13">LOE</text>
<text top="292" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="329" left="94" width="10" height="9" font="5">IIa</text>
<text top="329" left="160" width="21" height="9" font="5">B-NR</text>
<text top="317" left="233" width="574" height="11" font="12">A screening duplex ultrasound for abdominal aortic aneurysm (AAA) is reasonable in patients with symptomatic PAD</text>
<text top="332" left="233" width="21" height="11" font="4"><a href="e71.full.html#42">(127</a></text>
<text top="330" left="254" width="27" height="15" font="4"><a href="e71.full.html#42">–129)</a></text>
<text top="332" left="280" width="3" height="11" font="12">.</text>
<text top="357" left="74" width="13" height="8" font="23">See</text>
<text top="357" left="90" width="102" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 8</a></text>
<text top="357" left="193" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="355" left="233" width="532" height="11" font="2">PAD has been recognized as a risk factor for AAA. In observational studies, the prevalence of AAA (aortic</text>
<text top="371" left="233" width="44" height="11" font="2">diameter</text>
<text top="369" left="281" width="429" height="15" font="2">$3 cm) was higher in patients with symptomatic PAD than in the general population</text>
<text top="371" left="714" width="45" height="11" font="4"><a href="e71.full.html#42">(127,129)</a></text>
<text top="371" left="763" width="40" height="11" font="2">and in a</text>
<text top="387" left="233" width="275" height="11" font="2">population of patients with atherosclerotic risk factors</text>
<text top="387" left="512" width="26" height="11" font="4"><a href="e71.full.html#42">(128)</a></text>
<text top="387" left="538" width="255" height="11" font="2"><a href="e71.full.html#42">. </a>The prevalence of AAA among patients with PAD</text>
<text top="402" left="233" width="207" height="11" font="2">increased with age, beginning in patients</text>
<text top="400" left="444" width="323" height="15" font="2">$55 years of age, and was highest in patients $75 years of age</text>
<text top="402" left="771" width="26" height="11" font="4"><a href="e71.full.html#42">(129)</a></text>
<text top="402" left="796" width="3" height="11" font="2">.</text>
<text top="418" left="233" width="574" height="11" font="2">There are no data on AAA screening in patients with asymptomatic PAD. This recommendation refers to screening</text>
<text top="434" left="233" width="574" height="11" font="2">patients with symptomatic PAD for AAA regardless of patient age, sex, smoking history, or family history of AAA.</text>
<text top="449" left="233" width="555" height="11" font="2">Recommendations for screening the general population with risk factors for AAA (based on age, sex, smoking</text>
<text top="465" left="233" width="299" height="11" font="2">history, and family history) have been previously published</text>
<text top="465" left="536" width="15" height="11" font="4"><a href="e71.full.html#39">(9)</a></text>
<text top="465" left="551" width="3" height="11" font="2"><a href="e71.full.html#39">.</a></text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="793" width="15" height="9" font="5">e87</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="231" height="11" font="12">5.1. Antiplatelet Agents: Recommendations</text>
<text top="176" left="57" width="237" height="11" font="22">Recommendations for Antiplatelet Agents</text>
<text top="217" left="83" width="19" height="10" font="13">COR</text>
<text top="217" left="156" width="18" height="10" font="13">LOE</text>
<text top="217" left="227" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="254" left="92" width="3" height="9" font="5">I</text>
<text top="254" left="162" width="6" height="9" font="5">A</text>
<text top="242" left="227" width="246" height="11" font="12">Antiplatelet therapy with aspirin alone (range 75</text>
<text top="240" left="473" width="289" height="15" font="12">–325 mg per day) or clopidogrel alone (75 mg per day) is</text>
<text top="257" left="227" width="455" height="11" font="12">recommended to reduce MI, stroke, and vascular death in patients with symptomatic PAD</text>
<text top="257" left="686" width="22" height="11" font="4"><a href="e71.full.html#42">(139</a></text>
<text top="255" left="708" width="26" height="15" font="4"><a href="e71.full.html#42">–142)</a></text>
<text top="257" left="734" width="3" height="11" font="12">.</text>
<text top="282" left="67" width="13" height="8" font="23">See</text>
<text top="282" left="83" width="105" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 13</a></text>
<text top="282" left="188" width="2" height="8" font="23">.</text>
<text top="280" left="227" width="574" height="11" font="2">The effect of antiplatelet therapy on cardiovascular events has been systematically reviewed by the Antithrombotic</text>
<text top="296" left="227" width="39" height="11" font="2">Trialists</text>
<text top="294" left="266" width="73" height="15" font="2">’ Collaboration</text>
<text top="296" left="343" width="26" height="11" font="4"><a href="e71.full.html#42">(139)</a></text>
<text top="296" left="369" width="432" height="11" font="2"><a href="e71.full.html#42">. </a>Of note, this meta-analysis included studies of antiplatelet agents other than aspirin</text>
<text top="312" left="227" width="565" height="11" font="2">or clopidogrel. Among patients with symptomatic PAD treated with antiplatelet therapy, there was a 22% odds</text>
<text top="327" left="227" width="378" height="11" font="2">reduction for cardiovascular events, including MI, stroke, or vascular death</text>
<text top="327" left="609" width="26" height="11" font="4"><a href="e71.full.html#42">(139)</a></text>
<text top="327" left="635" width="142" height="11" font="2"><a href="e71.full.html#42">. </a>Symptomatic patients with</text>
<text top="343" left="227" width="574" height="11" font="2">lower extremity PAD included both those with claudication and those with prior lower extremity revascularization.</text>
<text top="359" left="227" width="141" height="11" font="2">The Antithrombotic Trialists</text>
<text top="357" left="368" width="429" height="15" font="2">’ Collaboration meta-analysis also compared the efﬁcacy of different doses of aspirin</text>
<text top="374" left="227" width="26" height="11" font="4"><a href="e71.full.html#42">(139)</a></text>
<text top="374" left="253" width="545" height="11" font="2"><a href="e71.full.html#42">. </a>The proportional reduction in vascular events was 32% with 75 to 150 mg daily, 26% with 160 to 325 mg</text>
<text top="390" left="227" width="354" height="11" font="2">daily, and 19% with 500 to 1500 mg daily, whereas there was a signi</text>
<text top="388" left="581" width="174" height="15" font="2">ﬁcantly smaller (13%) reduction in</text>
<text top="406" left="227" width="260" height="11" font="2">cardiovascular events in patients being treated with</text>
<text top="404" left="491" width="130" height="15" font="2">&lt;75 mg of aspirin per day</text>
<text top="406" left="625" width="26" height="11" font="4"><a href="e71.full.html#42">(139)</a></text>
<text top="406" left="651" width="151" height="11" font="2"><a href="e71.full.html#42">. </a>CLIPS (Critical Leg Ischaemia</text>
<text top="421" left="227" width="200" height="11" font="2">Prevention Study) demonstrated a bene</text>
<text top="419" left="428" width="373" height="15" font="2">ﬁt of aspirin (100 mg daily) compared with placebo in preventing vascular</text>
<text top="437" left="227" width="352" height="11" font="2">events, but the study was too small to derive meaningful conclusions</text>
<text top="437" left="583" width="27" height="11" font="4"><a href="e71.full.html#42">(140)</a></text>
<text top="437" left="610" width="180" height="11" font="2">. A meta-analysis of trials of aspirin</text>
<text top="453" left="227" width="573" height="11" font="2">(alone or in combination with dipyridamole) for prevention of cardiovascular events in patients with PAD found a</text>
<text top="468" left="227" width="19" height="11" font="2">non</text>
<text top="466" left="246" width="523" height="15" font="2">–statistically signiﬁcant reduction in the primary endpoint of cardiovascular death, MI, and stroke and a</text>
<text top="484" left="227" width="84" height="11" font="2">statistically signi</text>
<text top="482" left="311" width="449" height="15" font="2">ﬁcant reduction in the secondary endpoint of nonfatal stroke with aspirin versus placebo</text>
<text top="484" left="764" width="24" height="11" font="4"><a href="e71.full.html#42">(141)</a></text>
<text top="484" left="788" width="3" height="11" font="2">.</text>
<text top="500" left="227" width="530" height="11" font="2">The CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events) trial demonstrated a bene</text>
<text top="498" left="757" width="25" height="15" font="2">ﬁt of</text>
<text top="515" left="227" width="574" height="11" font="2">clopidogrel as compared with aspirin in cardiovascular risk reduction and bleeding events in a population of patients</text>
<text top="531" left="227" width="517" height="11" font="2">with symptomatic atherosclerotic vascular disease, including a subgroup of patients with symptomatic</text>
<text top="547" left="227" width="21" height="11" font="2">PAD</text>
<text top="547" left="252" width="25" height="11" font="4"><a href="e71.full.html#42">(142)</a></text>
<text top="547" left="278" width="3" height="11" font="2"><a href="e71.full.html#42">.</a></text>
<text top="591" left="88" width="10" height="9" font="5">IIa</text>
<text top="591" left="154" width="20" height="9" font="5">C-EO</text>
<text top="579" left="227" width="200" height="11" font="12">In asymptomatic patients with PAD (ABI</text>
<text top="577" left="431" width="370" height="15" font="12">£0.90), antiplatelet therapy is reasonable to reduce the risk of MI, stroke,</text>
<text top="594" left="227" width="90" height="11" font="12">or vascular death.</text>
<text top="621" left="67" width="13" height="8" font="23">See</text>
<text top="621" left="83" width="105" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 13</a></text>
<text top="621" left="188" width="2" height="8" font="23">.</text>
<text top="619" left="227" width="135" height="11" font="2">Patients with PAD (i.e., ABI</text>
<text top="617" left="366" width="435" height="15" font="2">#0.90) who do not have claudication may have leg symptoms atypical for claudication</text>
<text top="634" left="227" width="557" height="11" font="2">or may be too functionally limited to allow for adequate leg symptom assessment. Patients with PAD without</text>
<text top="650" left="227" width="237" height="11" font="2">claudication are at increased cardiovascular risk</text>
<text top="650" left="467" width="21" height="11" font="4"><a href="e71.full.html#41">(79)</a></text>
<text top="650" left="488" width="313" height="11" font="2">. Subgroup analysis in a trial evaluating asymptomatic patients</text>
<text top="666" left="227" width="365" height="11" font="2">did not show an effect of aspirin in patients with an abnormally low ABI (</text>
<text top="664" left="592" width="89" height="15" font="2">&lt;0.80 or #0.90)</text>
<text top="666" left="684" width="21" height="11" font="4"><a href="e71.full.html#41">(76)</a></text>
<text top="666" left="705" width="96" height="11" font="2"><a href="e71.full.html#41">. </a>However, the trial</text>
<text top="682" left="227" width="561" height="11" font="2">was not powered to analyze subgroups, and the uncertainty of the result does not rule out the possibility that</text>
<text top="697" left="227" width="131" height="11" font="2">aspirin could provide bene</text>
<text top="695" left="359" width="443" height="15" font="2">ﬁt in such patients, especially in those at increased risk of cardiovascular events. Another</text>
<text top="713" left="227" width="452" height="11" font="2">trial that included asymptomatic patients was too small to derive meaningful conclusions</text>
<text top="713" left="683" width="27" height="11" font="4"><a href="e71.full.html#42">(140)</a></text>
<text top="713" left="710" width="3" height="11" font="2">.</text>
<text top="757" left="88" width="10" height="9" font="5">IIb</text>
<text top="757" left="157" width="15" height="9" font="5">B-R</text>
<text top="745" left="227" width="255" height="11" font="12">In asymptomatic patients with borderline ABI (0.91</text>
<text top="743" left="483" width="318" height="15" font="12">–0.99), the usefulness of antiplatelet therapy to reduce the risk</text>
<text top="760" left="227" width="220" height="11" font="12">of MI, stroke, or vascular death is uncertain</text>
<text top="760" left="451" width="36" height="11" font="4"><a href="e71.full.html#41">(75,76)</a></text>
<text top="760" left="487" width="3" height="11" font="12"><a href="e71.full.html#41">.</a></text>
<text top="787" left="67" width="13" height="8" font="23">See</text>
<text top="787" left="83" width="105" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 13</a></text>
<text top="787" left="188" width="2" height="8" font="23">.</text>
<text top="785" left="227" width="574" height="11" font="2">In asymptomatic patients with an abnormal or borderline ABI, 2 RCTs found that aspirin had no effect in reducing</text>
<text top="801" left="227" width="108" height="11" font="2">cardiovascular events</text>
<text top="801" left="339" width="36" height="11" font="4"><a href="e71.full.html#41">(75,76)</a></text>
<text top="801" left="378" width="142" height="11" font="2">and might increase bleeding</text>
<text top="801" left="523" width="21" height="11" font="4"><a href="e71.full.html#41">(76)</a></text>
<text top="801" left="544" width="257" height="11" font="2"><a href="e71.full.html#41">. </a>However, the trials were not powered to examine</text>
<text top="816" left="227" width="574" height="11" font="2">patients with borderline ABI separately. Given that cardiovascular risk is lower in patients with borderline ABI than</text>
<text top="832" left="227" width="136" height="11" font="2">in those with abnormal ABI</text>
<text top="832" left="367" width="23" height="11" font="4"><a href="e71.full.html#41">(80)</a></text>
<text top="832" left="389" width="412" height="11" font="2">, it would be unlikely that aspirin would have a meaningful effect in this subgroup</text>
<text top="848" left="227" width="357" height="11" font="2">when there was no evidence of an effect in the total trial populations.</text>
<text top="892" left="88" width="10" height="9" font="5">IIb</text>
<text top="892" left="157" width="15" height="9" font="5">B-R</text>
<text top="880" left="227" width="574" height="11" font="12">The effectiveness of dual antiplatelet therapy (DAPT) (aspirin and clopidogrel) to reduce the risk of cardiovascular</text>
<text top="895" left="227" width="372" height="11" font="12">ischemic events in patients with symptomatic PAD is not well established</text>
<text top="895" left="603" width="47" height="11" font="4"><a href="e71.full.html#42">(143,144)</a></text>
<text top="895" left="650" width="3" height="11" font="12"><a href="e71.full.html#42">.</a></text>
<text top="922" left="67" width="13" height="8" font="23">See</text>
<text top="922" left="83" width="105" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 13</a></text>
<text top="922" left="188" width="2" height="8" font="23">.</text>
<text top="920" left="227" width="45" height="11" font="2">Based on</text>
<text top="917" left="275" width="526" height="15" font="2">ﬁndings from a subset of patients with PAD in the CHARISMA (Clopidogrel for High Atherothrombotic Risk</text>
<text top="935" left="227" width="574" height="11" font="2">and Ischemic Stabilization, Management, and Avoidance) trial, DAPT with aspirin plus clopidogrel may be considered</text>
<text top="951" left="227" width="574" height="11" font="2">for patients with PAD at particularly high risk of cardiovascular ischemic events who are not at high risk of bleeding</text>
<text top="967" left="227" width="47" height="11" font="4"><a href="e71.full.html#42">(143,144)</a></text>
<text top="967" left="274" width="238" height="11" font="2">. Currently, there are sparse data on newer P2Y</text>
<text top="971" left="512" width="8" height="7" font="7">12</text>
<text top="967" left="523" width="278" height="11" font="2">antagonists for PAD. There is uncertainty about the net</text>
<text top="982" left="227" width="24" height="11" font="2">bene</text>
<text top="980" left="252" width="549" height="15" font="2">ﬁt of long-term DAPT for patients with PAD—speciﬁcally the balance of risks of cardiovascular ischemic events</text>
<text top="998" left="227" width="574" height="11" font="2">versus major bleeding. Additional clinical trials are needed in the population with PAD. Refer to the DAPT guideline</text>
<text top="1014" left="227" width="249" height="11" font="2">focused update for DAPT recommendations speci</text>
<text top="1012" left="476" width="73" height="15" font="2">ﬁcally for CAD</text>
<text top="1014" left="553" width="22" height="11" font="4"><a href="e71.full.html#39">(20)</a></text>
<text top="1014" left="574" width="3" height="11" font="2">.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="16" height="9" font="5">e88</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1160" width="864">
<text top="545" left="63" width="195" height="11" font="12">5.2. Statin Agents: Recommendation</text>
<text top="881" left="63" width="259" height="11" font="12">5.3. Antihypertensive Agents: Recommendations</text>
<text top="175" left="94" width="10" height="9" font="5">IIb</text>
<text top="175" left="160" width="20" height="9" font="5">C-LD</text>
<text top="162" left="233" width="544" height="11" font="12">DAPT (aspirin and clopidogrel) may be reasonable to reduce the risk of limb-related events in patients with</text>
<text top="178" left="233" width="288" height="11" font="12">symptomatic PAD after lower extremity revascularization</text>
<text top="178" left="525" width="21" height="11" font="4"><a href="e71.full.html#42">(145</a></text>
<text top="176" left="547" width="27" height="15" font="4"><a href="e71.full.html#42">–148)</a></text>
<text top="178" left="574" width="3" height="11" font="12">.</text>
<text top="204" left="72" width="13" height="8" font="23">See</text>
<text top="204" left="88" width="109" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 13</a></text>
<text top="215" left="127" width="26" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 14</a></text>
<text top="215" left="152" width="2" height="8" font="23">.</text>
<text top="202" left="233" width="567" height="11" font="2">There are sparse data on DAPT after lower extremity revascularization. Still, DAPT is prescribed in up to 55% of</text>
<text top="218" left="233" width="263" height="11" font="2">patients after endovascular revascularization for CLI</text>
<text top="218" left="500" width="26" height="11" font="4"><a href="e71.full.html#42">(146)</a></text>
<text top="218" left="526" width="279" height="11" font="2"><a href="e71.full.html#42">. </a>One small RCT of aspirin or aspirin plus clopidogrel in</text>
<text top="234" left="233" width="547" height="11" font="2">patients undergoing endovascular revascularization demonstrated that patients with DAPT had fewer repeat</text>
<text top="249" left="233" width="253" height="11" font="2">revascularization procedures for clinical symptoms</text>
<text top="249" left="489" width="25" height="11" font="4"><a href="e71.full.html#42">(145)</a></text>
<text top="249" left="514" width="293" height="11" font="2">. A subsequent small RCT of aspirin plus placebo or aspirin</text>
<text top="265" left="233" width="560" height="11" font="2">plus clopidogrel in patients after endovascular revascularization also showed a decrease in the need for repeat</text>
<text top="281" left="233" width="312" height="11" font="2">revascularization at 6 months in patients receiving clopidogrel</text>
<text top="281" left="549" width="25" height="11" font="4"><a href="e71.full.html#42">(147)</a></text>
<text top="281" left="574" width="233" height="11" font="2"><a href="e71.full.html#42">. </a>An RCT of aspirin plus placebo or aspirin plus</text>
<text top="296" left="233" width="574" height="11" font="2">clopidogrel in patients who underwent below-knee bypass graft showed a decrease in limb-related events only in</text>
<text top="312" left="233" width="62" height="11" font="2">the prespeci</text>
<text top="310" left="295" width="278" height="15" font="2">ﬁed subgroup of patients with prosthetic bypass grafts</text>
<text top="312" left="577" width="26" height="11" font="4"><a href="e71.full.html#42">(148)</a></text>
<text top="312" left="603" width="191" height="11" font="2">. Refer to the DAPT guideline focused</text>
<text top="328" left="233" width="206" height="11" font="2">update for DAPT recommendations speci</text>
<text top="326" left="439" width="73" height="15" font="2">ﬁcally for CAD</text>
<text top="328" left="516" width="22" height="11" font="4"><a href="e71.full.html#39">(20)</a></text>
<text top="328" left="537" width="3" height="11" font="2">.</text>
<text top="372" left="94" width="10" height="9" font="5">IIb</text>
<text top="372" left="163" width="15" height="9" font="5">B-R</text>
<text top="360" left="233" width="121" height="11" font="12">The overall clinical bene</text>
<text top="358" left="354" width="453" height="15" font="12">ﬁt of vorapaxar added to existing antiplatelet therapy in patients with symptomatic PAD is</text>
<text top="375" left="233" width="47" height="11" font="12">uncertain</text>
<text top="375" left="283" width="22" height="11" font="4"><a href="e71.full.html#42">(149</a></text>
<text top="373" left="306" width="26" height="15" font="4"><a href="e71.full.html#42">–152)</a></text>
<text top="375" left="332" width="3" height="11" font="12"><a href="e71.full.html#42">.</a></text>
<text top="402" left="73" width="13" height="8" font="23">See</text>
<text top="402" left="89" width="105" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 13</a></text>
<text top="402" left="194" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="400" left="233" width="569" height="11" font="2">This novel antagonist of protease-activated receptor-1 added to existing antiplatelet therapy reduced the risk of</text>
<text top="415" left="233" width="558" height="11" font="2">cardiovascular ischemic events in patients with atherosclerosis who were receiving standard therapy in an RCT</text>
<text top="431" left="233" width="45" height="11" font="4"><a href="e71.full.html#42">(150,151)</a></text>
<text top="431" left="278" width="518" height="11" font="2"><a href="e71.full.html#42">. </a>However, it also increased the risk of moderate or severe bleeding. Although the cardiovascular bene</text>
<text top="429" left="796" width="11" height="15" font="2">ﬁt</text>
<text top="447" left="233" width="573" height="11" font="2">was not demonstrated in the subgroup with symptomatic PAD, there was a reduction in limb-related events with</text>
<text top="462" left="233" width="80" height="11" font="2">vorapaxar, speci</text>
<text top="460" left="314" width="331" height="15" font="2">ﬁcally in acute limb ischemia (ALI) and peripheral revascularization</text>
<text top="462" left="648" width="46" height="11" font="4"><a href="e71.full.html#42">(149,152)</a></text>
<text top="462" left="695" width="112" height="11" font="2"><a href="e71.full.html#42">. </a>More than half of ALI</text>
<text top="478" left="233" width="408" height="11" font="2">events in the PAD subset were due to thrombosis of lower extremity bypass grafts</text>
<text top="478" left="644" width="26" height="11" font="4"><a href="e71.full.html#42">(149)</a></text>
<text top="478" left="670" width="126" height="11" font="2">. Unfortunately, the bene</text>
<text top="476" left="796" width="11" height="15" font="2">ﬁt</text>
<text top="494" left="233" width="435" height="11" font="2">in limb events in patients with PAD was accompanied by an increased risk of bleeding</text>
<text top="494" left="672" width="46" height="11" font="4"><a href="e71.full.html#42">(149,152)</a></text>
<text top="494" left="718" width="79" height="11" font="2"><a href="e71.full.html#42">. </a>Therefore, the</text>
<text top="510" left="233" width="100" height="11" font="2">overall clinical bene</text>
<text top="507" left="334" width="250" height="15" font="2">ﬁt of vorapaxar in patients with PAD is uncertain.</text>
<text top="572" left="63" width="197" height="11" font="22">Recommendation for Statin Agents</text>
<text top="613" left="89" width="19" height="10" font="13">COR</text>
<text top="613" left="161" width="18" height="10" font="13">LOE</text>
<text top="613" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="650" left="97" width="3" height="9" font="5">I</text>
<text top="650" left="168" width="6" height="9" font="5">A</text>
<text top="638" left="233" width="367" height="11" font="12">Treatment with a statin medication is indicated for all patients with PAD</text>
<text top="638" left="604" width="38" height="11" font="4"><a href="e71.full.html#41">(96,153</a></text>
<text top="636" left="642" width="25" height="15" font="4"><a href="e71.full.html#41">–157)</a></text>
<text top="638" left="667" width="3" height="11" font="12">.</text>
<text top="674" left="72" width="13" height="8" font="23">See</text>
<text top="674" left="88" width="109" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 15</a></text>
<text top="684" left="127" width="26" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 16</a></text>
<text top="684" left="152" width="2" height="8" font="23">.</text>
<text top="672" left="233" width="425" height="11" font="2">Statin therapy improves both cardiovascular and limb outcomes in patients with PAD</text>
<text top="672" left="661" width="24" height="11" font="4"><a href="e71.full.html#43">(157)</a></text>
<text top="672" left="685" width="121" height="11" font="2"><a href="e71.full.html#43">. </a>In a subgroup of 6,748</text>
<text top="687" left="233" width="506" height="11" font="2">patients with PAD in the HPS (Heart Protection Study), simvastatin 40 mg daily reduced the rate of</text>
<text top="685" left="742" width="52" height="15" font="2">ﬁrst major</text>
<text top="703" left="233" width="213" height="11" font="2">vascular event by 22% relative to placebo</text>
<text top="703" left="450" width="25" height="11" font="4"><a href="e71.full.html#42">(155)</a></text>
<text top="703" left="475" width="3" height="11" font="2"><a href="e71.full.html#42">.</a></text>
<text top="719" left="248" width="559" height="11" font="2">In a multinational registry, statin use among patients with PAD reduced 4-year adverse limb-related events (i.e.,</text>
<text top="734" left="233" width="574" height="11" font="2">worsening claudication, new CLI, new lower extremity revascularization, new ischemic amputation) compared with</text>
<text top="750" left="233" width="44" height="11" font="2">no statin</text>
<text top="750" left="281" width="25" height="11" font="4"><a href="e71.full.html#42">(153)</a></text>
<text top="750" left="306" width="466" height="11" font="2"><a href="e71.full.html#42">. </a>Use of simvastatin in the HPS reduced relative risk of peripheral vascular events (including</text>
<text top="766" left="233" width="530" height="11" font="2">noncoronary revascularization, aneurysm repair, major amputation, or PAD death) compared with placebo</text>
<text top="766" left="766" width="25" height="11" font="4"><a href="e71.full.html#42">(155)</a></text>
<text top="766" left="791" width="16" height="11" font="2">. In</text>
<text top="781" left="233" width="571" height="11" font="2">Medicare patients undergoing lower extremity revascularization, 1-year limb salvage rates were improved among</text>
<text top="797" left="233" width="167" height="11" font="2">those receiving statin medication</text>
<text top="797" left="404" width="25" height="11" font="4"><a href="e71.full.html#42">(154)</a></text>
<text top="797" left="429" width="377" height="11" font="2">. In a multicenter RCT, use of atorvastatin 80 mg daily improved pain-free</text>
<text top="813" left="233" width="408" height="11" font="2">walking time and community-based walking at 12 months compared with placebo</text>
<text top="813" left="644" width="26" height="11" font="4"><a href="e71.full.html#42">(156)</a></text>
<text top="813" left="670" width="137" height="11" font="2"><a href="e71.full.html#42">. </a>In 1 cohort study of 5,480</text>
<text top="829" left="233" width="425" height="11" font="2">patients with asymptomatic PAD, statin treatment improved cardiovascular outcomes</text>
<text top="829" left="661" width="22" height="11" font="4"><a href="e71.full.html#41">(96)</a></text>
<text top="829" left="683" width="124" height="11" font="2"><a href="e71.full.html#41">. </a>Guidelines for dosing of</text>
<text top="844" left="233" width="254" height="11" font="2">statin medications have been previously published</text>
<text top="844" left="491" width="21" height="11" font="4"><a href="e71.full.html#40">(24)</a></text>
<text top="844" left="512" width="3" height="11" font="2"><a href="e71.full.html#40">.</a></text>
<text top="909" left="63" width="265" height="11" font="22">Recommendations for Antihypertensive Agents</text>
<text top="950" left="89" width="19" height="10" font="13">COR</text>
<text top="950" left="161" width="18" height="10" font="13">LOE</text>
<text top="950" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="987" left="97" width="3" height="9" font="5">I</text>
<text top="987" left="168" width="6" height="9" font="5">A</text>
<text top="974" left="233" width="574" height="11" font="12">Antihypertensive therapy should be administered to patients with hypertension and PAD to reduce the risk of MI,</text>
<text top="990" left="233" width="232" height="11" font="12">stroke, heart failure, and cardiovascular death</text>
<text top="990" left="469" width="22" height="11" font="4"><a href="e71.full.html#43">(158</a></text>
<text top="988" left="491" width="27" height="15" font="4"><a href="e71.full.html#43">–162)</a></text>
<text top="990" left="517" width="3" height="11" font="12">.</text>
<text top="1015" left="72" width="13" height="8" font="23">See</text>
<text top="1015" left="88" width="109" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 17</a></text>
<text top="1025" left="127" width="26" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 18</a></text>
<text top="1025" left="152" width="2" height="8" font="23">.</text>
<text top="1013" left="233" width="465" height="11" font="2">Treatment of elevated blood pressure is indicated to lower the risk of cardiovascular events</text>
<text top="1013" left="702" width="26" height="11" font="4"><a href="e71.full.html#43">(162)</a></text>
<text top="1013" left="728" width="72" height="11" font="2"><a href="e71.full.html#43">. </a>Target blood</text>
<text top="1028" left="233" width="554" height="11" font="2">pressure and selection of antihypertensive therapy should be consistent with current published guidelines for</text>
<text top="1044" left="233" width="569" height="11" font="2">hypertension management. Concerns have been raised that antihypertensive therapy may reduce limb perfusion.</text>
<text top="1060" left="233" width="571" height="11" font="2">However, multiple studies have demonstrated that blood pressure treatment, including the use of beta blockers,</text>
<text top="1076" left="233" width="447" height="11" font="2">does not worsen claudication symptoms or impair functional status in patients with PAD</text>
<text top="1076" left="684" width="22" height="11" font="4"><a href="e71.full.html#43">(163</a></text>
<text top="1074" left="706" width="27" height="15" font="4"><a href="e71.full.html#43">–165)</a></text>
<text top="1076" left="732" width="63" height="11" font="2">. There is no</text>
<text top="1091" left="233" width="574" height="11" font="2">evidence that one class of antihypertensive medication or strategy is superior for blood pressure lowering in PAD</text>
<text top="1107" left="233" width="68" height="11" font="4"><a href="e71.full.html#43">(158,166,167)</a></text>
<text top="1107" left="301" width="506" height="11" font="2">. An updated multisocietal guideline on the management of high blood pressure is anticipated in 2017.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="792" width="16" height="9" font="5">e89</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1160" width="864">
<text top="468" left="108" width="229" height="11" font="12">5.4. Smoking Cessation: Recommendations</text>
<text top="175" left="88" width="10" height="9" font="5">IIa</text>
<text top="175" left="162" width="6" height="9" font="5">A</text>
<text top="162" left="227" width="574" height="11" font="12">The use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers can be effective to reduce the</text>
<text top="178" left="227" width="297" height="11" font="12">risk of cardiovascular ischemic events in patients with PAD</text>
<text top="178" left="528" width="68" height="11" font="4"><a href="e71.full.html#43">(161,168,169)</a></text>
<text top="178" left="596" width="3" height="11" font="12"><a href="e71.full.html#43">.</a></text>
<text top="204" left="67" width="13" height="8" font="23">See</text>
<text top="204" left="83" width="105" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 17</a></text>
<text top="204" left="188" width="2" height="8" font="23">.</text>
<text top="202" left="227" width="574" height="11" font="2">The effect of ramipril versus placebo on cardiovascular events was studied in high-risk patients free of heart failure</text>
<text top="218" left="227" width="295" height="11" font="2">in the HOPE (Heart Outcomes Prevention Evaluation) trial</text>
<text top="218" left="526" width="48" height="11" font="4"><a href="e71.full.html#43">(168,169)</a></text>
<text top="218" left="575" width="222" height="11" font="2"><a href="e71.full.html#43">. </a>Patients were normotensive on average at</text>
<text top="234" left="227" width="555" height="11" font="2">the time of enrollment. In a subgroup of 4,051 patients with PAD, ramipril reduced the risk of MI, stroke, or</text>
<text top="249" left="227" width="202" height="11" font="2">vascular death by 25%, similar to the ef</text>
<text top="247" left="429" width="182" height="15" font="2">ﬁcacy in the entire study population</text>
<text top="249" left="614" width="48" height="11" font="4"><a href="e71.full.html#43">(168,169)</a></text>
<text top="249" left="663" width="39" height="11" font="2"><a href="e71.full.html#43">. </a>The ef</text>
<text top="247" left="701" width="100" height="15" font="2">ﬁcacy was similar in</text>
<text top="265" left="227" width="367" height="11" font="2">patients with PAD with symptomatic disease and asymptomatic low ABI</text>
<text top="265" left="598" width="27" height="11" font="4"><a href="e71.full.html#43">(168)</a></text>
<text top="265" left="625" width="176" height="11" font="2"><a href="e71.full.html#43">. </a>ONTARGET (Ongoing Telmisartan</text>
<text top="281" left="227" width="570" height="11" font="2">Alone and in Combination With Ramipril Global Endpoint Trial) compared telmisartan, ramipril, and combination</text>
<text top="296" left="227" width="437" height="11" font="2">therapy in patients with cardiovascular disease, including PAD, and/or diabetes mellitus</text>
<text top="296" left="668" width="24" height="11" font="4"><a href="e71.full.html#43">(161)</a></text>
<text top="296" left="692" width="109" height="11" font="2">. All 3 treatments had</text>
<text top="312" left="227" width="574" height="11" font="2">similar cardiovascular event rates with higher rates of adverse events (including hypotension, syncope, and renal</text>
<text top="328" left="227" width="251" height="11" font="2">failure) in the combination-therapy group. The ef</text>
<text top="326" left="479" width="296" height="15" font="2">ﬁcacy of telmisartan was similar in the subgroup of 3,468</text>
<text top="343" left="227" width="555" height="11" font="2">patients with PAD, which supports the use of angiotensin-receptor blockers as an alternative to angiotensin-</text>
<text top="359" left="227" width="147" height="11" font="2">converting enzyme inhibitors</text>
<text top="359" left="378" width="24" height="11" font="4"><a href="e71.full.html#43">(161)</a></text>
<text top="359" left="402" width="382" height="11" font="2">. The effect of angiotensin-receptor blockers in asymptomatic PAD has not</text>
<text top="375" left="227" width="68" height="11" font="2">been studied.</text>
<text top="506" left="57" width="231" height="11" font="22">Recommendations for Smoking Cessation</text>
<text top="547" left="83" width="19" height="10" font="13">COR</text>
<text top="547" left="156" width="18" height="10" font="13">LOE</text>
<text top="547" left="227" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="584" left="92" width="3" height="9" font="5">I</text>
<text top="584" left="162" width="6" height="9" font="5">A</text>
<text top="571" left="227" width="561" height="11" font="12">Patients with PAD who smoke cigarettes or use other forms of tobacco should be advised at every visit to quit</text>
<text top="587" left="227" width="22" height="11" font="4"><a href="e71.full.html#43">(170</a></text>
<text top="585" left="249" width="25" height="15" font="4"><a href="e71.full.html#43">–172)</a></text>
<text top="587" left="275" width="3" height="11" font="12"><a href="e71.full.html#43">.</a></text>
<text top="612" left="66" width="13" height="8" font="23">See</text>
<text top="612" left="82" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 19</a></text>
<text top="622" left="120" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 20</a></text>
<text top="622" left="147" width="2" height="8" font="23">.</text>
<text top="610" left="227" width="404" height="11" font="2">Tobacco use is a strong risk factor for the development and progression of PAD</text>
<text top="610" left="635" width="45" height="11" font="4"><a href="e71.full.html#43">(173,174)</a></text>
<text top="610" left="680" width="119" height="11" font="2">. Sparse evidence exists</text>
<text top="626" left="227" width="512" height="11" font="2">with regard to the association of novel tobacco product use, including electronic cigarettes, and PAD</text>
<text top="626" left="743" width="24" height="11" font="4"><a href="e71.full.html#43">(175)</a></text>
<text top="626" left="767" width="3" height="11" font="2">.</text>
<text top="641" left="227" width="558" height="11" font="2">Observational studies suggest that smoking cessation is associated with lower rates of cardiovascular ischemic</text>
<text top="657" left="227" width="472" height="11" font="2">events, limb-related events, bypass graft failure, amputation, and death in patients with PAD</text>
<text top="657" left="703" width="41" height="11" font="4"><a href="e71.full.html#43">(172,176</a></text>
<text top="655" left="744" width="26" height="15" font="4"><a href="e71.full.html#43">–178)</a></text>
<text top="657" left="771" width="3" height="11" font="2"><a href="e71.full.html#43">.</a></text>
<text top="673" left="227" width="571" height="11" font="2">Clinician advice increases quit rates, which supports simple provider-based measures as a component of smoking</text>
<text top="688" left="227" width="97" height="11" font="2">cessation programs</text>
<text top="688" left="328" width="59" height="11" font="4"><a href="e71.full.html#39">(22,171,179)</a></text>
<text top="688" left="387" width="3" height="11" font="2">.</text>
<text top="733" left="92" width="3" height="9" font="5">I</text>
<text top="733" left="162" width="6" height="9" font="5">A</text>
<text top="720" left="227" width="538" height="11" font="12">Patients with PAD who smoke cigarettes should be assisted in developing a plan for quitting that includes</text>
<text top="736" left="227" width="570" height="11" font="12">pharmacotherapy (i.e., varenicline, bupropion, and/or nicotine replacement therapy) and/or referral to a smoking</text>
<text top="751" left="227" width="92" height="11" font="12">cessation program</text>
<text top="751" left="323" width="44" height="11" font="4"><a href="e71.full.html#43">(170,180</a></text>
<text top="749" left="368" width="27" height="15" font="4"><a href="e71.full.html#43">–182)</a></text>
<text top="751" left="395" width="3" height="11" font="12"><a href="e71.full.html#43">.</a></text>
<text top="778" left="66" width="13" height="8" font="23">See</text>
<text top="778" left="82" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 19</a></text>
<text top="788" left="120" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 20</a></text>
<text top="788" left="147" width="2" height="8" font="23">.</text>
<text top="776" left="227" width="562" height="11" font="2">Coordinated smoking cessation interventions that include nonpharmacological and pharmacological approaches</text>
<text top="791" left="227" width="102" height="11" font="2">have the greatest ef</text>
<text top="789" left="330" width="438" height="15" font="2">ﬁcacy. An RCT of a follow-up program and smoking cessation medications provided to</text>
<text top="807" left="227" width="474" height="11" font="2">hospitalized patients, including those with PAD, demonstrated a modest increase in quit rates</text>
<text top="807" left="706" width="24" height="11" font="4"><a href="e71.full.html#43">(181)</a></text>
<text top="807" left="730" width="70" height="11" font="2"><a href="e71.full.html#43">. </a>In an RCT of</text>
<text top="823" left="227" width="120" height="11" font="2">patients with PAD speci</text>
<text top="821" left="347" width="397" height="15" font="2">ﬁcally, a comprehensive smoking cessation program combining counseling and</text>
<text top="838" left="227" width="563" height="11" font="2">pharmacological agents increased the rates of smoking cessation to 21.3%, compared with 6.8% with standard</text>
<text top="854" left="227" width="32" height="11" font="2">advice</text>
<text top="854" left="263" width="26" height="11" font="4"><a href="e71.full.html#43">(170)</a></text>
<text top="854" left="289" width="503" height="11" font="2"><a href="e71.full.html#43">. </a>Three pharmacological approaches (i.e., varenicline, bupropion, and nicotine replacement therapy)</text>
<text top="870" left="227" width="330" height="11" font="2">used alone or in combination all increase smoking cessation rates</text>
<text top="870" left="562" width="69" height="11" font="4"><a href="e71.full.html#43">(179,180,182)</a></text>
<text top="870" left="630" width="161" height="11" font="2">. Two meta-analyses of RCTs of</text>
<text top="885" left="227" width="530" height="11" font="2">smoking cessation medications showed no evidence of increased cardiovascular event rates with nicotine</text>
<text top="901" left="227" width="193" height="11" font="2">replacement, bupropion, or varenicline</text>
<text top="901" left="423" width="47" height="11" font="4"><a href="e71.full.html#43">(183,184)</a></text>
<text top="901" left="471" width="304" height="11" font="2"><a href="e71.full.html#43">. </a>Sparse data suggest that electronic cigarettes have no bene</text>
<text top="899" left="775" width="27" height="15" font="2">ﬁt on</text>
<text top="917" left="227" width="120" height="11" font="2">smoking cessation rates</text>
<text top="917" left="351" width="25" height="11" font="4"><a href="e71.full.html#43">(179)</a></text>
<text top="917" left="376" width="3" height="11" font="2">.</text>
<text top="961" left="92" width="3" height="9" font="5">I</text>
<text top="961" left="154" width="21" height="9" font="5">B-NR</text>
<text top="949" left="227" width="574" height="11" font="12">Patients with PAD should avoid exposure to environmental tobacco smoke at work, at home, and in public places</text>
<text top="964" left="227" width="47" height="11" font="4"><a href="e71.full.html#43">(185,186)</a></text>
<text top="964" left="275" width="3" height="11" font="12"><a href="e71.full.html#43">.</a></text>
<text top="991" left="66" width="13" height="8" font="23">See</text>
<text top="991" left="82" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 20</a></text>
<text top="991" left="189" width="2" height="8" font="23">.</text>
<text top="989" left="227" width="383" height="11" font="2">Passive smoke exposure has been associated with the development of PAD</text>
<text top="989" left="615" width="27" height="11" font="4"><a href="e71.full.html#43">(186)</a></text>
<text top="989" left="641" width="143" height="11" font="2">. Observational studies have</text>
<text top="1004" left="227" width="539" height="11" font="2">shown lower cardiovascular and cerebrovascular event rates in the general population after enactment of</text>
<text top="1020" left="227" width="112" height="11" font="2">smoke-free legislation</text>
<text top="1020" left="344" width="26" height="11" font="4"><a href="e71.full.html#43">(185)</a></text>
<text top="1020" left="369" width="412" height="11" font="2">. The effects of avoidance of passive smoke exposure on limb-related events are</text>
<text top="1036" left="227" width="57" height="11" font="2">not known.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="16" height="9" font="5">e90</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="218" height="11" font="12">5.5. Glycemic Control: Recommendations</text>
<text top="616" left="63" width="238" height="11" font="12">5.6. Oral Anticoagulation: Recommendations</text>
<text top="172" left="63" width="221" height="11" font="22">Recommendations for Glycemic Control</text>
<text top="213" left="89" width="19" height="10" font="13">COR</text>
<text top="213" left="161" width="18" height="10" font="13">LOE</text>
<text top="213" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="250" left="97" width="3" height="9" font="5">I</text>
<text top="250" left="160" width="20" height="9" font="5">C-EO</text>
<text top="237" left="233" width="539" height="11" font="12">Management of diabetes mellitus in the patient with PAD should be coordinated between members of the</text>
<text top="253" left="233" width="85" height="11" font="12">healthcare team.</text>
<text top="278" left="127" width="15" height="8" font="23">N/A</text>
<text top="277" left="233" width="369" height="11" font="2">Diabetes mellitus is an important risk factor for the development of PAD</text>
<text top="277" left="605" width="25" height="11" font="4"><a href="e71.full.html#43">(187)</a></text>
<text top="277" left="631" width="155" height="11" font="2"><a href="e71.full.html#43">. </a>Furthermore, the presence of</text>
<text top="293" left="233" width="569" height="11" font="2">diabetes mellitus increases the risk of adverse outcomes among patients with PAD, including progression to CLI,</text>
<text top="309" left="233" width="115" height="11" font="2">amputation, and death</text>
<text top="309" left="351" width="49" height="11" font="4"><a href="e71.full.html#43">(188,189)</a></text>
<text top="309" left="400" width="378" height="11" font="2">. A comprehensive care plan for patients with PAD and diabetes mellitus is</text>
<text top="325" left="233" width="574" height="11" font="2">important and may include diet and weight management, pharmacotherapy for glycemic control and management</text>
<text top="340" left="233" width="358" height="11" font="2">of other cardiovascular risk factors, and foot care and ulcer prevention</text>
<text top="340" left="595" width="42" height="11" font="4"><a href="e71.full.html#40">(25,190)</a></text>
<text top="340" left="637" width="164" height="11" font="2">. Guidelines for glycemic control</text>
<text top="356" left="233" width="531" height="11" font="2">among patients with diabetes mellitus and atherosclerotic vascular disease have been previously published</text>
<text top="356" left="767" width="36" height="11" font="4"><a href="e71.full.html#40">(25,29)</a></text>
<text top="356" left="804" width="3" height="11" font="2"><a href="e71.full.html#40">.</a></text>
<text top="372" left="233" width="311" height="11" font="2">Regular follow-up with and communication among the patient</text>
<text top="370" left="545" width="262" height="15" font="2">’s healthcare providers, including vascular specialists</text>
<text top="387" left="233" width="574" height="11" font="2">and diabetes care providers (e.g., primary care physicians, endocrinologists) constitute an important component of</text>
<text top="403" left="233" width="248" height="11" font="2">care for patients with PAD and diabetes mellitus.</text>
<text top="447" left="94" width="10" height="9" font="5">IIa</text>
<text top="447" left="160" width="21" height="9" font="5">B-NR</text>
<text top="435" left="233" width="150" height="11" font="12">Glycemic control can be bene</text>
<text top="433" left="383" width="300" height="15" font="12">ﬁcial for patients with CLI to reduce limb-related outcomes</text>
<text top="435" left="687" width="45" height="11" font="4"><a href="e71.full.html#43">(191,192)</a></text>
<text top="435" left="732" width="3" height="11" font="12">.</text>
<text top="472" left="72" width="13" height="8" font="23">See</text>
<text top="472" left="88" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 22</a></text>
<text top="472" left="194" width="2" height="8" font="23">.</text>
<text top="470" left="233" width="552" height="11" font="2">In a cohort of 1,974 participants with diabetes mellitus from the Strong Heart Study, compared with patients</text>
<text top="486" left="233" width="259" height="11" font="2">without PAD, patients with PAD and a Hg A1c level</text>
<text top="484" left="496" width="293" height="15" font="2">&lt;6.5% had lower age-adjusted odds of major amputation</text>
<text top="502" left="233" width="446" height="11" font="2">compared to patients with PAD and hemoglobin A1c 6.5% to 9.5% and hemoglobin A1c</text>
<text top="500" left="683" width="36" height="15" font="2">&gt;9.5%</text>
<text top="502" left="722" width="27" height="11" font="4"><a href="e71.full.html#43">(188)</a></text>
<text top="502" left="748" width="52" height="11" font="2">. Glycemic</text>
<text top="517" left="233" width="530" height="11" font="2">control is particularly important for patients with PAD and diabetes mellitus who have CLI. Single-center</text>
<text top="533" left="233" width="535" height="11" font="2">observational studies have demonstrated improved limb-related outcomes, including lower rates of major</text>
<text top="549" left="233" width="548" height="11" font="2">amputation and improved patency after infrapopliteal intervention, among patients with CLI who have more</text>
<text top="565" left="233" width="472" height="11" font="2">optimized glycemic control parameters compared with patients with inferior glycemic control</text>
<text top="565" left="709" width="45" height="11" font="4"><a href="e71.full.html#43">(191,192)</a></text>
<text top="565" left="754" width="3" height="11" font="2">.</text>
<text top="653" left="63" width="242" height="11" font="22">Recommendations for Oral Anticoagulation</text>
<text top="694" left="89" width="19" height="10" font="13">COR</text>
<text top="694" left="161" width="18" height="10" font="13">LOE</text>
<text top="694" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="731" left="94" width="10" height="9" font="5">IIb</text>
<text top="731" left="163" width="15" height="9" font="5">B-R</text>
<text top="718" left="233" width="574" height="11" font="12">The usefulness of anticoagulation to improve patency after lower extremity autogenous vein or prosthetic bypass is</text>
<text top="734" left="233" width="47" height="11" font="12">uncertain</text>
<text top="734" left="283" width="22" height="11" font="4"><a href="e71.full.html#43">(193</a></text>
<text top="731" left="305" width="27" height="15" font="4"><a href="e71.full.html#43">–195)</a></text>
<text top="734" left="332" width="3" height="11" font="12"><a href="e71.full.html#43">.</a></text>
<text top="759" left="71" width="13" height="8" font="23">See</text>
<text top="759" left="88" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 23</a></text>
<text top="769" left="126" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 24</a></text>
<text top="769" left="153" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="757" left="233" width="554" height="11" font="2">Two RCTs evaluating the effectiveness of oral anticoagulation (warfarin) in improving lower extremity bypass</text>
<text top="772" left="233" width="557" height="11" font="2">patency demonstrated improved patency among the subgroup of patients with autogenous vein bypass grafts</text>
<text top="788" left="233" width="47" height="11" font="4"><a href="e71.full.html#43">(193,194)</a></text>
<text top="788" left="280" width="337" height="11" font="2">. However, a Cochrane systematic review showed no patency bene</text>
<text top="786" left="617" width="172" height="15" font="2">ﬁt with the use of anticoagulation</text>
<text top="804" left="233" width="179" height="11" font="2">compared with antiplatelet therapy</text>
<text top="804" left="416" width="26" height="11" font="4"><a href="e71.full.html#43">(195)</a></text>
<text top="804" left="441" width="305" height="11" font="2">. All RCTs and observational studies evaluating the effect of</text>
<text top="819" left="233" width="567" height="11" font="2">anticoagulants on bypass patency demonstrated increased bleeding complications associated with anticoagulant</text>
<text top="835" left="233" width="574" height="11" font="2">use. One RCT evaluating the effectiveness of oral anticoagulation (warfarin) in addition to aspirin in improving lower</text>
<text top="851" left="233" width="487" height="11" font="2">extremity bypass patency demonstrated improved patency in a subgroup of patients with 6-mm</text>
<text top="867" left="233" width="46" height="11" font="2">polytetra</text>
<text top="864" left="279" width="228" height="15" font="2">ﬂuoroethylene (known as PTFE) bypass graft</text>
<text top="867" left="510" width="27" height="11" font="4"><a href="e71.full.html#43">(196)</a></text>
<text top="867" left="537" width="260" height="11" font="2"><a href="e71.full.html#43">. </a>Randomization to anticoagulation plus aspirin was</text>
<text top="882" left="233" width="420" height="11" font="2">associated with increased risk of death and major hemorrhage versus aspirin alone.</text>
<text top="927" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="927" left="168" width="6" height="9" font="5">A</text>
<text top="914" left="233" width="552" height="11" font="12">Anticoagulation should not be used to reduce the risk of cardiovascular ischemic events in patients with PAD</text>
<text top="929" left="233" width="44" height="11" font="4"><a href="e71.full.html#43">(194,196</a></text>
<text top="927" left="277" width="28" height="15" font="4"><a href="e71.full.html#43">–198)</a></text>
<text top="929" left="305" width="3" height="11" font="12">.</text>
<text top="956" left="71" width="13" height="8" font="23">See</text>
<text top="956" left="88" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 23</a></text>
<text top="967" left="126" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 24</a></text>
<text top="967" left="153" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="954" left="233" width="574" height="11" font="2">RCTs and observational studies have uniformly demonstrated that oral anticoagulation therapy aimed at decreasing</text>
<text top="970" left="233" width="274" height="11" font="2">major cardiovascular ischemic events provided no bene</text>
<text top="968" left="507" width="189" height="15" font="2">ﬁt and resulted in increased morbidity</text>
<text top="970" left="700" width="44" height="11" font="4"><a href="e71.full.html#43">(194,196</a></text>
<text top="968" left="744" width="28" height="15" font="4"><a href="e71.full.html#43">–198)</a></text>
<text top="970" left="772" width="35" height="11" font="2"><a href="e71.full.html#43">. </a>In the</text>
<text top="985" left="233" width="572" height="11" font="2">WAVE (Warfarin Antiplatelet Vascular Evaluation) trial of patients with atherosclerotic vascular disease, including</text>
<text top="1001" left="233" width="574" height="11" font="2">PAD, there was no difference in cardiovascular ischemic events among patients randomized to oral anticoagulation</text>
<text top="1017" left="233" width="292" height="11" font="2">and antiplatelet therapy versus antiplatelet therapy alone</text>
<text top="1017" left="529" width="27" height="11" font="4"><a href="e71.full.html#43">(198)</a></text>
<text top="1017" left="555" width="236" height="11" font="2">. In addition, there was an increase in bleeding</text>
<text top="1033" left="233" width="310" height="11" font="2">endpoints including life-threatening and intracranial bleeding</text>
<text top="1033" left="547" width="27" height="11" font="4"><a href="e71.full.html#43">(198)</a></text>
<text top="1033" left="573" width="230" height="11" font="2">. One RCT demonstrated increased death rate</text>
<text top="1048" left="233" width="541" height="11" font="2">among patients randomized to warfarin plus aspirin versus aspirin alone after lower extremity bypass grafting</text>
<text top="1048" left="777" width="27" height="11" font="4"><a href="e71.full.html#43">(196)</a></text>
<text top="1048" left="804" width="3" height="11" font="2"><a href="e71.full.html#43">.</a></text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="794" width="14" height="9" font="5">e91</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="174" height="11" font="12">5.7. Cilostazol: Recommendation</text>
<text top="394" left="108" width="198" height="11" font="12">5.8. Pentoxifylline: Recommendation</text>
<text top="650" left="108" width="220" height="11" font="12">5.9. Chelation Therapy: Recommendation</text>
<text top="842" left="108" width="257" height="11" font="12">5.10. Homocysteine Lowering: Recommendation</text>
<text top="171" left="57" width="174" height="11" font="22">Recommendation for Cilostazol</text>
<text top="212" left="83" width="19" height="10" font="13">COR</text>
<text top="212" left="156" width="18" height="10" font="13">LOE</text>
<text top="212" left="227" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="249" left="92" width="3" height="9" font="5">I</text>
<text top="249" left="162" width="6" height="9" font="5">A</text>
<text top="236" left="227" width="574" height="11" font="12">Cilostazol is an effective therapy to improve symptoms and increase walking distance in patients with claudication</text>
<text top="252" left="227" width="51" height="11" font="4"><a href="e71.full.html#43">(199,200)</a></text>
<text top="252" left="278" width="3" height="11" font="12">.</text>
<text top="277" left="66" width="13" height="8" font="23">See</text>
<text top="277" left="83" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 25</a></text>
<text top="277" left="189" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="275" left="227" width="567" height="11" font="2">In a Cochrane review including 15 double-blind RCTs with a total of 3,718 participants, cilostazol was associated</text>
<text top="291" left="227" width="574" height="11" font="2">with improvement in claudication symptoms but no changes in cardiovascular deaths or QoL when compared with</text>
<text top="306" left="227" width="39" height="11" font="2">placebo</text>
<text top="306" left="270" width="27" height="11" font="4"><a href="e71.full.html#43">(199)</a></text>
<text top="306" left="297" width="358" height="11" font="2"><a href="e71.full.html#43">. </a>In 1 RCT, cilostazol was more effective than pentoxifylline or placebo</text>
<text top="306" left="658" width="29" height="11" font="4"><a href="e71.full.html#43">(200)</a></text>
<text top="306" left="688" width="105" height="11" font="2"><a href="e71.full.html#43">. </a>Side effects include</text>
<text top="322" left="227" width="552" height="11" font="2">headache, abnormal stool (diarrhea), dizziness, and palpitations. Cilostazol is contraindicated in patients with</text>
<text top="338" left="227" width="119" height="11" font="2">congestive heart failure</text>
<text top="338" left="350" width="26" height="11" font="4"><a href="e71.full.html#43">(201)</a></text>
<text top="338" left="376" width="342" height="11" font="2">. In 1 trial, 20% of patients discontinued cilostazol within 3 months</text>
<text top="338" left="722" width="28" height="11" font="4"><a href="e71.full.html#43">(202)</a></text>
<text top="338" left="750" width="3" height="11" font="2"><a href="e71.full.html#43">.</a></text>
<text top="422" left="57" width="199" height="11" font="22">Recommendation for Pentoxifylline</text>
<text top="463" left="83" width="19" height="10" font="13">COR</text>
<text top="463" left="156" width="18" height="10" font="13">LOE</text>
<text top="463" left="227" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="500" left="65" width="47" height="9" font="5">III: No Bene</text>
<text top="498" left="112" width="9" height="12" font="5">ﬁt</text>
<text top="500" left="157" width="15" height="9" font="5">B-R</text>
<text top="487" left="227" width="298" height="11" font="12">Pentoxifylline is not effective for treatment of claudication</text>
<text top="487" left="529" width="52" height="11" font="4"><a href="e71.full.html#43">(200,203)</a></text>
<text top="487" left="581" width="3" height="11" font="12">.</text>
<text top="523" left="66" width="13" height="8" font="23">See</text>
<text top="523" left="82" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 26</a></text>
<text top="523" left="189" width="2" height="8" font="23">.</text>
<text top="521" left="227" width="571" height="11" font="2">In a Cochrane review of 24 studies with 3,377 participants, there was large variability in study design and results</text>
<text top="537" left="227" width="261" height="11" font="2">between individual studies, and therefore the review</text>
<text top="535" left="488" width="137" height="15" font="2">’s effectiveness was unclear</text>
<text top="537" left="628" width="28" height="11" font="4"><a href="e71.full.html#43">(203)</a></text>
<text top="537" left="656" width="145" height="11" font="2"><a href="e71.full.html#43">. </a>Pentoxifylline was shown to</text>
<text top="553" left="227" width="137" height="11" font="2">be generally well tolerated</text>
<text top="553" left="368" width="28" height="11" font="4"><a href="e71.full.html#43">(203)</a></text>
<text top="553" left="396" width="399" height="11" font="2"><a href="e71.full.html#43">. </a>In a multicenter RCT of pentoxifylline, cilostazol, or placebo for patients with</text>
<text top="568" left="227" width="549" height="11" font="2">moderate-to-severe claudication, there was no difference between pentoxifylline and placebo in the primary</text>
<text top="584" left="227" width="191" height="11" font="2">endpoint of maximal walking distance</text>
<text top="584" left="423" width="29" height="11" font="4"><a href="e71.full.html#43">(200)</a></text>
<text top="584" left="452" width="324" height="11" font="2"><a href="e71.full.html#43">. </a>Therefore, pentoxifylline is not recommended as treatment for</text>
<text top="600" left="227" width="63" height="11" font="2">claudication.</text>
<text top="679" left="57" width="222" height="11" font="22">Recommendation for Chelation Therapy</text>
<text top="720" left="83" width="19" height="10" font="13">COR</text>
<text top="720" left="156" width="18" height="10" font="13">LOE</text>
<text top="720" left="227" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="757" left="65" width="47" height="9" font="5">III: No Bene</text>
<text top="755" left="112" width="9" height="12" font="5">ﬁt</text>
<text top="757" left="157" width="15" height="9" font="5">B-R</text>
<text top="744" left="227" width="346" height="11" font="12">Chelation therapy (e.g., ethylenediaminetetraacetic acid) is not bene</text>
<text top="742" left="573" width="173" height="15" font="12">ﬁcial for treatment of claudication</text>
<text top="744" left="750" width="28" height="11" font="4"><a href="e71.full.html#44">(204)</a></text>
<text top="744" left="779" width="3" height="11" font="12"><a href="e71.full.html#44">.</a></text>
<text top="780" left="67" width="13" height="8" font="23">See</text>
<text top="780" left="83" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 27</a></text>
<text top="780" left="189" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="778" left="227" width="461" height="11" font="2">In a Cochrane review of 5 studies with 260 participants, chelation therapy showed no signi</text>
<text top="776" left="688" width="95" height="15" font="2">ﬁcant difference in</text>
<text top="794" left="227" width="385" height="11" font="2">symptoms (maximal and pain-free walking distance) compared with placebo</text>
<text top="794" left="616" width="28" height="11" font="4"><a href="e71.full.html#44">(204)</a></text>
<text top="794" left="645" width="3" height="11" font="2"><a href="e71.full.html#44">.</a></text>
<text top="871" left="57" width="254" height="11" font="22">Recommendation for Homocysteine Lowering</text>
<text top="911" left="83" width="19" height="10" font="13">COR</text>
<text top="911" left="156" width="18" height="10" font="13">LOE</text>
<text top="911" left="227" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="948" left="65" width="47" height="9" font="5">III: No Bene</text>
<text top="947" left="112" width="9" height="12" font="5">ﬁt</text>
<text top="948" left="157" width="15" height="9" font="5">B-R</text>
<text top="936" left="227" width="549" height="11" font="12">B-complex vitamin supplementation to lower homocysteine levels for prevention of cardiovascular events in</text>
<text top="951" left="227" width="198" height="11" font="12">patients with PAD is not recommended</text>
<text top="951" left="429" width="24" height="11" font="4"><a href="e71.full.html#44">(205</a></text>
<text top="949" left="453" width="28" height="15" font="4"><a href="e71.full.html#44">–207)</a></text>
<text top="951" left="481" width="3" height="11" font="12">.</text>
<text top="976" left="65" width="13" height="8" font="23">See</text>
<text top="976" left="82" width="111" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 28</a></text>
<text top="987" left="120" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 29</a></text>
<text top="987" left="147" width="2" height="8" font="23">.</text>
<text top="974" left="227" width="548" height="11" font="2">Although patients with PAD have been shown to have increased plasma homocysteine levels compared with</text>
<text top="990" left="227" width="574" height="11" font="2">patients without PAD, there is no evidence that B-complex vitamin supplementation improves clinical outcomes in</text>
<text top="1006" left="227" width="91" height="11" font="2">patients with PAD</text>
<text top="1006" left="322" width="27" height="11" font="4"><a href="e71.full.html#44">(207)</a></text>
<text top="1006" left="350" width="421" height="11" font="2"><a href="e71.full.html#44">. </a>The HOPE-2 trial randomized 5,522 patients with atherosclerotic vascular disease,</text>
<text top="1021" left="227" width="574" height="11" font="2">including symptomatic PAD, or diabetes mellitus with additional risk factors to receive folic acid/vitamin B6/vitamin</text>
<text top="1037" left="227" width="73" height="11" font="2">B12 or placebo</text>
<text top="1037" left="304" width="51" height="11" font="4"><a href="e71.full.html#44">(205,206)</a></text>
<text top="1037" left="356" width="446" height="11" font="2"><a href="e71.full.html#44">. </a>Despite lowering of homocysteine levels in the vitamin supplementation arm, there was</text>
<text top="1053" left="227" width="402" height="11" font="2">no improvement in the primary endpoint of cardiovascular death, MI, or stroke.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="15" height="9" font="5">e92</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="37" height="11" font="12">5.11. In</text>
<text top="141" left="100" width="202" height="15" font="12">ﬂuenza Vaccination: Recommendation</text>
<text top="399" left="63" width="251" height="16" font="14">6. STRUCTURED EXERCISE THERAPY:</text>
<text top="417" left="62" width="140" height="16" font="14">RECOMMENDATIONS</text>
<text top="454" left="63" width="333" height="12" font="2">Structured exercise therapy is an important element of</text>
<text top="472" left="63" width="333" height="12" font="2">care for the patient with PAD. Components of structured</text>
<text top="490" left="63" width="244" height="12" font="2">exercise programs for PAD are outlined in</text>
<text top="491" left="311" width="42" height="11" font="4"><a href="e71.full.html#24">Table 8</a></text>
<text top="490" left="354" width="3" height="12" font="2"><a href="e71.full.html#24">.</a></text>
<text top="517" left="63" width="284" height="11" font="22">Recommendations for Structured Exercise Therapy</text>
<text top="558" left="89" width="19" height="10" font="13">COR</text>
<text top="558" left="161" width="18" height="10" font="13">LOE</text>
<text top="558" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="595" left="97" width="3" height="9" font="5">I</text>
<text top="595" left="168" width="6" height="9" font="5">A</text>
<text top="582" left="233" width="574" height="11" font="12">In patients with claudication, a supervised exercise program is recommended to improve functional status and QoL</text>
<text top="598" left="233" width="144" height="11" font="12">and to reduce leg symptoms</text>
<text top="598" left="381" width="17" height="11" font="4"><a href="e71.full.html#40">(36</a></text>
<text top="596" left="398" width="115" height="15" font="4"><a href="e71.full.html#40">–38,40–46,48,210,211)</a></text>
<text top="598" left="514" width="3" height="11" font="12"><a href="e71.full.html#40">.</a></text>
<text top="623" left="72" width="13" height="8" font="23">See</text>
<text top="623" left="88" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 32</a></text>
<text top="623" left="194" width="2" height="8" font="23">.</text>
<text top="621" left="233" width="134" height="11" font="2">The data supporting the ef</text>
<text top="619" left="368" width="439" height="15" font="2">ﬁcacy of supervised exercise training as an initial treatment for claudication continue to</text>
<text top="637" left="233" width="309" height="11" font="2">develop and remain convincing, building on many earlier RCTs</text>
<text top="637" left="545" width="18" height="11" font="4"><a href="e71.full.html#40">(40</a></text>
<text top="635" left="563" width="80" height="15" font="4"><a href="e71.full.html#40">–46,48,210,211)</a></text>
<text top="637" left="643" width="164" height="11" font="2">. Trials with long-term follow-up</text>
<text top="652" left="233" width="81" height="11" font="2">from 18 months</text>
<text top="652" left="318" width="36" height="11" font="4"><a href="e71.full.html#40">(37,38)</a></text>
<text top="652" left="357" width="50" height="11" font="2">to 7 years</text>
<text top="652" left="411" width="21" height="11" font="4"><a href="e71.full.html#40">(36)</a></text>
<text top="652" left="435" width="188" height="11" font="2">have demonstrated a persistent bene</text>
<text top="650" left="623" width="182" height="15" font="2">ﬁt of supervised exercise in patients</text>
<text top="668" left="233" width="219" height="11" font="2">with claudication. Data also support a bene</text>
<text top="666" left="452" width="329" height="15" font="2">ﬁt of supervised exercise for patients with symptomatic PAD and</text>
<text top="684" left="233" width="86" height="11" font="2">diabetes mellitus</text>
<text top="684" left="323" width="25" height="11" font="4"><a href="e71.full.html#44">(212)</a></text>
<text top="684" left="347" width="46" height="11" font="2">. The risk</text>
<text top="682" left="394" width="413" height="15" font="2">–beneﬁt ratio for supervised exercise in PAD is favorable, with an excellent safety</text>
<text top="699" left="233" width="17" height="11" font="2">pro</text>
<text top="697" left="250" width="535" height="15" font="2">ﬁle in patients screened for absolute contraindications to exercise such as exercise-limiting cardiovascular</text>
<text top="715" left="233" width="194" height="11" font="2">disease, amputation or wheelchair con</text>
<text top="713" left="427" width="353" height="15" font="2">ﬁnement, and other major comorbidities that would preclude exercise</text>
<text top="731" left="233" width="70" height="11" font="4"><a href="e71.full.html#40">(36,39,49,213</a></text>
<text top="729" left="303" width="27" height="15" font="4"><a href="e71.full.html#40">–216)</a></text>
<text top="731" left="330" width="126" height="11" font="2"><a href="e71.full.html#40">. </a>Despite the health bene</text>
<text top="729" left="456" width="351" height="15" font="2">ﬁts associated with supervised exercise in patients with PAD, initiating</text>
<text top="746" left="233" width="532" height="11" font="2">and maintaining a high level of adherence remain challenging. Frequent contact with patients both when</text>
<text top="762" left="233" width="565" height="11" font="2">performing exercise in the supervised setting and at home has been somewhat effective in promoting retention</text>
<text top="778" left="233" width="36" height="11" font="4"><a href="e71.full.html#40">(37,38)</a></text>
<text top="778" left="269" width="3" height="11" font="2"><a href="e71.full.html#40">.</a></text>
<text top="822" left="97" width="3" height="9" font="5">I</text>
<text top="822" left="163" width="15" height="9" font="5">B-R</text>
<text top="810" left="233" width="534" height="11" font="12">A supervised exercise program should be discussed as a treatment option for claudication before possible</text>
<text top="825" left="233" width="84" height="11" font="12">revascularization</text>
<text top="825" left="321" width="17" height="11" font="4"><a href="e71.full.html#40">(36</a></text>
<text top="823" left="338" width="22" height="15" font="4"><a href="e71.full.html#40">–38)</a></text>
<text top="825" left="360" width="3" height="11" font="12"><a href="e71.full.html#40">.</a></text>
<text top="852" left="72" width="13" height="8" font="23">See</text>
<text top="852" left="88" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 32</a></text>
<text top="852" left="194" width="2" height="8" font="23">.</text>
<text top="850" left="233" width="531" height="11" font="2">The CLEVER (Claudication: Exercise Versus Endoluminal Revascularization) trial randomized patients with</text>
<text top="865" left="233" width="290" height="11" font="2">symptomatic aortoiliac PAD and showed comparable bene</text>
<text top="863" left="524" width="283" height="15" font="2">ﬁts for supervised exercise and stent revascularization at</text>
<text top="881" left="233" width="381" height="11" font="2">6 and 18 months, with each therapy being superior to optimal medical care</text>
<text top="881" left="617" width="36" height="11" font="4"><a href="e71.full.html#40">(37,38)</a></text>
<text top="881" left="653" width="120" height="11" font="2">. Overall, the safety pro</text>
<text top="879" left="773" width="34" height="15" font="2">ﬁle for</text>
<text top="897" left="233" width="524" height="11" font="2">supervised exercise was excellent. An RCT that compared 7-year effectiveness of supervised exercise or</text>
<text top="912" left="233" width="570" height="11" font="2">endovascular revascularization in patients with stable claudication with iliac or femoropopliteal disease found no</text>
<text top="928" left="233" width="259" height="11" font="2">differences in improved walking and QoL outcomes</text>
<text top="928" left="496" width="21" height="11" font="4"><a href="e71.full.html#40">(36)</a></text>
<text top="928" left="517" width="286" height="11" font="2">. Although more secondary interventions occurred in the</text>
<text top="944" left="233" width="539" height="11" font="2">exercise group, the total number of interventions was greater in the endovascular revascularization group.</text>
<text top="960" left="233" width="574" height="11" font="2">Collectively, these studies provide strong support for offering patients a supervised exercise program for reducing</text>
<text top="975" left="233" width="346" height="11" font="2">claudication symptoms and for improving functional status and QoL.</text>
<text top="991" left="248" width="559" height="11" font="2">A 3-month RCT that compared percutaneous transluminal angioplasty (PTA), supervised exercise, and combined</text>
<text top="1007" left="233" width="553" height="11" font="2">treatment for claudication found that both supervised exercise and PTA improved clinical and QoL outcomes,</text>
<text top="1022" left="233" width="309" height="11" font="2">whereas PTA plus supervised exercise produced greater bene</text>
<text top="1020" left="542" width="148" height="15" font="2">ﬁts than either therapy alone</text>
<text top="1022" left="694" width="24" height="11" font="4"><a href="e71.full.html#44">(217)</a></text>
<text top="1022" left="718" width="62" height="11" font="2"><a href="e71.full.html#44">. </a>The ERASE</text>
<text top="1038" left="233" width="548" height="11" font="2">(Endovascular Revascularization and Supervised Exercise) study randomized participants with claudication to</text>
<text top="1054" left="233" width="574" height="11" font="2">endovascular revascularization plus supervised exercise or supervised exercise alone. After 1 year, patients in both</text>
<text top="1069" left="233" width="81" height="11" font="2">groups had signi</text>
<text top="1067" left="314" width="493" height="15" font="2">ﬁcant improvements in walking distances and health-related QoL, with greater improvements in the</text>
<text top="1085" left="233" width="124" height="11" font="2">combined-therapy group</text>
<text top="1085" left="360" width="26" height="11" font="4"><a href="e71.full.html#44">(218)</a></text>
<text top="1085" left="385" width="422" height="11" font="2">. Collectively, these studies support the continued provision of supervised exercise to</text>
<text top="1101" left="233" width="455" height="11" font="2">patients with claudication, whether as a monotherapy or combined with revascularization.</text>
<text top="179" left="63" width="131" height="11" font="22">Recommendation for In</text>
<text top="177" left="194" width="108" height="15" font="22">ﬂuenza Vaccination</text>
<text top="220" left="89" width="19" height="10" font="13">COR</text>
<text top="220" left="161" width="18" height="10" font="13">LOE</text>
<text top="220" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="257" left="97" width="3" height="9" font="5">I</text>
<text top="257" left="160" width="20" height="9" font="5">C-EO</text>
<text top="245" left="233" width="221" height="11" font="12">Patients with PAD should have an annual in</text>
<text top="243" left="454" width="99" height="15" font="12">ﬂuenza vaccination.</text>
<text top="281" left="71" width="13" height="8" font="23">See</text>
<text top="281" left="87" width="111" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 30</a></text>
<text top="291" left="127" width="25" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 31</a></text>
<text top="291" left="152" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="279" left="233" width="570" height="11" font="2">Observational studies have demonstrated reduced cardiovascular event rates among patients with cardiovascular</text>
<text top="295" left="233" width="158" height="11" font="2">disease who have received an in</text>
<text top="293" left="391" width="95" height="15" font="2">ﬂuenza vaccination</text>
<text top="295" left="489" width="21" height="11" font="4"><a href="e71.full.html#40">(30)</a></text>
<text top="295" left="511" width="296" height="11" font="2"><a href="e71.full.html#40">. </a>Two RCTs that enrolled patients with CAD demonstrated a</text>
<text top="310" left="233" width="24" height="11" font="2">bene</text>
<text top="308" left="258" width="549" height="15" font="2">ﬁt of an inﬂuenza vaccination on the prevention of cardiovascular events, particularly coronary ischemic events</text>
<text top="326" left="233" width="53" height="11" font="4"><a href="e71.full.html#44">(208,209)</a></text>
<text top="326" left="286" width="181" height="11" font="2"><a href="e71.full.html#44">. </a>Although these trials did not speci</text>
<text top="324" left="466" width="340" height="15" font="2">ﬁcally enroll participants with PAD, a majority of patients with PAD</text>
<text top="342" left="233" width="71" height="11" font="2">also have CAD</text>
<text top="342" left="307" width="21" height="11" font="4"><a href="e71.full.html#40">(30)</a></text>
<text top="342" left="329" width="216" height="11" font="2"><a href="e71.full.html#40">. </a>On the basis of this evidence, an annual in</text>
<text top="340" left="545" width="262" height="15" font="2">ﬂuenza vaccination is recommended as a component</text>
<text top="357" left="233" width="211" height="11" font="2">of medical therapy for patients with PAD.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="792" width="15" height="9" font="5">e93</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1160" width="864">
<text top="725" left="115" width="48" height="10" font="15">T A B L E 8</text>
<text top="725" left="179" width="224" height="10" font="16">Structured Exercise Programs for PAD: De</text>
<text top="723" left="404" width="43" height="14" font="16">ﬁnitions</text>
<text top="748" left="108" width="189" height="9" font="13">Supervised exercise program (COR I, LOE A)</text>
<text top="759" left="108" width="6" height="10" font="7">n</text>
<text top="759" left="122" width="245" height="9" font="13">Program takes place in a hospital or outpatient facility.</text>
<text top="771" left="108" width="6" height="10" font="7">n</text>
<text top="771" left="122" width="314" height="9" font="13">Program uses intermittent walking exercise as the treatment modality.</text>
<text top="783" left="108" width="6" height="10" font="7">n</text>
<text top="783" left="122" width="311" height="9" font="13">Program can be standalone or within a cardiac rehabilitation program.</text>
<text top="794" left="108" width="6" height="10" font="7">n</text>
<text top="795" left="122" width="172" height="9" font="13">Program is directly supervised by quali</text>
<text top="794" left="294" width="120" height="12" font="13">ﬁed healthcare provider(s).</text>
<text top="806" left="108" width="6" height="10" font="7">n</text>
<text top="807" left="122" width="190" height="9" font="13">Training is performed for a minimum of 30</text>
<text top="806" left="312" width="375" height="12" font="13">–45 min/session; sessions are performed at least 3 times/wk for a minimum of 12 wk</text>
<text top="807" left="690" width="15" height="9" font="18"><a href="e71.full.html#40">(36</a></text>
<text top="806" left="705" width="20" height="12" font="18"><a href="e71.full.html#40">–46)</a></text>
<text top="807" left="725" width="3" height="9" font="13"><a href="e71.full.html#40">.</a></text>
<text top="818" left="108" width="6" height="10" font="7">n</text>
<text top="819" left="122" width="531" height="9" font="13">Training involves intermittent bouts of walking to moderate-to-maximum claudication, alternating with periods of rest.</text>
<text top="830" left="108" width="6" height="10" font="7">n</text>
<text top="831" left="122" width="344" height="9" font="13">Warm-up and cool-down periods precede and follow each session of walking.</text>
<text top="850" left="108" width="317" height="9" font="13">Structured community- or home-based exercise program (COR IIa, LOE A)</text>
<text top="862" left="108" width="6" height="10" font="7">n</text>
<text top="862" left="122" width="398" height="9" font="13">Program takes place in the personal setting of the patient rather than in a clinical setting</text>
<text top="862" left="523" width="27" height="9" font="18"><a href="e71.full.html#40">(41,47</a></text>
<text top="861" left="551" width="17" height="12" font="18"><a href="e71.full.html#40">–51)</a></text>
<text top="862" left="568" width="3" height="9" font="13">.</text>
<text top="873" left="108" width="6" height="10" font="7">n</text>
<text top="874" left="122" width="281" height="9" font="13">Program is self-directed with guidance of healthcare providers.</text>
<text top="885" left="108" width="6" height="10" font="7">n</text>
<text top="886" left="122" width="406" height="9" font="13">Healthcare providers prescribe an exercise regimen similar to that of a supervised program.</text>
<text top="897" left="108" width="6" height="10" font="7">n</text>
<text top="898" left="122" width="504" height="9" font="13">Patient counseling ensures understanding of how to begin and maintain the program and how to progress the dif</text>
<text top="897" left="626" width="159" height="12" font="13">ﬁculty of the walking (by increasing</text>
<text top="910" left="122" width="84" height="9" font="13">distance or speed).</text>
<text top="921" left="108" width="6" height="10" font="7">n</text>
<text top="922" left="122" width="481" height="9" font="13">Program may incorporate behavioral change techniques, such as health coaching or use of activity monitors.</text>
<text top="946" left="108" width="391" height="8" font="5">COR indicates Class of Recommendation; LOE, Level of Evidence; and PAD, peripheral artery disease.</text>
<text top="175" left="88" width="10" height="9" font="5">IIa</text>
<text top="175" left="162" width="6" height="9" font="5">A</text>
<text top="162" left="227" width="574" height="11" font="12">In patients with PAD, a structured community- or home-based exercise program with behavioral change techniques</text>
<text top="178" left="227" width="61" height="11" font="12">can be bene</text>
<text top="176" left="289" width="269" height="15" font="12">ﬁcial to improve walking ability and functional status</text>
<text top="178" left="561" width="76" height="11" font="4"><a href="e71.full.html#40">(49,88,94,213)</a></text>
<text top="178" left="637" width="3" height="11" font="12"><a href="e71.full.html#40">.</a></text>
<text top="204" left="66" width="13" height="8" font="23">See</text>
<text top="204" left="83" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 32</a></text>
<text top="204" left="189" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="202" left="227" width="501" height="11" font="2">Unstructured community-based or home-based walking programs that consist of providing general</text>
<text top="218" left="227" width="397" height="11" font="2">recommendations to patients with claudication to simply walk more are not ef</text>
<text top="216" left="625" width="43" height="15" font="2">ﬁcacious</text>
<text top="218" left="671" width="22" height="11" font="4"><a href="e71.full.html#40">(50)</a></text>
<text top="218" left="693" width="101" height="11" font="2"><a href="e71.full.html#40">. </a>Studies supporting</text>
<text top="234" left="227" width="551" height="11" font="2">structured community- or home-based programs for patients with symptomatic PAD (claudication and/or leg</text>
<text top="249" left="227" width="564" height="11" font="2">symptoms atypical for claudication) are more recent than studies supporting supervised exercise programs, and</text>
<text top="265" left="227" width="438" height="11" font="2">have provided strong evidence in support of the community- or home-based approach</text>
<text top="265" left="669" width="105" height="11" font="4"><a href="e71.full.html#40">(47,49,51,88,94,213)</a></text>
<text top="265" left="774" width="23" height="11" font="2">. For</text>
<text top="281" left="227" width="309" height="11" font="2">example, the GOALS (Group Oriented Arterial Leg Study) trial</text>
<text top="281" left="539" width="22" height="11" font="4"><a href="e71.full.html#41">(94)</a></text>
<text top="281" left="564" width="133" height="11" font="2">included patients with con</text>
<text top="279" left="697" width="104" height="15" font="2">ﬁrmed PAD with and</text>
<text top="296" left="227" width="543" height="11" font="2">without claudication (atypical lower extremity symptoms or no symptoms) and showed increases in several</text>
<text top="312" left="227" width="566" height="11" font="2">parameters of functional status for both of these patient cohort subgroups, versus nonexercising controls, after</text>
<text top="328" left="227" width="48" height="11" font="2">6 months</text>
<text top="328" left="279" width="22" height="11" font="4"><a href="e71.full.html#41">(88)</a></text>
<text top="328" left="301" width="227" height="11" font="2">, with improvement maintained at 12 months</text>
<text top="328" left="533" width="22" height="11" font="4"><a href="e71.full.html#41">(94)</a></text>
<text top="328" left="554" width="3" height="11" font="2">.</text>
<text top="344" left="242" width="299" height="11" font="2">As with supervised exercise programs, despite proven bene</text>
<text top="342" left="542" width="223" height="15" font="2">ﬁt, initiating and maintaining a high level of</text>
<text top="359" left="227" width="571" height="11" font="2">adherence to community- or home-based exercise programs remains challenging. Studies that have incorporated</text>
<text top="375" left="227" width="574" height="11" font="2">behavioral change techniques, such as health coaching and activity tracking used in supervised settings, appear to</text>
<text top="391" left="227" width="566" height="11" font="2">reduce attrition and promote higher levels of adherence, thereby improving functional and QoL outcomes, both</text>
<text top="406" left="227" width="129" height="11" font="2">short term and long term</text>
<text top="406" left="360" width="56" height="11" font="4"><a href="e71.full.html#40">(49,88,94)</a></text>
<text top="406" left="416" width="3" height="11" font="2"><a href="e71.full.html#40">.</a></text>
<text top="451" left="88" width="10" height="9" font="5">IIa</text>
<text top="451" left="162" width="6" height="9" font="5">A</text>
<text top="438" left="227" width="571" height="11" font="12">In patients with claudication, alternative strategies of exercise therapy, including upper-body ergometry, cycling,</text>
<text top="453" left="227" width="550" height="11" font="12">and pain-free or low-intensity walking that avoids moderate-to-maximum claudication while walking, can be</text>
<text top="469" left="227" width="24" height="11" font="12">bene</text>
<text top="467" left="252" width="269" height="15" font="12">ﬁcial to improve walking ability and functional status</text>
<text top="469" left="524" width="85" height="11" font="4"><a href="e71.full.html#40">(39,215,219,220)</a></text>
<text top="469" left="609" width="3" height="11" font="12">.</text>
<text top="495" left="66" width="13" height="8" font="23">See</text>
<text top="495" left="82" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 32</a></text>
<text top="506" left="121" width="26" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 33</a></text>
<text top="506" left="147" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="493" left="227" width="574" height="11" font="2">Protocols for exercise therapy for PAD traditionally have recommended intermittent walking bouts to moderate or</text>
<text top="509" left="227" width="454" height="11" font="2">higher pain levels interspersed with short periods of rest. Although these protocols are ef</text>
<text top="507" left="682" width="119" height="15" font="2">ﬁcacious, intolerance of</text>
<text top="525" left="227" width="574" height="11" font="2">pain may lead to poor exercise adherence. An increasing number of studies have shown that modalities of exercise</text>
<text top="541" left="227" width="543" height="11" font="2">that avoid claudication or walking performed at intensities that are pain free or produce only mild levels of</text>
<text top="556" left="227" width="185" height="11" font="2">claudication can achieve health bene</text>
<text top="554" left="413" width="384" height="15" font="2">ﬁts comparable to walking at moderate or higher levels of claudication pain</text>
<text top="572" left="227" width="72" height="11" font="4"><a href="e71.full.html#40">(39,41,215,219</a></text>
<text top="570" left="300" width="26" height="15" font="4"><a href="e71.full.html#40">–221)</a></text>
<text top="572" left="326" width="3" height="11" font="2"><a href="e71.full.html#40">.</a></text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="16" height="9" font="5">e94</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1160" width="864">
<text top="141" left="63" width="318" height="16" font="14">7. MINIMIZING TISSUE LOSS IN PATIENTS WITH</text>
<text top="159" left="63" width="177" height="16" font="14">PAD: RECOMMENDATIONS</text>
<text top="212" left="63" width="376" height="11" font="22">Recommendations for Minimizing Tissue Loss in Patients With PAD</text>
<text top="252" left="89" width="19" height="10" font="13">COR</text>
<text top="252" left="161" width="18" height="10" font="13">LOE</text>
<text top="252" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="289" left="97" width="3" height="9" font="5">I</text>
<text top="289" left="160" width="20" height="9" font="5">C-LD</text>
<text top="277" left="233" width="364" height="11" font="12">Patients with PAD and diabetes mellitus should be counseled about self</text>
<text top="275" left="597" width="178" height="15" font="12">–foot examination and healthy foot</text>
<text top="292" left="233" width="48" height="11" font="12">behaviors</text>
<text top="292" left="285" width="47" height="11" font="4"><a href="e71.full.html#44">(222,223)</a></text>
<text top="292" left="332" width="3" height="11" font="12">.</text>
<text top="317" left="72" width="13" height="8" font="23">See</text>
<text top="317" left="88" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 34</a></text>
<text top="317" left="195" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="315" left="233" width="574" height="11" font="2">Some RCTs have suggested that patient education may help reduce the incidence of serious foot ulcers and lower</text>
<text top="331" left="233" width="441" height="11" font="2">extremity amputations, but the quality of evidence supporting patient education is low</text>
<text top="331" left="677" width="26" height="11" font="4"><a href="e71.full.html#44">(222)</a></text>
<text top="331" left="704" width="103" height="11" font="2"><a href="e71.full.html#44">. </a>Educational efforts</text>
<text top="347" left="233" width="574" height="11" font="2">generally include teaching patients about healthy foot behaviors (e.g., daily inspection of feet, wearing of shoes and</text>
<text top="362" left="233" width="566" height="11" font="2">socks; avoidance of barefoot walking), the selection of proper footwear, and the importance of seeking medical</text>
<text top="378" left="233" width="161" height="11" font="2">attention for new foot problems</text>
<text top="378" left="397" width="26" height="11" font="4"><a href="e71.full.html#44">(223)</a></text>
<text top="378" left="423" width="384" height="11" font="2"><a href="e71.full.html#44">. </a>Educational efforts are especially important for patients with PAD who have</text>
<text top="394" left="233" width="230" height="11" font="2">diabetes mellitus with peripheral neuropathy.</text>
<text top="438" left="97" width="3" height="9" font="5">I</text>
<text top="438" left="160" width="20" height="9" font="5">C-LD</text>
<text top="426" left="233" width="560" height="11" font="12">In patients with PAD, prompt diagnosis and treatment of foot infection are recommended to avoid amputation</text>
<text top="441" left="233" width="23" height="11" font="4"><a href="e71.full.html#44">(224</a></text>
<text top="439" left="256" width="28" height="15" font="4"><a href="e71.full.html#44">–228)</a></text>
<text top="441" left="284" width="3" height="11" font="12">.</text>
<text top="468" left="72" width="13" height="8" font="23">See</text>
<text top="468" left="88" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 34</a></text>
<text top="468" left="195" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="466" left="233" width="565" height="11" font="2">Foot infections (infection of any of the structures distal to the malleoli) may include cellulitis, abscess, fasciitis,</text>
<text top="481" left="233" width="564" height="11" font="2">tenosynovitis, septic joint space infection, and osteomyelitis. Studies have investigated the accuracy of physical</text>
<text top="495" left="233" width="483" height="15" font="2">ﬁndings for identiﬁcation of infection and determining infection severity and risk of amputation</text>
<text top="497" left="720" width="23" height="11" font="4"><a href="e71.full.html#44">(224</a></text>
<text top="495" left="743" width="28" height="15" font="4"><a href="e71.full.html#44">–226)</a></text>
<text top="497" left="771" width="3" height="11" font="2">.</text>
<text top="513" left="233" width="348" height="11" font="2">Because of the consequences associated with untreated foot infection</text>
<text top="511" left="581" width="226" height="15" font="2">—especially in the presence of PAD—clinicians</text>
<text top="529" left="233" width="209" height="11" font="2">should maintain a high index of suspicion</text>
<text top="529" left="446" width="27" height="11" font="4"><a href="e71.full.html#44">(228)</a></text>
<text top="529" left="473" width="329" height="11" font="2"><a href="e71.full.html#44">. </a>It is also recognized that the presence of diabetes mellitus with</text>
<text top="544" left="233" width="574" height="11" font="2">peripheral neuropathy and PAD may make the presentation of foot infection more subtle than in patients without</text>
<text top="560" left="233" width="574" height="11" font="2">these problems. Foot infection should be suspected if the patient presents with local pain or tenderness; periwound</text>
<text top="576" left="233" width="216" height="11" font="2">erythema; periwound edema, induration or</text>
<text top="574" left="453" width="347" height="15" font="2">ﬂuctuance; pretibial edema; any discharge (especially purulent); foul</text>
<text top="591" left="233" width="387" height="11" font="2">odor; visible bone or a wound that probes-to-bone; or signs of a systemic in</text>
<text top="589" left="621" width="159" height="15" font="2">ﬂammatory response (including</text>
<text top="607" left="233" width="62" height="11" font="2">temperature</text>
<text top="605" left="298" width="22" height="15" font="2">&gt;38</text>
<text top="604" left="320" width="4" height="10" font="7"></text>
<text top="607" left="324" width="20" height="11" font="2">C or</text>
<text top="605" left="347" width="22" height="15" font="2">&lt;36</text>
<text top="604" left="369" width="4" height="10" font="7"></text>
<text top="607" left="374" width="62" height="11" font="2">C, heart rate</text>
<text top="605" left="438" width="205" height="15" font="2">&gt;90/min, respiratory rate &gt;20/min or Pa</text>
<text top="610" left="644" width="15" height="9" font="7">CO2</text>
<text top="605" left="661" width="146" height="15" font="2">&lt;32 mm Hg, white blood cell</text>
<text top="623" left="233" width="28" height="11" font="2">count</text>
<text top="621" left="265" width="265" height="15" font="2">&gt;12,000 or &lt;4,000/mcL or &gt;10% immature forms)</text>
<text top="623" left="534" width="27" height="11" font="4"><a href="e71.full.html#44">(226)</a></text>
<text top="623" left="561" width="246" height="11" font="2">. Probe-to-bone test is moderately predictive for</text>
<text top="638" left="233" width="201" height="11" font="2">osteomyelitis but is not pathognomonic</text>
<text top="638" left="438" width="26" height="11" font="4"><a href="e71.full.html#44">(227)</a></text>
<text top="638" left="464" width="3" height="11" font="2"><a href="e71.full.html#44">.</a></text>
<text top="683" left="94" width="10" height="9" font="5">IIa</text>
<text top="683" left="160" width="20" height="9" font="5">C-LD</text>
<text top="670" left="233" width="496" height="11" font="12">In patients with PAD and signs of foot infection, prompt referral to an interdisciplinary care team (</text>
<text top="670" left="729" width="38" height="11" font="4"><a href="e71.full.html#26">Table 9</a></text>
<text top="670" left="767" width="40" height="11" font="12"><a href="e71.full.html#26">) </a>can be</text>
<text top="686" left="233" width="24" height="11" font="12">bene</text>
<text top="684" left="258" width="23" height="15" font="12">ﬁcial</text>
<text top="686" left="285" width="23" height="11" font="4"><a href="e71.full.html#44">(228</a></text>
<text top="684" left="308" width="29" height="15" font="4"><a href="e71.full.html#44">–230)</a></text>
<text top="686" left="336" width="3" height="11" font="12">.</text>
<text top="712" left="72" width="13" height="8" font="23">See</text>
<text top="712" left="88" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 34</a></text>
<text top="712" left="195" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="710" left="233" width="574" height="11" font="2">The EuroDIALE (European Study Group on Diabetes and the Lower Extremity) study demonstrated that the presence</text>
<text top="726" left="233" width="574" height="11" font="2">of both PAD and foot infection conferred a nearly 3-fold higher risk of leg amputation than either infection or PAD</text>
<text top="742" left="233" width="27" height="11" font="2">alone</text>
<text top="742" left="264" width="27" height="11" font="4"><a href="e71.full.html#44">(228)</a></text>
<text top="742" left="291" width="493" height="11" font="2">. The treatment of deep soft-tissue infection typically requires prompt surgical drainage; vascular</text>
<text top="757" left="233" width="564" height="11" font="2">imaging and expeditious revascularization generally follow. Experienced clinical teams have reported very good</text>
<text top="773" left="233" width="351" height="11" font="2">outcomes when this is performed in a coordinated and timely fashion</text>
<text top="773" left="588" width="50" height="11" font="4"><a href="e71.full.html#44">(229,230)</a></text>
<text top="773" left="638" width="166" height="11" font="2"><a href="e71.full.html#44">. </a>Previous groups have described</text>
<text top="789" left="233" width="574" height="11" font="2">various combinations of functions of interdisciplinary care teams (See Online Data Supplement 34a for a complete</text>
<text top="804" left="233" width="108" height="11" font="2">list of functions). See</text>
<text top="804" left="345" width="57" height="11" font="4"><a href="e71.full.html#32">Section 9.2</a></text>
<text top="804" left="405" width="388" height="11" font="2">for recommendations related to the role of the interdisciplinary care team in</text>
<text top="820" left="233" width="165" height="11" font="2">wound healing therapies for CLI.</text>
<text top="865" left="94" width="10" height="9" font="5">IIa</text>
<text top="865" left="160" width="20" height="9" font="5">C-EO</text>
<text top="852" left="233" width="414" height="11" font="12">It is reasonable to counsel patients with PAD without diabetes mellitus about self</text>
<text top="850" left="647" width="154" height="15" font="12">–foot examination and healthy</text>
<text top="867" left="233" width="76" height="11" font="12">foot behaviors.</text>
<text top="894" left="127" width="15" height="8" font="23">N/A</text>
<text top="894" left="233" width="355" height="11" font="2">Although there are limited data to support patient education about self</text>
<text top="892" left="588" width="219" height="15" font="2">–foot examination and foot care for patients</text>
<text top="909" left="233" width="574" height="11" font="2">with diabetes mellitus, there are no data that have evaluated this practice in a population of patients with PAD but</text>
<text top="925" left="233" width="497" height="11" font="2">without diabetes mellitus. Nonetheless, this is a very low-risk intervention with potential for bene</text>
<text top="923" left="730" width="76" height="15" font="2">ﬁt. Educational</text>
<text top="941" left="233" width="574" height="11" font="2">efforts generally include teaching patients about healthy foot behaviors (e.g., daily inspection of feet; foot care and</text>
<text top="956" left="233" width="533" height="11" font="2">hygiene, including appropriate toenail cutting strategies; avoidance of barefoot walking), the selection of</text>
<text top="972" left="233" width="67" height="11" font="2">appropriately</text>
<text top="970" left="304" width="433" height="15" font="2">ﬁtting shoes, and the importance of seeking medical attention for new foot problems</text>
<text top="972" left="741" width="26" height="11" font="4"><a href="e71.full.html#44">(223)</a></text>
<text top="972" left="767" width="3" height="11" font="2"><a href="e71.full.html#44">.</a></text>
<text top="1016" left="94" width="10" height="9" font="5">IIa</text>
<text top="1016" left="160" width="20" height="9" font="5">C-EO</text>
<text top="1004" left="233" width="498" height="11" font="12">Biannual foot examination by a clinician is reasonable for patients with PAD and diabetes mellitus.</text>
<text top="1041" left="127" width="15" height="8" font="23">N/A</text>
<text top="1041" left="233" width="303" height="11" font="2">A history of foot ulcers, foot infections, or amputation identi</text>
<text top="1039" left="536" width="270" height="15" font="2">ﬁes patients with a very high (&gt;10%) yearly incidence</text>
<text top="1057" left="233" width="93" height="11" font="2">of recurrent ulcers</text>
<text top="1057" left="330" width="25" height="11" font="4"><a href="e71.full.html#44">(231)</a></text>
<text top="1057" left="354" width="453" height="11" font="2">. Examination includes a visual inspection for foot ulcers (full-thickness epithelial defects)</text>
<text top="1072" left="233" width="202" height="11" font="2">and structural (bony) deformities, mono</text>
<text top="1070" left="435" width="364" height="15" font="2">ﬁlament testing for sensory neuropathy, and palpation for pedal pulses.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="792" width="15" height="9" font="5">e95</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1160" width="864">
<text top="460" left="108" width="309" height="16" font="14">8. REVASCULARIZATION FOR CLAUDICATION</text>
<text top="498" left="108" width="333" height="12" font="2">An individualized approach to revascularization for</text>
<text top="516" left="108" width="333" height="12" font="2">claudication is recommended for each patient to optimize</text>
<text top="534" left="108" width="333" height="12" font="2">outcome. Revascularization is but one component of</text>
<text top="552" left="108" width="333" height="12" font="2">care for the patient with claudication, as each patient</text>
<text top="569" left="108" width="333" height="12" font="2">should have a customized care plan that also includes</text>
<text top="587" left="108" width="104" height="12" font="2">medical therapy (</text>
<text top="587" left="212" width="54" height="12" font="4"><a href="e71.full.html#17">Section 5</a></text>
<text top="587" left="266" width="175" height="12" font="2"><a href="e71.full.html#17">), </a>structured exercise therapy</text>
<text top="605" left="108" width="4" height="12" font="2">(</text>
<text top="605" left="112" width="53" height="12" font="4"><a href="e71.full.html#23">Section 6</a></text>
<text top="605" left="165" width="203" height="12" font="2"><a href="e71.full.html#23">), </a>and care to minimize tissue loss (</text>
<text top="605" left="369" width="52" height="12" font="4"><a href="e71.full.html#25">Section 7</a></text>
<text top="605" left="421" width="20" height="12" font="2">). If</text>
<text top="623" left="108" width="333" height="12" font="2">a strategy of revascularization for claudication is under-</text>
<text top="641" left="108" width="333" height="12" font="2">taken, the revascularization strategy should be evidence</text>
<text top="659" left="108" width="333" height="12" font="2">based and can include endovascular revascularization,</text>
<text top="677" left="108" width="97" height="12" font="2">surgery, or both.</text>
<text top="695" left="123" width="318" height="12" font="2">Because of the variability of ischemic limb symptoms</text>
<text top="713" left="108" width="333" height="12" font="2">and impact of these symptoms on functional status and</text>
<text top="462" left="468" width="333" height="12" font="2">QoL, patients should be selected for revascularization</text>
<text top="480" left="468" width="333" height="12" font="2">on the basis of severity of their symptoms. Factors to</text>
<text top="498" left="468" width="146" height="12" font="2">consider include a signi</text>
<text top="496" left="614" width="188" height="15" font="2">ﬁcant disability as assessed by</text>
<text top="516" left="468" width="333" height="12" font="2">the patient, adequacy of response to medical and</text>
<text top="534" left="468" width="333" height="12" font="2">structured exercise therapy, status of comorbid condi-</text>
<text top="552" left="468" width="158" height="12" font="2">tions, and a favorable risk</text>
<text top="550" left="627" width="175" height="15" font="2">–beneﬁt ratio. Patient prefer-</text>
<text top="569" left="468" width="333" height="12" font="2">ences and goals of care are important considerations in</text>
<text top="587" left="468" width="333" height="12" font="2">the evaluation for revascularization. The revasculariza-</text>
<text top="605" left="468" width="333" height="12" font="2">tion strategy should have a reasonable likelihood of</text>
<text top="623" left="468" width="56" height="12" font="2">providing</text>
<text top="623" left="537" width="44" height="12" font="2">durable</text>
<text top="623" left="594" width="30" height="12" font="2">relief</text>
<text top="623" left="637" width="11" height="12" font="2">of</text>
<text top="623" left="661" width="64" height="12" font="2">symptoms.</text>
<text top="623" left="738" width="8" height="12" font="2">A</text>
<text top="623" left="759" width="43" height="12" font="2">general</text>
<text top="641" left="468" width="333" height="12" font="2">recommendation for revascularization as a treatment</text>
<text top="659" left="468" width="333" height="12" font="2">option for claudication is provided below followed by</text>
<text top="677" left="468" width="29" height="12" font="2">speci</text>
<text top="675" left="497" width="261" height="15" font="2">ﬁc recommendations for endovascular (</text>
<text top="677" left="759" width="42" height="12" font="4"><a href="e71.full.html#27">Section</a></text>
<text top="695" left="468" width="25" height="12" font="4"><a href="e71.full.html#27">8.1.1</a></text>
<text top="695" left="493" width="92" height="12" font="2">) and surgical <a href="e71.full.html#28">(</a></text>
<text top="695" left="585" width="75" height="12" font="4"><a href="e71.full.html#28">Section 8.1.2</a></text>
<text top="695" left="660" width="141" height="12" font="2">) procedures if a revas-</text>
<text top="713" left="468" width="212" height="12" font="2">cularization strategy is undertaken.</text>
<text top="766" left="108" width="302" height="11" font="12">8.1. Revascularization for Claudication: Recommendation</text>
<text top="803" left="57" width="311" height="11" font="22">Recommendation for Revascularization for Claudication</text>
<text top="844" left="83" width="19" height="10" font="13">COR</text>
<text top="844" left="156" width="18" height="10" font="13">LOE</text>
<text top="844" left="227" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="881" left="88" width="10" height="9" font="5">IIa</text>
<text top="881" left="162" width="6" height="9" font="5">A</text>
<text top="868" left="227" width="550" height="11" font="12">Revascularization is a reasonable treatment option for the patient with lifestyle-limiting claudication with an</text>
<text top="884" left="227" width="152" height="11" font="12">inadequate response to GDMT</text>
<text top="884" left="384" width="92" height="11" font="4"><a href="e71.full.html#39">(12,37,38,232,233)</a></text>
<text top="884" left="476" width="3" height="11" font="12"><a href="e71.full.html#39">.</a></text>
<text top="909" left="66" width="13" height="8" font="23">See</text>
<text top="909" left="82" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 35</a></text>
<text top="919" left="120" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 36</a></text>
<text top="919" left="147" width="2" height="8" font="23">.</text>
<text top="907" left="227" width="271" height="11" font="2">A minority of patients with claudication (estimated at</text>
<text top="905" left="502" width="286" height="15" font="2">&lt;10% to 15% over 5 years or more) will progress to CLI</text>
<text top="922" left="227" width="23" height="11" font="4"><a href="e71.full.html#44">(234</a></text>
<text top="920" left="250" width="27" height="15" font="4"><a href="e71.full.html#44">–237)</a></text>
<text top="922" left="277" width="515" height="11" font="2"><a href="e71.full.html#44">. </a>Therefore, the role of revascularization in claudication is improvement in claudication symptoms and</text>
<text top="938" left="227" width="560" height="11" font="2">functional status, and consequently in QoL, rather than limb salvage. Revascularization is reasonable when the</text>
<text top="954" left="227" width="574" height="11" font="2">patient who is being treated with GDMT (including structured exercise therapy) presents with persistent lifestyle-</text>
<text top="970" left="227" width="101" height="11" font="2">limiting claudication</text>
<text top="970" left="332" width="92" height="11" font="4"><a href="e71.full.html#39">(12,37,38,232,233)</a></text>
<text top="970" left="424" width="182" height="11" font="2">. Lifestyle-limiting claudication is de</text>
<text top="968" left="606" width="195" height="15" font="2">ﬁned by the patient rather than by any</text>
<text top="985" left="227" width="549" height="11" font="2">test. It includes impairment of activities of daily living and/or vocational and/or recreational activities due to</text>
<text top="1001" left="227" width="473" height="11" font="2">claudication. There should be clear discussion with the patient about expected risks and bene</text>
<text top="999" left="701" width="30" height="15" font="2">ﬁts of</text>
<text top="1017" left="227" width="407" height="11" font="2">revascularization, as well as discussion of the durability of proposed procedures.</text>
<text top="149" left="115" width="48" height="10" font="15">T A B L E 9</text>
<text top="149" left="179" width="191" height="10" font="16">Interdisciplinary Care Team for PAD</text>
<text top="171" left="108" width="692" height="9" font="13">A team of professionals representing different disciplines to assist in the evaluation and management of the patient with PAD. For the care of patients with CLI, the</text>
<text top="183" left="123" width="679" height="9" font="13">interdisciplinary care team should include individuals who are skilled in endovascular revascularization, surgical revascularization, wound healing therapies and foot</text>
<text top="195" left="123" width="175" height="9" font="13">surgery, and medical evaluation and care.</text>
<text top="212" left="108" width="6" height="10" font="7">n</text>
<text top="213" left="122" width="220" height="9" font="13">Interdisciplinary care team members may include:</text>
<text top="224" left="130" width="6" height="10" font="20">n</text>
<text top="225" left="144" width="594" height="9" font="13">Vascular medical and surgical specialists (i.e., vascular medicine, vascular surgery, interventional radiology, interventional cardiology)</text>
<text top="236" left="130" width="6" height="10" font="20">n</text>
<text top="237" left="144" width="30" height="9" font="13">Nurses</text>
<text top="248" left="130" width="6" height="10" font="20">n</text>
<text top="249" left="144" width="160" height="9" font="13">Orthopedic surgeons and podiatrists</text>
<text top="260" left="130" width="6" height="10" font="20">n</text>
<text top="261" left="144" width="73" height="9" font="13">Endocrinologists</text>
<text top="272" left="130" width="6" height="10" font="20">n</text>
<text top="273" left="144" width="125" height="9" font="13">Internal medicine specialists</text>
<text top="284" left="130" width="6" height="10" font="20">n</text>
<text top="285" left="144" width="127" height="9" font="13">Infectious disease specialists</text>
<text top="296" left="130" width="6" height="10" font="20">n</text>
<text top="297" left="144" width="188" height="9" font="13">Radiology and vascular imaging specialists</text>
<text top="308" left="130" width="6" height="10" font="20">n</text>
<text top="309" left="144" width="202" height="9" font="13">Physical medicine and rehabilitation clinicians</text>
<text top="320" left="130" width="6" height="10" font="20">n</text>
<text top="321" left="144" width="160" height="9" font="13">Orthotics and prosthetics specialists</text>
<text top="332" left="130" width="6" height="10" font="20">n</text>
<text top="333" left="144" width="63" height="9" font="13">Social workers</text>
<text top="344" left="130" width="6" height="10" font="20">n</text>
<text top="345" left="144" width="97" height="9" font="13">Exercise physiologists</text>
<text top="356" left="130" width="6" height="10" font="20">n</text>
<text top="356" left="144" width="161" height="9" font="13">Physical and occupational therapists</text>
<text top="368" left="130" width="6" height="10" font="20">n</text>
<text top="368" left="144" width="100" height="9" font="13">Nutritionists/dieticians</text>
<text top="392" left="108" width="273" height="8" font="5">CLI indicates critical limb ischemia; and PAD, peripheral artery disease.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="16" height="9" font="5">e96</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="283" height="11" font="2">8.1.1. Endovascular Revascularization for Claudication:</text>
<text top="161" left="94" width="95" height="11" font="2">Recommendations</text>
<text top="182" left="63" width="333" height="12" font="2">Endovascular techniques to treat claudication include</text>
<text top="200" left="63" width="333" height="12" font="2">balloon dilation (angioplasty), stents, and atherectomy.</text>
<text top="218" left="63" width="333" height="12" font="2">These techniques continue to involve and now include</text>
<text top="236" left="63" width="46" height="12" font="2">covered</text>
<text top="236" left="121" width="39" height="12" font="2">stents,</text>
<text top="236" left="173" width="73" height="12" font="2">drug-eluting</text>
<text top="236" left="259" width="35" height="12" font="2">stents</text>
<text top="236" left="307" width="35" height="12" font="2">(DES),</text>
<text top="236" left="355" width="41" height="12" font="2">cutting</text>
<text top="254" left="63" width="333" height="12" font="2">balloons, and drug-coated balloons. The technique</text>
<text top="272" left="63" width="333" height="12" font="2">chosen for endovascular treatment is related to lesion</text>
<text top="290" left="63" width="333" height="12" font="2">characteristics (e.g., anatomic location, lesion length,</text>
<text top="308" left="63" width="39" height="12" font="2">degree</text>
<text top="308" left="116" width="11" height="12" font="2">of</text>
<text top="308" left="142" width="26" height="12" font="2">calci</text>
<text top="306" left="168" width="228" height="15" font="2">ﬁcation) and operator experience.</text>
<text top="326" left="63" width="283" height="12" font="2">Assessment of the appropriateness of speci</text>
<text top="324" left="346" width="50" height="15" font="2">ﬁc end-</text>
<text top="344" left="63" width="185" height="12" font="2">ovascular techniques for speci</text>
<text top="342" left="248" width="148" height="15" font="2">ﬁc lesions for the treat-</text>
<text top="362" left="63" width="333" height="12" font="2">ment of claudication is beyond the scope of this</text>
<text top="380" left="63" width="62" height="12" font="2">document.</text>
<text top="143" left="438" width="318" height="12" font="2">Revascularization is performed on lesions that are</text>
<text top="161" left="423" width="218" height="12" font="2">deemed to be hemodynamically signi</text>
<text top="159" left="641" width="115" height="15" font="2">ﬁcant, and stenoses</text>
<text top="178" left="423" width="333" height="12" font="2">selected for endovascular treatment should have a</text>
<text top="196" left="423" width="333" height="12" font="2">reasonable likelihood of limiting perfusion to the distal</text>
<text top="214" left="423" width="333" height="12" font="2">limb. Stenoses of 50% to 75% diameter by angiography</text>
<text top="232" left="423" width="208" height="12" font="2">may not be hemodynamically signi</text>
<text top="230" left="632" width="125" height="15" font="2">ﬁcant, and resting or</text>
<text top="250" left="423" width="333" height="12" font="2">provoked intravascular pressure measurements may be</text>
<text top="268" left="423" width="301" height="12" font="2">used to determine whether lesions are signi</text>
<text top="266" left="724" width="32" height="15" font="2">ﬁcant</text>
<text top="286" left="423" width="52" height="12" font="4"><a href="e71.full.html#44">(238,239)</a></text>
<text top="286" left="476" width="281" height="12" font="2"><a href="e71.full.html#44">. </a>Multiple RCTs have compared endovascular</text>
<text top="304" left="423" width="333" height="12" font="2">procedures to various combinations of medical treatment</text>
<text top="322" left="423" width="333" height="12" font="2">with or without supervised or unsupervised exercise</text>
<text top="340" left="423" width="54" height="12" font="2">programs</text>
<text top="340" left="481" width="143" height="12" font="4"><a href="e71.full.html#39">(12,37,38,217,232,233,240</a></text>
<text top="338" left="624" width="28" height="15" font="4"><a href="e71.full.html#39">–251)</a></text>
<text top="340" left="652" width="104" height="12" font="2"><a href="e71.full.html#39">. </a>These trials have</text>
<text top="358" left="423" width="333" height="12" font="2">used different endpoints and enrolled patients with</text>
<text top="376" left="423" width="283" height="12" font="2">anatomic disease distribution at different levels.</text>
<text top="461" left="63" width="394" height="11" font="22">Recommendations for Endovascular Revascularization for Claudication</text>
<text top="502" left="89" width="19" height="10" font="13">COR</text>
<text top="502" left="161" width="18" height="10" font="13">LOE</text>
<text top="502" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="539" left="97" width="3" height="9" font="5">I</text>
<text top="539" left="168" width="6" height="9" font="5">A</text>
<text top="526" left="233" width="574" height="11" font="12">Endovascular procedures are effective as a revascularization option for patients with lifestyle-limiting claudication</text>
<text top="542" left="233" width="136" height="11" font="12">and hemodynamically signi</text>
<text top="539" left="369" width="167" height="15" font="12">ﬁcant aortoiliac occlusive disease</text>
<text top="542" left="540" width="140" height="11" font="4"><a href="e71.full.html#39">(12,37,38,232,240,242,246)</a></text>
<text top="542" left="680" width="3" height="11" font="12"><a href="e71.full.html#39">.</a></text>
<text top="567" left="71" width="13" height="8" font="23">See</text>
<text top="567" left="88" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 35</a></text>
<text top="577" left="126" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 36</a></text>
<text top="577" left="153" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="565" left="233" width="569" height="11" font="2">Two separate systematic analyses that included RCTs that enrolled patients with aortoiliac disease reported that</text>
<text top="580" left="233" width="396" height="11" font="2">endovascular treatment of claudication improved walking parameters and QoL</text>
<text top="580" left="633" width="52" height="11" font="4"><a href="e71.full.html#39">(11,12,233)</a></text>
<text top="580" left="685" width="92" height="11" font="2">. The CLEVER trial</text>
<text top="596" left="233" width="570" height="11" font="2">enrolled only patients with aortoiliac disease and compared endovascular therapy to supervised exercise therapy</text>
<text top="612" left="233" width="127" height="11" font="2">and to medications alone</text>
<text top="612" left="364" width="36" height="11" font="4"><a href="e71.full.html#40">(37,38)</a></text>
<text top="612" left="400" width="404" height="11" font="2"><a href="e71.full.html#40">. </a>At 6-month follow-up, both the endovascular therapy and supervised exercise</text>
<text top="627" left="233" width="552" height="11" font="2">groups had improved peak walking time compared with medication alone, with a greater improvement in the</text>
<text top="643" left="233" width="130" height="11" font="2">supervised exercise group</text>
<text top="643" left="367" width="20" height="11" font="4"><a href="e71.full.html#40">(37)</a></text>
<text top="643" left="387" width="175" height="11" font="2"><a href="e71.full.html#40">. </a>By 18 months, there was no signi</text>
<text top="641" left="562" width="219" height="15" font="2">ﬁcant difference between the endovascular</text>
<text top="659" left="233" width="316" height="11" font="2">therapy and supervised exercise groups, with a sustained bene</text>
<text top="657" left="549" width="136" height="15" font="2">ﬁt versus medication alone</text>
<text top="659" left="689" width="21" height="11" font="4"><a href="e71.full.html#40">(38)</a></text>
<text top="659" left="710" width="88" height="11" font="2"><a href="e71.full.html#40">. </a>Other RCTs that</text>
<text top="675" left="233" width="554" height="11" font="2">included patients with aortoiliac disease have shown QoL, as assessed by questionnaires and time to onset of</text>
<text top="690" left="233" width="574" height="11" font="2">claudication, may be superior with endovascular treatment in combination with a medical and an exercise treatment</text>
<text top="706" left="233" width="240" height="11" font="2">plan, compared versus medical treatment alone</text>
<text top="706" left="477" width="70" height="11" font="4"><a href="e71.full.html#44">(232,233,246)</a></text>
<text top="706" left="548" width="218" height="11" font="2"><a href="e71.full.html#44">. </a>The ERASE trial randomized patients with</text>
<text top="722" left="233" width="569" height="11" font="2">claudication and aortoiliac (as well as femoropopliteal) disease to endovascular revascularization plus supervised</text>
<text top="737" left="233" width="417" height="11" font="2">exercise or supervised exercise alone. After 1 year, patients in both groups had signi</text>
<text top="735" left="651" width="156" height="15" font="2">ﬁcant improvements in walking</text>
<text top="753" left="233" width="467" height="11" font="2">distances and health-related QoL, with greater improvements in the combined-therapy group</text>
<text top="753" left="703" width="26" height="11" font="4"><a href="e71.full.html#44">(218)</a></text>
<text top="753" left="729" width="78" height="11" font="2"><a href="e71.full.html#44">. </a>The long-term</text>
<text top="769" left="233" width="75" height="11" font="2">comparative ef</text>
<text top="767" left="308" width="484" height="15" font="2">ﬁcacy of endovascular revascularization versus supervised exercise therapy and medical therapy</text>
<text top="784" left="233" width="562" height="11" font="2">compared to supervised exercise therapy and medical therapy without revascularization for aortoiliac disease is</text>
<text top="800" left="233" width="49" height="11" font="2">unknown.</text>
<text top="845" left="94" width="10" height="9" font="5">IIa</text>
<text top="845" left="163" width="15" height="9" font="5">B-R</text>
<text top="832" left="233" width="524" height="11" font="12">Endovascular procedures are reasonable as a revascularization option for patients with lifestyle-limiting</text>
<text top="847" left="233" width="200" height="11" font="12">claudication and hemodynamically signi</text>
<text top="845" left="433" width="152" height="15" font="12">ﬁcant femoropopliteal disease</text>
<text top="847" left="588" width="64" height="11" font="4"><a href="e71.full.html#44">(217,232,243</a></text>
<text top="845" left="652" width="71" height="15" font="4"><a href="e71.full.html#44">–245,250,251)</a></text>
<text top="847" left="723" width="3" height="11" font="12">.</text>
<text top="874" left="72" width="13" height="8" font="23">See</text>
<text top="874" left="88" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 35</a></text>
<text top="874" left="194" width="2" height="8" font="23">.</text>
<text top="872" left="233" width="242" height="11" font="2">Multiple RCTs have demonstrated short-term ef</text>
<text top="870" left="475" width="332" height="15" font="2">ﬁcacy with endovascular treatment of femoropopliteal disease for</text>
<text top="888" left="233" width="394" height="11" font="2">claudication versus supervised exercise training or medical therapy, with bene</text>
<text top="886" left="627" width="140" height="15" font="2">ﬁt that diminishes by 1 year</text>
<text top="903" left="233" width="65" height="11" font="4"><a href="e71.full.html#44">(217,232,240</a></text>
<text top="901" left="298" width="72" height="15" font="4"><a href="e71.full.html#44">–246,250,251)</a></text>
<text top="903" left="370" width="411" height="11" font="2">. Two separate systematic reviews that included RCTs that enrolled patients with</text>
<text top="919" left="233" width="571" height="11" font="2">femoropopliteal disease, reported that endovascular treatment of claudication improved walking parameters and</text>
<text top="935" left="233" width="20" height="11" font="2">QoL</text>
<text top="935" left="257" width="52" height="11" font="4"><a href="e71.full.html#39">(11,12,233)</a></text>
<text top="935" left="309" width="482" height="11" font="2">. The durability of endovascular treatment for claudication is directly related to vessel patency.</text>
<text top="950" left="233" width="562" height="11" font="2">Long-term patency is greater in the iliac artery than in the femoropopliteal segment. Furthermore, durability is</text>
<text top="966" left="233" width="574" height="11" font="2">diminished with greater lesion length, occlusion rather than stenosis, the presence of multiple and diffuse lesions,</text>
<text top="982" left="233" width="446" height="11" font="2">poor-quality runoff, diabetes mellitus, chronic kidney disease, renal failure, and smoking</text>
<text top="982" left="683" width="22" height="11" font="4"><a href="e71.full.html#45">(252</a></text>
<text top="980" left="705" width="27" height="15" font="4"><a href="e71.full.html#45">–255)</a></text>
<text top="982" left="732" width="75" height="11" font="2">. The choice of</text>
<text top="998" left="233" width="561" height="11" font="2">endovascular therapy as a revascularization approach for claudication due to femoropopliteal disease therefore</text>
<text top="1013" left="233" width="574" height="11" font="2">should include a discussion of outcomes, addressing the risk of restenosis and repeat intervention, particularly for</text>
<text top="1029" left="233" width="262" height="11" font="2">lesions with poor likelihood of long-term durability.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="793" width="15" height="9" font="5">e97</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1160" width="864">
<text top="550" left="108" width="355" height="11" font="2">8.1.2. Surgical Revascularization for Claudication: Recommendations</text>
<text top="175" left="88" width="10" height="9" font="5">IIb</text>
<text top="175" left="155" width="20" height="9" font="5">C-LD</text>
<text top="162" left="227" width="552" height="11" font="12">The usefulness of endovascular procedures as a revascularization option for patients with claudication due to</text>
<text top="178" left="227" width="244" height="11" font="12">isolated infrapopliteal artery disease is unknown</text>
<text top="178" left="475" width="23" height="11" font="4"><a href="e71.full.html#45">(256</a></text>
<text top="176" left="498" width="28" height="15" font="4"><a href="e71.full.html#45">–258)</a></text>
<text top="178" left="526" width="3" height="11" font="12">.</text>
<text top="204" left="66" width="13" height="8" font="23">See</text>
<text top="204" left="83" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 35</a></text>
<text top="204" left="189" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="202" left="227" width="568" height="11" font="2">Isolated infrapopliteal disease is unlikely to cause claudication. Incidence of in-stent restenosis is high and long-</text>
<text top="218" left="227" width="52" height="11" font="2">term bene</text>
<text top="216" left="279" width="325" height="15" font="2">ﬁt lacking with bare-metal stenting of the infrapopliteal arteries</text>
<text top="218" left="608" width="27" height="11" font="4"><a href="e71.full.html#45">(256)</a></text>
<text top="218" left="635" width="140" height="11" font="2">. Studies that have enrolled</text>
<text top="234" left="227" width="341" height="11" font="2">patients with claudication as well as CLI have demonstrated a bene</text>
<text top="232" left="568" width="227" height="15" font="2">ﬁt of DES versus bare-metal stents or versus</text>
<text top="249" left="227" width="336" height="11" font="2">drug-coated balloons for revascularization of infrapopliteal lesions</text>
<text top="249" left="567" width="48" height="11" font="4"><a href="e71.full.html#45">(257,258)</a></text>
<text top="249" left="615" width="173" height="11" font="2">. However, these differences were</text>
<text top="265" left="227" width="574" height="11" font="2">mainly for patency and restenosis endpoints, and neither of these studies included patient-oriented outcomes, such</text>
<text top="281" left="227" width="263" height="11" font="2">as walking function or QoL parameters. Additional ef</text>
<text top="279" left="490" width="311" height="15" font="2">ﬁcacy data on the use of infrapopliteal drug-coated balloon or</text>
<text top="296" left="227" width="418" height="11" font="2">DES for the treatment of claudication are likely to be published in the near future.</text>
<text top="341" left="76" width="35" height="9" font="5">III: Harm</text>
<text top="341" left="154" width="21" height="9" font="5">B-NR</text>
<text top="328" left="227" width="548" height="11" font="12">Endovascular procedures should not be performed in patients with PAD solely to prevent progression to CLI</text>
<text top="344" left="227" width="23" height="11" font="4"><a href="e71.full.html#44">(234</a></text>
<text top="342" left="250" width="72" height="15" font="4"><a href="e71.full.html#44">–237,259–261)</a></text>
<text top="344" left="322" width="3" height="11" font="12">.</text>
<text top="370" left="65" width="13" height="8" font="23">See</text>
<text top="370" left="82" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 36</a></text>
<text top="381" left="120" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 38</a></text>
<text top="381" left="147" width="2" height="8" font="23">.</text>
<text top="368" left="227" width="574" height="11" font="2">There are no data to support a practice paradigm of performing endovascular procedures on patients with PAD for</text>
<text top="384" left="227" width="532" height="11" font="2">the purpose of preventing progression of claudication symptoms to CLI. Reported rates of amputation or</text>
<text top="400" left="227" width="421" height="11" font="2">progression to CLI from prospective cohort studies of patients with claudication are</text>
<text top="398" left="652" width="149" height="15" font="2">&lt;10% to 15% over 5 years or</text>
<text top="415" left="227" width="574" height="11" font="2">more, and increased mortality rate associated with claudication is usually the result of cardiovascular events rather</text>
<text top="431" left="227" width="125" height="11" font="2">than limb-related events</text>
<text top="431" left="356" width="23" height="11" font="4"><a href="e71.full.html#44">(234</a></text>
<text top="429" left="379" width="49" height="15" font="4"><a href="e71.full.html#44">–237,262)</a></text>
<text top="431" left="428" width="371" height="11" font="2"><a href="e71.full.html#44">. </a>Similarly, there are no data to support revascularization in patients with</text>
<text top="447" left="227" width="565" height="11" font="2">asymptomatic PAD. Procedural risks include bleeding, renal failure from contrast-induced nephropathy, and the</text>
<text top="462" left="227" width="184" height="11" font="2">possibility of adverse limb outcomes</text>
<text top="462" left="416" width="23" height="11" font="4"><a href="e71.full.html#45">(259</a></text>
<text top="460" left="439" width="27" height="15" font="4"><a href="e71.full.html#45">–261)</a></text>
<text top="462" left="466" width="335" height="11" font="2"><a href="e71.full.html#45">. </a>Therefore, the known risks of endovascular procedures outweigh</text>
<text top="478" left="227" width="112" height="11" font="2">any hypothetical bene</text>
<text top="476" left="339" width="386" height="15" font="2">ﬁt of preventing progression from asymptomatic PAD or claudication to CLI.</text>
<text top="581" left="57" width="365" height="11" font="22">Recommendations for Surgical Revascularization for Claudication</text>
<text top="622" left="83" width="19" height="10" font="13">COR</text>
<text top="622" left="156" width="18" height="10" font="13">LOE</text>
<text top="622" left="227" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="659" left="92" width="3" height="9" font="5">I</text>
<text top="659" left="162" width="6" height="9" font="5">A</text>
<text top="646" left="227" width="574" height="11" font="12">When surgical revascularization is performed, bypass to the popliteal artery with autogenous vein is recommended</text>
<text top="662" left="227" width="208" height="11" font="12">in preference to prosthetic graft material</text>
<text top="662" left="439" width="23" height="11" font="4"><a href="e71.full.html#45">(263</a></text>
<text top="660" left="462" width="25" height="15" font="4"><a href="e71.full.html#45">–271)</a></text>
<text top="662" left="487" width="3" height="11" font="12">.</text>
<text top="687" left="66" width="13" height="8" font="23">See</text>
<text top="687" left="82" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 37</a></text>
<text top="697" left="120" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 38</a></text>
<text top="697" left="147" width="2" height="8" font="23">.</text>
<text top="685" left="227" width="49" height="11" font="2">The super</text>
<text top="683" left="276" width="525" height="15" font="2">ﬁcial femoral and proximal popliteal arteries are the most common anatomic sites of stenosis or occlusion</text>
<text top="700" left="227" width="550" height="11" font="2">among individuals with claudication. Femoral-popliteal bypass is therefore one of the most common surgical</text>
<text top="716" left="227" width="573" height="11" font="2">procedures for claudication and may be performed under general or regional anesthesia. The type of conduit and</text>
<text top="732" left="227" width="574" height="11" font="2">site of popliteal artery anastomosis (above versus below knee) are major determinants of outcomes associated with</text>
<text top="748" left="227" width="385" height="11" font="2">femoral-popliteal bypass. Systematic reviews and meta-analyses have identi</text>
<text top="746" left="612" width="175" height="15" font="2">ﬁed a clear and consistent primary</text>
<text top="763" left="227" width="68" height="11" font="2">patency bene</text>
<text top="761" left="295" width="390" height="15" font="2">ﬁt for autogenous vein versus to prosthetic grafts for popliteal artery bypass</text>
<text top="763" left="689" width="47" height="11" font="4"><a href="e71.full.html#45">(270,271)</a></text>
<text top="763" left="736" width="57" height="11" font="2"><a href="e71.full.html#45">. </a>Prosthetic</text>
<text top="779" left="227" width="520" height="11" font="2">grafts to the popliteal artery above the knee have reduced patency rates and increased rates of repeat</text>
<text top="795" left="227" width="61" height="11" font="2">intervention</text>
<text top="795" left="292" width="95" height="11" font="4"><a href="e71.full.html#45">(263,266,269,272)</a></text>
<text top="795" left="387" width="381" height="11" font="2"><a href="e71.full.html#45">. </a>Sparse evidence suggests a long-term patency advantage for Dacron over</text>
<text top="810" left="227" width="46" height="11" font="2">polytetra</text>
<text top="808" left="273" width="308" height="15" font="2">ﬂuoroethylene (known as PTFE) graft for above-knee bypass</text>
<text top="810" left="585" width="27" height="11" font="4"><a href="e71.full.html#45">(270)</a></text>
<text top="810" left="612" width="74" height="11" font="2">, although this</text>
<text top="808" left="689" width="104" height="15" font="2">ﬁnding has not been</text>
<text top="826" left="227" width="191" height="11" font="2">consistently demonstrated in all RCTs</text>
<text top="826" left="422" width="71" height="11" font="4"><a href="e71.full.html#45">(266,273,274)</a></text>
<text top="826" left="493" width="3" height="11" font="2"><a href="e71.full.html#45">.</a></text>
<text top="870" left="88" width="10" height="9" font="5">IIa</text>
<text top="870" left="154" width="21" height="9" font="5">B-NR</text>
<text top="858" left="227" width="574" height="11" font="12">Surgical procedures are reasonable as a revascularization option for patients with lifestyle-limiting claudication with</text>
<text top="873" left="227" width="561" height="11" font="12">inadequate response to GDMT, acceptable perioperative risk, and technical factors suggesting advantages over</text>
<text top="889" left="227" width="125" height="11" font="12">endovascular procedures</text>
<text top="889" left="356" width="65" height="11" font="4"><a href="e71.full.html#44">(232,265,275</a></text>
<text top="887" left="421" width="26" height="15" font="4"><a href="e71.full.html#44">–277)</a></text>
<text top="889" left="448" width="3" height="11" font="12"><a href="e71.full.html#44">.</a></text>
<text top="915" left="66" width="13" height="8" font="23">See</text>
<text top="915" left="82" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 37</a></text>
<text top="926" left="120" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 38</a></text>
<text top="926" left="147" width="2" height="8" font="23">.</text>
<text top="913" left="227" width="574" height="11" font="2">Systematic reviews have concluded that surgical procedures are an effective treatment for claudication and have a</text>
<text top="929" left="227" width="314" height="11" font="2">positive impact on QoL and walking parameters but have identi</text>
<text top="927" left="542" width="259" height="15" font="2">ﬁed sparse evidence supporting the effectiveness of</text>
<text top="945" left="227" width="205" height="11" font="2">surgery compared with other treatments</text>
<text top="945" left="437" width="82" height="11" font="4"><a href="e71.full.html#39">(11,233,278,279)</a></text>
<text top="945" left="519" width="281" height="11" font="2"><a href="e71.full.html#39">. </a>Although symptom and patency outcomes for surgical</text>
<text top="960" left="227" width="427" height="11" font="2">interventions may be superior versus less invasive endovascular treatments for speci</text>
<text top="958" left="655" width="101" height="15" font="2">ﬁc patients, surgical</text>
<text top="976" left="227" width="410" height="11" font="2">interventions are also associated with greater risk of adverse perioperative events</text>
<text top="976" left="641" width="25" height="11" font="4"><a href="e71.full.html#45">(280</a></text>
<text top="974" left="665" width="29" height="15" font="4"><a href="e71.full.html#45">–286)</a></text>
<text top="976" left="695" width="107" height="11" font="2"><a href="e71.full.html#45">. </a>Treatment selection</text>
<text top="992" left="227" width="310" height="11" font="2">should therefore be individualized on the basis of the patient</text>
<text top="990" left="538" width="258" height="15" font="2">’s goals, perioperative risk, and anticipated beneﬁt.</text>
<text top="1007" left="227" width="536" height="11" font="2">Surgical procedures for claudication are usually reserved for individuals who a) do not derive adequate bene</text>
<text top="1005" left="763" width="38" height="15" font="2">ﬁt from</text>
<text top="1023" left="227" width="561" height="11" font="2">nonsurgical therapy, b) have arterial anatomy favorable to obtaining a durable result with surgery, and c) have</text>
<text top="1039" left="227" width="342" height="11" font="2">acceptable risk of perioperative adverse events. Acceptable risk is de</text>
<text top="1037" left="570" width="231" height="15" font="2">ﬁned by the individual patient and provider on</text>
<text top="1054" left="227" width="556" height="11" font="2">the basis of symptom severity, comorbid conditions, and appropriate GDMT risk evaluation. Guidelines for the</text>
<text top="1070" left="227" width="562" height="11" font="2">evaluation and management of patients undergoing noncardiac surgery, including vascular surgical procedures,</text>
<text top="1086" left="227" width="159" height="11" font="2">have been previously published</text>
<text top="1086" left="390" width="19" height="11" font="4"><a href="e71.full.html#39">(21)</a></text>
<text top="1086" left="409" width="3" height="11" font="2"><a href="e71.full.html#39">.</a></text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="16" height="9" font="5">e98</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1160" width="864">
<text top="442" left="63" width="164" height="16" font="14">9. MANAGEMENT OF CLI</text>
<text top="480" left="63" width="333" height="12" font="2">Patients with CLI are at increased risk of amputation and</text>
<text top="498" left="63" width="333" height="12" font="2">major cardiovascular ischemic events. Care of the patient</text>
<text top="516" left="63" width="333" height="12" font="2">with CLI includes evaluation for revascularization and</text>
<text top="444" left="423" width="333" height="12" font="2">wound healing therapies, with the objective to minimize</text>
<text top="462" left="423" width="333" height="12" font="2">tissue loss, completely heal wounds, and preserve a</text>
<text top="480" left="423" width="333" height="12" font="2">functional foot. Medical therapy to prevent cardiovascu-</text>
<text top="498" left="423" width="333" height="12" font="2">lar ischemic events is also an important component of</text>
<text top="516" left="423" width="174" height="12" font="2">care for the patient with CLI <a href="e71.full.html#17">(</a></text>
<text top="516" left="597" width="53" height="12" font="4"><a href="e71.full.html#17">Section 5</a></text>
<text top="516" left="650" width="8" height="12" font="2">).</text>
<text top="566" left="63" width="259" height="11" font="12">9.1. Revascularization for CLI: Recommendations</text>
<text top="175" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="175" left="163" width="15" height="9" font="5">B-R</text>
<text top="162" left="233" width="574" height="11" font="12">Femoral-tibial artery bypasses with prosthetic graft material should not be used for the treatment of claudication</text>
<text top="178" left="233" width="23" height="11" font="4"><a href="e71.full.html#45">(287</a></text>
<text top="176" left="256" width="29" height="15" font="4"><a href="e71.full.html#45">–289)</a></text>
<text top="178" left="285" width="3" height="11" font="12">.</text>
<text top="204" left="72" width="13" height="8" font="23">See</text>
<text top="204" left="89" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 37</a></text>
<text top="204" left="194" width="2" height="8" font="23">.</text>
<text top="202" left="233" width="574" height="11" font="2">Bypasses to the tibial arteries with prosthetic material for treatment of claudication should be avoided because of</text>
<text top="218" left="233" width="236" height="11" font="2">very high rates of graft failure and amputation</text>
<text top="218" left="473" width="23" height="11" font="4"><a href="e71.full.html#45">(287</a></text>
<text top="216" left="496" width="29" height="15" font="4"><a href="e71.full.html#45">–289)</a></text>
<text top="218" left="525" width="3" height="11" font="2"><a href="e71.full.html#45">.</a></text>
<text top="262" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="262" left="160" width="21" height="9" font="5">B-NR</text>
<text top="250" left="233" width="522" height="11" font="12">Surgical procedures should not be performed in patients with PAD solely to prevent progression to CLI</text>
<text top="265" left="233" width="23" height="11" font="4"><a href="e71.full.html#44">(234</a></text>
<text top="263" left="256" width="49" height="15" font="4"><a href="e71.full.html#44">–237,262)</a></text>
<text top="265" left="305" width="3" height="11" font="12">.</text>
<text top="292" left="72" width="13" height="8" font="23">See</text>
<text top="292" left="88" width="109" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 37</a></text>
<text top="302" left="126" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 38</a></text>
<text top="302" left="153" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="290" left="233" width="540" height="11" font="2">Claudication does not commonly progress to CLI. Reported rates of amputation or progression to CLI from</text>
<text top="306" left="233" width="300" height="11" font="2">prospective cohort studies of patients with claudication are</text>
<text top="304" left="537" width="248" height="15" font="2">&lt;10% to 15% for 5 years or more, and increased</text>
<text top="321" left="233" width="568" height="11" font="2">mortality rate associated with claudication is usually the result of cardiovascular events rather than limb-related</text>
<text top="337" left="233" width="33" height="11" font="2">events</text>
<text top="337" left="270" width="23" height="11" font="4"><a href="e71.full.html#44">(234</a></text>
<text top="335" left="293" width="49" height="15" font="4"><a href="e71.full.html#44">–237,262)</a></text>
<text top="337" left="342" width="451" height="11" font="2"><a href="e71.full.html#44">. </a>Surgical intervention should not be performed primarily to prevent disease progression,</text>
<text top="353" left="233" width="356" height="11" font="2">given the risk of adverse perioperative events without potential for signi</text>
<text top="351" left="589" width="218" height="15" font="2">ﬁcant beneﬁt. Similarly, there are no data to</text>
<text top="368" left="233" width="505" height="11" font="2">support surgical revascularization in patients with asymptomatic PAD to prevent progression to CLI.</text>
<text top="598" left="63" width="259" height="11" font="22">Recommendation for Revascularization for CLI</text>
<text top="639" left="89" width="19" height="10" font="13">COR</text>
<text top="639" left="161" width="18" height="10" font="13">LOE</text>
<text top="639" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="676" left="97" width="3" height="9" font="5">I</text>
<text top="676" left="160" width="21" height="9" font="5">B-NR</text>
<text top="663" left="233" width="492" height="11" font="12">In patients with CLI, revascularization should be performed when possible to minimize tissue loss</text>
<text top="663" left="729" width="29" height="11" font="4"><a href="e71.full.html#45">(290)</a></text>
<text top="663" left="758" width="3" height="11" font="12"><a href="e71.full.html#45">.</a></text>
<text top="710" left="78" width="13" height="8" font="23">See</text>
<text top="710" left="94" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 39</a></text>
<text top="710" left="201" width="2" height="8" font="23">.</text>
<text top="697" left="233" width="574" height="11" font="2">Patients with CLI are at high risk of major cardiovascular ischemic events, as well as nonhealing wounds and major</text>
<text top="713" left="233" width="542" height="11" font="2">amputation. In a systematic review of 13 studies of patients with CLI who did not receive revascularization,</text>
<text top="729" left="233" width="560" height="11" font="2">which included patients enrolled in medical and angiogenic therapy trials, there was a 22% all-cause mortality</text>
<text top="744" left="233" width="394" height="11" font="2">rate and a 22% rate of major amputation at a median follow-up of 12 months</text>
<text top="744" left="631" width="29" height="11" font="4"><a href="e71.full.html#45">(290)</a></text>
<text top="744" left="659" width="121" height="11" font="2">. The goal of surgical or</text>
<text top="760" left="233" width="288" height="11" font="2">endovascular revascularization is to provide in-line blood</text>
<text top="758" left="525" width="248" height="15" font="2">ﬂow to the foot through at least 1 patent artery,</text>
<text top="776" left="233" width="548" height="11" font="2">which will help decrease ischemic pain and allow healing of any wounds, while preserving a functional limb.</text>
<text top="791" left="233" width="558" height="11" font="2">Multiple RCTs comparing contemporary surgical and endovascular treatment for patients with CLI are ongoing</text>
<text top="807" left="233" width="47" height="11" font="4"><a href="e71.full.html#39">(15,16,17)</a></text>
<text top="807" left="280" width="356" height="11" font="2">. Revascularization is not warranted in the setting of a nonviable limb.</text>
<text top="851" left="97" width="3" height="9" font="5">I</text>
<text top="851" left="160" width="20" height="9" font="5">C-EO</text>
<text top="839" left="233" width="496" height="11" font="12">An evaluation for revascularization options should be performed by an interdisciplinary care team <a href="e71.full.html#26">(</a></text>
<text top="839" left="729" width="38" height="11" font="4"><a href="e71.full.html#26">Table 9</a></text>
<text top="839" left="767" width="40" height="11" font="12">) before</text>
<text top="854" left="233" width="178" height="11" font="12">amputation in the patient with CLI.</text>
<text top="881" left="127" width="15" height="8" font="23">N/A</text>
<text top="881" left="233" width="569" height="11" font="2">Patients with CLI should be evaluated by an interdisciplinary care team. Before amputation, evaluation generally</text>
<text top="896" left="233" width="574" height="11" font="2">includes imaging for assessment of revascularization options (e.g., duplex ultrasound, CTA, MRA, or catheter-based</text>
<text top="912" left="233" width="525" height="11" font="2">angiogram). The objective of this strategy is to minimize tissue loss and preserve a functional limb with</text>
<text top="928" left="233" width="87" height="11" font="2">revascularization.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="792" width="16" height="9" font="5">e99</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="11" font="2">9.1.1. Endovascular Revascularization for CLI: Recommendations</text>
<text top="189" left="57" width="343" height="11" font="22">Recommendations for Endovascular Revascularization for CLI</text>
<text top="230" left="83" width="19" height="10" font="13">COR</text>
<text top="230" left="156" width="18" height="10" font="13">LOE</text>
<text top="230" left="227" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="267" left="92" width="3" height="9" font="5">I</text>
<text top="267" left="157" width="15" height="9" font="5">B-R</text>
<text top="255" left="227" width="349" height="11" font="12">Endovascular procedures are recommended to establish in-line blood</text>
<text top="253" left="580" width="222" height="15" font="12">ﬂow to the foot in patients with nonhealing</text>
<text top="270" left="227" width="103" height="11" font="12">wounds or gangrene</text>
<text top="270" left="335" width="49" height="11" font="4"><a href="e71.full.html#45">(292,293)</a></text>
<text top="270" left="384" width="3" height="11" font="12"><a href="e71.full.html#45">.</a></text>
<text top="295" left="66" width="13" height="8" font="23">See</text>
<text top="295" left="82" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 39</a></text>
<text top="295" left="189" width="2" height="8" font="23">.</text>
<text top="293" left="227" width="531" height="11" font="2">The technique chosen for endovascular treatment of CLI is related to anatomic location of lesions, lesion</text>
<text top="309" left="227" width="496" height="11" font="2">characteristics, and operator experience. Revascularization is performed on hemodynamically signi</text>
<text top="307" left="723" width="75" height="15" font="2">ﬁcant stenoses</text>
<text top="325" left="227" width="174" height="11" font="2">that are likely to be limiting blood</text>
<text top="323" left="405" width="366" height="15" font="2">ﬂow to the limb. For stenoses of 50% to 75%, where the hemodynamic</text>
<text top="340" left="227" width="23" height="11" font="2">signi</text>
<text top="338" left="250" width="551" height="15" font="2">ﬁcance is unclear, intravascular pressure measurements may be used to determine hemodynamic signiﬁcance</text>
<text top="356" left="227" width="28" height="11" font="4"><a href="e71.full.html#45">(294)</a></text>
<text top="356" left="255" width="546" height="11" font="2">. The BASIL (Bypass versus Angioplasty in Severe Ischemia of the Leg) RCT demonstrated that endovascular</text>
<text top="372" left="227" width="456" height="11" font="2">revascularization is an effective option for patients with CLI as compared with open surgery</text>
<text top="372" left="686" width="49" height="11" font="4"><a href="e71.full.html#45">(292,293)</a></text>
<text top="372" left="736" width="66" height="11" font="2"><a href="e71.full.html#45">. </a>The primary</text>
<text top="387" left="227" width="574" height="11" font="2">endpoint of amputation-free survival was the same in the endovascular and surgical arms. Of note, the endovascular</text>
<text top="403" left="227" width="95" height="11" font="2">arm used only PTA</text>
<text top="403" left="326" width="49" height="11" font="4"><a href="e71.full.html#45">(292,293)</a></text>
<text top="403" left="376" width="412" height="11" font="2"><a href="e71.full.html#45">. </a>Multiple RCTs comparing contemporary surgical and endovascular treatment for</text>
<text top="419" left="227" width="149" height="11" font="2">patients with CLI are ongoing</text>
<text top="419" left="380" width="47" height="11" font="4"><a href="e71.full.html#39">(15,16,17)</a></text>
<text top="419" left="427" width="3" height="11" font="2">.</text>
<text top="419" left="434" width="44" height="11" font="4"><a href="e71.full.html#31">Table 10</a></text>
<text top="419" left="482" width="297" height="11" font="2">addresses factors that may prompt an endovascular versus</text>
<text top="435" left="227" width="210" height="11" font="2">surgical approach to the patient with CLI.</text>
<text top="479" left="88" width="10" height="9" font="5">IIa</text>
<text top="479" left="155" width="20" height="9" font="5">C-LD</text>
<text top="466" left="227" width="482" height="11" font="12">A staged approach to endovascular procedures is reasonable in patients with ischemic rest pain</text>
<text top="466" left="713" width="50" height="11" font="4"><a href="e71.full.html#46">(295,296)</a></text>
<text top="466" left="764" width="3" height="11" font="12"><a href="e71.full.html#46">.</a></text>
<text top="504" left="121" width="15" height="8" font="23">N/A</text>
<text top="503" left="227" width="371" height="11" font="2">For patients with multilevel disease who suffer from ischemic rest pain, in-</text>
<text top="501" left="598" width="203" height="15" font="2">ﬂow lesions are generally addressed ﬁrst</text>
<text top="519" left="227" width="50" height="11" font="4"><a href="e71.full.html#46">(295,296)</a></text>
<text top="519" left="278" width="499" height="11" font="2"><a href="e71.full.html#46">. </a>Depending on procedural characteristics, including contrast volume used, radiation exposure, and</text>
<text top="535" left="227" width="105" height="11" font="2">procedure time, out-</text>
<text top="533" left="332" width="469" height="15" font="2">ﬂow lesions can be addressed in the same setting or at a later time if symptoms persist. This</text>
<text top="551" left="227" width="574" height="11" font="2">strategy for ischemic rest pain is distinct from the strategy recommended for CLI in the patient with a nonhealing</text>
<text top="566" left="227" width="327" height="11" font="2">wound or gangrene. In that scenario, restoration of direct in-line</text>
<text top="564" left="559" width="239" height="15" font="2">ﬂow to the foot is essential for wound healing.</text>
<text top="611" left="88" width="10" height="9" font="5">IIa</text>
<text top="611" left="157" width="15" height="9" font="5">B-R</text>
<text top="598" left="227" width="484" height="11" font="12">Evaluation of lesion characteristics can be useful in selecting the endovascular approach for CLI</text>
<text top="598" left="715" width="50" height="11" font="4"><a href="e71.full.html#46">(297,298)</a></text>
<text top="598" left="765" width="3" height="11" font="12">.</text>
<text top="636" left="66" width="13" height="8" font="23">See</text>
<text top="636" left="82" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 39</a></text>
<text top="636" left="189" width="2" height="8" font="23">.</text>
<text top="634" left="227" width="546" height="11" font="2">The lesion characteristics to consider include length, anatomic location, and extent of occlusive disease. For</text>
<text top="649" left="227" width="435" height="11" font="2">example, if an adequate angioplasty result can be achieved with PTA alone for short (</text>
<text top="647" left="663" width="123" height="15" font="2">&lt;10 cm) stenoses in the</text>
<text top="665" left="227" width="322" height="11" font="2">femoropopliteal segment, then stent placement is not necessary</text>
<text top="665" left="552" width="50" height="11" font="4"><a href="e71.full.html#46">(297,298)</a></text>
<text top="665" left="602" width="162" height="11" font="2">. Presence of thrombosis or calci</text>
<text top="663" left="764" width="37" height="15" font="2">ﬁcation</text>
<text top="681" left="227" width="569" height="11" font="2">at the lesion site will also affect the endovascular approach. In general, the advantages of DES and drug-coated</text>
<text top="696" left="227" width="542" height="11" font="2">balloons over PTA alone or bare-metal stents are more consistent in the femoropopliteal segment than for</text>
<text top="712" left="227" width="136" height="11" font="2">infrapopliteal interventions</text>
<text top="712" left="366" width="67" height="11" font="4"><a href="e71.full.html#45">(257,258,299</a></text>
<text top="710" left="434" width="30" height="15" font="4"><a href="e71.full.html#45">–309)</a></text>
<text top="712" left="463" width="338" height="11" font="2">. However, these differences are mainly for patency, restenosis, and</text>
<text top="728" left="227" width="564" height="11" font="2">repeat-revascularization endpoints. Most studies were underpowered or did not examine other patient-oriented</text>
<text top="743" left="227" width="569" height="11" font="2">outcomes, such as amputation or wound healing in CLI. Endovascular techniques continue to evolve rapidly, and</text>
<text top="759" left="227" width="428" height="11" font="2">there has been limited literature comparing techniques with regard to clinically signi</text>
<text top="757" left="655" width="124" height="15" font="2">ﬁcant outcomes, such as</text>
<text top="775" left="227" width="152" height="11" font="2">amputation or wound healing.</text>
<text top="819" left="88" width="10" height="9" font="5">IIb</text>
<text top="819" left="154" width="21" height="9" font="5">B-NR</text>
<text top="807" left="227" width="574" height="11" font="12">Use of angiosome-directed endovascular therapy may be reasonable for patients with CLI and nonhealing wounds</text>
<text top="822" left="227" width="61" height="11" font="12">or gangrene</text>
<text top="822" left="292" width="22" height="11" font="4"><a href="e71.full.html#46">(310</a></text>
<text top="820" left="314" width="27" height="15" font="4"><a href="e71.full.html#46">–319)</a></text>
<text top="822" left="341" width="3" height="11" font="12"><a href="e71.full.html#46">.</a></text>
<text top="849" left="65" width="13" height="8" font="23">See</text>
<text top="849" left="82" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 39</a></text>
<text top="859" left="120" width="28" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 40</a></text>
<text top="859" left="148" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="847" left="227" width="558" height="11" font="2">During the past decade, the goal of care with regard to endovascular therapy for the treatment of nonhealing</text>
<text top="862" left="227" width="323" height="11" font="2">wounds due to CLI has been establishment of direct in-line blood</text>
<text top="860" left="554" width="248" height="15" font="2">ﬂow to the affected limb. The angiosome concept</text>
<text top="878" left="227" width="570" height="11" font="2">has also been described in the literature in relation to the treatment of nonhealing wounds. Angiosome-directed</text>
<text top="894" left="227" width="215" height="11" font="2">treatment entails establishing direct blood</text>
<text top="892" left="446" width="352" height="15" font="2">ﬂow to the infrapopliteal artery directly responsible for perfusing the</text>
<text top="910" left="227" width="565" height="11" font="2">region of the leg or foot with the nonhealing wound. Multiple retrospective studies and 1 small nonrandomized</text>
<text top="925" left="227" width="170" height="11" font="2">prospective study assessing the ef</text>
<text top="923" left="398" width="211" height="15" font="2">ﬁcacy of this concept have been published</text>
<text top="925" left="612" width="42" height="11" font="4"><a href="e71.full.html#42">(119,310</a></text>
<text top="923" left="654" width="26" height="15" font="4"><a href="e71.full.html#42">–321)</a></text>
<text top="925" left="679" width="122" height="11" font="2">. Meta-analyses of these</text>
<text top="941" left="227" width="567" height="11" font="2">studies found improved wound healing and limb salvage with angiosome-guided therapy but cautioned that the</text>
<text top="957" left="227" width="159" height="11" font="2">quality of the evidence was low</text>
<text top="957" left="389" width="47" height="11" font="4"><a href="e71.full.html#46">(322,323)</a></text>
<text top="957" left="436" width="365" height="11" font="2">. Although the angiosome concept is theoretically satisfying, randomized</text>
<text top="972" left="227" width="222" height="11" font="2">data comparing the establishment of in-line</text>
<text top="970" left="453" width="328" height="15" font="2">ﬂow versus angiosome-guided therapy have yet to be published.</text>
<text top="988" left="227" width="369" height="11" font="2">Furthermore, there is no evidence yet to demonstrate the potential bene</text>
<text top="986" left="597" width="192" height="15" font="2">ﬁt of treating additional infrapopliteal</text>
<text top="1004" left="227" width="100" height="11" font="2">arteries once in-line</text>
<text top="1002" left="331" width="462" height="15" font="2">ﬂow has been established in one artery, regardless of angiosome. Important considerations</text>
<text top="1019" left="227" width="539" height="11" font="2">with regard to angiosome-guided therapy include the potential for longer procedural times, more contrast</text>
<text top="1035" left="227" width="573" height="11" font="2">exposure, and more technically complex procedures. The impact of all these factors needs to be weighed against</text>
<text top="1051" left="227" width="432" height="11" font="2">the likelihood of a technically successful procedure providing hypothetical added bene</text>
<text top="1049" left="659" width="142" height="15" font="2">ﬁt over the establishment of</text>
<text top="1066" left="227" width="64" height="11" font="2">in-line blood</text>
<text top="1064" left="295" width="25" height="15" font="2">ﬂow.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="21" height="9" font="5">e100</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1160" width="864">
<text top="527" left="63" width="308" height="11" font="2">9.1.2. Surgical Revascularization for CLI: Recommendations</text>
<text top="557" left="63" width="313" height="11" font="22">Recommendations for Surgical Revascularization for CLI</text>
<text top="596" left="89" width="19" height="10" font="13">COR</text>
<text top="596" left="161" width="18" height="10" font="13">LOE</text>
<text top="596" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="633" left="97" width="3" height="9" font="5">I</text>
<text top="633" left="168" width="6" height="9" font="5">A</text>
<text top="621" left="233" width="570" height="11" font="12">When surgery is performed for CLI, bypass to the popliteal or infrapopliteal arteries (i.e., tibial, pedal) should be</text>
<text top="636" left="233" width="214" height="11" font="12">constructed with suitable autogenous vein</text>
<text top="636" left="451" width="95" height="11" font="4"><a href="e71.full.html#45">(263,266,269,272)</a></text>
<text top="636" left="546" width="3" height="11" font="12"><a href="e71.full.html#45">.</a></text>
<text top="661" left="72" width="13" height="8" font="23">See</text>
<text top="661" left="89" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 37</a></text>
<text top="661" left="194" width="2" height="8" font="23">.</text>
<text top="659" left="233" width="574" height="11" font="2">Many large RCTs have demonstrated that bypasses above the knee should be autogenous vein either reversed or in</text>
<text top="675" left="233" width="42" height="11" font="2">situ vein</text>
<text top="675" left="279" width="95" height="11" font="4"><a href="e71.full.html#45">(263,266,269,272)</a></text>
<text top="675" left="374" width="260" height="11" font="2"><a href="e71.full.html#45">. </a>There are large single-center trials showing the ef</text>
<text top="673" left="633" width="174" height="15" font="2">ﬁcacy of autogenous vein to distal</text>
<text top="691" left="233" width="64" height="11" font="2">tibial vessels</text>
<text top="691" left="301" width="48" height="11" font="4"><a href="e71.full.html#46">(324,325)</a></text>
<text top="691" left="349" width="458" height="11" font="2">. In addition, composite sequential femoropopliteal-tibial bypass and bypass to an isolated</text>
<text top="706" left="233" width="242" height="11" font="2">popliteal arterial segment that has collateral out</text>
<text top="704" left="479" width="328" height="15" font="2">ﬂow to the foot are both acceptable methods of revascularization</text>
<text top="722" left="233" width="519" height="11" font="2">and should be considered when no other form of bypass with adequate autogenous conduit is possible</text>
<text top="722" left="756" width="48" height="11" font="4"><a href="e71.full.html#46">(326,327)</a></text>
<text top="722" left="804" width="3" height="11" font="2"><a href="e71.full.html#46">.</a></text>
<text top="766" left="97" width="3" height="9" font="5">I</text>
<text top="766" left="160" width="20" height="9" font="5">C-LD</text>
<text top="754" left="233" width="323" height="11" font="12">Surgical procedures are recommended to establish in-line blood</text>
<text top="752" left="560" width="223" height="15" font="12">ﬂow to the foot in patients with nonhealing</text>
<text top="769" left="233" width="103" height="11" font="12">wounds or gangrene</text>
<text top="769" left="340" width="23" height="11" font="4"><a href="e71.full.html#46">(328</a></text>
<text top="767" left="363" width="28" height="15" font="4"><a href="e71.full.html#46">–330)</a></text>
<text top="769" left="392" width="3" height="11" font="12"><a href="e71.full.html#46">.</a></text>
<text top="796" left="72" width="13" height="8" font="23">See</text>
<text top="796" left="88" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 42</a></text>
<text top="796" left="195" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="794" left="233" width="574" height="11" font="2">In patients presenting with nonhealing ulcers or gangrene, surgical procedures should be performed to establish in-</text>
<text top="810" left="233" width="51" height="11" font="2">line blood</text>
<text top="808" left="287" width="81" height="15" font="2">ﬂow to the foot</text>
<text top="810" left="372" width="23" height="11" font="4"><a href="e71.full.html#46">(328</a></text>
<text top="808" left="395" width="28" height="15" font="4"><a href="e71.full.html#46">–330)</a></text>
<text top="810" left="424" width="3" height="11" font="2"><a href="e71.full.html#46">.</a></text>
<text top="810" left="431" width="44" height="11" font="4"><a href="e71.full.html#31">Table 10</a></text>
<text top="810" left="479" width="312" height="11" font="2">addresses factors that may prompt a surgical approach to the</text>
<text top="825" left="233" width="84" height="11" font="2">patient with CLI.</text>
<text top="870" left="94" width="10" height="9" font="5">IIa</text>
<text top="870" left="160" width="21" height="9" font="5">B-NR</text>
<text top="857" left="233" width="553" height="11" font="12">In patients with CLI for whom endovascular revascularization has failed and a suitable autogenous vein is not</text>
<text top="872" left="233" width="520" height="11" font="12">available, prosthetic material can be effective for bypass to the below-knee popliteal and tibial arteries</text>
<text top="872" left="756" width="21" height="11" font="4"><a href="e71.full.html#46">(331</a></text>
<text top="870" left="777" width="27" height="15" font="4"><a href="e71.full.html#46">–333)</a></text>
<text top="872" left="804" width="3" height="11" font="12"><a href="e71.full.html#46">.</a></text>
<text top="899" left="72" width="13" height="8" font="23">See</text>
<text top="899" left="88" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 42</a></text>
<text top="899" left="195" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="897" left="233" width="574" height="11" font="2">There are studies demonstrating that patients for whom endovascular treatment for CLI has failed can be treated</text>
<text top="913" left="233" width="235" height="11" font="2">successfully with autogenous vein bypass graft</text>
<text top="913" left="472" width="47" height="11" font="4"><a href="e71.full.html#46">(332,333)</a></text>
<text top="913" left="522" width="108" height="11" font="2">or prosthetic material</text>
<text top="913" left="633" width="25" height="11" font="4"><a href="e71.full.html#46">(331)</a></text>
<text top="913" left="658" width="149" height="11" font="2">. Although autogenous vein is</text>
<text top="929" left="233" width="573" height="11" font="2">the preferred conduit for surgical revascularization, prosthetic conduit is a secondary option for patients with CLI</text>
<text top="944" left="233" width="359" height="11" font="2">without suitable saphenous vein who require surgical revascularization.</text>
<text top="989" left="94" width="10" height="9" font="5">IIa</text>
<text top="989" left="160" width="20" height="9" font="5">C-LD</text>
<text top="976" left="233" width="455" height="11" font="12">A staged approach to surgical procedures is reasonable in patients with ischemic rest pain</text>
<text top="976" left="692" width="23" height="11" font="4"><a href="e71.full.html#46">(334</a></text>
<text top="974" left="715" width="28" height="15" font="4"><a href="e71.full.html#46">–336)</a></text>
<text top="976" left="743" width="3" height="11" font="12"><a href="e71.full.html#46">.</a></text>
<text top="1024" left="133" width="15" height="8" font="23">N/A</text>
<text top="1013" left="233" width="574" height="11" font="2">It is reasonable to perform a staged approach to revascularization in patients with ischemic rest pain with multilevel</text>
<text top="1029" left="233" width="175" height="11" font="2">disease. For example, aortoiliac (in</text>
<text top="1027" left="408" width="391" height="15" font="2">ﬂow) disease may be treated ﬁrst with endovascular treatment or by surgical</text>
<text top="1045" left="233" width="491" height="11" font="2">reconstruction, depending on lesion characteristics, patient comorbidities, and patient preference</text>
<text top="1045" left="728" width="48" height="11" font="4"><a href="e71.full.html#46">(337,338)</a></text>
<text top="1045" left="776" width="3" height="11" font="2"><a href="e71.full.html#46">.</a></text>
<text top="1060" left="233" width="574" height="11" font="2">Combined percutaneous and surgical revascularization may require separate interventions, typically with the most</text>
<text top="1076" left="233" width="154" height="11" font="2">proximal procedure performed</text>
<text top="1074" left="391" width="23" height="15" font="2">ﬁrst.</text>
<text top="152" left="67" width="54" height="10" font="15">T A B L E 1 0</text>
<text top="152" left="135" width="526" height="10" font="16">Therapy for CLI: Findings That Prompt Consideration of Surgical or Endovascular Revascularization</text>
<text top="178" left="63" width="298" height="9" font="13">Findings That Favor Consideration of Surgical Revascularization</text>
<text top="178" left="569" width="44" height="9" font="13">Examples</text>
<text top="194" left="63" width="266" height="9" font="13">Factors associated with technical failure or poor durability with</text>
<text top="206" left="75" width="99" height="9" font="13">endovascular treatment</text>
<text top="194" left="426" width="330" height="9" font="13">Lesion involving common femoral artery, including origin of deep femoral artery</text>
<text top="213" left="426" width="326" height="9" font="13">Long segment lesion involving the below-knee popliteal and/or infrapopliteal</text>
<text top="225" left="441" width="313" height="9" font="13">arteries in a patient with suitable single-segment autogenous vein conduit</text>
<text top="244" left="426" width="330" height="9" font="13">Diffuse multilevel disease that would require endovascular revascularization at</text>
<text top="256" left="441" width="103" height="9" font="13">multiple anatomic levels</text>
<text top="275" left="426" width="305" height="9" font="13">Small-diameter target artery proximal to site of stenosis or densely calci</text>
<text top="274" left="732" width="16" height="12" font="13">ﬁed</text>
<text top="287" left="441" width="186" height="9" font="13">lesion at location of endovascular treatment</text>
<text top="307" left="63" width="287" height="9" font="13">Endovascular treatment likely to preclude or complicate subsequent</text>
<text top="319" left="78" width="121" height="9" font="13">achievement of in-line blood</text>
<text top="317" left="202" width="163" height="12" font="13">ﬂow through surgical revascularization</text>
<text top="307" left="426" width="146" height="9" font="13">Single-vessel runoff distal to ankle</text>
<text top="336" left="63" width="322" height="9" font="13">Findings That Favor Consideration of Endovascular Revascularization</text>
<text top="336" left="570" width="44" height="9" font="13">Examples</text>
<text top="352" left="63" width="315" height="9" font="13">The presence of patient comorbidities may place patients at increased risk of</text>
<text top="364" left="78" width="319" height="9" font="13">perioperative complications from surgical revascularization. In these patients,</text>
<text top="376" left="78" width="71" height="9" font="13">an endovascular-</text>
<text top="374" left="148" width="216" height="12" font="13">ﬁrst approach should be used regardless of anatomy</text>
<text top="352" left="426" width="330" height="9" font="13">Patient comorbidities, including coronary ischemia, cardiomyopathy, congestive</text>
<text top="364" left="441" width="256" height="9" font="13">heart failure, severe lung disease, and chronic kidney disease</text>
<text top="395" left="63" width="319" height="9" font="13">Patients with rest pain and disease at multiple levels may undergo a staged</text>
<text top="407" left="78" width="143" height="9" font="13">approach as part of endovascular-</text>
<text top="405" left="221" width="58" height="12" font="13">ﬁrst approach</text>
<text top="395" left="426" width="12" height="9" font="13">In-</text>
<text top="393" left="438" width="318" height="12" font="13">ﬂow disease can be addressed ﬁrst, and out-ﬂow disease can be addressed in</text>
<text top="407" left="441" width="315" height="9" font="13">a staged manner, when required, if clinical factors or patient safety prevent</text>
<text top="419" left="441" width="201" height="9" font="13">addressing all diseased segments at one setting</text>
<text top="438" left="63" width="249" height="9" font="13">Patients without suitable autologous vein for bypass grafts</text>
<text top="438" left="426" width="321" height="9" font="13">Some patients have had veins harvested for previous coronary artery bypass</text>
<text top="450" left="441" width="298" height="9" font="13">surgery and do not have adequate remaining veins for use as conduits.</text>
<text top="462" left="441" width="309" height="9" font="13">Similarly, patients may not have undergone prior saphenous vein harvest,</text>
<text top="474" left="441" width="184" height="9" font="13">but available vein is of inadequate diameter</text>
<text top="498" left="63" width="134" height="8" font="5">CLI indicates critical limb ischemia.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="789" width="18" height="9" font="5">e101</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="305" height="11" font="12">9.2. Wound Healing Therapies for CLI: Recommendations</text>
<text top="182" left="57" width="310" height="11" font="22">Recommendations for Wound Healing Therapies for CLI</text>
<text top="220" left="83" width="19" height="10" font="13">COR</text>
<text top="220" left="156" width="18" height="10" font="13">LOE</text>
<text top="220" left="227" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="257" left="92" width="3" height="9" font="5">I</text>
<text top="257" left="154" width="21" height="9" font="5">B-NR</text>
<text top="245" left="227" width="574" height="11" font="12">An interdisciplinary care team should evaluate and provide comprehensive care for patients with CLI and tissue loss</text>
<text top="260" left="227" width="290" height="11" font="12">to achieve complete wound healing and a functional foot</text>
<text top="260" left="521" width="45" height="11" font="4"><a href="e71.full.html#44">(229,339</a></text>
<text top="258" left="566" width="26" height="15" font="4"><a href="e71.full.html#44">–341)</a></text>
<text top="260" left="593" width="3" height="11" font="12"><a href="e71.full.html#44">.</a></text>
<text top="285" left="66" width="13" height="8" font="23">See</text>
<text top="285" left="82" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 44</a></text>
<text top="285" left="189" width="2" height="8" font="23">.</text>
<text top="283" left="227" width="537" height="11" font="2">The management of patients with CLI and nonhealing wounds should include coordinated efforts for both</text>
<text top="299" left="227" width="574" height="11" font="2">revascularization and wound healing, because the risk of limb-threatening infections remains until complete wound</text>
<text top="315" left="227" width="574" height="11" font="2">healing is achieved. The structure and activities of interdisciplinary care teams for CLI may vary according to several</text>
<text top="330" left="227" width="547" height="11" font="2">factors, including the local availability of resources. Previous groups have described various combinations of</text>
<text top="346" left="227" width="574" height="11" font="2">activities of this team, which are in addition to revascularization and include functions such as wound care, infection</text>
<text top="362" left="227" width="542" height="11" font="2">management, orthotics, and prosthetics (see Online Data Supplement 34a for a complete list of functions).</text>
<text top="378" left="227" width="574" height="11" font="2">Coordination of these activities and some degree of organized team structure are recommended, as opposed to ad</text>
<text top="393" left="227" width="509" height="11" font="2">hoc or unstructured referrals among various specialty clinicians not involved in interdisciplinary care.</text>
<text top="409" left="242" width="515" height="11" font="2">Ambulatory patients with PAD and nonhealing foot ulcers should be considered for efforts to prevent</text>
<text top="425" left="227" width="385" height="11" font="2">amputation. The components of this effort may include revascularization, of</text>
<text top="423" left="613" width="185" height="15" font="2">ﬂoading, treatment of infection, and</text>
<text top="440" left="227" width="541" height="11" font="2">wound care. The long-term outcome of the limb is excellent when complete wound healing can be achieved</text>
<text top="440" left="771" width="27" height="11" font="4"><a href="e71.full.html#47">(339)</a></text>
<text top="440" left="798" width="3" height="11" font="2">.</text>
<text top="456" left="226" width="539" height="11" font="2">Revascularization should be coordinated with the efforts of clinicians who manage foot infections, provide</text>
<text top="472" left="227" width="10" height="11" font="2">of</text>
<text top="470" left="238" width="563" height="15" font="2">ﬂoading, and achieve complete wound healing, either through medical therapy, surgical options, or a combination</text>
<text top="487" left="227" width="571" height="11" font="2">thereof. Coordinated and timely interdisciplinary care can achieve excellent limb outcomes for patients with PAD</text>
<text top="503" left="227" width="145" height="11" font="2">and nonhealing foot wounds</text>
<text top="503" left="376" width="45" height="11" font="4"><a href="e71.full.html#44">(229,339</a></text>
<text top="501" left="421" width="26" height="15" font="4"><a href="e71.full.html#44">–341)</a></text>
<text top="503" left="447" width="3" height="11" font="2">.</text>
<text top="547" left="92" width="3" height="9" font="5">I</text>
<text top="547" left="155" width="20" height="9" font="5">C-LD</text>
<text top="535" left="227" width="562" height="11" font="12">In patients with CLI, wound care after revascularization should be performed with the goal of complete wound</text>
<text top="550" left="227" width="36" height="11" font="12">healing</text>
<text top="550" left="268" width="27" height="11" font="4"><a href="e71.full.html#47">(339)</a></text>
<text top="550" left="294" width="3" height="11" font="12">.</text>
<text top="577" left="66" width="13" height="8" font="23">See</text>
<text top="577" left="82" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 44</a></text>
<text top="577" left="189" width="2" height="8" font="23">.</text>
<text top="575" left="227" width="574" height="11" font="2">A comprehensive plan for treatment of CLI must include a plan for achieving an intact skin surface on a functional</text>
<text top="591" left="227" width="574" height="11" font="2">foot. One study demonstrated a limb salvage rate of 100% at 3 years in a cohort of patients with CLI who achieved</text>
<text top="606" left="227" width="444" height="11" font="2">complete wound healing with endovascular revascularization and dedicated wound care</text>
<text top="606" left="675" width="27" height="11" font="4"><a href="e71.full.html#47">(339)</a></text>
<text top="606" left="702" width="40" height="11" font="2"><a href="e71.full.html#47">. </a>Before</text>
<text top="622" left="227" width="554" height="11" font="2">revascularization, the interdisciplinary care team should devise a plan to achieve the goal of complete wound</text>
<text top="638" left="227" width="545" height="11" font="2">healing. After successful revascularization, most patients with gangrene of the foot are evaluated for minor</text>
<text top="653" left="227" width="450" height="11" font="2">amputation with staged/delayed primary closure or surgical reconstruction when feasible</text>
<text top="653" left="682" width="23" height="11" font="4"><a href="e71.full.html#47">(342</a></text>
<text top="651" left="704" width="28" height="15" font="4"><a href="e71.full.html#47">–344)</a></text>
<text top="653" left="733" width="56" height="11" font="2"><a href="e71.full.html#47">. </a>Negative-</text>
<text top="669" left="227" width="574" height="11" font="2">pressure wound therapy dressings are helpful to achieve wound healing after revascularization and minor (i.e., digit</text>
<text top="685" left="227" width="433" height="11" font="2">or partial foot) amputation when primary or delayed secondary closure is not feasible</text>
<text top="685" left="664" width="50" height="11" font="4"><a href="e71.full.html#47">(345,346)</a></text>
<text top="685" left="714" width="71" height="11" font="2">. Spontaneous</text>
<text top="701" left="227" width="574" height="11" font="2">amputation, or autoamputation, of gangrenous digits should be reserved for palliation in patients without options</text>
<text top="716" left="227" width="102" height="11" font="2">for revascularization</text>
<text top="716" left="333" width="71" height="11" font="4"><a href="e71.full.html#47">(345,347,348)</a></text>
<text top="716" left="404" width="3" height="11" font="2">.</text>
<text top="732" left="242" width="545" height="11" font="2">Other evidence-based guidelines relevant to those with nonhealing foot wounds following revascularization</text>
<text top="748" left="227" width="250" height="11" font="2">cover the full spectrum of diabetic foot problems</text>
<text top="748" left="482" width="28" height="11" font="4"><a href="e71.full.html#47">(349)</a></text>
<text top="748" left="513" width="262" height="11" font="2">or separately consider the management of infection</text>
<text top="763" left="227" width="49" height="11" font="4"><a href="e71.full.html#44">(225,350)</a></text>
<text top="763" left="276" width="17" height="11" font="2">, of</text>
<text top="761" left="294" width="41" height="15" font="2">ﬂoading</text>
<text top="763" left="338" width="25" height="11" font="4"><a href="e71.full.html#47">(351)</a></text>
<text top="763" left="363" width="87" height="11" font="2"><a href="e71.full.html#47">, </a>and wound care</text>
<text top="763" left="454" width="26" height="11" font="4"><a href="e71.full.html#47">(352)</a></text>
<text top="763" left="480" width="312" height="11" font="2"><a href="e71.full.html#47">. </a>To date, there are no RCTs or high-quality studies that have</text>
<text top="779" left="227" width="564" height="11" font="2">focused on wound healing adjuncts in limbs with severe PAD (e.g., topical cytokine ointments, skin substitutes,</text>
<text top="795" left="227" width="295" height="11" font="2">cell-based therapies intended to optimize wound healing).</text>
<text top="839" left="88" width="10" height="9" font="5">IIb</text>
<text top="839" left="154" width="21" height="9" font="5">B-NR</text>
<text top="827" left="227" width="568" height="11" font="12">In patients with CLI, intermittent pneumatic compression (arterial pump) devices may be considered to augment</text>
<text top="842" left="227" width="297" height="11" font="12">wound healing and/or ameliorate severe ischemic rest pain</text>
<text top="842" left="528" width="26" height="11" font="4"><a href="e71.full.html#47">(353)</a></text>
<text top="842" left="554" width="3" height="11" font="12">.</text>
<text top="869" left="66" width="13" height="8" font="23">See</text>
<text top="869" left="82" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 44</a></text>
<text top="869" left="189" width="2" height="8" font="23">.</text>
<text top="867" left="227" width="461" height="11" font="2">A systematic review of studies that used intermittent pneumatic compression devices speci</text>
<text top="864" left="688" width="93" height="15" font="2">ﬁcally designed to</text>
<text top="882" left="227" width="535" height="11" font="2">augment arterial perfusion of the lower extremities suggests that these may provide modest clinical bene</text>
<text top="880" left="763" width="11" height="15" font="2">ﬁt</text>
<text top="898" left="227" width="29" height="11" font="2">(speci</text>
<text top="896" left="256" width="499" height="15" font="2">ﬁcally, decreased amputation rates and improved QoL) in patients with CLI who were ineligible for</text>
<text top="914" left="227" width="84" height="11" font="2">revascularization</text>
<text top="914" left="315" width="26" height="11" font="4"><a href="e71.full.html#47">(353)</a></text>
<text top="914" left="341" width="102" height="11" font="2"><a href="e71.full.html#47">. </a>The potential bene</text>
<text top="912" left="443" width="348" height="15" font="2">ﬁt appears to outweigh the low risk associated with the use of these</text>
<text top="929" left="227" width="40" height="11" font="2">devices.</text>
<text top="974" left="88" width="10" height="9" font="5">IIb</text>
<text top="974" left="155" width="20" height="9" font="5">C-LD</text>
<text top="961" left="227" width="500" height="11" font="12">In patients with CLI, the effectiveness of hyperbaric oxygen therapy for wound healing is unknown</text>
<text top="961" left="732" width="27" height="11" font="4"><a href="e71.full.html#47">(354)</a></text>
<text top="961" left="758" width="3" height="11" font="12">.</text>
<text top="1009" left="72" width="13" height="8" font="23">See</text>
<text top="1009" left="88" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 44</a></text>
<text top="1009" left="196" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="997" left="227" width="574" height="11" font="2">The literature evaluating the utility of hyperbaric oxygen therapy has focused on patients without severe PAD and has</text>
<text top="1012" left="227" width="177" height="11" font="2">not demonstrated a long-term bene</text>
<text top="1010" left="404" width="397" height="15" font="2">ﬁt on wound healing or improving amputation-free survival when compared with</text>
<text top="1028" left="227" width="79" height="11" font="2">sham treatment</text>
<text top="1028" left="310" width="26" height="11" font="4"><a href="e71.full.html#47">(355)</a></text>
<text top="1028" left="336" width="465" height="11" font="2"><a href="e71.full.html#47">. </a>There are no published studies evaluating the role of hyperbaric oxygen therapy for patients</text>
<text top="1044" left="227" width="496" height="11" font="2">with nonreconstructible PAD. One small RCT that focused on patients with foot ulcers and PAD (ABI</text>
<text top="1042" left="727" width="47" height="15" font="2">&lt;0.80 or</text>
<text top="1059" left="227" width="16" height="11" font="2">TBI</text>
<text top="1057" left="246" width="555" height="15" font="2">&lt;0.70) for whom no revascularization was planned demonstrated a signiﬁcant decrease in ulcer area at 6 weeks,</text>
<text top="1075" left="227" width="58" height="11" font="2">but no signi</text>
<text top="1073" left="285" width="516" height="15" font="2">ﬁcant differences in ulcer size at 6 months, complete ulcer healing at 6 weeks or 6 months, and major or</text>
<text top="1091" left="227" width="94" height="11" font="2">minor amputations</text>
<text top="1091" left="324" width="27" height="11" font="4"><a href="e71.full.html#47">(354)</a></text>
<text top="1091" left="351" width="431" height="11" font="2">. Further research on the utility of hyperbaric oxygen therapy in this context is needed.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="19" height="9" font="5">e102</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1160" width="864">
<text top="294" left="63" width="171" height="16" font="14">10. MANAGEMENT OF ALI</text>
<text top="331" left="63" width="333" height="12" font="2">ALI is one of the most treatable and potentially devas-</text>
<text top="349" left="63" width="333" height="12" font="2">tating presentations of PAD. Timely recognition of arterial</text>
<text top="367" left="63" width="333" height="12" font="2">occlusion as the cause of an ischemic, cold, painful leg is</text>
<text top="385" left="63" width="333" height="12" font="2">crucial to successful treatment. The writing committee</text>
<text top="403" left="63" width="136" height="12" font="2">has used a standard de</text>
<text top="401" left="199" width="197" height="15" font="2">ﬁnition of ALI in which symptom</text>
<text top="421" left="63" width="63" height="12" font="2">duration is</text>
<text top="419" left="129" width="62" height="15" font="2">&lt;2 weeks (</text>
<text top="421" left="191" width="40" height="11" font="4"><a href="e71.full.html#7">Table 3</a></text>
<text top="421" left="232" width="4" height="12" font="2"><a href="e71.full.html#7">)</a></text>
<text top="421" left="239" width="39" height="12" font="4"><a href="e71.full.html#40">(33,34)</a></text>
<text top="421" left="279" width="118" height="12" font="2"><a href="e71.full.html#40">. </a>Category I refers to</text>
<text top="295" left="423" width="333" height="12" font="2">viable limbs that are not immediately threatened. Cate-</text>
<text top="313" left="423" width="333" height="12" font="2">gory II refers to threatened limbs. Category IIa limbs are</text>
<text top="331" left="423" width="333" height="12" font="2">marginally threatened and salvageable, if promptly</text>
<text top="349" left="423" width="333" height="12" font="2">treated. Category IIb are immediately threatened limbs</text>
<text top="367" left="423" width="333" height="12" font="2">that require immediate revascularization if salvage is to</text>
<text top="385" left="423" width="333" height="12" font="2">be accomplished. Category III are irreversibly damaged</text>
<text top="403" left="423" width="333" height="12" font="2">limbs, in which case resultant major tissue loss or per-</text>
<text top="421" left="423" width="205" height="12" font="2">manent nerve damage is inevitable</text>
<text top="421" left="632" width="22" height="12" font="4"><a href="e71.full.html#40">(34)</a></text>
<text top="421" left="655" width="3" height="12" font="2"><a href="e71.full.html#40">.</a></text>
<text top="473" left="63" width="278" height="11" font="12">10.1. Clinical Presentation of ALI: Recommendations</text>
<text top="175" left="71" width="47" height="9" font="5">III: No Bene</text>
<text top="173" left="118" width="9" height="12" font="5">ﬁt</text>
<text top="175" left="163" width="15" height="9" font="5">B-R</text>
<text top="162" left="233" width="250" height="11" font="12">Prostanoids are not indicated in patients with CLI</text>
<text top="162" left="486" width="27" height="11" font="4"><a href="e71.full.html#47">(356)</a></text>
<text top="162" left="513" width="3" height="11" font="12">.</text>
<text top="200" left="72" width="13" height="8" font="23">See</text>
<text top="200" left="88" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 43</a></text>
<text top="200" left="195" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="198" left="233" width="574" height="11" font="2">A systematic review and meta-analysis concluded that RCTs have not demonstrated meaningful long-term clinical</text>
<text top="213" left="233" width="24" height="11" font="2">bene</text>
<text top="211" left="258" width="514" height="15" font="2">ﬁt from the administration of prostanoids to patients with CLI attributable to nonreconstructible PAD</text>
<text top="213" left="775" width="27" height="11" font="4"><a href="e71.full.html#47">(356)</a></text>
<text top="213" left="802" width="3" height="11" font="2">.</text>
<text top="512" left="63" width="279" height="11" font="22">Recommendations for Clinical Presentation of ALI</text>
<text top="550" left="89" width="19" height="10" font="13">COR</text>
<text top="550" left="161" width="18" height="10" font="13">LOE</text>
<text top="550" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="587" left="97" width="3" height="9" font="5">I</text>
<text top="587" left="160" width="20" height="9" font="5">C-EO</text>
<text top="575" left="233" width="366" height="11" font="12">Patients with ALI should be emergently evaluated by a clinician with suf</text>
<text top="573" left="599" width="206" height="15" font="12">ﬁcient experience to assess limb viability</text>
<text top="590" left="233" width="182" height="11" font="12">and implement appropriate therapy.</text>
<text top="615" left="127" width="15" height="8" font="23">N/A</text>
<text top="615" left="233" width="574" height="11" font="2">Patients with ALI should be rapidly evaluated by a vascular specialist if one is available. Depending on local clinical</text>
<text top="631" left="233" width="567" height="11" font="2">expertise, the vascular specialist may be a vascular surgeon, interventional radiologist, cardiologist, or a general</text>
<text top="646" left="233" width="574" height="11" font="2">surgeon with specialized training and experience in treating PAD. If such expertise is not locally or rapidly available,</text>
<text top="662" left="233" width="574" height="11" font="2">there should be strong consideration of transfer of the patient to a facility with such resources. The more advanced</text>
<text top="678" left="233" width="560" height="11" font="2">the degree of ischemia, the more rapidly the communication (including communication about potential patient</text>
<text top="693" left="233" width="125" height="11" font="2">transfer) needs to occur.</text>
<text top="738" left="97" width="3" height="9" font="5">I</text>
<text top="738" left="160" width="20" height="9" font="5">C-LD</text>
<text top="725" left="233" width="574" height="11" font="12">In patients with suspected ALI, initial clinical evaluation should rapidly assess limb viability and potential for salvage</text>
<text top="741" left="233" width="148" height="11" font="12">and does not require imaging</text>
<text top="741" left="385" width="22" height="11" font="4"><a href="e71.full.html#47">(357</a></text>
<text top="739" left="407" width="27" height="15" font="4"><a href="e71.full.html#47">–361)</a></text>
<text top="741" left="434" width="3" height="11" font="12"><a href="e71.full.html#47">.</a></text>
<text top="767" left="71" width="13" height="8" font="23">See</text>
<text top="767" left="88" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 45</a></text>
<text top="778" left="126" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 46</a></text>
<text top="778" left="153" width="2" height="8" font="23">.</text>
<text top="765" left="233" width="574" height="11" font="2">ALI is a medical emergency and must be recognized rapidly. The time constraint is due to the period that skeletal</text>
<text top="781" left="233" width="144" height="11" font="2">muscle will tolerate ischemia</text>
<text top="779" left="377" width="111" height="15" font="2">—roughly 4 to 6 hours</text>
<text top="781" left="491" width="27" height="11" font="4"><a href="e71.full.html#47">(362)</a></text>
<text top="781" left="518" width="289" height="11" font="2"><a href="e71.full.html#47">. </a>A rapid assessment of limb viability and ability to restore</text>
<text top="797" left="233" width="68" height="11" font="2">arterial blood</text>
<text top="795" left="305" width="498" height="15" font="2">ﬂow should be performed by a clinician able to either complete the revascularization or triage the</text>
<text top="812" left="233" width="35" height="11" font="2">patient</text>
<text top="812" left="272" width="27" height="11" font="4"><a href="e71.full.html#47">(358)</a></text>
<text top="812" left="299" width="486" height="11" font="2">. Lower extremity symptoms in ALI can include both pain and loss of function. The longer these</text>
<text top="828" left="233" width="343" height="11" font="2">symptoms are present, the less likely the possibility of limb salvage</text>
<text top="828" left="580" width="49" height="11" font="4"><a href="e71.full.html#47">(360,361)</a></text>
<text top="828" left="630" width="172" height="11" font="2"><a href="e71.full.html#47">. </a>Clinical assessment must include</text>
<text top="844" left="233" width="306" height="11" font="2">symptom duration, pain intensity, and motor and sensory de</text>
<text top="842" left="539" width="239" height="15" font="2">ﬁcit severity to distinguish a threatened from a</text>
<text top="859" left="233" width="108" height="11" font="2">nonviable extremity <a href="e71.full.html#34">(</a></text>
<text top="859" left="341" width="42" height="11" font="4"><a href="e71.full.html#34">Figure 3</a></text>
<text top="859" left="383" width="409" height="11" font="2">). The bedside assessment should include arterial and venous examination with a</text>
<text top="875" left="233" width="408" height="11" font="2">handheld continuous-wave Doppler because of the inaccuracy of pulse palpation</text>
<text top="875" left="645" width="21" height="11" font="4"><a href="e71.full.html#40">(34)</a></text>
<text top="875" left="666" width="126" height="11" font="2"><a href="e71.full.html#40">. </a>The loss of dopplerable</text>
<text top="891" left="233" width="574" height="11" font="2">arterial signal indicates that the limb is threatened. The absence of both arterial and venous Doppler signal indicates</text>
<text top="906" left="233" width="570" height="11" font="2">that the limb may be irreversibly damaged (nonsalvageable). Comorbidities should be investigated and managed</text>
<text top="922" left="233" width="574" height="11" font="2">aggressively, but this must not delay therapy. Even in the setting of rapid and effective revascularization, the 1-year</text>
<text top="938" left="233" width="294" height="11" font="2">morbidity and mortality rates associated with ALI are high</text>
<text top="938" left="531" width="51" height="11" font="4"><a href="e71.full.html#47">(360,363)</a></text>
<text top="938" left="581" width="3" height="11" font="2">.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="788" width="19" height="9" font="5">e103</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1160" width="864">
<text top="826" left="108" width="262" height="11" font="12">10.2. Medical Therapy for ALI: Recommendations</text>
<text top="861" left="57" width="234" height="11" font="22">Recommendation for ALI Medical Therapy</text>
<text top="902" left="83" width="19" height="10" font="13">COR</text>
<text top="902" left="156" width="18" height="10" font="13">LOE</text>
<text top="902" left="227" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="939" left="92" width="3" height="9" font="5">I</text>
<text top="939" left="154" width="20" height="9" font="5">C-EO</text>
<text top="927" left="227" width="538" height="11" font="12">In patients with ALI, systemic anticoagulation with heparin should be administered unless contraindicated.</text>
<text top="973" left="128" width="15" height="8" font="23">N/A</text>
<text top="962" left="227" width="433" height="11" font="2">Heparin (generally intravenous unfractionated heparin) is given to all patients acutely</text>
<text top="962" left="664" width="43" height="11" font="4"><a href="e71.full.html#40">(35,364)</a></text>
<text top="962" left="707" width="74" height="11" font="2">. This can stop</text>
<text top="978" left="227" width="252" height="11" font="2">thrombus propagation and may provide an anti-in</text>
<text top="976" left="479" width="321" height="15" font="2">ﬂammatory effect that lessens the ischemia. Patients who have</text>
<text top="994" left="227" width="535" height="11" font="2">received heparin before the onset of ALI and have a decrease in platelet count may have heparin-induced</text>
<text top="1009" left="227" width="92" height="11" font="2">thrombocytopenia</text>
<text top="1009" left="323" width="50" height="11" font="4"><a href="e71.full.html#47">(365,366)</a></text>
<text top="1009" left="373" width="385" height="11" font="2"><a href="e71.full.html#47">. </a>In this situation, a direct thrombin inhibitor is given, rather than heparin, if</text>
<text top="1025" left="227" width="330" height="11" font="2">heparin-induced thrombocytopenia with thrombosis is suspected.</text>
<text top="154" left="125" width="45" height="11" font="25">FIGURE 3</text>
<text top="155" left="178" width="151" height="9" font="23">Diagnosis and Management of ALI</text>
<text top="155" left="333" width="32" height="9" font="6"><a href="e71.full.html#40">(33,34)</a></text>
<text top="707" left="125" width="213" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="707" left="342" width="31" height="9" font="18"><a href="e71.full.html#4">Table 1</a></text>
<text top="707" left="373" width="3" height="9" font="13"><a href="e71.full.html#4">.</a></text>
<text top="722" left="125" width="144" height="9" font="13">ALI indicates acute limb ischemia.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="20" height="9" font="5">e104</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="267" height="11" font="12">10.3. Revascularization for ALI: Recommendations</text>
<text top="173" left="63" width="267" height="11" font="22">Recommendations for Revascularization for ALI</text>
<text top="212" left="89" width="19" height="10" font="13">COR</text>
<text top="212" left="161" width="18" height="10" font="13">LOE</text>
<text top="212" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="249" left="97" width="3" height="9" font="5">I</text>
<text top="249" left="160" width="20" height="9" font="5">C-LD</text>
<text top="236" left="233" width="563" height="11" font="12">In patients with ALI, the revascularization strategy should be determined by local resources and patient factors</text>
<text top="252" left="233" width="195" height="11" font="12">(e.g., etiology and degree of ischemia)</text>
<text top="252" left="432" width="23" height="11" font="4"><a href="e71.full.html#47">(367</a></text>
<text top="250" left="455" width="29" height="15" font="4"><a href="e71.full.html#47">–369)</a></text>
<text top="252" left="484" width="3" height="11" font="12"><a href="e71.full.html#47">.</a></text>
<text top="277" left="72" width="13" height="8" font="23">See</text>
<text top="277" left="88" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 47</a></text>
<text top="277" left="195" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="275" left="233" width="376" height="11" font="2">For marginally or immediately threatened limbs (Category IIa and IIb ALI [</text>
<text top="275" left="609" width="42" height="11" font="4"><a href="e71.full.html#34">Figure 3</a></text>
<text top="275" left="651" width="152" height="11" font="2"><a href="e71.full.html#34">]), </a>revascularization should be</text>
<text top="291" left="233" width="373" height="11" font="2">performed emergently (within 6 hours). For viable limbs (Category I ALI [</text>
<text top="291" left="606" width="42" height="11" font="4"><a href="e71.full.html#34">Figure 3</a></text>
<text top="291" left="648" width="152" height="11" font="2">]), revascularization should be</text>
<text top="306" left="233" width="554" height="11" font="2">performed an on urgent basis (within 6 to 24 hours). The revascularization strategy can range from catheter-</text>
<text top="322" left="233" width="570" height="11" font="2">directed thrombolysis to surgical thromboembolectomy. Available facilities and clinical expertise are factors that</text>
<text top="338" left="233" width="569" height="11" font="2">should be considered when determining the revascularization strategy. The technique that will provide the most</text>
<text top="353" left="233" width="134" height="11" font="2">rapid restoration of arterial</text>
<text top="351" left="369" width="437" height="15" font="2">ﬂow with the least risk to the patient should be selected. For example, catheter-directed</text>
<text top="369" left="233" width="265" height="11" font="2">thrombolysis can provide rapid restoration of arterial</text>
<text top="367" left="501" width="306" height="15" font="2">ﬂow to a viable or marginally threatened limb, particularly in</text>
<text top="385" left="233" width="428" height="11" font="2">the setting of recent occlusion, thrombosis of synthetic grafts, and stent thrombosis</text>
<text top="385" left="665" width="27" height="11" font="4"><a href="e71.full.html#47">(367)</a></text>
<text top="385" left="691" width="116" height="11" font="2">. If this is not available</text>
<text top="400" left="233" width="552" height="11" font="2">locally, surgical options for timely revascularization should be considered, along with the feasibility of timely</text>
<text top="416" left="233" width="251" height="11" font="2">transfer to a facility with the necessary expertise.</text>
<text top="460" left="97" width="3" height="9" font="5">I</text>
<text top="460" left="168" width="6" height="9" font="5">A</text>
<text top="448" left="233" width="431" height="11" font="12">Catheter-based thrombolysis is effective for patients with ALI and a salvageable limb</text>
<text top="448" left="668" width="23" height="11" font="4"><a href="e71.full.html#47">(367</a></text>
<text top="446" left="691" width="25" height="15" font="4"><a href="e71.full.html#47">–371)</a></text>
<text top="448" left="716" width="3" height="11" font="12">.</text>
<text top="485" left="72" width="13" height="8" font="23">See</text>
<text top="485" left="88" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 47</a></text>
<text top="485" left="195" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="483" left="233" width="570" height="11" font="2">Assessment of the comparative effectiveness of catheter-based thrombolysis versus open surgery is complicated</text>
<text top="499" left="233" width="71" height="11" font="2">by variable de</text>
<text top="497" left="304" width="476" height="15" font="2">ﬁnitions of ALI in this literature. Four RCTs comparing catheter-based thrombolysis to surgery</text>
<text top="515" left="233" width="46" height="11" font="4"><a href="e71.full.html#47">(367,369</a></text>
<text top="513" left="279" width="25" height="15" font="4"><a href="e71.full.html#47">–371)</a></text>
<text top="515" left="304" width="138" height="11" font="2">, as well as a meta-analysis</text>
<text top="515" left="446" width="28" height="11" font="4"><a href="e71.full.html#47">(368)</a></text>
<text top="515" left="474" width="313" height="11" font="2">, have demonstrated similar limb salvage rates between the 2</text>
<text top="531" left="233" width="574" height="11" font="2">approaches but better survival with catheter-based therapy. The survival advantage of catheter-based therapy may</text>
<text top="546" left="233" width="574" height="11" font="2">be at least in part attributable to multiple comorbidities found among the population of patients who present with</text>
<text top="562" left="233" width="569" height="11" font="2">ALI. Increased comorbidities are likely to contribute to increased perioperative risk. Several of the RCTs included</text>
<text top="578" left="233" width="527" height="11" font="2">patients with relatively chronic ischemia. Acuity and severity are both factors in the decision to consider</text>
<text top="593" left="233" width="65" height="11" font="2">thrombolysis</text>
<text top="593" left="302" width="46" height="11" font="4"><a href="e71.full.html#47">(367,369</a></text>
<text top="591" left="347" width="25" height="15" font="4"><a href="e71.full.html#47">–371)</a></text>
<text top="593" left="373" width="3" height="11" font="2"><a href="e71.full.html#47">.</a></text>
<text top="638" left="97" width="3" height="9" font="5">I</text>
<text top="638" left="160" width="20" height="9" font="5">C-LD</text>
<text top="625" left="233" width="203" height="11" font="12">Amputation should be performed as the</text>
<text top="623" left="439" width="273" height="15" font="12">ﬁrst procedure in patients with a nonsalvageable limb</text>
<text top="625" left="716" width="46" height="11" font="4"><a href="e71.full.html#47">(372,373)</a></text>
<text top="625" left="762" width="3" height="11" font="12">.</text>
<text top="663" left="71" width="13" height="8" font="23">See</text>
<text top="663" left="88" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 48</a></text>
<text top="663" left="195" width="2" height="8" font="23">.</text>
<text top="661" left="233" width="176" height="11" font="2">For patients with Category III ALI (</text>
<text top="661" left="409" width="42" height="11" font="4"><a href="e71.full.html#34">Figure 3</a></text>
<text top="661" left="451" width="355" height="11" font="2">), amputation should be performed as the index procedure. Prolonged</text>
<text top="676" left="233" width="566" height="11" font="2">duration of ischemia is the most common factor in patients requiring amputation for treatment of ALI. The risks</text>
<text top="692" left="233" width="301" height="11" font="2">associated with reconstruction outweigh the potential bene</text>
<text top="690" left="534" width="249" height="15" font="2">ﬁt in a limb that is already insensate or immobile</text>
<text top="708" left="233" width="560" height="11" font="2">because of prolonged ischemia. Patients who have an insensate and immobile limb in the setting of prolonged</text>
<text top="723" left="233" width="50" height="11" font="2">ischemia (</text>
<text top="721" left="284" width="313" height="15" font="2">&gt;6 to 8 hours) are unlikely to have potential for limb salvage</text>
<text top="723" left="601" width="43" height="11" font="4"><a href="e71.full.html#40">(34,362)</a></text>
<text top="723" left="644" width="157" height="11" font="2"><a href="e71.full.html#40">. </a>In addition, in this setting the</text>
<text top="739" left="233" width="562" height="11" font="2">reperfusion and circulation of ischemic metabolites can result in multiorgan failure and cardiovascular collapse.</text>
<text top="755" left="233" width="574" height="11" font="2">However, if pain can be controlled and there is no evidence of infection, amputation may be deferred if this meets</text>
<text top="771" left="233" width="81" height="11" font="2">with the patient</text>
<text top="768" left="314" width="41" height="15" font="2">’s goals.</text>
<text top="815" left="97" width="3" height="9" font="5">I</text>
<text top="815" left="160" width="20" height="9" font="5">C-LD</text>
<text top="802" left="233" width="519" height="11" font="12">Patients with ALI should be monitored and treated (e.g., fasciotomy) for compartment syndrome after</text>
<text top="818" left="233" width="84" height="11" font="12">revascularization</text>
<text top="818" left="321" width="46" height="11" font="4"><a href="e71.full.html#47">(372,373)</a></text>
<text top="818" left="367" width="3" height="11" font="12">.</text>
<text top="844" left="71" width="13" height="8" font="23">See</text>
<text top="844" left="88" width="107" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 48</a></text>
<text top="844" left="195" width="2" height="8" font="23">.</text>
<text top="842" left="233" width="561" height="11" font="2">The lower extremity muscles reside in compartments, surrounded by fascia and bones. Reperfusion to ischemic</text>
<text top="858" left="233" width="565" height="11" font="2">muscles can cause cellular edema, resulting in increased compartment pressure. When compartment pressure is</text>
<text top="872" left="233" width="525" height="15" font="2">&gt;30 mm Hg, there is capillary and venule compression that leads to malperfusion of the muscle; this is</text>
<text top="889" left="233" width="550" height="11" font="2">compartment syndrome. Fasciotomy is indicated when the compartment pressure increases. Measurement of</text>
<text top="905" left="233" width="574" height="11" font="2">intracompartment pressure is not always easily accessible. In such cases, evaluation for fasciotomy is prompted by</text>
<text top="921" left="233" width="571" height="11" font="2">development of increased pain, tense muscle, or nerve injury. Fasciotomy should be considered for patients with</text>
<text top="937" left="233" width="320" height="11" font="2">Category IIb ischemia for whom the time to revascularization is</text>
<text top="934" left="557" width="50" height="15" font="2">&gt;4 hours.</text>
<text top="981" left="94" width="10" height="9" font="5">IIa</text>
<text top="981" left="160" width="21" height="9" font="5">B-NR</text>
<text top="968" left="233" width="573" height="11" font="12">In patients with ALI with a salvageable limb, percutaneous mechanical thrombectomy can be useful as adjunctive</text>
<text top="984" left="233" width="121" height="11" font="12">therapy to thrombolysis</text>
<text top="984" left="358" width="22" height="11" font="4"><a href="e71.full.html#47">(374</a></text>
<text top="982" left="380" width="28" height="15" font="4"><a href="e71.full.html#47">–378)</a></text>
<text top="984" left="408" width="3" height="11" font="12">.</text>
<text top="1010" left="71" width="13" height="8" font="23">See</text>
<text top="1010" left="87" width="111" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 49</a></text>
<text top="1021" left="126" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 50</a></text>
<text top="1021" left="153" width="2" height="8" font="23">.</text>
<text top="1008" left="233" width="574" height="11" font="2">Multiple nonrandomized studies have suggested that percutaneous mechanical thrombectomy in combination with</text>
<text top="1024" left="233" width="189" height="11" font="2">pharmacological therapy can be bene</text>
<text top="1022" left="422" width="213" height="15" font="2">ﬁcial in the treatment of threatened limbs</text>
<text top="1024" left="639" width="23" height="11" font="4"><a href="e71.full.html#47">(374</a></text>
<text top="1022" left="661" width="28" height="15" font="4"><a href="e71.full.html#47">–378)</a></text>
<text top="1024" left="689" width="3" height="11" font="2">.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="788" width="19" height="9" font="5">e105</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1160" width="864">
<text top="917" left="108" width="216" height="16" font="14">11. LONGITUDINAL FOLLOW-UP:</text>
<text top="935" left="107" width="140" height="16" font="14">RECOMMENDATIONS</text>
<text top="973" left="108" width="333" height="12" font="2">PAD is a lifelong chronic medical condition. Ongoing care</text>
<text top="991" left="108" width="333" height="12" font="2">focuses on cardiovascular risk reduction with medical</text>
<text top="1009" left="108" width="333" height="12" font="2">therapy, optimizing functional status with structured</text>
<text top="1027" left="108" width="282" height="12" font="2">exercise and, when indicated, revascularization.</text>
<text top="175" left="88" width="10" height="9" font="5">IIa</text>
<text top="175" left="155" width="20" height="9" font="5">C-LD</text>
<text top="162" left="227" width="574" height="11" font="12">In patients with ALI due to embolism and with a salvageable limb, surgical thromboembolectomy can be effective</text>
<text top="178" left="227" width="23" height="11" font="4"><a href="e71.full.html#47">(379</a></text>
<text top="176" left="250" width="27" height="15" font="4"><a href="e71.full.html#47">–381)</a></text>
<text top="178" left="277" width="3" height="11" font="12"><a href="e71.full.html#47">.</a></text>
<text top="204" left="65" width="13" height="8" font="23">See</text>
<text top="204" left="81" width="111" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 49</a></text>
<text top="215" left="120" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 50</a></text>
<text top="215" left="147" width="2" height="8" font="23">.</text>
<text top="202" left="227" width="574" height="11" font="2">Patients with arterial embolism and an absent pulse ipsilateral to the ischemic limb can be treated by exposure of an</text>
<text top="218" left="227" width="482" height="11" font="2">artery in the affected limb and balloon-catheter thromboembolectomy. These patients may bene</text>
<text top="216" left="709" width="92" height="15" font="2">ﬁt from adjunctive</text>
<text top="234" left="227" width="70" height="11" font="2">intraoperative</text>
<text top="232" left="301" width="496" height="15" font="2">ﬁbrinolytics. In the event that thromboembolectomy does not restore arterial ﬂow, bypass can be</text>
<text top="249" left="227" width="52" height="11" font="2">performed</text>
<text top="249" left="284" width="22" height="11" font="4"><a href="e71.full.html#47">(381</a></text>
<text top="247" left="305" width="28" height="15" font="4"><a href="e71.full.html#47">–383)</a></text>
<text top="249" left="333" width="3" height="11" font="2">.</text>
<text top="294" left="88" width="10" height="9" font="5">IIb</text>
<text top="294" left="155" width="20" height="9" font="5">C-LD</text>
<text top="281" left="227" width="574" height="11" font="12">The usefulness of ultrasound-accelerated catheter-based thrombolysis for patients with ALI with a salvageable limb</text>
<text top="297" left="227" width="57" height="11" font="12">is unknown</text>
<text top="297" left="288" width="24" height="11" font="4"><a href="e71.full.html#47">(384</a></text>
<text top="295" left="312" width="29" height="15" font="4"><a href="e71.full.html#47">–386)</a></text>
<text top="297" left="341" width="3" height="11" font="12"><a href="e71.full.html#47">.</a></text>
<text top="323" left="66" width="13" height="8" font="23">See</text>
<text top="323" left="82" width="110" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 47</a></text>
<text top="334" left="120" width="27" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 50</a></text>
<text top="334" left="147" width="2" height="8" font="23">.</text>
<text top="321" left="227" width="543" height="11" font="2">The use of ultrasound-accelerated catheter delivery of thrombolytic agents has been published in case series</text>
<text top="321" left="774" width="28" height="11" font="4"><a href="e71.full.html#47">(384)</a></text>
<text top="337" left="227" width="134" height="11" font="2">and retrospective analyses</text>
<text top="337" left="365" width="27" height="11" font="4"><a href="e71.full.html#47">(385)</a></text>
<text top="337" left="392" width="403" height="11" font="2"><a href="e71.full.html#47">. </a>However, the single RCT comparing this technique to standard catheter-based</text>
<text top="353" left="227" width="560" height="11" font="2">thrombolytic therapy failed to demonstrate a difference in outcomes, including bleeding, despite a lower total</text>
<text top="368" left="227" width="127" height="11" font="2">amount of lytic delivered</text>
<text top="368" left="358" width="28" height="11" font="4"><a href="e71.full.html#48">(386)</a></text>
<text top="368" left="386" width="3" height="11" font="2">.</text>
<text top="465" left="57" width="358" height="11" font="22">Recommendations for Diagnostic Evaluation of the Cause of ALI</text>
<text top="504" left="83" width="19" height="10" font="13">COR</text>
<text top="504" left="156" width="18" height="10" font="13">LOE</text>
<text top="504" left="227" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="541" left="92" width="3" height="9" font="5">I</text>
<text top="541" left="154" width="20" height="9" font="5">C-EO</text>
<text top="528" left="227" width="574" height="11" font="12">In the patient with ALI, a comprehensive history should be obtained to determine the cause of thrombosis and/or</text>
<text top="543" left="227" width="68" height="11" font="12">embolization.</text>
<text top="572" left="121" width="15" height="8" font="23">N/A</text>
<text top="571" left="227" width="574" height="11" font="2">In addition to identifying a known history of PAD, the history should focus on uncovering clinical evidence of other</text>
<text top="587" left="227" width="574" height="11" font="2">conditions that can result in ALI through either embolic or thrombotic mechanisms. These conditions include atrial</text>
<text top="601" left="227" width="574" height="15" font="2">ﬁbrillation, left ventricular thrombus, aortic dissection, trauma, hypercoagulable state, and presence of a limb artery</text>
<text top="618" left="227" width="574" height="11" font="2">bypass graft. The clinical history should identify the presence or absence of a history of MI, symptoms and signs of</text>
<text top="634" left="227" width="547" height="11" font="2">left ventricular dysfunction resulting in congestive heart failure, or possible endocarditis. The history should</text>
<text top="650" left="227" width="571" height="11" font="2">evaluate for possibility of deep vein thrombosis with intracardiac shunt (e.g., patent foramen ovale or other that</text>
<text top="665" left="227" width="514" height="11" font="2">may result in paradoxical arterial embolism), hypercoagulable state, and family history of thrombosis.</text>
<text top="710" left="88" width="10" height="9" font="5">IIa</text>
<text top="710" left="154" width="20" height="9" font="5">C-EO</text>
<text top="697" left="227" width="535" height="11" font="12">In the patient with a history of ALI, testing for a cardiovascular cause of thromboembolism can be useful.</text>
<text top="742" left="121" width="15" height="8" font="23">N/A</text>
<text top="742" left="227" width="555" height="11" font="2">Treatment of ALI should not be delayed for testing for the underlying cause of the limb ischemia. Delay from</text>
<text top="757" left="227" width="359" height="11" font="2">symptom onset to revascularization is a major determinant of outcome</text>
<text top="757" left="590" width="49" height="11" font="4"><a href="e71.full.html#47">(360,361)</a></text>
<text top="757" left="639" width="105" height="11" font="2">. The evaluation of a</text>
<text top="773" left="227" width="574" height="11" font="2">cardiovascular cause of ALI is most useful in the patient without underlying PAD. Evaluation for cardiovascular cause</text>
<text top="789" left="227" width="408" height="11" font="2">includes electrocardiogram or additional heart rhythm monitoring to detect atrial</text>
<text top="787" left="638" width="163" height="15" font="2">ﬁbrillation, electrocardiogram to</text>
<text top="804" left="227" width="533" height="11" font="2">detect evidence of MI, and echocardiography to further determine whether there is a cardiac etiology for</text>
<text top="820" left="227" width="541" height="11" font="2">thromboembolism, such as valvular vegetation, left atrial or left ventricular thrombus, or intracardiac shunt</text>
<text top="820" left="771" width="27" height="11" font="4"><a href="e71.full.html#48">(387)</a></text>
<text top="820" left="798" width="3" height="11" font="2">.</text>
<text top="434" left="108" width="356" height="11" font="12">10.4. Diagnostic Evaluation of the Cause of ALI: Recommendations</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="20" height="9" font="5">e106</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1160" width="864">
<text top="152" left="63" width="257" height="11" font="22">Recommendations for Longitudinal Follow-Up</text>
<text top="190" left="89" width="19" height="10" font="13">COR</text>
<text top="190" left="161" width="18" height="10" font="13">LOE</text>
<text top="190" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="227" left="97" width="3" height="9" font="5">I</text>
<text top="227" left="160" width="20" height="9" font="5">C-EO</text>
<text top="215" left="233" width="574" height="11" font="12">Patients with PAD should be followed up with periodic clinical evaluation, including assessment of cardiovascular</text>
<text top="230" left="233" width="256" height="11" font="12">risk factors, limb symptoms, and functional status.</text>
<text top="255" left="127" width="15" height="8" font="23">N/A</text>
<text top="255" left="233" width="574" height="11" font="2">A comprehensive care plan for patients with PAD includes periodic clinical evaluation by a healthcare provider with</text>
<text top="271" left="233" width="560" height="11" font="2">experience in the care of vascular patients. Clinical evaluation should include assessment of cardiovascular risk</text>
<text top="286" left="233" width="512" height="11" font="2">factors, assessment of adherence to medical therapy, and re-evaluation of smoking cessation efforts.</text>
<text top="302" left="233" width="149" height="11" font="2">Comprehensive lifestyle modi</text>
<text top="300" left="382" width="285" height="15" font="2">ﬁcation, including heart-healthy nutrition, is encouraged</text>
<text top="302" left="670" width="20" height="11" font="4"><a href="e71.full.html#39">(22)</a></text>
<text top="302" left="691" width="98" height="11" font="2"><a href="e71.full.html#39">. </a>Patients with PAD</text>
<text top="318" left="233" width="563" height="11" font="2">should also undergo periodic assessment of limb symptoms, functional status, and their ability to participate in</text>
<text top="333" left="233" width="574" height="11" font="2">vocational and recreational activities. Ongoing participation in a structured exercise program should be facilitated.</text>
<text top="349" left="233" width="480" height="11" font="2">Foot examination and patient counseling about healthy foot behaviors in PAD are addressed in</text>
<text top="349" left="717" width="46" height="11" font="4"><a href="">Section 7</a></text>
<text top="349" left="763" width="3" height="11" font="2"><a href="">.</a></text>
<text top="393" left="97" width="3" height="9" font="5">I</text>
<text top="393" left="160" width="20" height="9" font="5">C-EO</text>
<text top="381" left="233" width="574" height="11" font="12">Patients with PAD who have undergone lower extremity revascularization (surgical and/or endovascular) should be</text>
<text top="396" left="233" width="341" height="11" font="12">followed up with periodic clinical evaluation and ABI measurement.</text>
<text top="423" left="127" width="15" height="8" font="23">N/A</text>
<text top="423" left="233" width="559" height="11" font="2">In addition to the clinical evaluation of cardiovascular risk factors, functional status, and adherence to medical</text>
<text top="438" left="233" width="502" height="11" font="2">therapy and smoking cessation, patients with PAD who have previously undergone lower extremity</text>
<text top="454" left="233" width="571" height="11" font="2">revascularization (surgical and/or endovascular) require additional ongoing assessment and care. Follow-up visits</text>
<text top="470" left="233" width="332" height="11" font="2">after revascularization should include reassessment of the patient</text>
<text top="468" left="566" width="204" height="15" font="2">’s limb symptoms and interval change in</text>
<text top="485" left="233" width="574" height="11" font="2">functional status, as well as participation in a structured exercise program. Pulse examination and ABI are included</text>
<text top="501" left="233" width="359" height="11" font="2">in the assessment. A change in ABI of 0.15 is considered clinically signi</text>
<text top="499" left="592" width="28" height="15" font="2">ﬁcant</text>
<text top="501" left="624" width="28" height="11" font="4"><a href="e71.full.html#48">(388)</a></text>
<text top="501" left="652" width="3" height="11" font="2"><a href="e71.full.html#48">.</a></text>
<text top="545" left="94" width="10" height="9" font="5">IIa</text>
<text top="545" left="163" width="15" height="9" font="5">B-R</text>
<text top="533" left="233" width="157" height="11" font="12">Duplex ultrasound can be bene</text>
<text top="531" left="390" width="397" height="15" font="12">ﬁcial for routine surveillance of infrainguinal, autogenous vein bypass grafts in</text>
<text top="548" left="233" width="91" height="11" font="12">patients with PAD</text>
<text top="548" left="328" width="24" height="11" font="4"><a href="e71.full.html#48">(389</a></text>
<text top="546" left="352" width="28" height="15" font="4"><a href="e71.full.html#48">–395)</a></text>
<text top="548" left="380" width="3" height="11" font="12"><a href="e71.full.html#48">.</a></text>
<text top="575" left="72" width="13" height="8" font="23">See</text>
<text top="575" left="88" width="109" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 51</a></text>
<text top="585" left="126" width="26" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 52</a></text>
<text top="585" left="153" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="573" left="233" width="452" height="11" font="2">A general surveillance schedule may be at 4 to 6 weeks, 6 months, and 12 months in the</text>
<text top="571" left="689" width="101" height="15" font="2">ﬁrst year and yearly</text>
<text top="589" left="233" width="569" height="11" font="2">thereafter. It is important that testing frequency is individualized to the patient, type of arterial bypass, and any</text>
<text top="604" left="233" width="86" height="11" font="2">prior duplex scan</text>
<text top="602" left="322" width="485" height="15" font="2">ﬁndings. Duplex graft surveillance focuses on the identiﬁcation of high-grade stenosis (e.g., peak</text>
<text top="620" left="233" width="80" height="11" font="2">systolic velocity</text>
<text top="618" left="317" width="482" height="15" font="2">&gt;300 cm/s and peak systolic velocity ratio across the stenosis &gt;3.5) or impending graft failure</text>
<text top="636" left="233" width="48" height="11" font="2">(e.g., PSV</text>
<text top="634" left="284" width="54" height="15" font="2">&lt;40 cm/s)</text>
<text top="636" left="340" width="49" height="11" font="4"><a href="e71.full.html#48">(392,395)</a></text>
<text top="636" left="389" width="417" height="11" font="2">. Detection of a graft stenosis prompts the consideration of further revascularization</text>
<text top="651" left="233" width="368" height="11" font="2">to treat the stenosis and maintain graft patency. Duplex may detect signi</text>
<text top="649" left="601" width="206" height="15" font="2">ﬁcant stenoses that may not be detected</text>
<text top="667" left="233" width="94" height="11" font="2">by a decline in ABI</text>
<text top="667" left="331" width="28" height="11" font="4"><a href="e71.full.html#48">(394)</a></text>
<text top="667" left="359" width="443" height="11" font="2"><a href="e71.full.html#48">. </a>Although case series have demonstrated high rates of primary assisted patency with a</text>
<text top="683" left="233" width="574" height="11" font="2">duplex ultrasound-surveillance strategy, RCTs of duplex surveillance versus clinical surveillance with the ABI have</text>
<text top="698" left="233" width="237" height="11" font="2">demonstrated mixed results in terms of a bene</text>
<text top="696" left="471" width="170" height="15" font="2">ﬁt on patency and limb outcomes</text>
<text top="698" left="645" width="71" height="11" font="4"><a href="e71.full.html#48">(391,393,396)</a></text>
<text top="698" left="715" width="3" height="11" font="2">.</text>
<text top="743" left="94" width="10" height="9" font="5">IIa</text>
<text top="743" left="160" width="20" height="9" font="5">C-LD</text>
<text top="730" left="233" width="546" height="11" font="12">Duplex ultrasound is reasonable for routine surveillance after endovascular procedures in patients with PAD</text>
<text top="746" left="233" width="23" height="11" font="4"><a href="e71.full.html#48">(397</a></text>
<text top="744" left="256" width="29" height="15" font="4"><a href="e71.full.html#48">–399)</a></text>
<text top="746" left="285" width="3" height="11" font="12"><a href="e71.full.html#48">.</a></text>
<text top="772" left="72" width="13" height="8" font="23">See</text>
<text top="772" left="88" width="106" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplement 52</a></text>
<text top="772" left="194" width="2" height="8" font="23">.</text>
<text top="770" left="233" width="574" height="11" font="2">Studies have developed duplex ultrasound diagnostic criteria for diagnosing restenosis at the site of endovascular</text>
<text top="786" left="233" width="472" height="11" font="2">revascularization. Diagnostic criteria need to be customized to the location (e.g., iliac or super</text>
<text top="784" left="705" width="102" height="15" font="2">ﬁcial femoral artery)</text>
<text top="802" left="233" width="574" height="11" font="2">and type of intervention (e.g., angioplasty, uncovered stent, or covered stent). The optimal timing for surveillance</text>
<text top="817" left="233" width="202" height="11" font="2">after endovascular procedures is unclear</text>
<text top="817" left="438" width="23" height="11" font="4"><a href="e71.full.html#48">(397</a></text>
<text top="815" left="461" width="29" height="15" font="4"><a href="e71.full.html#48">–399)</a></text>
<text top="817" left="490" width="317" height="11" font="2"><a href="e71.full.html#48">. </a>There are limited outcome data on routine duplex surveillance</text>
<text top="833" left="233" width="383" height="11" font="2">versus clinical surveillance plus the ABI after endovascular revascularization</text>
<text top="833" left="620" width="23" height="11" font="4"><a href="e71.full.html#48">(397</a></text>
<text top="831" left="642" width="29" height="15" font="4"><a href="e71.full.html#48">–399)</a></text>
<text top="833" left="671" width="107" height="11" font="2">. The value of duplex</text>
<text top="849" left="233" width="569" height="11" font="2">ultrasound may be greater in cases with higher rates of restenosis, such as after interventions to treat very long</text>
<text top="864" left="233" width="103" height="11" font="2">lesions or occlusions</text>
<text top="864" left="340" width="30" height="11" font="4"><a href="e71.full.html#48">(400)</a></text>
<text top="864" left="370" width="3" height="11" font="2">.</text>
<text top="909" left="94" width="10" height="9" font="5">IIb</text>
<text top="909" left="163" width="15" height="9" font="5">B-R</text>
<text top="896" left="233" width="574" height="11" font="12">The effectiveness of duplex ultrasound for routine surveillance of infrainguinal prosthetic bypass grafts in patients</text>
<text top="912" left="233" width="109" height="11" font="12">with PAD is uncertain</text>
<text top="912" left="345" width="45" height="11" font="4"><a href="e71.full.html#48">(393,401</a></text>
<text top="910" left="390" width="29" height="15" font="4"><a href="e71.full.html#48">–403)</a></text>
<text top="912" left="420" width="3" height="11" font="12"><a href="e71.full.html#48">.</a></text>
<text top="938" left="72" width="13" height="8" font="23">See</text>
<text top="938" left="88" width="109" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">Online Data Supplements 51</a></text>
<text top="949" left="126" width="26" height="8" font="6"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">and 52</a></text>
<text top="949" left="153" width="2" height="8" font="23"><a href="http://jaccjacc.acc.org/Clinical_Document/2016_LEPAD_Data_Supplement.pdf">.</a></text>
<text top="936" left="233" width="541" height="11" font="2">Duplex ultrasound of prosthetic bypass grafts may be used to characterize mid-graft velocity, because low</text>
<text top="952" left="233" width="227" height="11" font="2">velocities can predict impending graft failure</text>
<text top="952" left="463" width="23" height="11" font="4"><a href="e71.full.html#48">(401</a></text>
<text top="950" left="487" width="29" height="15" font="4"><a href="e71.full.html#48">–403)</a></text>
<text top="952" left="516" width="274" height="11" font="2"><a href="e71.full.html#48">. </a>Outcome studies of duplex surveillance of prosthetic</text>
<text top="968" left="233" width="197" height="11" font="2">grafts have not shown consistent bene</text>
<text top="966" left="430" width="11" height="15" font="2">ﬁt</text>
<text top="968" left="444" width="45" height="11" font="4"><a href="e71.full.html#48">(393,401</a></text>
<text top="966" left="489" width="29" height="15" font="4"><a href="e71.full.html#48">–403)</a></text>
<text top="968" left="519" width="284" height="11" font="2"><a href="e71.full.html#48">. </a>One RCT of duplex versus clinical surveillance with the</text>
<text top="983" left="233" width="252" height="11" font="2">ABI for femoropopliteal grafts did not show a bene</text>
<text top="981" left="485" width="322" height="15" font="2">ﬁt of duplex on outcome in the subset of patients with prosthetic</text>
<text top="999" left="233" width="163" height="11" font="2">grafts, though there was a bene</text>
<text top="997" left="396" width="239" height="15" font="2">ﬁt of duplex surveillance for vein bypass grafts</text>
<text top="999" left="638" width="27" height="11" font="4"><a href="e71.full.html#48">(393)</a></text>
<text top="999" left="665" width="3" height="11" font="2">.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="788" width="19" height="9" font="5">e107</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1160" width="864">
<text top="141" left="108" width="225" height="16" font="14">12. EVIDENCE GAPS AND FUTURE</text>
<text top="159" left="107" width="161" height="16" font="14">RESEARCH DIRECTIONS</text>
<text top="196" left="108" width="333" height="12" font="2">In performing the evidence review and in developing the</text>
<text top="214" left="108" width="288" height="12" font="2">present guidelines, the writing committee identi</text>
<text top="213" left="396" width="45" height="15" font="2">ﬁed the</text>
<text top="232" left="108" width="333" height="12" font="2">following critical evidence gaps and future directions for</text>
<text top="250" left="108" width="126" height="12" font="2">PAD-related research:</text>
<text top="287" left="108" width="6" height="10" font="7">n</text>
<text top="286" left="121" width="320" height="12" font="2">Basic science and translational studies to better un-</text>
<text top="304" left="121" width="320" height="12" font="2">derstand the vascular biology of endovascular therapies</text>
<text top="322" left="121" width="320" height="12" font="2">and bypass grafting and to develop new methods for</text>
<text top="340" left="121" width="264" height="12" font="2">preventing restenosis after revascularization.</text>
<text top="359" left="108" width="6" height="10" font="7">n</text>
<text top="358" left="121" width="320" height="12" font="2">Determination of risk factors for progression from</text>
<text top="375" left="121" width="320" height="12" font="2">asymptomatic PAD to symptomatic disease, including</text>
<text top="393" left="121" width="23" height="12" font="2">CLI.</text>
<text top="413" left="108" width="6" height="10" font="7">n</text>
<text top="411" left="121" width="320" height="12" font="2">RCTs needed to determine the value of using the ABI to</text>
<text top="429" left="121" width="320" height="12" font="2">identify asymptomatic patients with PAD for therapies</text>
<text top="447" left="121" width="320" height="12" font="2">to reduce cardiovascular risk (e.g., antiplatelet agents,</text>
<text top="465" left="121" width="169" height="12" font="2">statins, and other therapies).</text>
<text top="484" left="108" width="6" height="10" font="7">n</text>
<text top="483" left="121" width="320" height="12" font="2">Advancement in PAD diagnostics, such as technologies</text>
<text top="501" left="121" width="57" height="12" font="2">for simpli</text>
<text top="499" left="178" width="263" height="15" font="2">ﬁed yet highly accurate measurement of the</text>
<text top="519" left="121" width="320" height="12" font="2">ABI and tools for more reliable noninvasive perfusion</text>
<text top="537" left="121" width="108" height="12" font="2">assessment in CLI.</text>
<text top="556" left="108" width="6" height="10" font="7">n</text>
<text top="555" left="121" width="320" height="12" font="2">Comparative-effectiveness studies to determine the</text>
<text top="573" left="121" width="320" height="12" font="2">optimal antiplatelet therapy (drug or drugs and dosage)</text>
<text top="591" left="121" width="320" height="12" font="2">for prevention of cardiovascular and limb-related</text>
<text top="609" left="121" width="167" height="12" font="2">events in patients with PAD.</text>
<text top="628" left="108" width="6" height="10" font="7">n</text>
<text top="627" left="121" width="320" height="12" font="2">Development of additional medical therapies for clau-</text>
<text top="644" left="121" width="47" height="12" font="2">dication</text>
<text top="643" left="168" width="273" height="15" font="2">—an area of unmet medical need with a</text>
<text top="662" left="121" width="203" height="12" font="2">currently limited research pipeline</text>
<text top="662" left="328" width="31" height="12" font="4"><a href="e71.full.html#48">(404)</a></text>
<text top="662" left="359" width="3" height="12" font="2"><a href="e71.full.html#48">.</a></text>
<text top="682" left="108" width="6" height="10" font="7">n</text>
<text top="680" left="121" width="320" height="12" font="2">Studies to investigate the role of dietary intervention,</text>
<text top="698" left="121" width="320" height="12" font="2">in addition to statin therapy, to improve outcome and</text>
<text top="716" left="121" width="202" height="12" font="2">modify the natural history of PAD.</text>
<text top="735" left="108" width="6" height="10" font="7">n</text>
<text top="734" left="121" width="320" height="12" font="2">Additional research to identify the best community- or</text>
<text top="752" left="121" width="320" height="12" font="2">home-based exercise programs for patients with PAD to</text>
<text top="770" left="121" width="320" height="12" font="2">maximize functional status and improve QoL, as well as</text>
<text top="788" left="121" width="320" height="12" font="2">the role of such exercise programs before or in addition</text>
<text top="806" left="121" width="119" height="12" font="2">to revascularization.</text>
<text top="825" left="108" width="6" height="10" font="7">n</text>
<text top="824" left="121" width="320" height="12" font="2">Development and validation of improved clinical clas-</text>
<text top="842" left="121" width="9" height="12" font="2">si</text>
<text top="840" left="130" width="311" height="15" font="2">ﬁcation systems for PAD that incorporate symptoms,</text>
<text top="860" left="121" width="209" height="12" font="2">anatomic factors, and patient-speci</text>
<text top="858" left="330" width="111" height="15" font="2">ﬁc risk factors and</text>
<text top="878" left="121" width="320" height="12" font="2">can be used to predict clinical outcome and optimize</text>
<text top="896" left="121" width="320" height="12" font="2">treatment approach. An example of a recently devel-</text>
<text top="913" left="121" width="66" height="12" font="2">oped classi</text>
<text top="912" left="187" width="254" height="15" font="2">ﬁcation system is the Society for Vascular</text>
<text top="931" left="121" width="114" height="12" font="2">Surgery limb classi</text>
<text top="930" left="236" width="205" height="15" font="2">ﬁcation system, based on wound,</text>
<text top="949" left="121" width="320" height="12" font="2">ischemia, and foot infection (WIfI), which has been</text>
<text top="967" left="121" width="320" height="12" font="2">validated in different populations and may permit more</text>
<text top="985" left="121" width="246" height="12" font="2">meaningful prognosis in patients with CLI</text>
<text top="985" left="371" width="25" height="12" font="4"><a href="e71.full.html#48">(405</a></text>
<text top="983" left="397" width="32" height="15" font="4"><a href="e71.full.html#48">–409)</a></text>
<text top="985" left="429" width="3" height="12" font="2">.</text>
<text top="1004" left="108" width="6" height="10" font="7">n</text>
<text top="1003" left="121" width="320" height="12" font="2">Comparative- and cost-effectiveness studies of the</text>
<text top="1021" left="121" width="320" height="12" font="2">different endovascular technologies for treatment of</text>
<text top="1039" left="121" width="320" height="12" font="2">claudication and CLI, including drug-coated balloons</text>
<text top="1057" left="121" width="320" height="12" font="2">and DES. Studies should include patient-centered</text>
<text top="1075" left="121" width="320" height="12" font="2">endpoints, such as functional parameters, time to</text>
<text top="1093" left="121" width="320" height="12" font="2">wound healing, and QoL, in addition to standard</text>
<text top="143" left="481" width="320" height="12" font="2">patency-focused outcomes. These studies could then</text>
<text top="161" left="481" width="320" height="12" font="2">be incorporated into value-based clinical algorithms</text>
<text top="178" left="481" width="320" height="12" font="2">for approach to revascularization for claudication</text>
<text top="196" left="481" width="49" height="12" font="2">and CLI.</text>
<text top="216" left="468" width="6" height="10" font="7">n</text>
<text top="214" left="481" width="320" height="12" font="2">Additional studies to demonstrate the impact of mul-</text>
<text top="232" left="481" width="320" height="12" font="2">tisocietal registries on clinical outcomes and appro-</text>
<text top="250" left="481" width="320" height="12" font="2">priate use. At present, these include the Vascular</text>
<text top="268" left="481" width="320" height="12" font="2">Quality Initiative (VQI), the National Cardiovascular</text>
<text top="286" left="481" width="320" height="12" font="2">Data Registry Peripheral Vascular Intervention Regis-</text>
<text top="304" left="481" width="16" height="12" font="2">try</text>
<text top="302" left="498" width="303" height="15" font="2"> (PVI Registry), and the National Radiology Data</text>
<text top="322" left="481" width="320" height="12" font="2">Registry for Interventional Radiology (NRDR). These</text>
<text top="340" left="481" width="244" height="12" font="2">registries provide an opportunity to obtain</text>
<text top="338" left="729" width="73" height="15" font="2">“real-world”</text>
<text top="358" left="481" width="320" height="12" font="2">data on surgical and endovascular procedures for PAD</text>
<text top="376" left="481" width="320" height="12" font="2">and to improve quality by providing feedback to</text>
<text top="394" left="481" width="320" height="12" font="2">participating centers. Future efforts should incorporate</text>
<text top="412" left="481" width="320" height="12" font="2">these registries into interventional RCTs and post-</text>
<text top="430" left="481" width="245" height="12" font="2">marketing studies of PAD-related devices.</text>
<text top="481" left="468" width="182" height="16" font="14">13. ADVOCACY PRIORITIES</text>
<text top="519" left="468" width="177" height="12" font="2">The writing committee identi</text>
<text top="517" left="645" width="156" height="15" font="2">ﬁed 3 priorities for multi-</text>
<text top="537" left="468" width="333" height="12" font="2">societal advocacy initiatives to improve health care for</text>
<text top="555" left="468" width="333" height="13" font="2">patients with PAD. First, the writing committee sup-</text>
<text top="573" left="468" width="333" height="12" font="2">ports the availability of the ABI as the initial diagnostic</text>
<text top="591" left="468" width="333" height="12" font="2">test to establish the diagnosis of PAD in patients with</text>
<text top="609" left="468" width="193" height="12" font="2">history or physical examination</text>
<text top="607" left="668" width="133" height="15" font="2">ﬁndings suggestive of</text>
<text top="627" left="468" width="34" height="12" font="2">PAD (</text>
<text top="627" left="502" width="43" height="11" font="4"><a href="e71.full.html#10">Table 5</a></text>
<text top="627" left="545" width="256" height="12" font="2">). Although the ABI test is generally reim-</text>
<text top="644" left="468" width="333" height="12" font="2">bursed by third-party payers for patients with classic</text>
<text top="662" left="468" width="333" height="12" font="2">claudication or lower extremity wounds, payers may not</text>
<text top="680" left="468" width="281" height="12" font="2">provide reimbursement for the ABI with other</text>
<text top="679" left="754" width="47" height="15" font="2">ﬁndings</text>
<text top="698" left="468" width="333" height="12" font="2">suggestive of PAD, such as lower extremity pulse ab-</text>
<text top="716" left="468" width="333" height="12" font="2">normalities or femoral bruits. The writing committee</text>
<text top="734" left="468" width="11" height="12" font="2">af</text>
<text top="732" left="479" width="322" height="15" font="2">ﬁrms the importance of conﬁrming the diagnosis of</text>
<text top="752" left="468" width="333" height="12" font="2">PAD in such patients to allow for GDMT as delineated in</text>
<text top="770" left="468" width="333" height="13" font="2">this document. Second, the writing committee supports</text>
<text top="788" left="468" width="333" height="12" font="2">the vital importance of insuring access to supervised</text>
<text top="806" left="468" width="333" height="12" font="2">exercise programs for patients with PAD. Although</text>
<text top="824" left="468" width="333" height="12" font="2">extensive high-quality evidence supports supervised</text>
<text top="842" left="468" width="333" height="12" font="2">exercise programs to improve functional status and</text>
<text top="860" left="468" width="333" height="12" font="2">QoL, only a minority of patients with PAD participate in</text>
<text top="878" left="468" width="333" height="12" font="2">such programs because of lack of reimbursement by</text>
<text top="896" left="468" width="333" height="13" font="2">third-party payers. Third, the writing committee recog-</text>
<text top="913" left="468" width="333" height="12" font="2">nizes the need for incorporation of patient-centered</text>
<text top="931" left="468" width="333" height="12" font="2">outcomes into the process of regulatory approval of</text>
<text top="949" left="468" width="333" height="12" font="2">new medical therapies and revascularization technolo-</text>
<text top="967" left="468" width="26" height="12" font="2">gies.</text>
<text top="967" left="507" width="19" height="12" font="2">For</text>
<text top="967" left="539" width="99" height="12" font="2">revascularization</text>
<text top="967" left="652" width="77" height="12" font="2">technologies,</text>
<text top="967" left="742" width="60" height="12" font="2">regulatory</text>
<text top="985" left="468" width="51" height="12" font="2">approval</text>
<text top="985" left="532" width="9" height="12" font="2">is</text>
<text top="985" left="554" width="37" height="12" font="2">driven</text>
<text top="985" left="605" width="53" height="12" font="2">primarily</text>
<text top="985" left="672" width="14" height="12" font="2">by</text>
<text top="985" left="699" width="25" height="12" font="2">data</text>
<text top="985" left="737" width="14" height="12" font="2">on</text>
<text top="985" left="765" width="36" height="12" font="2">angio-</text>
<text top="1003" left="468" width="60" height="12" font="2">graphic ef</text>
<text top="1001" left="528" width="273" height="15" font="2">ﬁcacy (i.e., target lesion patency) and safety</text>
<text top="1021" left="468" width="333" height="12" font="2">endpoints. The nature of the functional limitation</text>
<text top="1039" left="468" width="333" height="12" font="2">associated with PAD warrants the incorporation of</text>
<text top="1057" left="468" width="333" height="12" font="2">patient-centered outcomes, such as functional parame-</text>
<text top="1075" left="468" width="177" height="12" font="2">ters and QoL, into the ef</text>
<text top="1073" left="645" width="156" height="15" font="2">ﬁcacy outcomes for the</text>
<text top="1093" left="468" width="103" height="12" font="2">approval process.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="20" height="9" font="5">e108</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="26" size="7" family="Times" color="#e3202b"/>
<text top="141" left="63" width="166" height="16" font="14">PRESIDENTS AND STAFF</text>
<text top="178" left="63" width="188" height="12" font="2">American College of Cardiology</text>
<text top="196" left="63" width="233" height="12" font="2">Richard A. Chazal, MD, FACC, President</text>
<text top="214" left="63" width="225" height="12" font="2">Shalom Jacobovitz, Chief Executive Of</text>
<text top="213" left="288" width="25" height="15" font="2">ﬁcer</text>
<text top="232" left="63" width="299" height="12" font="2">William J. Oetgen, MD, MBA, FACC, Executive Vice</text>
<text top="250" left="78" width="252" height="12" font="2">President, Science, Education, Quality, and</text>
<text top="268" left="78" width="71" height="12" font="2">Publications</text>
<text top="286" left="63" width="306" height="12" font="2">Amelia Scholtz, PhD, Publications Manager, Science,</text>
<text top="304" left="78" width="203" height="12" font="2">Education, Quality, and Publishing</text>
<text top="322" left="63" width="333" height="12" font="2">American College of Cardiology/American Heart Association</text>
<text top="340" left="63" width="333" height="12" font="2">Katherine Sheehan, PhD, Director, AHA/ACC Guideline</text>
<text top="358" left="63" width="141" height="12" font="2">Strategy and Operations</text>
<text top="376" left="63" width="53" height="12" font="2">Lisa Brad</text>
<text top="374" left="117" width="280" height="15" font="2">ﬁeld, CAE, Director, Guideline Methodology and</text>
<text top="394" left="78" width="35" height="12" font="2">Policy</text>
<text top="143" left="423" width="327" height="12" font="2">Abdul R. Abdullah, MD, Associate Science and Medicine</text>
<text top="161" left="438" width="44" height="12" font="2">Advisor</text>
<text top="178" left="423" width="298" height="12" font="2">Allison Rabinowitz, MPH, Project Manager, Clinical</text>
<text top="196" left="438" width="111" height="12" font="2">Practice Guidelines</text>
<text top="214" left="423" width="168" height="12" font="2">American Heart Association</text>
<text top="232" left="423" width="236" height="12" font="2">Steven R. Houser, PhD, FAHA, President</text>
<text top="250" left="423" width="195" height="12" font="2">Nancy Brown, Chief Executive Of</text>
<text top="248" left="618" width="25" height="15" font="2">ﬁcer</text>
<text top="268" left="423" width="308" height="12" font="2">Rose Marie Robertson, MD, FAHA, Chief Science and</text>
<text top="286" left="438" width="70" height="12" font="2">Medicine Of</text>
<text top="284" left="509" width="25" height="15" font="2">ﬁcer</text>
<text top="304" left="423" width="318" height="12" font="2">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice</text>
<text top="322" left="438" width="76" height="12" font="2">President, Of</text>
<text top="320" left="514" width="150" height="15" font="2">ﬁce of Science Operations</text>
<text top="340" left="423" width="333" height="12" font="2">Comilla Sasson, MD, PhD, FACEP, Vice President, Science</text>
<text top="358" left="438" width="79" height="12" font="2">and Medicine</text>
<text top="376" left="423" width="253" height="12" font="2">Jody Hundley, Production Manager, Scienti</text>
<text top="374" left="677" width="13" height="15" font="2">ﬁc</text>
<text top="394" left="438" width="92" height="12" font="2">Publications, Of</text>
<text top="392" left="531" width="150" height="15" font="2">ﬁce of Science Operations</text>
<text top="443" left="63" width="82" height="12" font="26">R E F E R E N C E S</text>
<text top="468" left="63" width="6" height="9" font="5">1.</text>
<text top="468" left="72" width="209" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref1">Committee on Standards for Developing Trust-</a></text>
<text top="481" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref1">worthy Clinical Practice Guidelines, Institute of Medi-</a></text>
<text top="495" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref1">cine. Clinical Practice Guidelines We Can Trust.</a></text>
<text top="508" left="63" width="214" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref1">Washington, DC: The National Academies Press, 2011</a></text>
<text top="508" left="277" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref1">.</a></text>
<text top="527" left="63" width="7" height="9" font="5">2.</text>
<text top="527" left="73" width="208" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref2">Committee on Standards for Systematic Reviews of</a></text>
<text top="540" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref2">Comparative Effectiveness Research, Institute of</a></text>
<text top="554" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref2">Medicine. Finding What Works in Health Care: Stan-</a></text>
<text top="567" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref2">dards for Systematic Reviews. Washington, DC: The</a></text>
<text top="581" left="63" width="127" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref2">National Academies Press, 2011</a></text>
<text top="581" left="189" width="3" height="9" font="5">.</text>
<text top="599" left="63" width="218" height="9" font="5">3. ACCF/AHA Task Force on Practice Guidelines.</text>
<text top="613" left="63" width="218" height="9" font="5">Methodology Manual and Policies From the ACCF/</text>
<text top="626" left="63" width="218" height="9" font="5">AHA Task Force on Practice Guidelines. American Col-</text>
<text top="639" left="63" width="218" height="9" font="5">lege of Cardiology and American Heart Association.</text>
<text top="653" left="63" width="85" height="9" font="5">2010. Available at:</text>
<text top="653" left="155" width="126" height="9" font="6"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">http://assets.cardiosource.com/</a></text>
<text top="666" left="63" width="218" height="9" font="6"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">Methodology_Manual_for_ACC_AHA_Writing_Committees.</a></text>
<text top="680" left="63" width="13" height="9" font="6"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">pdf</a></text>
<text top="680" left="90" width="15" height="9" font="5">and</text>
<text top="680" left="118" width="163" height="9" font="6"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">http://my.americanheart.org/idc/groups/</a></text>
<text top="693" left="63" width="217" height="9" font="6"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">ahamah-public/@wcm/@sop/documents/downloadable/</a></text>
<text top="707" left="63" width="64" height="9" font="6"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">ucm_319826.pdf</a></text>
<text top="707" left="126" width="116" height="9" font="5">. Accessed January 23, 2015.</text>
<text top="725" left="63" width="8" height="9" font="5">4.</text>
<text top="725" left="74" width="207" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref4">Halperin JL, Levine GN, Al-Khatib SM, et al. Further</a></text>
<text top="739" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref4">evolution of the ACC/AHA clinical practice guideline</a></text>
<text top="752" left="63" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref4">recommendation classi</a></text>
<text top="750" left="154" width="127" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref4">ﬁcation system: a report of the</a></text>
<text top="766" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref4">American College of Cardiology/American Heart Asso-</a></text>
<text top="779" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref4">ciation Task Force on Clinical Practice Guidelines. J Am</a></text>
<text top="792" left="63" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref4">Coll Cardiol. 2016;67:1572</a></text>
<text top="791" left="168" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref4">–4</a></text>
<text top="792" left="178" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref4">.</a></text>
<text top="811" left="63" width="7" height="9" font="5">5.</text>
<text top="811" left="73" width="208" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref5">Jacobs AK, Kushner FG, Ettinger SM, et al.</a></text>
<text top="824" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref5">ACCF/AHA clinical practice guideline methodology</a></text>
<text top="838" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref5">summit report: a report of the American College of</a></text>
<text top="851" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref5">Cardiology Foundation/American Heart Association</a></text>
<text top="865" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref5">Task Force on Practice Guidelines. J Am Coll Cardiol.</a></text>
<text top="878" left="63" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref5">2013;61:213</a></text>
<text top="877" left="110" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref5">–65</a></text>
<text top="878" left="124" width="3" height="9" font="5">.</text>
<text top="897" left="63" width="8" height="9" font="5">6.</text>
<text top="897" left="74" width="207" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref6">Jacobs AK, Anderson JL, Halperin JL. The evolution</a></text>
<text top="910" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref6">and future of ACC/AHA clinical practice guidelines: a</a></text>
<text top="924" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref6">30-year journey: a report of the American College of</a></text>
<text top="937" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref6">Cardiology/American Heart Association Task Force on</a></text>
<text top="951" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref6">Practice Guidelines. J Am Coll Cardiol. 2014;64:</a></text>
<text top="964" left="63" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref6">1373</a></text>
<text top="962" left="81" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref6">–84</a></text>
<text top="964" left="96" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref6">.</a></text>
<text top="983" left="63" width="7" height="9" font="5">7.</text>
<text top="983" left="73" width="208" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref7">Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/</a></text>
<text top="996" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref7">AHA statement on cost/value methodology in clinical</a></text>
<text top="1009" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref7">practice guidelines and performance measures: a</a></text>
<text top="1023" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref7">report of the American College of Cardiology/American</a></text>
<text top="1036" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref7">Heart Association Task Force on Performance Measures</a></text>
<text top="1050" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref7">and Task Force on Practice Guidelines. J Am Coll Car-</a></text>
<text top="1063" left="63" width="77" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref7">diol. 2014;63:2304</a></text>
<text top="1062" left="140" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref7">–22</a></text>
<text top="1063" left="154" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref7">.</a></text>
<text top="1082" left="63" width="8" height="9" font="5">8.</text>
<text top="1082" left="74" width="207" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref8">Arnett DK, Goodman RA, Halperin JL, et al. AHA/</a></text>
<text top="1095" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref8">ACC/HHS strategies to enhance application of clinical</a></text>
<text top="468" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref8">practice guidelines in patients with cardiovascular</a></text>
<text top="481" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref8">disease and comorbid conditions: from the American</a></text>
<text top="495" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref8">Heart Association, American College of Cardiology, and</a></text>
<text top="508" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref8">U.S. Department of Health and Human Services. J Am</a></text>
<text top="522" left="301" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref8">Coll Cardiol. 2014;64:1851</a></text>
<text top="520" left="407" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref8">–6</a></text>
<text top="522" left="416" width="3" height="9" font="5">.</text>
<text top="541" left="301" width="8" height="9" font="5">9.</text>
<text top="541" left="311" width="207" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA</a></text>
<text top="554" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">2005 guidelines for the management of patients</a></text>
<text top="568" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">with peripheral arterial disease (lower extremity,</a></text>
<text top="581" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">renal, mesenteric, and abdominal aortic): executive</a></text>
<text top="595" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">summary: a collaborative report from the American</a></text>
<text top="608" left="301" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">Association</a></text>
<text top="608" left="359" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">for</a></text>
<text top="608" left="383" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">Vascular</a></text>
<text top="608" left="430" width="65" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">Surgery/Society</a></text>
<text top="608" left="507" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">for</a></text>
<text top="622" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">Vascular Surgery, Society for Cardiovascular Angi-</a></text>
<text top="635" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">ography and Interventions, Society for Vascular</a></text>
<text top="649" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">Medicine and Biology, Society of Interventional</a></text>
<text top="662" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">Radiology, and the ACC/AHA Task Force on Practice</a></text>
<text top="676" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">Guidelines (Writing Committee to Develop Guide-</a></text>
<text top="689" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">lines for the Management of Patients With Periph-</a></text>
<text top="702" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">eral Arterial Disease). J Am Coll Cardiol. 2006;47:</a></text>
<text top="716" left="301" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">1239</a></text>
<text top="714" left="320" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">–312</a></text>
<text top="716" left="338" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref9">.</a></text>
<text top="735" left="301" width="12" height="9" font="5">10.</text>
<text top="735" left="316" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref10">Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/</a></text>
<text top="749" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref10">AHA focused update of the guideline for the manage-</a></text>
<text top="762" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref10">ment of patients with peripheral artery disease</a></text>
<text top="776" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref10">(updating the 2005 guideline): a report of the Amer-</a></text>
<text top="789" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref10">ican College of Cardiology Foundation/American Heart</a></text>
<text top="803" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref10">Association Task Force on Practice Guidelines. J Am</a></text>
<text top="816" left="301" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref10">Coll Cardiol. 2011;58:2020</a></text>
<text top="814" left="408" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref10">–45</a></text>
<text top="816" left="423" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref10">.</a></text>
<text top="835" left="301" width="218" height="9" font="5">11. Jones WS, Schmit KM, Vemulapalli S, et al. Treat-</text>
<text top="849" left="301" width="218" height="9" font="5">ment Strategies for Patients With Peripheral Artery</text>
<text top="862" left="301" width="218" height="9" font="5">Disease. Comparative Effectiveness Review No. 118.</text>
<text top="876" left="301" width="218" height="9" font="5">The Duke Evidence-based Practice Center under Con-</text>
<text top="889" left="301" width="218" height="9" font="5">tract No 290-2007-10066-I. 2013. Available at:</text>
<text top="903" left="301" width="217" height="9" font="6"><a href="http://www.effectivehealthcare.ahrq.gov/ehc/products/368/1415/Peripheral-Artery-Disease-Treatment-130301.pdf">http://www.effectivehealthcare.ahrq.gov/ehc/products/</a></text>
<text top="916" left="301" width="218" height="9" font="6"><a href="http://www.effectivehealthcare.ahrq.gov/ehc/products/368/1415/Peripheral-Artery-Disease-Treatment-130301.pdf">368/1415/Peripheral-Artery-Disease-Treatment-130301.</a></text>
<text top="929" left="301" width="13" height="9" font="6"><a href="http://www.effectivehealthcare.ahrq.gov/ehc/products/368/1415/Peripheral-Artery-Disease-Treatment-130301.pdf">pdf</a></text>
<text top="929" left="314" width="129" height="9" font="5"><a href="http://www.effectivehealthcare.ahrq.gov/ehc/products/368/1415/Peripheral-Artery-Disease-Treatment-130301.pdf">. </a>Accessed September 25, 2016.</text>
<text top="949" left="301" width="11" height="9" font="5">12.</text>
<text top="949" left="315" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref12">Vemulapalli S, Dolor RJ, Hasselblad V, et al.</a></text>
<text top="962" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref12">Comparative effectiveness of medical therapy, super-</a></text>
<text top="976" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref12">vised exercise, and revascularization for patients with</a></text>
<text top="989" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref12">intermittent claudication: a network meta-analysis.</a></text>
<text top="1003" left="301" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref12">Clin Cardiol. 2015;38:378</a></text>
<text top="1001" left="402" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref12">–86</a></text>
<text top="1003" left="417" width="3" height="9" font="5">.</text>
<text top="1022" left="301" width="11" height="9" font="5">13.</text>
<text top="1022" left="315" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref13">Schmit K, Dolor RJ, Jones WS, et al. Comparative</a></text>
<text top="1035" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref13">effectiveness review of antiplatelet agents in periph-</a></text>
<text top="1049" left="301" width="216" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref13">eral artery disease. J Am Heart Assoc. 2014;3:e001330</a></text>
<text top="1049" left="516" width="3" height="9" font="5">.</text>
<text top="1068" left="301" width="12" height="9" font="5">14.</text>
<text top="1068" left="315" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref14">Jones WS, Dolor RJ, Hasselblad V, et al. Compar-</a></text>
<text top="1082" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref14">ative effectiveness of endovascular and surgical</a></text>
<text top="1095" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref14">revascularization for patients with peripheral artery</a></text>
<text top="468" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref14">disease and critical limb ischemia: systematic review of</a></text>
<text top="481" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref14">revascularization in critical limb ischemia. Am Heart J.</a></text>
<text top="495" left="538" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref14">2014;167:489</a></text>
<text top="493" left="594" width="27" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref14">–98.e7</a></text>
<text top="495" left="621" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref14">.</a></text>
<text top="514" left="538" width="11" height="9" font="5">15.</text>
<text top="514" left="552" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref15">Menard MT, Farber A. The BEST-CLI trial: a multi-</a></text>
<text top="528" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref15">disciplinary effort to assess whether surgical or endo-</a></text>
<text top="541" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref15">vascular therapy is better for patients with critical limb</a></text>
<text top="555" left="538" width="157" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref15">ischemia. Semin Vasc Surg. 2014;27:82</a></text>
<text top="553" left="695" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref15">–4</a></text>
<text top="555" left="704" width="3" height="9" font="5">.</text>
<text top="574" left="538" width="12" height="9" font="5">16.</text>
<text top="574" left="553" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref16">Popplewell MA, Davies H, Jarrett H, et al. Bypass</a></text>
<text top="588" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref16">versus angioplasty in severe ischaemia of the leg - 2</a></text>
<text top="601" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref16">(BASIL-2) trial: study protocol for a randomised</a></text>
<text top="615" left="538" width="134" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref16">controlled trial. Trials. 2016;17:11</a></text>
<text top="615" left="672" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref16">.</a></text>
<text top="634" left="538" width="11" height="9" font="5">17.</text>
<text top="634" left="552" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref17">Menard MT, Farber A, Assmann SF, et al. Design</a></text>
<text top="648" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref17">and rationale of the Best Endovascular Versus Best</a></text>
<text top="661" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref17">Surgical Therapy for Patients With Critical Limb</a></text>
<text top="675" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref17">Ischemia (BEST-CLI) Trial. J Am Heart Assoc. 2016;5:</a></text>
<text top="688" left="538" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref17">e003219</a></text>
<text top="688" left="574" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref17">.</a></text>
<text top="708" left="538" width="12" height="9" font="5">18.</text>
<text top="708" left="553" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref18">Mozaffarian D, Benjamin EJ, Go AS, et al. Heart</a></text>
<text top="721" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref18">disease and stroke statistics-2016 update: a report</a></text>
<text top="734" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref18">from the American Heart Association [published</a></text>
<text top="748" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref18">correction appears in Circulation. 2016;133:e599]. Cir-</a></text>
<text top="761" left="538" width="91" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref18">culation. 2016;133:e38</a></text>
<text top="760" left="629" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref18">–360</a></text>
<text top="761" left="650" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref18">.</a></text>
<text top="781" left="538" width="12" height="9" font="5">19.</text>
<text top="781" left="553" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref19">Fowkes FG, Rudan D, Rudan I, et al. Comparison of</a></text>
<text top="794" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref19">global estimates of prevalence and risk factors for</a></text>
<text top="808" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref19">peripheral artery disease in 2000 and 2010: a</a></text>
<text top="821" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref19">systematic review and analysis. Lancet. 2013;382:</a></text>
<text top="835" left="538" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref19">1329</a></text>
<text top="833" left="557" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref19">–40</a></text>
<text top="835" left="573" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref19">.</a></text>
<text top="854" left="538" width="13" height="9" font="5">20.</text>
<text top="854" left="554" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref20">Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA</a></text>
<text top="868" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref20">guideline focused update on duration of dual anti-</a></text>
<text top="881" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref20">platelet therapy in patients with coronary artery dis-</a></text>
<text top="895" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref20">ease: a report of the American College of Cardiology/</a></text>
<text top="908" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref20">American Heart Association Task Force on Clinical</a></text>
<text top="922" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref20">Practice Guidelines. J Am Coll Cardiol. 2016;68:</a></text>
<text top="935" left="538" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref20">1082</a></text>
<text top="933" left="558" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref20">–115</a></text>
<text top="935" left="575" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref20">.</a></text>
<text top="955" left="538" width="11" height="9" font="5">21.</text>
<text top="955" left="552" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref21">Fleisher LA, Fleischmann KE, Auerbach AD, et al.</a></text>
<text top="968" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref21">2014 ACC/AHA guideline on perioperative cardiovas-</a></text>
<text top="981" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref21">cular evaluation and management of patients under-</a></text>
<text top="995" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref21">going noncardiac surgery: a report of the American</a></text>
<text top="1008" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref21">College of Cardiology/American Heart Association Task</a></text>
<text top="1022" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref21">Force on Practice Guidelines. J Am Coll Cardiol. 2014;</a></text>
<text top="1035" left="538" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref21">64:e77</a></text>
<text top="1034" left="566" width="17" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref21">–137</a></text>
<text top="1035" left="583" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref21">.</a></text>
<text top="1055" left="538" width="12" height="9" font="5">22.</text>
<text top="1055" left="553" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref22">Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC</a></text>
<text top="1068" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref22">guideline on lifestyle management to reduce cardio-</a></text>
<text top="1082" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref22">vascular risk: a report of the American College of</a></text>
<text top="1095" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref22">Cardiology/American Heart Association Task Force on</a></text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="787" width="20" height="9" font="5">e109</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref22">Practice Guidelines. J Am Coll Cardiol. 2014;63:</a></text>
<text top="156" left="108" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref22">2960</a></text>
<text top="155" left="130" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref22">–84</a></text>
<text top="156" left="145" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref22">.</a></text>
<text top="176" left="108" width="12" height="9" font="5">23.</text>
<text top="176" left="123" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref23">Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013</a></text>
<text top="189" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref23">ACC/AHA guideline on the assessment of cardiovas-</a></text>
<text top="203" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref23">cular risk: a report of the American College of Cardi-</a></text>
<text top="216" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref23">ology/American Heart Association Task Force on</a></text>
<text top="229" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref23">Practice Guidelines. J Am Coll Cardiol. 2014;63:</a></text>
<text top="243" left="108" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref23">2935</a></text>
<text top="241" left="128" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref23">–59</a></text>
<text top="243" left="142" width="3" height="9" font="5">.</text>
<text top="262" left="108" width="13" height="9" font="5">24.</text>
<text top="262" left="124" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref24">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013</a></text>
<text top="276" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref24">ACC/AHA guideline on the treatment of blood</a></text>
<text top="289" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref24">cholesterol to reduce atherosclerotic cardiovascular</a></text>
<text top="302" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref24">risk in adults: a report of the American College of</a></text>
<text top="316" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref24">Cardiology/American Heart Association Task Force on</a></text>
<text top="329" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref24">Practice Guidelines. J Am Coll Cardiol. 2014;63:</a></text>
<text top="343" left="108" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref24">2889</a></text>
<text top="341" left="129" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref24">–934</a></text>
<text top="343" left="149" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref24">.</a></text>
<text top="362" left="108" width="12" height="9" font="5">25.</text>
<text top="362" left="123" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref25">Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF</a></text>
<text top="375" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref25">secondary prevention and risk reduction therapy for</a></text>
<text top="389" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref25">patients with coronary and other atherosclerotic</a></text>
<text top="402" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref25">vascular disease: 2011 update: a guideline from the</a></text>
<text top="416" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref25">American Heart Association and American College of</a></text>
<text top="429" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref25">Cardiology Foundation. J Am Coll Cardiol. 2011;58:</a></text>
<text top="443" left="108" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref25">2432</a></text>
<text top="441" left="127" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref25">–46</a></text>
<text top="443" left="142" width="3" height="9" font="5">.</text>
<text top="462" left="108" width="13" height="9" font="5">26.</text>
<text top="462" left="123" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref26">Conte MS, Pomposelli FB, Clair DG, et al. Society</a></text>
<text top="475" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref26">for Vascular Surgery practice guidelines for athero-</a></text>
<text top="489" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref26">sclerotic occlusive disease of the lower extremities:</a></text>
<text top="502" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref26">management of asymptomatic disease and claudica-</a></text>
<text top="516" left="108" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref26">tion. J Vasc Surg. 2015;61:2S</a></text>
<text top="514" left="224" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref26">–41S</a></text>
<text top="516" left="242" width="3" height="9" font="5">.</text>
<text top="535" left="108" width="12" height="9" font="5">27.</text>
<text top="535" left="123" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref27">Aboyans V, Criqui MH, Abraham P, et al. Measure-</a></text>
<text top="548" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref27">ment and interpretation of the ankle-brachial index: a</a></text>
<text top="562" left="108" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref27">scienti</a></text>
<text top="560" left="133" width="193" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref27">ﬁc statement from the American Heart Associa-</a></text>
<text top="575" left="108" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref27">tion. Circulation. 2012;126:2890</a></text>
<text top="573" left="238" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref27">–909</a></text>
<text top="575" left="259" width="3" height="9" font="5">.</text>
<text top="594" left="108" width="13" height="9" font="5">28.</text>
<text top="594" left="123" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref28">Lentine KL, Costa SP, Weir MR, et al. Cardiac dis-</a></text>
<text top="608" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref28">ease evaluation and management among kidney and</a></text>
<text top="621" left="108" width="165" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref28">liver transplantation candidates: a scienti</a></text>
<text top="620" left="273" width="53" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref28">ﬁc statement</a></text>
<text top="635" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref28">from the American Heart Association and the American</a></text>
<text top="648" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref28">College of Cardiology Foundation. J Am Coll Cardiol.</a></text>
<text top="661" left="108" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref28">2012;60:434</a></text>
<text top="660" left="160" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref28">–80</a></text>
<text top="661" left="175" width="3" height="9" font="5">.</text>
<text top="681" left="108" width="13" height="9" font="5">29.</text>
<text top="681" left="123" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">Skyler JS, Bergenstal R, Bonow RO, et al. Intensive</a></text>
<text top="694" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">glycemic control and the prevention of cardiovascular</a></text>
<text top="708" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">events: implications of the ACCORD, ADVANCE, and VA</a></text>
<text top="721" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">Diabetes Trials: a position statement of the American</a></text>
<text top="734" left="108" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">Diabetes Association and a scienti</a></text>
<text top="733" left="245" width="81" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">ﬁc statement of the</a></text>
<text top="748" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">American College of Cardiology Foundation and the</a></text>
<text top="761" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">American Heart Association. J Am Coll Cardiol. 2009;</a></text>
<text top="775" left="108" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">53:298</a></text>
<text top="773" left="136" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref29">–304</a></text>
<text top="775" left="156" width="3" height="9" font="5">.</text>
<text top="794" left="108" width="13" height="9" font="5">30.</text>
<text top="794" left="124" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref30">Davis MM, Taubert K, Benin AL, et al. In</a></text>
<text top="792" left="297" width="29" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref30">ﬂuenza</a></text>
<text top="807" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref30">vaccination as secondary prevention for cardiovascular</a></text>
<text top="821" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref30">disease: a science advisory from the American Heart</a></text>
<text top="834" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref30">Association/American College of Cardiology. J Am Coll</a></text>
<text top="848" left="108" width="93" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref30">Cardiol. 2006;48:1498</a></text>
<text top="846" left="200" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref30">–502</a></text>
<text top="848" left="220" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref30">.</a></text>
<text top="867" left="108" width="11" height="9" font="5">31.</text>
<text top="867" left="122" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref31">White CJ, Jaff MR, Haskal ZJ, et al. Indications for</a></text>
<text top="880" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref31">renal arteriography at the time of coronary arteriog-</a></text>
<text top="894" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref31">raphy: a science advisory from the American Heart</a></text>
<text top="907" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref31">Association Committee on Diagnostic and Interven-</a></text>
<text top="921" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref31">tional Cardiac Catheterization, Council on Clinical Car-</a></text>
<text top="934" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref31">diology, and the Councils on Cardiovascular Radiology</a></text>
<text top="948" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref31">and Intervention and on Kidney in Cardiovascular Dis-</a></text>
<text top="961" left="108" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref31">ease. Circulation. 2006;114:1892</a></text>
<text top="959" left="239" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref31">–5</a></text>
<text top="961" left="248" width="3" height="9" font="5">.</text>
<text top="980" left="108" width="12" height="9" font="5">32.</text>
<text top="980" left="123" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref32">Chobanian AV, Bakris GL, Black HR, et al. Seventh</a></text>
<text top="994" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref32">report of the Joint National Committee on Prevention,</a></text>
<text top="1007" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref32">Detection, Evaluation, and Treatment of High Blood</a></text>
<text top="1020" left="108" width="155" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref32">Pressure. Hypertension. 2003;42:1206</a></text>
<text top="1019" left="263" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref32">–52</a></text>
<text top="1020" left="277" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref32">.</a></text>
<text top="1040" left="108" width="12" height="9" font="5">33.</text>
<text top="1040" left="123" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">Creager MA, Belkin M, Bluth EI, et al. 2012 ACCF/</a></text>
<text top="1053" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data ele-</a></text>
<text top="1067" left="108" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">ments and de</a></text>
<text top="1065" left="167" width="159" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">ﬁnitions for peripheral atherosclerotic</a></text>
<text top="1080" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">vascular disease: a report of the American College of</a></text>
<text top="1093" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">Cardiology Foundation/American Heart Association</a></text>
<text top="143" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">Task Force on Clinical Data Standards (Writing Com-</a></text>
<text top="156" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">mittee to Develop Clinical Data Standards for Periph-</a></text>
<text top="170" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">eral Atherosclerotic Vascular Disease). J Am Coll</a></text>
<text top="183" left="345" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">Cardiol. 2012;59:294</a></text>
<text top="182" left="430" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">–357</a></text>
<text top="183" left="448" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref33">.</a></text>
<text top="202" left="345" width="13" height="9" font="5">34.</text>
<text top="202" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref34">Rutherford RB, Baker JD, Ernst C, et al. Recom-</a></text>
<text top="215" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref34">mended standards for reports dealing with lower ex-</a></text>
<text top="229" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref34">tremity ischemia: revised version. J Vasc Surg. 1997;26:</a></text>
<text top="242" left="345" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref34">517</a></text>
<text top="241" left="358" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref34">–38</a></text>
<text top="242" left="373" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref34">.</a></text>
<text top="261" left="345" width="12" height="9" font="5">35.</text>
<text top="261" left="360" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref35">Norgren L, Hiatt WR, Dormandy JA, et al. Inter-</a></text>
<text top="274" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref35">society consensus for the management of peripheral</a></text>
<text top="288" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref35">arterial disease (TASC II). Eur J Vasc Endovasc Surg</a></text>
<text top="301" left="345" width="79" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref35">2007; 33 suppl 1:S1</a></text>
<text top="299" left="424" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref35">–75</a></text>
<text top="301" left="438" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref35">.</a></text>
<text top="320" left="345" width="13" height="9" font="5">36.</text>
<text top="320" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref36">Fakhry F, Rouwet EV, den Hoed PT, et al. Long-</a></text>
<text top="333" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref36">term clinical effectiveness of supervised exercise</a></text>
<text top="347" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref36">therapy versus endovascular revascularization for</a></text>
<text top="360" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref36">intermittent claudication from a randomized clinical</a></text>
<text top="373" left="345" width="123" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref36">trial. Br J Surg. 2013;100:1164</a></text>
<text top="372" left="468" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref36">–71</a></text>
<text top="373" left="480" width="3" height="9" font="5">.</text>
<text top="392" left="345" width="12" height="9" font="5">37.</text>
<text top="392" left="360" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">Murphy TP, Cutlip DE, Regensteiner JG, et al. Su-</a></text>
<text top="405" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">pervised exercise versus primary stenting for claudi-</a></text>
<text top="419" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">cation resulting from aortoiliac peripheral artery</a></text>
<text top="432" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">disease: six-month outcomes from the claudication:</a></text>
<text top="446" left="345" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">exercise</a></text>
<text top="446" left="392" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">versus</a></text>
<text top="446" left="432" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">endoluminal</a></text>
<text top="446" left="497" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">revascularization</a></text>
<text top="459" left="345" width="169" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">(CLEVER) study. Circulation. 2012;125:130</a></text>
<text top="458" left="514" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">–9</a></text>
<text top="459" left="524" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref37">.</a></text>
<text top="478" left="345" width="13" height="9" font="5">38.</text>
<text top="478" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref38">Murphy TP, Cutlip DE, Regensteiner JG, et al. Su-</a></text>
<text top="491" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref38">pervised exercise, stent revascularization, or medical</a></text>
<text top="505" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref38">therapy for claudication due to aortoiliac peripheral</a></text>
<text top="518" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref38">artery disease: the CLEVER study. J Am Coll Cardiol.</a></text>
<text top="532" left="345" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref38">2015;65:999</a></text>
<text top="530" left="397" width="26" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref38">–1009</a></text>
<text top="532" left="423" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref38">.</a></text>
<text top="550" left="345" width="13" height="9" font="5">39.</text>
<text top="550" left="361" width="169" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref39">Treat-Jacobson D, Bronas UG, Leon AS. Ef</a></text>
<text top="548" left="530" width="34" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref39">ﬁcacy of</a></text>
<text top="564" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref39">arm-ergometry versus treadmill exercise training to</a></text>
<text top="577" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref39">improve walking distance in patients with claudication.</a></text>
<text top="590" left="345" width="97" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref39">Vasc Med. 2009;14:203</a></text>
<text top="589" left="442" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref39">–13</a></text>
<text top="590" left="454" width="3" height="9" font="5">.</text>
<text top="609" left="345" width="14" height="9" font="5">40.</text>
<text top="609" left="362" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref40">Hiatt WR, Regensteiner JG, Hargarten ME, et al.</a></text>
<text top="622" left="345" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref40">Bene</a></text>
<text top="621" left="365" width="198" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref40">ﬁt of exercise conditioning for patients with pe-</a></text>
<text top="636" left="345" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref40">ripheral arterial disease. Circulation. 1990;81:602</a></text>
<text top="634" left="545" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref40">–9</a></text>
<text top="636" left="554" width="3" height="9" font="5">.</text>
<text top="654" left="345" width="12" height="9" font="5">41.</text>
<text top="654" left="360" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref41">Parmenter BJ, Dieberg G, Smart NA. Exercise</a></text>
<text top="668" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref41">training for management of peripheral arterial disease:</a></text>
<text top="681" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref41">a systematic review and meta-analysis. Sports Med.</a></text>
<text top="695" left="345" width="48" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref41">2015;45:231</a></text>
<text top="693" left="394" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref41">–44</a></text>
<text top="695" left="408" width="3" height="9" font="5">.</text>
<text top="713" left="345" width="13" height="9" font="5">42.</text>
<text top="713" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref42">Parmenter BJ, Dieberg G, Phipps G, et al. Exercise</a></text>
<text top="727" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref42">training for health-related quality of life in peripheral</a></text>
<text top="740" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref42">artery disease: a systematic review and meta-analysis.</a></text>
<text top="754" left="345" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref42">Vasc Med. 2015;20:30</a></text>
<text top="752" left="436" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref42">–40</a></text>
<text top="754" left="451" width="3" height="9" font="5">.</text>
<text top="772" left="345" width="13" height="9" font="5">43.</text>
<text top="772" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref43">Pilz M, Kandioler-Honetz E, Wenkstetten-Holub A,</a></text>
<text top="786" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref43">et al. Evaluation of 6- and 12-month supervised exer-</a></text>
<text top="799" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref43">cise training on strength and endurance parameters in</a></text>
<text top="813" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref43">patients with peripheral arterial disease. Wien Klin</a></text>
<text top="826" left="345" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref43">Wochenschr. 2014;126:383</a></text>
<text top="824" left="454" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref43">–9</a></text>
<text top="826" left="463" width="3" height="9" font="5">.</text>
<text top="845" left="345" width="14" height="9" font="5">44.</text>
<text top="845" left="362" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref44">Regensteiner JG, Steiner JF, Hiatt WR. Exercise</a></text>
<text top="858" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref44">training improves functional status in patients with</a></text>
<text top="871" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref44">peripheral arterial disease. J Vasc Surg. 1996;23:</a></text>
<text top="885" left="345" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref44">104</a></text>
<text top="883" left="360" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref44">–15</a></text>
<text top="885" left="373" width="3" height="9" font="5">.</text>
<text top="903" left="345" width="13" height="9" font="5">45.</text>
<text top="903" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref45">Regensteiner JG. Exercise in the treatment of</a></text>
<text top="917" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref45">claudication: assessment and treatment of functional</a></text>
<text top="930" left="345" width="140" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref45">impairment. Vasc Med. 1997;2:238</a></text>
<text top="929" left="485" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref45">–42</a></text>
<text top="930" left="499" width="3" height="9" font="5">.</text>
<text top="949" left="345" width="14" height="9" font="5">46.</text>
<text top="949" left="362" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref46">Stewart KJ, Hiatt WR, Regensteiner JG, et al. Ex-</a></text>
<text top="962" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref46">ercise training for claudication. N Engl J Med. 2002;</a></text>
<text top="976" left="345" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref46">347:1941</a></text>
<text top="974" left="381" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref46">–51</a></text>
<text top="976" left="394" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref46">.</a></text>
<text top="994" left="345" width="13" height="9" font="5">47.</text>
<text top="994" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref47">Collins TC, Lunos S, Carlson T, et al. Effects of a</a></text>
<text top="1008" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref47">home-based walking intervention on mobility and</a></text>
<text top="1021" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref47">quality of life in people with diabetes and peripheral</a></text>
<text top="1035" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref47">arterial disease: a randomized controlled trial. Diabetes</a></text>
<text top="1048" left="345" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref47">Care. 2011;34:2174</a></text>
<text top="1046" left="421" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref47">–9</a></text>
<text top="1048" left="430" width="3" height="9" font="5">.</text>
<text top="1067" left="345" width="14" height="9" font="5">48.</text>
<text top="1067" left="362" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref48">Fakhry F, Spronk S, de Ridder M, et al. Long-term</a></text>
<text top="1080" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref48">effects of structured home-based exercise program on</a></text>
<text top="1093" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref48">functional capacity and quality of life in patients with</a></text>
<text top="143" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref48">intermittent claudication. Arch Phys Med Rehabil.</a></text>
<text top="156" left="583" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref48">2011;92:1066</a></text>
<text top="155" left="638" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref48">–73</a></text>
<text top="156" left="651" width="3" height="9" font="5">.</text>
<text top="176" left="583" width="14" height="9" font="5">49.</text>
<text top="176" left="600" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref49">Gardner AW, Parker DE, Montgomery PS, et al.</a></text>
<text top="189" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref49">Step-monitored home exercise improves ambulation,</a></text>
<text top="202" left="583" width="104" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref49">vascular function, and in</a></text>
<text top="201" left="688" width="114" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref49">ﬂammation in symptomatic</a></text>
<text top="216" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref49">patients with peripheral artery disease: a randomized</a></text>
<text top="229" left="583" width="207" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref49">controlled trial. J Am Heart Assoc. 2014;3:e001107</a></text>
<text top="229" left="790" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref49">.</a></text>
<text top="248" left="583" width="13" height="9" font="5">50.</text>
<text top="248" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref50">Mays RJ, Rogers RK, Hiatt WR, et al. Community</a></text>
<text top="262" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref50">walking programs for treatment of peripheral artery</a></text>
<text top="275" left="583" width="141" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref50">disease. J Vasc Surg. 2013;58:1678</a></text>
<text top="274" left="724" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref50">–87</a></text>
<text top="275" left="738" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref50">.</a></text>
<text top="294" left="583" width="11" height="9" font="5">51.</text>
<text top="294" left="597" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref51">McDermott MM, Domanchuk K, Liu K, et al. The</a></text>
<text top="308" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref51">Group Oriented Arterial Leg Study (GOALS) to improve</a></text>
<text top="321" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref51">walking performance in patients with peripheral arte-</a></text>
<text top="335" left="583" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref51">rial disease. Contemp Clin Trials. 2012;33:1311</a></text>
<text top="333" left="767" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref51">–20</a></text>
<text top="335" left="782" width="3" height="9" font="5">.</text>
<text top="354" left="583" width="12" height="9" font="5">52.</text>
<text top="354" left="598" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref52">Rose GA. The diagnosis of ischaemic heart pain and</a></text>
<text top="367" left="583" width="112" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref52">intermittent claudication in</a></text>
<text top="366" left="699" width="102" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref52">ﬁeld surveys. Bull World</a></text>
<text top="381" left="583" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref52">Health Organ. 1962;27:645</a></text>
<text top="379" left="692" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref52">–58</a></text>
<text top="381" left="707" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref52">.</a></text>
<text top="400" left="583" width="12" height="9" font="5">53.</text>
<text top="400" left="598" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref53">McDermott MM, Mehta S, Greenland P. Exertional</a></text>
<text top="413" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref53">leg symptoms other than intermittent claudication are</a></text>
<text top="427" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref53">common in peripheral arterial disease. Arch Intern Med.</a></text>
<text top="440" left="583" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref53">1999;159:387</a></text>
<text top="438" left="638" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref53">–92</a></text>
<text top="440" left="652" width="3" height="9" font="5">.</text>
<text top="459" left="583" width="13" height="9" font="5">54.</text>
<text top="459" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref54">McDermott MM, Greenland P, Liu K, et al. Leg</a></text>
<text top="473" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref54">symptoms in peripheral arterial disease: associated</a></text>
<text top="486" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref54">clinical characteristics and functional impairment.</a></text>
<text top="499" left="583" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref54">JAMA. 2001;286:1599</a></text>
<text top="498" left="673" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref54">–606</a></text>
<text top="499" left="695" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref54">.</a></text>
<text top="518" left="583" width="12" height="9" font="5">55.</text>
<text top="518" left="598" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref55">Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Pe-</a></text>
<text top="532" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref55">ripheral arterial disease detection, awareness, and</a></text>
<text top="545" left="583" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref55">treatment in primary care. JAMA. 2001;286:1317</a></text>
<text top="544" left="779" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref55">–24</a></text>
<text top="545" left="793" width="3" height="9" font="5">.</text>
<text top="564" left="583" width="13" height="9" font="5">56.</text>
<text top="564" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref56">Khan NA, Rahim SA, Anand SS, et al. Does the</a></text>
<text top="578" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref56">clinical examination predict lower extremity peripheral</a></text>
<text top="591" left="583" width="154" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref56">arterial disease? JAMA. 2006;295:536</a></text>
<text top="590" left="737" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref56">–46</a></text>
<text top="591" left="752" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref56">.</a></text>
<text top="610" left="583" width="12" height="9" font="5">57.</text>
<text top="610" left="598" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref57">Criqui MH, Denenberg JO, Bird CE, et al. The cor-</a></text>
<text top="624" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref57">relation between symptoms and non-invasive test re-</a></text>
<text top="637" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref57">sults in patients referred for peripheral arterial disease</a></text>
<text top="651" left="583" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref57">testing. Vasc Med. 1996;1:65</a></text>
<text top="649" left="700" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref57">–71</a></text>
<text top="651" left="712" width="3" height="9" font="5">.</text>
<text top="670" left="583" width="13" height="9" font="5">58.</text>
<text top="670" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref58">Armstrong DWJ, Tobin C, Matangi MF. The accu-</a></text>
<text top="683" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref58">racy of the physical examination for the detection of</a></text>
<text top="697" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref58">lower extremity peripheral arterial disease. Can J Car-</a></text>
<text top="710" left="583" width="77" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref58">diol. 2010;26:e346</a></text>
<text top="709" left="660" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref58">–50</a></text>
<text top="710" left="675" width="3" height="9" font="5">.</text>
<text top="729" left="583" width="13" height="9" font="5">59.</text>
<text top="729" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref59">Cournot M, Boccalon H, Cambou JP, et al. Accuracy</a></text>
<text top="743" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref59">of the screening physical examination to identify sub-</a></text>
<text top="756" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref59">clinical atherosclerosis and peripheral arterial disease</a></text>
<text top="770" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref59">in asymptomatic subjects. J Vasc Surg. 2007;46:</a></text>
<text top="783" left="583" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref59">1215</a></text>
<text top="781" left="600" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref59">–21</a></text>
<text top="783" left="613" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref59">.</a></text>
<text top="802" left="583" width="14" height="9" font="5">60.</text>
<text top="802" left="600" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref60">Clark CE, Taylor RS, Shore AC, et al. Association of</a></text>
<text top="816" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref60">a difference in systolic blood pressure between arms</a></text>
<text top="829" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref60">with vascular disease and mortality: a systematic re-</a></text>
<text top="842" left="583" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref60">view and meta-analysis. Lancet. 2012;379:905</a></text>
<text top="841" left="771" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref60">–14</a></text>
<text top="842" left="784" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref60">.</a></text>
<text top="861" left="583" width="12" height="9" font="5">61.</text>
<text top="861" left="598" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref61">Singh S, Sethi A, Singh M, et al. Simultaneously</a></text>
<text top="875" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref61">measured inter-arm and inter-leg systolic blood pres-</a></text>
<text top="888" left="583" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref61">sure differences and cardiovascular risk strati</a></text>
<text top="887" left="762" width="39" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref61">ﬁcation: a</a></text>
<text top="902" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref61">systemic review and meta-analysis. J Am Soc Hyper-</a></text>
<text top="915" left="583" width="70" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref61">tens. 2015;9:640</a></text>
<text top="914" left="653" width="31" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref61">–50.e12</a></text>
<text top="915" left="684" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref61">.</a></text>
<text top="934" left="583" width="13" height="9" font="5">62.</text>
<text top="934" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref62">Shadman R, Criqui MH, Bundens WP, et al. Sub-</a></text>
<text top="948" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref62">clavian artery stenosis: prevalence, risk factors, and</a></text>
<text top="961" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref62">association with cardiovascular diseases. J Am Coll</a></text>
<text top="975" left="583" width="87" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref62">Cardiol. 2004;44:618</a></text>
<text top="973" left="670" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref62">–23</a></text>
<text top="975" left="683" width="3" height="9" font="5">.</text>
<text top="994" left="583" width="13" height="9" font="5">63.</text>
<text top="994" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref63">Wassel CL, Loomba R, Ix JH, et al. Family history of</a></text>
<text top="1007" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref63">peripheral artery disease is associated with prevalence</a></text>
<text top="1021" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref63">and severity of peripheral artery disease: the San Diego</a></text>
<text top="1034" left="583" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref63">Population Study. J Am Coll Cardiol. 2011;58:1386</a></text>
<text top="1032" left="784" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref63">–92</a></text>
<text top="1034" left="799" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref63">.</a></text>
<text top="1053" left="583" width="14" height="9" font="5">64.</text>
<text top="1053" left="600" width="186" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref64">Schröder F, Diehm N, Kareem S, et al. A modi</a></text>
<text top="1051" left="786" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref64">ﬁed</a></text>
<text top="1067" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref64">calculation of ankle-brachial pressure index is far more</a></text>
<text top="1080" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref64">sensitive in the detection of peripheral arterial disease.</a></text>
<text top="1093" left="583" width="104" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref64">J Vasc Surg. 2006;44:531</a></text>
<text top="1092" left="687" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref64">–6</a></text>
<text top="1093" left="696" width="3" height="9" font="5">.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="18" height="9" font="5">e110</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="13" height="9" font="5">65.</text>
<text top="143" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref65">Premalatha G, Ravikumar R, Sanjay R, et al. Com-</a></text>
<text top="156" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref65">parison of colour duplex ultrasound and ankle-brachial</a></text>
<text top="170" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref65">pressure index measurements in peripheral vascular</a></text>
<text top="183" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref65">disease in type 2 diabetic patients with foot infections.</a></text>
<text top="197" left="63" width="159" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref65">J Assoc Physicians India. 2002;50:1240</a></text>
<text top="195" left="222" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref65">–4</a></text>
<text top="197" left="231" width="3" height="9" font="5">.</text>
<text top="216" left="63" width="14" height="9" font="5">66.</text>
<text top="216" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref66">Allen J, Oates CP, Henderson J, et al. Comparison</a></text>
<text top="230" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref66">of lower limb arterial assessments using color-duplex</a></text>
<text top="243" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref66">ultrasound and ankle/brachial pressure index mea-</a></text>
<text top="257" left="63" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref66">surements. Angiology. 1996;47:225</a></text>
<text top="255" left="206" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref66">–32</a></text>
<text top="257" left="219" width="3" height="9" font="5">.</text>
<text top="276" left="63" width="13" height="9" font="5">67.</text>
<text top="276" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref67">Lijmer JG, Hunink MG, van den Dungen JJ, et al.</a></text>
<text top="289" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref67">ROC analysis of noninvasive tests for peripheral arterial</a></text>
<text top="303" left="63" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref67">disease. Ultrasound Med Biol. 1996;22:391</a></text>
<text top="301" left="235" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref67">–8</a></text>
<text top="303" left="244" width="3" height="9" font="5">.</text>
<text top="322" left="63" width="14" height="9" font="5">68.</text>
<text top="322" left="79" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref68">Guo X, Li J, Pang W, et al. Sensitivity and speci</a></text>
<text top="321" left="261" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref68">ﬁcity</a></text>
<text top="336" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref68">of ankle-brachial index for detecting angiographic</a></text>
<text top="349" left="63" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref68">stenosis of peripheral arteries. Circ J. 2008;72:605</a></text>
<text top="348" left="265" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref68">–10</a></text>
<text top="349" left="278" width="3" height="9" font="5">.</text>
<text top="369" left="63" width="14" height="9" font="5">69.</text>
<text top="369" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">Niazi K, Khan TH, Easley KA. Diagnostic utility of</a></text>
<text top="382" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">the two methods of ankle brachial index in the</a></text>
<text top="396" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">detection of peripheral arterial disease of lower ex-</a></text>
<text top="409" left="63" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">tremities.</a></text>
<text top="409" left="110" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">Catheter</a></text>
<text top="409" left="154" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">Cardiovasc</a></text>
<text top="409" left="206" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">Interv.</a></text>
<text top="409" left="242" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">2006;68:</a></text>
<text top="422" left="63" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">788</a></text>
<text top="421" left="78" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">–92</a></text>
<text top="422" left="93" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref69">.</a></text>
<text top="442" left="63" width="13" height="9" font="5">70.</text>
<text top="442" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref70">Eslahpazir BA, Allemang MT, Lakin RO, et al. Pulse</a></text>
<text top="455" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref70">volume recording does not enhance segmental pres-</a></text>
<text top="469" left="63" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref70">sure readings for peripheral arterial disease strati</a></text>
<text top="467" left="263" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref70">ﬁca-</a></text>
<text top="482" left="63" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref70">tion. Ann Vasc Surg. 2014;28:18</a></text>
<text top="481" left="192" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref70">–27</a></text>
<text top="482" left="206" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref70">.</a></text>
<text top="502" left="63" width="11" height="9" font="5">71.</text>
<text top="502" left="77" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref71">Raines JK, Darling RC, Buth J, et al. Vascular lab-</a></text>
<text top="515" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref71">oratory criteria for the management of peripheral</a></text>
<text top="529" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref71">vascular disease of the lower extremities. Surgery.</a></text>
<text top="542" left="63" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref71">1976;79:21</a></text>
<text top="540" left="106" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref71">–9</a></text>
<text top="542" left="116" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref71">.</a></text>
<text top="561" left="63" width="12" height="9" font="5">72.</text>
<text top="561" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref72">Aboyans V, Ho E, Denenberg JO, et al. The asso-</a></text>
<text top="575" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref72">ciation between elevated ankle systolic pressures and</a></text>
<text top="588" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref72">peripheral occlusive arterial disease in diabetic and</a></text>
<text top="602" left="63" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref72">nondiabetic subjects. J Vasc Surg. 2008;48:1197</a></text>
<text top="600" left="258" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref72">–203</a></text>
<text top="602" left="278" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref72">.</a></text>
<text top="621" left="63" width="12" height="9" font="5">73.</text>
<text top="621" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref73">Ouriel K, McDonnell AE, Metz CE, et al. Critical</a></text>
<text top="635" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref73">evaluation of stress testing in the diagnosis of pe-</a></text>
<text top="648" left="63" width="191" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref73">ripheral vascular disease. Surgery. 1982;91:686</a></text>
<text top="647" left="253" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref73">–93</a></text>
<text top="648" left="268" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref73">.</a></text>
<text top="668" left="63" width="13" height="9" font="5">74.</text>
<text top="668" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref74">Stein R, Hriljac I, Halperin JL, et al. Limitation of</a></text>
<text top="681" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref74">the resting ankle-brachial index in symptomatic pa-</a></text>
<text top="694" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref74">tients with peripheral arterial disease. Vasc Med. 2006;</a></text>
<text top="708" left="63" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref74">11:29</a></text>
<text top="706" left="83" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref74">–33</a></text>
<text top="708" left="97" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref74">.</a></text>
<text top="727" left="63" width="12" height="9" font="5">75.</text>
<text top="727" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">Belch J, MacCuish A, Campbell I, et al. The Pre-</a></text>
<text top="741" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">vention of Progression of Arterial Disease and Diabetes</a></text>
<text top="754" left="63" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">(POPADAD)</a></text>
<text top="754" left="120" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">trial:</a></text>
<text top="754" left="149" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">factorial</a></text>
<text top="754" left="193" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">randomised</a></text>
<text top="754" left="250" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">placebo</a></text>
<text top="768" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">controlled trial of aspirin and antioxidants in patients</a></text>
<text top="781" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">with diabetes and asymptomatic peripheral arterial</a></text>
<text top="795" left="63" width="124" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">disease. BMJ. 2008;337:a1840</a></text>
<text top="795" left="187" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref75">.</a></text>
<text top="814" left="63" width="13" height="9" font="5">76.</text>
<text top="814" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref76">Fowkes FG, Price JF, Stewart MC, et al. Aspirin for</a></text>
<text top="827" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref76">prevention of cardiovascular events in a general pop-</a></text>
<text top="841" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref76">ulation screened for a low ankle brachial index: a ran-</a></text>
<text top="854" left="63" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref76">domized controlled trial. JAMA. 2010;303:841</a></text>
<text top="853" left="250" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref76">–8</a></text>
<text top="854" left="259" width="3" height="9" font="5">.</text>
<text top="874" left="63" width="12" height="9" font="5">77.</text>
<text top="874" left="78" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">Alahdab</a></text>
<text top="874" left="120" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">F,</a></text>
<text top="874" left="136" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">Wang</a></text>
<text top="874" left="168" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">AT,</a></text>
<text top="874" left="190" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">Elraiyah</a></text>
<text top="874" left="231" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">TA,</a></text>
<text top="874" left="254" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">et</a></text>
<text top="874" left="271" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">al.</a></text>
<text top="887" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">A systematic review for the screening for peripheral</a></text>
<text top="901" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">arterial disease in asymptomatic patients. J Vasc Surg.</a></text>
<text top="914" left="63" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">2015;61:42S</a></text>
<text top="912" left="112" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref77">–53S</a></text>
<text top="914" left="130" width="3" height="9" font="5">.</text>
<text top="934" left="63" width="13" height="9" font="5">78.</text>
<text top="934" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref78">Lin JS, Olson CM, Johnson ES, et al. The ankle-</a></text>
<text top="947" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref78">brachial index for peripheral artery disease screening</a></text>
<text top="960" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref78">and cardiovascular disease prediction among asymp-</a></text>
<text top="974" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref78">tomatic adults: a systematic evidence review for the</a></text>
<text top="987" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref78">U.S. Preventive Services Task Force. Ann Intern Med.</a></text>
<text top="1001" left="63" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref78">2013;159:333</a></text>
<text top="999" left="116" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref78">–41</a></text>
<text top="1001" left="129" width="3" height="9" font="5">.</text>
<text top="1020" left="63" width="13" height="9" font="5">79.</text>
<text top="1020" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref79">Diehm C, Allenberg JR, Pittrow D, et al. Mortality</a></text>
<text top="1034" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref79">and vascular morbidity in older adults with asymp-</a></text>
<text top="1047" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref79">tomatic versus symptomatic peripheral artery disease.</a></text>
<text top="1061" left="63" width="111" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref79">Circulation. 2009;120:2053</a></text>
<text top="1059" left="174" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref79">–61</a></text>
<text top="1061" left="187" width="3" height="9" font="5">.</text>
<text top="1080" left="63" width="14" height="9" font="5">80.</text>
<text top="1080" left="80" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref80">Fowkes FG, Murray GD, Butcher I, et al. Ankle</a></text>
<text top="1093" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref80">brachial index combined with Framingham Risk Score</a></text>
<text top="143" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref80">to predict cardiovascular events and mortality: a meta-</a></text>
<text top="156" left="301" width="124" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref80">analysis. JAMA. 2008;300:197</a></text>
<text top="155" left="424" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref80">–208</a></text>
<text top="156" left="445" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref80">.</a></text>
<text top="175" left="301" width="12" height="9" font="5">81.</text>
<text top="175" left="315" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref81">Ratanakorn D, Keandoungchun J, Tegeler CH.</a></text>
<text top="188" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref81">Prevalence and association between risk factors, stroke</a></text>
<text top="202" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref81">subtypes, and abnormal ankle brachial index in acute</a></text>
<text top="215" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref81">ischemic stroke. J Stroke Cerebrovasc Dis. 2012;21:</a></text>
<text top="229" left="301" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref81">498</a></text>
<text top="227" left="317" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref81">–503</a></text>
<text top="229" left="337" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref81">.</a></text>
<text top="247" left="301" width="13" height="9" font="5">82.</text>
<text top="247" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref82">Sen S, Lynch DR, Kaltsas E, et al. Association of</a></text>
<text top="261" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref82">asymptomatic peripheral arterial disease with vascular</a></text>
<text top="274" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref82">events in patients with stroke or transient ischemic</a></text>
<text top="288" left="301" width="120" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref82">attack. Stroke. 2009;40:3472</a></text>
<text top="286" left="420" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref82">–7</a></text>
<text top="288" left="429" width="3" height="9" font="5">.</text>
<text top="306" left="301" width="13" height="9" font="5">83.</text>
<text top="306" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref83">Bundó M, Muñoz L, Pérez C, et al. Asymptomatic</a></text>
<text top="320" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref83">peripheral arterial disease in type 2 diabetes patients: a</a></text>
<text top="333" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref83">10-year follow-up study of the utility of the ankle</a></text>
<text top="347" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref83">brachial index as a prognostic marker of cardiovascular</a></text>
<text top="360" left="301" width="150" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref83">disease. Ann Vasc Surg. 2010;24:985</a></text>
<text top="358" left="451" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref83">–93</a></text>
<text top="360" left="465" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref83">.</a></text>
<text top="379" left="301" width="14" height="9" font="5">84.</text>
<text top="379" left="317" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref84">Bouisset F, Bongard V, Ruidavets JB, et al. Prog-</a></text>
<text top="392" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref84">nostic usefulness of clinical and subclinical peripheral</a></text>
<text top="405" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref84">arterial disease in men with stable coronary heart dis-</a></text>
<text top="419" left="301" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref84">ease. Am J Cardiol. 2012;110:197</a></text>
<text top="417" left="433" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref84">–202</a></text>
<text top="419" left="452" width="3" height="9" font="5">.</text>
<text top="437" left="301" width="13" height="9" font="5">85.</text>
<text top="437" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref85">Hiramoto JS, Katz R, Ix JH, et al. Sex differences in</a></text>
<text top="451" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref85">the prevalence and clinical outcomes of subclinical</a></text>
<text top="464" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref85">peripheral artery disease in the Health, Aging, and</a></text>
<text top="478" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref85">Body Composition (Health ABC) study. Vascular. 2014;</a></text>
<text top="491" left="301" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref85">22:142</a></text>
<text top="490" left="327" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref85">–8</a></text>
<text top="491" left="336" width="3" height="9" font="5">.</text>
<text top="510" left="301" width="14" height="9" font="5">86.</text>
<text top="510" left="317" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref86">Jiménez M, Dorado L, Hernández-Pérez M, et al.</a></text>
<text top="523" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref86">Ankle-brachial index in screening for asymptomatic</a></text>
<text top="537" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref86">carotid and intracranial atherosclerosis. Atheroscle-</a></text>
<text top="550" left="301" width="73" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref86">rosis. 2014;233:72</a></text>
<text top="548" left="373" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref86">–5</a></text>
<text top="550" left="382" width="3" height="9" font="5">.</text>
<text top="569" left="301" width="13" height="9" font="5">87.</text>
<text top="569" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref87">Tsivgoulis G, Bogiatzi C, Heliopoulos I, et al. Low</a></text>
<text top="582" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref87">ankle-brachial index predicts early risk of recurrent</a></text>
<text top="596" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref87">stroke in patients with acute cerebral ischemia.</a></text>
<text top="609" left="301" width="123" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref87">Atherosclerosis. 2012;220:407</a></text>
<text top="607" left="423" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref87">–12</a></text>
<text top="609" left="436" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref87">.</a></text>
<text top="628" left="301" width="14" height="9" font="5">88.</text>
<text top="628" left="317" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref88">McDermott MM, Liu K, Guralnik JM, et al. Home-</a></text>
<text top="641" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref88">based walking exercise intervention in peripheral ar-</a></text>
<text top="654" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref88">tery disease: a randomized clinical trial. JAMA. 2013;</a></text>
<text top="668" left="301" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref88">310:57</a></text>
<text top="666" left="327" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref88">–65</a></text>
<text top="668" left="342" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref88">.</a></text>
<text top="686" left="301" width="14" height="9" font="5">89.</text>
<text top="686" left="317" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref89">McDermott MM, Fried L, Simonsick E, et al.</a></text>
<text top="700" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref89">Asymptomatic peripheral arterial disease is indepen-</a></text>
<text top="713" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref89">dently associated with impaired lower extremity</a></text>
<text top="727" left="301" width="102" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref89">functioning: the Women</a></text>
<text top="725" left="402" width="116" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref89">’s Health and Aging Study.</a></text>
<text top="740" left="301" width="110" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref89">Circulation. 2000;101:1007</a></text>
<text top="739" left="411" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref89">–12</a></text>
<text top="740" left="423" width="3" height="9" font="5">.</text>
<text top="759" left="301" width="14" height="9" font="5">90.</text>
<text top="759" left="317" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref90">McDermott MM, Applegate WB, Bonds DE, et al.</a></text>
<text top="772" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref90">Ankle brachial index values, leg symptoms, and func-</a></text>
<text top="786" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref90">tional performance among community-dwelling older</a></text>
<text top="799" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref90">men and women in the Lifestyle Interventions and In-</a></text>
<text top="813" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref90">dependence for Elders Study. J Am Heart Assoc. 2013;</a></text>
<text top="826" left="301" width="45" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref90">2:e000257</a></text>
<text top="826" left="345" width="3" height="9" font="5">.</text>
<text top="845" left="301" width="12" height="9" font="5">91.</text>
<text top="845" left="315" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref91">McDermott MM, Liu K, Greenland P, et al. Func-</a></text>
<text top="858" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref91">tional decline in peripheral arterial disease: associa-</a></text>
<text top="871" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref91">tions with the ankle brachial index and leg symptoms.</a></text>
<text top="885" left="301" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref91">JAMA. 2004;292:453</a></text>
<text top="883" left="387" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref91">–61</a></text>
<text top="885" left="400" width="3" height="9" font="5">.</text>
<text top="903" left="301" width="13" height="9" font="5">92.</text>
<text top="903" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref92">McDermott MM, Ferrucci L, Liu K, et al. Leg</a></text>
<text top="917" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref92">symptom categories and rates of mobility decline in</a></text>
<text top="930" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref92">peripheral arterial disease. J Am Geriatr Soc. 2010;58:</a></text>
<text top="944" left="301" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref92">1256</a></text>
<text top="942" left="319" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref92">–62</a></text>
<text top="944" left="334" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref92">.</a></text>
<text top="962" left="301" width="13" height="9" font="5">93.</text>
<text top="962" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref93">McDermott MM, Liu K, Ferrucci L, et al. Physical</a></text>
<text top="976" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref93">performance in peripheral arterial disease: a slower</a></text>
<text top="989" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref93">rate of decline in patients who walk more. Ann Intern</a></text>
<text top="1003" left="301" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref93">Med. 2006;144:10</a></text>
<text top="1001" left="375" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref93">–20</a></text>
<text top="1003" left="390" width="3" height="9" font="5">.</text>
<text top="1021" left="301" width="14" height="9" font="5">94.</text>
<text top="1021" left="317" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref94">McDermott MM, Guralnik JM, Criqui MH, et al.</a></text>
<text top="1035" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref94">Home-based walking exercise in peripheral artery dis-</a></text>
<text top="1048" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref94">ease: 12-month follow-up of the GOALS randomized</a></text>
<text top="1061" left="301" width="163" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref94">trial. J Am Heart Assoc. 2014;3:e000711</a></text>
<text top="1061" left="463" width="3" height="9" font="5">.</text>
<text top="1080" left="301" width="13" height="9" font="5">95.</text>
<text top="1080" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref95">Selvin E, Erlinger TP. Prevalence of and risk factors</a></text>
<text top="1093" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref95">for peripheral arterial disease in the United States:</a></text>
<text top="143" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref95">results from the National Health and Nutrition Exami-</a></text>
<text top="156" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref95">nation Survey, 1999-2000. Circulation. 2004;110:</a></text>
<text top="170" left="538" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref95">738</a></text>
<text top="168" left="553" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref95">–43</a></text>
<text top="170" left="567" width="3" height="9" font="5">.</text>
<text top="189" left="538" width="14" height="9" font="5">96.</text>
<text top="189" left="555" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref96">Ramos R, García-Gil M, Comas-Cufí M, et al. Statins</a></text>
<text top="203" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref96">for prevention of cardiovascular events in a low-risk</a></text>
<text top="216" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref96">population with low ankle brachial index. J Am Coll</a></text>
<text top="230" left="538" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref96">Cardiol. 2016;67:630</a></text>
<text top="228" left="624" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref96">–40</a></text>
<text top="230" left="639" width="3" height="9" font="5">.</text>
<text top="249" left="538" width="13" height="9" font="5">97.</text>
<text top="249" left="554" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref97">Fowkes FG, Murray GD, Butcher I, et al. Develop-</a></text>
<text top="263" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref97">ment and validation of an ankle brachial index risk</a></text>
<text top="276" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref97">model for the prediction of cardiovascular events. Eur J</a></text>
<text top="290" left="538" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref97">Prev Cardiol. 2014;21:310</a></text>
<text top="288" left="641" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref97">–20</a></text>
<text top="290" left="656" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref97">.</a></text>
<text top="309" left="538" width="14" height="9" font="5">98.</text>
<text top="309" left="555" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref98">Criqui MH, Vargas V, Denenberg JO, et al. Ethnicity</a></text>
<text top="323" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref98">and peripheral arterial disease: the San Diego Popula-</a></text>
<text top="336" left="538" width="155" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref98">tion Study. Circulation. 2005;112:2703</a></text>
<text top="334" left="693" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref98">–7</a></text>
<text top="336" left="701" width="3" height="9" font="5">.</text>
<text top="356" left="538" width="14" height="9" font="5">99.</text>
<text top="356" left="555" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref99">Carter SA, Tate RB. Value of toe pulse waves in</a></text>
<text top="369" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref99">addition to systolic pressures in the assessment of the</a></text>
<text top="383" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref99">severity of peripheral arterial disease and critical limb</a></text>
<text top="396" left="538" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref99">ischemia. J Vasc Surg. 1996;24:258</a></text>
<text top="394" left="681" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref99">–65</a></text>
<text top="396" left="695" width="3" height="9" font="5">.</text>
<text top="415" left="538" width="18" height="9" font="5">100.</text>
<text top="415" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref100">Ramsey DE, Manke DA, Sumner DS. Toe blood</a></text>
<text top="429" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref100">pressure. A valuable adjunct to ankle pressure mea-</a></text>
<text top="442" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref100">surement for assessing peripheral arterial disease.</a></text>
<text top="456" left="538" width="156" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref100">J Cardiovasc Surg (Torino). 1983;24:43</a></text>
<text top="454" left="695" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref100">–8</a></text>
<text top="456" left="704" width="3" height="9" font="5">.</text>
<text top="475" left="538" width="16" height="9" font="5">101.</text>
<text top="475" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref101">Vincent DG, Salles-Cunha SX, Bernhard VM, et al.</a></text>
<text top="489" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref101">Noninvasive assessment of toe systolic pressures with</a></text>
<text top="502" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref101">special reference to diabetes mellitus. J Cardiovasc</a></text>
<text top="516" left="538" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref101">Surg (Torino). 1983;24:22</a></text>
<text top="514" left="641" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref101">–8</a></text>
<text top="516" left="651" width="3" height="9" font="5">.</text>
<text top="535" left="538" width="17" height="9" font="5">102.</text>
<text top="535" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref102">Carter SA. Clinical measurement of systolic pres-</a></text>
<text top="549" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref102">sures in limbs with arterial occlusive disease. JAMA.</a></text>
<text top="562" left="538" width="62" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref102">1969;207:1869</a></text>
<text top="560" left="600" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref102">–74</a></text>
<text top="562" left="614" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref102">.</a></text>
<text top="582" left="538" width="17" height="9" font="5">103.</text>
<text top="582" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref103">Carter SA. Indirect systolic pressures and pulse</a></text>
<text top="595" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref103">waves in arterial occlusive diseases of the lower ex-</a></text>
<text top="608" left="538" width="140" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref103">tremities. Circulation. 1968;37:624</a></text>
<text top="607" left="678" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref103">–37</a></text>
<text top="608" left="691" width="3" height="9" font="5">.</text>
<text top="628" left="538" width="18" height="9" font="5">104.</text>
<text top="628" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref104">Weinberg I, Giri J, Calfon MA, et al. Anatomic</a></text>
<text top="641" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref104">correlates of supra-normal ankle brachial indices.</a></text>
<text top="655" left="538" width="165" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref104">Catheter Cardiovasc Interv. 2013;81:1025</a></text>
<text top="653" left="704" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref104">–30</a></text>
<text top="655" left="718" width="3" height="9" font="5">.</text>
<text top="674" left="538" width="17" height="9" font="5">105.</text>
<text top="674" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref105">Park SC, Choi CY, Ha YI, et al. Utility of toe-</a></text>
<text top="688" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref105">brachial index for diagnosis of peripheral artery dis-</a></text>
<text top="701" left="538" width="140" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref105">ease. Arch Plast Surg. 2012;39:227</a></text>
<text top="700" left="678" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref105">–31</a></text>
<text top="701" left="691" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref105">.</a></text>
<text top="721" left="538" width="18" height="9" font="5">106.</text>
<text top="721" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref106">Covic A, Kanbay M, Voroneanu L, et al. Vascular</a></text>
<text top="734" left="538" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref106">calci</a></text>
<text top="733" left="556" width="201" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref106">ﬁcation in chronic kidney disease. Clin Sci. 2010;</a></text>
<text top="748" left="538" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref106">119:111</a></text>
<text top="746" left="565" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref106">–21</a></text>
<text top="748" left="578" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref106">.</a></text>
<text top="767" left="538" width="17" height="9" font="5">107.</text>
<text top="767" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref107">Mahe G, Pollak AW, Liedl DA, et al. Discordant</a></text>
<text top="781" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref107">diagnosis of lower extremity peripheral artery disease</a></text>
<text top="794" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref107">using American Heart Association postexercise guide-</a></text>
<text top="808" left="538" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref107">lines. Medicine (Baltimore). 2015;94:e1277</a></text>
<text top="808" left="709" width="3" height="9" font="5">.</text>
<text top="827" left="538" width="18" height="9" font="5">108.</text>
<text top="827" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref108">Nicolaï SP, Viechtbauer W, Kruidenier LM, et al.</a></text>
<text top="841" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref108">Reliability of treadmill testing in peripheral arterial</a></text>
<text top="854" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref108">disease: a meta-regression analysis. J Vasc Surg. 2009;</a></text>
<text top="867" left="538" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref108">50:322</a></text>
<text top="866" left="566" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref108">–9</a></text>
<text top="867" left="576" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref108">.</a></text>
<text top="887" left="538" width="18" height="9" font="5">109.</text>
<text top="887" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref109">Laing SP, Greenhalgh RM. Standard exercise test</a></text>
<text top="900" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref109">to assess peripheral arterial disease. Br Med J. 1980;</a></text>
<text top="914" left="538" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref109">280:13</a></text>
<text top="912" left="566" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref109">–6</a></text>
<text top="914" left="575" width="3" height="9" font="5">.</text>
<text top="933" left="538" width="16" height="9" font="5">110.</text>
<text top="933" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref110">Sumner DS, Strandness DE. The relationship be-</a></text>
<text top="947" left="538" width="72" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref110">tween calf blood</a></text>
<text top="945" left="615" width="141" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref110">ﬂow and ankle blood pressure in</a></text>
<text top="960" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref110">patients with intermittent claudication. Surgery. 1969;</a></text>
<text top="974" left="538" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref110">65:763</a></text>
<text top="972" left="566" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref110">–71</a></text>
<text top="974" left="579" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref110">.</a></text>
<text top="993" left="538" width="14" height="9" font="5">111.</text>
<text top="993" left="555" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref111">McPhail IR, Spittell PC, Weston SA, et al. Inter-</a></text>
<text top="1007" left="538" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref111">mittent</a></text>
<text top="1007" left="579" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref111">claudication:</a></text>
<text top="1007" left="640" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref111">an</a></text>
<text top="1007" left="660" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref111">objective</a></text>
<text top="1007" left="707" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref111">of</a></text>
<text top="1005" left="715" width="41" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref111">ﬁce-based</a></text>
<text top="1020" left="538" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref111">assessment. J Am Coll Cardiol. 2001;37:1381</a></text>
<text top="1019" left="717" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref111">–5</a></text>
<text top="1020" left="726" width="3" height="9" font="5">.</text>
<text top="1040" left="538" width="15" height="9" font="5">112.</text>
<text top="1040" left="556" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref112">Biotteau E, Mahe G, Rousseau P, et al. Trans-</a></text>
<text top="1053" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref112">cutaneous oxygen pressure measurements in diabetic</a></text>
<text top="1067" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref112">and non-diabetic patients clinically suspected of severe</a></text>
<text top="1080" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref112">limb ischemia: a matched paired retrospective analysis.</a></text>
<text top="1093" left="538" width="99" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref112">Int Angiol. 2009;28:479</a></text>
<text top="1092" left="637" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref112">–83</a></text>
<text top="1093" left="651" width="3" height="9" font="5">.</text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="792" width="16" height="9" font="5">e111</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="27" size="3" family="Times" color="#327eb1"/>
<text top="143" left="108" width="15" height="9" font="5">113.</text>
<text top="143" left="126" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref113">Yamada T, Ohta T, Ishibashi H, et al. Clinical reli-</a></text>
<text top="156" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref113">ability and utility of skin perfusion pressure measure-</a></text>
<text top="170" left="108" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref113">ment in ischemic limbs</a></text>
<text top="168" left="217" width="109" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref113">—comparison with other</a></text>
<text top="183" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref113">noninvasive diagnostic methods. J Vasc Surg. 2008;47:</a></text>
<text top="197" left="108" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref113">318</a></text>
<text top="195" left="122" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref113">–23</a></text>
<text top="197" left="135" width="3" height="9" font="5">.</text>
<text top="215" left="108" width="16" height="9" font="5">114.</text>
<text top="215" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref114">Castronuovo JJ, Adera HM, Smiell JM, et al. Skin</a></text>
<text top="229" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref114">perfusion pressure measurement is valuable in the</a></text>
<text top="242" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref114">diagnosis of critical limb ischemia. J Vasc Surg. 1997;</a></text>
<text top="256" left="108" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref114">26:629</a></text>
<text top="254" left="137" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref114">–37</a></text>
<text top="256" left="150" width="3" height="9" font="5">.</text>
<text top="274" left="108" width="15" height="9" font="5">115.</text>
<text top="274" left="126" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref115">Bunte MC, Jacob J, Nudelman B, et al. Validation</a></text>
<text top="288" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref115">of the relationship between ankle-brachial and toe-</a></text>
<text top="301" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref115">brachial indices and infragenicular arterial patency in</a></text>
<text top="315" left="108" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref115">critical limb ischemia. Vasc Med. 2015;20:23</a></text>
<text top="313" left="286" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref115">–9</a></text>
<text top="315" left="296" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref115">.</a></text>
<text top="333" left="108" width="16" height="9" font="5">116.</text>
<text top="333" left="126" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref116">Shishehbor MH, Hammad TA, Zeller T, et al. An</a></text>
<text top="347" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref116">analysis of IN.PACT DEEP randomized trial on the</a></text>
<text top="360" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref116">limitations of the societal guidelines-recommended</a></text>
<text top="373" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref116">hemodynamic parameters to diagnose critical limb</a></text>
<text top="387" left="108" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref116">ischemia. J Vasc Surg. 2016;63:1311</a></text>
<text top="385" left="251" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref116">–7</a></text>
<text top="387" left="259" width="3" height="9" font="5">.</text>
<text top="405" left="108" width="15" height="9" font="5">117.</text>
<text top="405" left="126" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref117">Fife CE, Smart DR, Shef</a></text>
<text top="404" left="231" width="95" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref117">ﬁeld PJ, et al. Trans-</a></text>
<text top="419" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref117">cutaneous oximetry in clinical practice: consensus</a></text>
<text top="432" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref117">statements from an expert panel based on evidence.</a></text>
<text top="446" left="108" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref117">Undersea Hyperb Med. 2009;36:43</a></text>
<text top="444" left="251" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref117">–53</a></text>
<text top="446" left="265" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref117">.</a></text>
<text top="464" left="108" width="16" height="9" font="5">118.</text>
<text top="464" left="126" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref118">Burbelko M, Augsten M, Kalinowski MO, et al.</a></text>
<text top="478" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref118">Comparison of contrast-enhanced multi-station MR</a></text>
<text top="491" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref118">angiography and digital subtraction angiography of the</a></text>
<text top="505" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref118">lower extremity arterial disease. J Magn Reson Imag-</a></text>
<text top="518" left="108" width="70" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref118">ing. 2013;37:1427</a></text>
<text top="517" left="178" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref118">–35</a></text>
<text top="518" left="192" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref118">.</a></text>
<text top="537" left="108" width="16" height="9" font="5">119.</text>
<text top="537" left="126" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref119">Söderstrom M, Albäck A, Biancari F, et al.</a></text>
<text top="550" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref119">Angiosome-targeted infrapopliteal endovascular re-</a></text>
<text top="564" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref119">vascularization for treatment of diabetic foot ulcers.</a></text>
<text top="577" left="108" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref119">J Vasc Surg. 2013;57:427</a></text>
<text top="575" left="208" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref119">–35</a></text>
<text top="577" left="222" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref119">.</a></text>
<text top="596" left="108" width="17" height="9" font="5">120.</text>
<text top="596" left="128" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref120">Shareghi S, Gopal A, Gul K, et al. Diagnostic ac-</a></text>
<text top="609" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref120">curacy of 64 multidetector computed tomographic</a></text>
<text top="622" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref120">angiography in peripheral vascular disease. Catheter</a></text>
<text top="636" left="108" width="120" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref120">Cardiovasc Interv. 2010;75:23</a></text>
<text top="634" left="227" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref120">–31</a></text>
<text top="636" left="240" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref120">.</a></text>
<text top="654" left="108" width="15" height="9" font="5">121.</text>
<text top="654" left="126" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref121">Ota H, Takase K, Igarashi K, et al. MDCT compared</a></text>
<text top="668" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref121">with digital subtraction angiography for assessment of</a></text>
<text top="681" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref121">lower extremity arterial occlusive disease: importance</a></text>
<text top="695" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref121">of reviewing cross-sectional images. AJR Am J Roent-</a></text>
<text top="708" left="108" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref121">genol. 2004;182:201</a></text>
<text top="707" left="192" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref121">–9</a></text>
<text top="708" left="202" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref121">.</a></text>
<text top="727" left="108" width="16" height="9" font="5">122.</text>
<text top="727" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref122">de Vries SO, Hunink MG, Polak JF. Summary</a></text>
<text top="740" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref122">receiver operating characteristic curves as a technique</a></text>
<text top="754" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref122">for meta-analysis of the diagnostic performance of</a></text>
<text top="767" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref122">duplex ultrasonography in peripheral arterial disease.</a></text>
<text top="780" left="108" width="97" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref122">Acad Radiol. 1996;3:361</a></text>
<text top="779" left="205" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref122">–9</a></text>
<text top="780" left="215" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref122">.</a></text>
<text top="799" left="108" width="16" height="9" font="5">123.</text>
<text top="799" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref123">Andreucci M, Solomon R, Tasanarong A. Side ef-</a></text>
<text top="813" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref123">fects of radiographic contrast media: pathogenesis, risk</a></text>
<text top="826" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref123">factors, and prevention. Biomed Res Int. 2014;2014:</a></text>
<text top="839" left="108" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref123">741018</a></text>
<text top="839" left="137" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref123">.</a></text>
<text top="858" left="108" width="17" height="9" font="5">124.</text>
<text top="858" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref124">Stacul F, van der Molen AJ, Reimer P, et al.</a></text>
<text top="871" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref124">Contrast induced nephropathy: updated ESUR Contrast</a></text>
<text top="885" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref124">Media Safety Committee guidelines. Eur Radiol. 2011;</a></text>
<text top="898" left="108" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref124">21:2527</a></text>
<text top="897" left="138" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref124">–41</a></text>
<text top="898" left="151" width="3" height="9" font="5">.</text>
<text top="917" left="108" width="16" height="9" font="5">125.</text>
<text top="917" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref125">Zhang B, Liang L, Chen W, et al. An updated study</a></text>
<text top="930" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref125">to determine association between gadolinium-based</a></text>
<text top="944" left="108" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref125">contrast agents and nephrogenic systemic</a></text>
<text top="942" left="295" width="31" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref125">ﬁbrosis.</a></text>
<text top="957" left="108" width="121" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref125">PLoS ONE. 2015;10:e0129720</a></text>
<text top="957" left="228" width="3" height="9" font="5">.</text>
<text top="976" left="108" width="17" height="9" font="5">126.</text>
<text top="976" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref126">McCullough PA, Capasso P. Patient discomfort</a></text>
<text top="989" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref126">associated with the use of intra-arterial iodinated</a></text>
<text top="1003" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref126">contrast media: a meta-analysis of comparative ran-</a></text>
<text top="1016" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref126">domized controlled trials. BMC Med Imaging. 2011;</a></text>
<text top="1029" left="108" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref126">11:12</a></text>
<text top="1029" left="126" width="3" height="9" font="5">.</text>
<text top="1048" left="108" width="16" height="9" font="5">127.</text>
<text top="1048" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref127">Barba A, Estallo L, Rodríguez L, et al. Detection of</a></text>
<text top="1061" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref127">abdominal aortic aneurysm in patients with peripheral</a></text>
<text top="1075" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref127">artery disease. Eur J Vasc Endovasc Surg. 2005;30:</a></text>
<text top="1088" left="108" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref127">504</a></text>
<text top="1087" left="124" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref127">–8</a></text>
<text top="1088" left="134" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref127">.</a></text>
<text top="143" left="345" width="17" height="9" font="5">128.</text>
<text top="143" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref128">Kurvers HA, van der Graaf Y, Blankensteijn JD,</a></text>
<text top="156" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref128">et al. Screening for asymptomatic internal carotid ar-</a></text>
<text top="170" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref128">tery stenosis and aneurysm of the abdominal aorta:</a></text>
<text top="183" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref128">comparing the yield between patients with manifest</a></text>
<text top="197" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref128">atherosclerosis and patients with risk factors for</a></text>
<text top="210" left="345" width="192" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref128">atherosclerosis only. J Vasc Surg. 2003;37:1226</a></text>
<text top="209" left="538" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref128">–33</a></text>
<text top="210" left="551" width="3" height="9" font="5">.</text>
<text top="230" left="345" width="17" height="9" font="5">129.</text>
<text top="230" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref129">Giugliano G, Laurenzano E, Rengo C, et al.</a></text>
<text top="243" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref129">Abdominal aortic aneurysm in patients affected by</a></text>
<text top="257" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref129">intermittent claudication: prevalence and clinical pre-</a></text>
<text top="270" left="345" width="155" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref129">dictors. BMC Surg. 2012;12 suppl 1:S17</a></text>
<text top="270" left="501" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref129">.</a></text>
<text top="290" left="345" width="17" height="9" font="5">130.</text>
<text top="290" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref130">Lee JY, Lee SW, Lee WS, et al. Prevalence and</a></text>
<text top="303" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref130">clinical implications of newly revealed, asymptomatic</a></text>
<text top="317" left="345" width="209" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref130">abnormal ankle-brachial index in patients with signi</a></text>
<text top="315" left="555" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref130">ﬁ-</a></text>
<text top="330" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref130">cant coronary artery disease. J Am Coll Cardiol Intv.</a></text>
<text top="343" left="345" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref130">2013;6:1303</a></text>
<text top="342" left="395" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref130">–13</a></text>
<text top="343" left="407" width="3" height="9" font="5">.</text>
<text top="363" left="345" width="15" height="9" font="5">131.</text>
<text top="363" left="363" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref131">McFalls EO, Ward HB, Moritz TE, et al. Coronary-</a></text>
<text top="376" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref131">artery revascularization before elective major vascular</a></text>
<text top="390" left="345" width="156" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref131">surgery. N Engl J Med. 2004;351:2795</a></text>
<text top="388" left="501" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref131">–804</a></text>
<text top="390" left="522" width="3" height="9" font="5">.</text>
<text top="409" left="345" width="16" height="9" font="5">132.</text>
<text top="409" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref132">Sultan S, Chua BY, Hamada N, et al. Preoperative</a></text>
<text top="423" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref132">vascular screening in the presence of aortic, carotid</a></text>
<text top="436" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref132">and peripheral pathology for patients undergoing their</a></text>
<text top="448" left="345" width="218" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref132">ﬁrst arterial intervention: 18 month follow-up. Int</a></text>
<text top="463" left="345" width="80" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref132">Angiol. 2013;32:281</a></text>
<text top="461" left="425" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref132">–90</a></text>
<text top="463" left="441" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref132">.</a></text>
<text top="483" left="345" width="16" height="9" font="5">133.</text>
<text top="483" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref133">Hansen KJ, Edwards MS, Craven TE, et al. Preva-</a></text>
<text top="496" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref133">lence of renovascular disease in the elderly: a</a></text>
<text top="509" left="345" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref133">population-based study. J Vasc Surg. 2002;36:443</a></text>
<text top="508" left="548" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref133">–51</a></text>
<text top="509" left="561" width="3" height="9" font="5">.</text>
<text top="529" left="345" width="17" height="9" font="5">134.</text>
<text top="529" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref134">Leertouwer TC, Pattynama PM, van den Berg-</a></text>
<text top="542" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref134">Huysmans A. Incidental renal artery stenosis in pe-</a></text>
<text top="556" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref134">ripheral vascular disease: a case for treatment? Kidney</a></text>
<text top="569" left="345" width="74" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref134">Int. 2001;59:1480</a></text>
<text top="568" left="419" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref134">–3</a></text>
<text top="569" left="428" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref134">.</a></text>
<text top="589" left="345" width="16" height="9" font="5">135.</text>
<text top="589" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref135">Olin JW, Melia M, Young JR, et al. Prevalence of</a></text>
<text top="602" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref135">atherosclerotic renal artery stenosis in patients with</a></text>
<text top="616" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref135">atherosclerosis elsewhere. Am J Med. 1990;88:</a></text>
<text top="629" left="345" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref135">46N</a></text>
<text top="627" left="363" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref135">–51N</a></text>
<text top="629" left="381" width="3" height="9" font="5">.</text>
<text top="649" left="345" width="17" height="9" font="5">136.</text>
<text top="649" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref136">Krishnamurthy V, Munir K, Rectenwald JE, et al.</a></text>
<text top="662" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref136">Contemporary outcomes with percutaneous vascular</a></text>
<text top="676" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref136">interventions for peripheral critical limb ischemia in</a></text>
<text top="689" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref136">those with and without poly-vascular disease. Vasc</a></text>
<text top="702" left="345" width="72" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref136">Med. 2014;19:491</a></text>
<text top="701" left="417" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref136">–9</a></text>
<text top="702" left="427" width="3" height="9" font="5">.</text>
<text top="722" left="345" width="16" height="9" font="5">137.</text>
<text top="722" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref137">Selvin E, Hirsch AT. Contemporary risk factor</a></text>
<text top="735" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref137">control and walking dysfunction in individuals with</a></text>
<text top="749" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref137">peripheral arterial disease: NHANES 1999-2004.</a></text>
<text top="762" left="345" width="124" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref137">Atherosclerosis. 2008;201:425</a></text>
<text top="761" left="469" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref137">–33</a></text>
<text top="762" left="483" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref137">.</a></text>
<text top="782" left="345" width="17" height="9" font="5">138.</text>
<text top="782" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">Pande RL, Perlstein TS, Beckman JA, et al. Sec-</a></text>
<text top="795" left="345" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">ondary</a></text>
<text top="795" left="383" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">prevention</a></text>
<text top="795" left="435" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">and</a></text>
<text top="795" left="460" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">mortality</a></text>
<text top="795" left="506" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">in</a></text>
<text top="795" left="523" width="40" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">peripheral</a></text>
<text top="809" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">artery disease: National Health and Nutrition Exami-</a></text>
<text top="822" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">nation Study, 1999 to 2004. Circulation. 2011;124:</a></text>
<text top="836" left="345" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">17</a></text>
<text top="834" left="354" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref138">–23</a></text>
<text top="836" left="367" width="3" height="9" font="5">.</text>
<text top="855" left="345" width="17" height="9" font="5">139.</text>
<text top="855" left="365" width="96" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref139">Antithrombotic Trialists</a></text>
<text top="853" left="462" width="102" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref139">’ Collaboration. Collabo-</a></text>
<text top="869" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref139">rative meta-analysis of randomised trials of antiplate-</a></text>
<text top="882" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref139">let therapy for prevention of death, myocardial</a></text>
<text top="895" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref139">infarction, and stroke in high risk patients. BMJ. 2002;</a></text>
<text top="909" left="345" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref139">324:71</a></text>
<text top="907" left="371" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref139">–86</a></text>
<text top="909" left="386" width="3" height="9" font="5">.</text>
<text top="928" left="345" width="18" height="9" font="5">140.</text>
<text top="928" left="366" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref140">Catalano M, Born G, Peto R. Prevention of serious</a></text>
<text top="942" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref140">vascular events by aspirin amongst patients with pe-</a></text>
<text top="955" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref140">ripheral arterial disease: randomized, double-blind</a></text>
<text top="969" left="345" width="134" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref140">trial. J Intern Med. 2007;261:276</a></text>
<text top="967" left="479" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref140">–84</a></text>
<text top="969" left="495" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref140">.</a></text>
<text top="988" left="345" width="16" height="9" font="5">141.</text>
<text top="988" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref141">Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin</a></text>
<text top="1002" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref141">for the prevention of cardiovascular events in patients</a></text>
<text top="1015" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref141">with peripheral artery disease: a meta-analysis of ran-</a></text>
<text top="1029" left="345" width="154" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref141">domized trials. JAMA. 2009;301:1909</a></text>
<text top="1027" left="499" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref141">–19</a></text>
<text top="1029" left="513" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref141">.</a></text>
<text top="1048" left="345" width="17" height="9" font="5">142.</text>
<text top="1048" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref142">CAPRIE Steering Committee. A randomised, blin-</a></text>
<text top="1061" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref142">ded, trial of clopidogrel versus aspirin in patients at risk</a></text>
<text top="1075" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref142">of ischaemic events (CAPRIE). Lancet. 1996;348:</a></text>
<text top="1088" left="345" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref142">1329</a></text>
<text top="1087" left="364" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref142">–39</a></text>
<text top="1088" left="379" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref142">.</a></text>
<text top="143" left="583" width="17" height="9" font="5">143.</text>
<text top="143" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref143">Cacoub PP, Bhatt DL, Steg PG, et al. Patients with</a></text>
<text top="156" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref143">peripheral arterial disease in the CHARISMA trial. Eur</a></text>
<text top="170" left="583" width="88" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref143">Heart J. 2009;30:192</a></text>
<text top="168" left="670" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref143">–201</a></text>
<text top="170" left="689" width="3" height="9" font="5">.</text>
<text top="190" left="583" width="18" height="9" font="5">144.</text>
<text top="190" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref144">Bhatt DL, Flather MD, Hacke W, et al. Patients</a></text>
<text top="203" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref144">with prior myocardial infarction, stroke, or symptom-</a></text>
<text top="217" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref144">atic peripheral arterial disease in the CHARISMA trial.</a></text>
<text top="230" left="583" width="133" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref144">J Am Coll Cardiol. 2007;49:1982</a></text>
<text top="229" left="716" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref144">–8</a></text>
<text top="230" left="725" width="3" height="9" font="5">.</text>
<text top="250" left="583" width="17" height="9" font="5">145.</text>
<text top="250" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref145">Tepe G, Bantleon R, Brechtel K, et al. Manage-</a></text>
<text top="264" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref145">ment of peripheral arterial interventions with mono or</a></text>
<text top="277" left="583" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref145">dual antiplatelet therapy</a></text>
<text top="275" left="684" width="117" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref145">—the MIRROR study: a rand-</a></text>
<text top="290" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref145">omised and double-blinded clinical trial. Eur Radiol.</a></text>
<text top="304" left="583" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref145">2012;22:1998</a></text>
<text top="302" left="638" width="27" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref145">–2006</a></text>
<text top="304" left="665" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref145">.</a></text>
<text top="324" left="583" width="18" height="9" font="5">146.</text>
<text top="324" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref146">Armstrong EJ, Anderson DR, Yeo KK, et al. As-</a></text>
<text top="337" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref146">sociation of dual-antiplatelet therapy with reduced</a></text>
<text top="351" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref146">major adverse cardiovascular events in patients with</a></text>
<text top="364" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref146">symptomatic peripheral arterial disease. J Vasc Surg.</a></text>
<text top="378" left="583" width="48" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref146">2015;62:157</a></text>
<text top="376" left="631" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref146">–65</a></text>
<text top="378" left="646" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref146">.</a></text>
<text top="398" left="583" width="17" height="9" font="5">147.</text>
<text top="398" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref147">Strobl FF, Brechtel K, Schmehl J, et al. Twelve-</a></text>
<text top="411" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref147">month results of a randomized trial comparing mono</a></text>
<text top="425" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref147">with dual antiplatelet therapy in endovascularly</a></text>
<text top="438" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref147">treated patients with peripheral artery disease.</a></text>
<text top="451" left="583" width="123" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref147">J Endovasc Ther. 2013;20:699</a></text>
<text top="450" left="706" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref147">–706</a></text>
<text top="451" left="727" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref147">.</a></text>
<text top="471" left="583" width="18" height="9" font="5">148.</text>
<text top="471" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref148">Belch JJ, Dormandy J, CASPAR Writing Commit-</a></text>
<text top="485" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref148">tee, et al. Results of the randomized, placebo-</a></text>
<text top="498" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref148">controlled Clopidogrel and Acetylsalicylic Acid in</a></text>
<text top="512" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref148">Bypass Surgery for Peripheral Arterial Disease (CAS-</a></text>
<text top="525" left="583" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref148">PAR) trial. J Vasc Surg. 2010;52:825</a></text>
<text top="524" left="730" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref148">–33</a></text>
<text top="525" left="743" width="3" height="9" font="5">.</text>
<text top="545" left="583" width="18" height="9" font="5">149.</text>
<text top="545" left="604" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref149">Bonaca MP, Scirica BM, Creager MA, et al. Vor-</a></text>
<text top="559" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref149">apaxar in patients with peripheral artery disease: re-</a></text>
<text top="572" left="583" width="72" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref149">sults from TRA2</a></text>
<text top="570" left="655" width="4" height="6" font="27"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref149">o</a></text>
<text top="572" left="659" width="142" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref149">P-TIMI 50. Circulation. 2013;127:</a></text>
<text top="586" left="583" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref149">1522</a></text>
<text top="584" left="601" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref149">–9</a></text>
<text top="586" left="611" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref149">.</a></text>
<text top="605" left="583" width="17" height="9" font="5">150.</text>
<text top="605" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref150">Morrow DA, Braunwald E, Bonaca MP, et al.</a></text>
<text top="619" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref150">Vorapaxar in the secondary prevention of athero-</a></text>
<text top="632" left="583" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref150">thrombotic events. N Engl J Med. 2012;366:1404</a></text>
<text top="631" left="783" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref150">–13</a></text>
<text top="632" left="796" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref150">.</a></text>
<text top="652" left="583" width="15" height="9" font="5">151.</text>
<text top="652" left="601" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">Bohula EA, Aylward PE, Bonaca MP, et al. Ef</a></text>
<text top="651" left="779" width="23" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">ﬁcacy</a></text>
<text top="666" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">and safety of vorapaxar with and without a thieno-</a></text>
<text top="679" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">pyridine for secondary prevention in patients with</a></text>
<text top="693" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">previous myocardial infarction and no history of stroke</a></text>
<text top="706" left="583" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">or transient ischemic attack: results from TRA 2</a></text>
<text top="704" left="771" width="4" height="6" font="27"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">o</a></text>
<text top="706" left="775" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">P-TIMI</a></text>
<text top="720" left="583" width="120" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">50. Circulation. 2015;132:1871</a></text>
<text top="718" left="703" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">–9</a></text>
<text top="720" left="713" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref151">.</a></text>
<text top="740" left="583" width="16" height="9" font="5">152.</text>
<text top="740" left="602" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">Bonaca MP, Gutierrez JA, Creager MA, et al. Acute</a></text>
<text top="753" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">limb ischemia and outcomes with vorapaxar in patients</a></text>
<text top="766" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">with peripheral artery disease: results from the Trial to</a></text>
<text top="780" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">Assess the Effects of Vorapaxar in Preventing Heart</a></text>
<text top="793" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">Attack and Stroke in patients With Atherosclerosis-</a></text>
<text top="807" left="583" width="205" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">Thrombolysis in Myocardial Infarction 50 (TRA2</a></text>
<text top="805" left="788" width="4" height="6" font="27"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">o</a></text>
<text top="807" left="792" width="9" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">P-</a></text>
<text top="820" left="583" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">TIMI 50). Circulation. 2016;133:997</a></text>
<text top="819" left="726" width="25" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref152">–1005</a></text>
<text top="820" left="750" width="3" height="9" font="5">.</text>
<text top="840" left="583" width="16" height="9" font="5">153.</text>
<text top="840" left="602" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref153">Kumbhani DJ, Steg PG, Cannon CP, et al. Statin</a></text>
<text top="854" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref153">therapy and long-term adverse limb outcomes in pa-</a></text>
<text top="867" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref153">tients with peripheral artery disease: insights from the</a></text>
<text top="881" left="583" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref153">REACH registry. Eur Heart J. 2014;35:2864</a></text>
<text top="879" left="757" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref153">–72</a></text>
<text top="881" left="770" width="3" height="9" font="5">.</text>
<text top="900" left="583" width="17" height="9" font="5">154.</text>
<text top="900" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref154">Vogel TR, Dombrovskiy VY, Galiñanes EL, et al.</a></text>
<text top="914" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref154">Preoperative statins and limb salvage after lower ex-</a></text>
<text top="927" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref154">tremity revascularization in the Medicare population.</a></text>
<text top="941" left="583" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref154">Circ Cardiovasc Interv. 2013;6:694</a></text>
<text top="939" left="722" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref154">–700</a></text>
<text top="941" left="743" width="3" height="9" font="5">.</text>
<text top="961" left="583" width="16" height="9" font="5">155.</text>
<text top="961" left="602" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref155">Heart Protection Study Collaborative Group.</a></text>
<text top="974" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref155">Randomized trial of the effects of cholesterol-lowering</a></text>
<text top="988" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref155">with simvastatin on peripheral vascular and other</a></text>
<text top="1001" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref155">major vascular outcomes in 20,536 people with pe-</a></text>
<text top="1015" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref155">ripheral arterial disease and other high-risk conditions.</a></text>
<text top="1028" left="583" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref155">J Vasc Surg. 2007;45:645</a></text>
<text top="1026" left="688" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref155">–54</a></text>
<text top="1028" left="702" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref155">.</a></text>
<text top="1048" left="583" width="17" height="9" font="5">156.</text>
<text top="1048" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref156">Mohler ER, Hiatt WR, Creager MA. Cholesterol</a></text>
<text top="1061" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref156">reduction with atorvastatin improves walking distance</a></text>
<text top="1075" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref156">in patients with peripheral arterial disease. Circulation.</a></text>
<text top="1088" left="583" width="61" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref156">2003;108:1481</a></text>
<text top="1087" left="644" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref156">–6</a></text>
<text top="1088" left="653" width="3" height="9" font="5">.</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="17" height="9" font="5">e112</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="28" size="8" family="Times" color="#327eb1"/>
<text top="143" left="63" width="16" height="9" font="5">157.</text>
<text top="143" left="82" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref157">Aung PP, Maxwell HG, Jepson RG, et al. Lip-</a></text>
<text top="156" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref157">id-lowering for peripheral arterial disease of the</a></text>
<text top="170" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref157">lower limb. Cochrane Database Syst Rev. 2007:</a></text>
<text top="183" left="63" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref157">CD000123</a></text>
<text top="183" left="106" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref157">.</a></text>
<text top="203" left="63" width="17" height="9" font="5">158.</text>
<text top="203" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref158">Bavry AA, Anderson RD, Gong Y, et al. Outcomes</a></text>
<text top="217" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref158">Among hypertensive patients with concomitant pe-</a></text>
<text top="230" left="63" width="146" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref158">ripheral and coronary artery disease:</a></text>
<text top="228" left="212" width="69" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref158">ﬁndings from the</a></text>
<text top="244" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref158">INternational VErapamil-SR/Trandolapril STudy. Hy-</a></text>
<text top="257" left="63" width="94" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref158">pertension. 2010;55:48</a></text>
<text top="255" left="157" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref158">–53</a></text>
<text top="257" left="171" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref158">.</a></text>
<text top="277" left="63" width="17" height="9" font="5">159.</text>
<text top="277" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref159">Feringa HH, van Waning VH, Bax JJ, et al. Car-</a></text>
<text top="290" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref159">dioprotective medication is associated with improved</a></text>
<text top="304" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref159">survival in patients with peripheral arterial disease.</a></text>
<text top="317" left="63" width="131" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref159">J Am Coll Cardiol. 2006;47:1182</a></text>
<text top="316" left="194" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref159">–7</a></text>
<text top="317" left="202" width="3" height="9" font="5">.</text>
<text top="337" left="63" width="18" height="9" font="5">160.</text>
<text top="337" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref160">Sleight P. The HOPE Study (Heart Outcomes</a></text>
<text top="351" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref160">Prevention Evaluation). J Renin Angiotensin Aldoste-</a></text>
<text top="364" left="63" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref160">rone Syst. 2000;1:18</a></text>
<text top="362" left="147" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref160">–20</a></text>
<text top="364" left="162" width="3" height="9" font="5">.</text>
<text top="384" left="63" width="16" height="9" font="5">161.</text>
<text top="384" left="82" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref161">Yusuf S, Teo KK, Pogue J, et al. Telmisartan,</a></text>
<text top="397" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref161">ramipril, or both in patients at high risk for vascular</a></text>
<text top="411" left="63" width="153" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref161">events. N Engl J Med. 2008;358:1547</a></text>
<text top="409" left="216" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref161">–59</a></text>
<text top="411" left="231" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref161">.</a></text>
<text top="431" left="63" width="17" height="9" font="5">162.</text>
<text top="431" left="83" width="44" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">ALLHAT Of</a></text>
<text top="429" left="126" width="155" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">ﬁcers and Coordinators for the ALLHAT</a></text>
<text top="444" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">Collaborative Research Group. The Antihypertensive</a></text>
<text top="458" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">and Lipid-Lowering Treatment to Prevent Heart Attack</a></text>
<text top="471" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">Trial. Major outcomes in high-risk hypertensive pa-</a></text>
<text top="484" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">tients randomized to angiotensin-converting enzyme</a></text>
<text top="498" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">inhibitor or calcium channel blocker vs diuretic: The</a></text>
<text top="511" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">Antihypertensive and Lipid-Lowering Treatment to</a></text>
<text top="525" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;</a></text>
<text top="538" left="63" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">288:2981</a></text>
<text top="537" left="101" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref162">–97</a></text>
<text top="538" left="115" width="3" height="9" font="5">.</text>
<text top="558" left="63" width="17" height="9" font="5">163.</text>
<text top="558" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref163">Diehm C, Pittrow D, Lawall H. Effect of nebivolol</a></text>
<text top="571" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref163">vs. hydrochlorothiazide on the walking capacity in</a></text>
<text top="585" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref163">hypertensive patients with intermittent claudication.</a></text>
<text top="598" left="63" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref163">J Hypertens. 2011;29:1448</a></text>
<text top="597" left="170" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref163">–56</a></text>
<text top="598" left="185" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref163">.</a></text>
<text top="618" left="63" width="18" height="9" font="5">164.</text>
<text top="618" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref164">Paravastu SC, Mendonca DA, Da Silva A. Beta</a></text>
<text top="632" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref164">blockers for peripheral arterial disease. Cochrane</a></text>
<text top="645" left="63" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref164">Database Syst Rev. 2013:CD005508</a></text>
<text top="645" left="209" width="3" height="9" font="5">.</text>
<text top="665" left="63" width="17" height="9" font="5">165.</text>
<text top="665" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref165">Espinola-Klein C, Weisser G, Jagodzinski A, et al.</a></text>
<text top="676" left="63" width="5" height="13" font="28"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref165">b</a></text>
<text top="678" left="68" width="213" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref165">-Blockers in patients with intermittent claudication</a></text>
<text top="692" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref165">and arterial hypertension: results from the nebivolol or</a></text>
<text top="705" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref165">metoprolol in arterial occlusive disease trial. Hyper-</a></text>
<text top="719" left="63" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref165">tension. 2011;58:148</a></text>
<text top="717" left="146" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref165">–54</a></text>
<text top="719" left="161" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref165">.</a></text>
<text top="739" left="63" width="18" height="9" font="5">166.</text>
<text top="739" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref166">Piller LB, Simpson LM, Baraniuk S, et al. Charac-</a></text>
<text top="752" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref166">teristics and long-term follow-up of participants with</a></text>
<text top="766" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref166">peripheral arterial disease during ALLHAT. J Gen Intern</a></text>
<text top="779" left="63" width="77" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref166">Med. 2014;29:1475</a></text>
<text top="777" left="140" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref166">–83</a></text>
<text top="779" left="154" width="3" height="9" font="5">.</text>
<text top="799" left="63" width="17" height="9" font="5">167.</text>
<text top="799" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref167">Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes</a></text>
<text top="812" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref167">in subgroups of hypertensive patients treated with</a></text>
<text top="826" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref167">regimens based on valsartan and amlodipine: an anal-</a></text>
<text top="839" left="63" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref167">ysis of</a></text>
<text top="838" left="95" width="186" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref167">ﬁndings from the VALUE trial. J Hypertens.</a></text>
<text top="853" left="63" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref167">2006;24:2163</a></text>
<text top="851" left="120" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref167">–8</a></text>
<text top="853" left="129" width="3" height="9" font="5">.</text>
<text top="872" left="63" width="18" height="9" font="5">168.</text>
<text top="872" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref168">Ostergren J, Sleight P, Dagenais G, et al. Impact</a></text>
<text top="886" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref168">of ramipril in patients with evidence of clinical or</a></text>
<text top="899" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref168">subclinical peripheral arterial disease. Eur Heart J.</a></text>
<text top="913" left="63" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref168">2004;25:17</a></text>
<text top="911" left="108" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref168">–24</a></text>
<text top="913" left="123" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref168">.</a></text>
<text top="933" left="63" width="18" height="9" font="5">169.</text>
<text top="933" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref169">Yusuf S, Sleight P, Pogue J, et al. Effects of an</a></text>
<text top="946" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref169">angiotensin-converting-enzyme inhibitor, ramipril, on</a></text>
<text top="960" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref169">cardiovascular events in high-risk patients. The Heart</a></text>
<text top="973" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref169">Outcomes Prevention Evaluation Study Investigators.</a></text>
<text top="986" left="63" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref169">N Engl J Med. 2000;342:145</a></text>
<text top="985" left="180" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref169">–53</a></text>
<text top="986" left="194" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref169">.</a></text>
<text top="1006" left="63" width="17" height="9" font="5">170.</text>
<text top="1006" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref170">Hennrikus D, Joseph AM, Lando HA, et al. Effec-</a></text>
<text top="1020" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref170">tiveness of a smoking cessation program for peripheral</a></text>
<text top="1033" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref170">artery disease patients: a randomized controlled trial.</a></text>
<text top="1047" left="63" width="131" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref170">J Am Coll Cardiol. 2010;56:2105</a></text>
<text top="1045" left="194" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref170">–12</a></text>
<text top="1047" left="206" width="3" height="9" font="5">.</text>
<text top="1067" left="63" width="15" height="9" font="5">171.</text>
<text top="1067" left="81" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref171">Stead LF, Buitrago D, Preciado N, et al. Physician</a></text>
<text top="1080" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref171">advice for smoking cessation. Cochrane Database Syst</a></text>
<text top="1093" left="63" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref171">Rev. 2013:CD000165</a></text>
<text top="1093" left="149" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref171">.</a></text>
<text top="143" left="301" width="16" height="9" font="5">172.</text>
<text top="143" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref172">Hoel AW, Nolan BW, Goodney PP, et al. Variation</a></text>
<text top="156" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref172">in smoking cessation after vascular operations. J Vasc</a></text>
<text top="170" left="301" width="76" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref172">Surg. 2013;57:1338</a></text>
<text top="168" left="377" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref172">–44</a></text>
<text top="170" left="392" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref172">.</a></text>
<text top="188" left="301" width="16" height="9" font="5">173.</text>
<text top="188" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref173">Willigendael EM, Teijink JA, Bartelink ML, et al.</a></text>
<text top="202" left="301" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref173">In</a></text>
<text top="200" left="308" width="211" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref173">ﬂuence of smoking on incidence and prevalence of</a></text>
<text top="215" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref173">peripheral arterial disease. J Vasc Surg. 2004;40:</a></text>
<text top="229" left="301" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref173">1158</a></text>
<text top="227" left="318" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref173">–65</a></text>
<text top="229" left="333" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref173">.</a></text>
<text top="247" left="301" width="17" height="9" font="5">174.</text>
<text top="247" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref174">Duval S, Long KH, Roy SS, et al. The contribution</a></text>
<text top="261" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref174">of tobacco use to high health care utilization and</a></text>
<text top="274" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref174">medical costs in peripheral artery disease: a state-</a></text>
<text top="288" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref174">based cohort analysis. J Am Coll Cardiol. 2015;66:</a></text>
<text top="301" left="301" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref174">1566</a></text>
<text top="300" left="320" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref174">–74</a></text>
<text top="301" left="334" width="3" height="9" font="5">.</text>
<text top="320" left="301" width="16" height="9" font="5">175.</text>
<text top="320" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref175">Bhatnagar A, Whitsel LP, Ribisl KM, et al. Elec-</a></text>
<text top="333" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref175">tronic cigarettes: a policy statement from the American</a></text>
<text top="347" left="301" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref175">Heart Association. Circulation. 2014;130:1418</a></text>
<text top="345" left="482" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref175">–36</a></text>
<text top="347" left="497" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref175">.</a></text>
<text top="365" left="301" width="17" height="9" font="5">176.</text>
<text top="365" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref176">Armstrong EJ, Wu J, Singh GD, et al. Smoking</a></text>
<text top="379" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref176">cessation is associated with decreased mortality and</a></text>
<text top="392" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref176">improved amputation-free survival among patients</a></text>
<text top="405" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref176">with symptomatic peripheral artery disease. J Vasc</a></text>
<text top="419" left="301" width="80" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref176">Surg. 2014;60:1565</a></text>
<text top="417" left="380" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref176">–71</a></text>
<text top="419" left="392" width="3" height="9" font="5">.</text>
<text top="437" left="301" width="16" height="9" font="5">177.</text>
<text top="437" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref177">Clair C, Rigotti NA, Porneala B, et al. Association</a></text>
<text top="451" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref177">of smoking cessation and weight change with cardio-</a></text>
<text top="464" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref177">vascular disease among adults with and without dia-</a></text>
<text top="478" left="301" width="116" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref177">betes. JAMA. 2013;309:1014</a></text>
<text top="476" left="416" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref177">–21</a></text>
<text top="478" left="429" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref177">.</a></text>
<text top="496" left="301" width="17" height="9" font="5">178.</text>
<text top="496" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref178">Selvarajah S, Black JH 3rd, Malas MB, et al. Pre-</a></text>
<text top="510" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref178">operative smoking is associated with early graft failure</a></text>
<text top="523" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref178">after infrainguinal bypass surgery. J Vasc Surg. 2014;</a></text>
<text top="537" left="301" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref178">59:1308</a></text>
<text top="535" left="334" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref178">–14</a></text>
<text top="537" left="347" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref178">.</a></text>
<text top="555" left="301" width="218" height="9" font="5">179. Patnode CD, Henderson JT, Thompson JH, et al.</text>
<text top="569" left="301" width="42" height="9" font="5">Behavioral</text>
<text top="569" left="352" width="43" height="9" font="5">counseling</text>
<text top="569" left="404" width="15" height="9" font="5">and</text>
<text top="569" left="428" width="70" height="9" font="5">pharmacotherapy</text>
<text top="569" left="508" width="11" height="9" font="5">in-</text>
<text top="582" left="301" width="218" height="9" font="5">terventions for tobacco cessation in adults, including</text>
<text top="596" left="301" width="218" height="9" font="5">pregnant women: a review of reviews for the U.S.</text>
<text top="609" left="301" width="218" height="9" font="5">Preventive Services Task Force. Rockville (MD): Agency</text>
<text top="622" left="301" width="218" height="9" font="5">for Healthcare Research and Quality (US), 2015.</text>
<text top="636" left="301" width="36" height="9" font="5">Available</text>
<text top="636" left="349" width="11" height="9" font="5">at:</text>
<text top="636" left="372" width="147" height="9" font="6"><a href="http://www.ncbi.nlm.nih.gov/books/NBK321744/">http://www.ncbi.nlm.nih.gov/books/</a></text>
<text top="649" left="301" width="49" height="9" font="6"><a href="http://www.ncbi.nlm.nih.gov/books/NBK321744/">NBK321744/</a></text>
<text top="649" left="350" width="129" height="9" font="5"><a href="http://www.ncbi.nlm.nih.gov/books/NBK321744/">. </a>Accessed September 25, 2016.</text>
<text top="668" left="301" width="18" height="9" font="5">180.</text>
<text top="668" left="321" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref180">Rigotti NA, Pipe AL, Benowitz NL, et al. Ef</a></text>
<text top="666" left="496" width="23" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref180">ﬁcacy</a></text>
<text top="681" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref180">and safety of varenicline for smoking cessation in pa-</a></text>
<text top="695" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref180">tients with cardiovascular disease: a randomized trial.</a></text>
<text top="708" left="301" width="100" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref180">Circulation. 2010;121:221</a></text>
<text top="707" left="400" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref180">–9</a></text>
<text top="708" left="410" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref180">.</a></text>
<text top="727" left="301" width="16" height="9" font="5">181.</text>
<text top="727" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref181">Rigotti NA, Regan S, Levy DE, et al. Sustained care</a></text>
<text top="740" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref181">intervention and postdischarge smoking cessation</a></text>
<text top="754" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref181">among hospitalized adults: a randomized clinical trial.</a></text>
<text top="767" left="301" width="81" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref181">JAMA. 2014;312:719</a></text>
<text top="765" left="381" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref181">–28</a></text>
<text top="767" left="396" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref181">.</a></text>
<text top="786" left="301" width="17" height="9" font="5">182.</text>
<text top="786" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref182">Tonstad S, Farsang C, Klaene G, et al. Bupropion</a></text>
<text top="799" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref182">SR for smoking cessation in smokers with cardiovas-</a></text>
<text top="813" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref182">cular disease: a multicentre, randomised study. Eur</a></text>
<text top="826" left="301" width="88" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref182">Heart J. 2003;24:946</a></text>
<text top="824" left="389" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref182">–55</a></text>
<text top="826" left="403" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref182">.</a></text>
<text top="845" left="301" width="17" height="9" font="5">183.</text>
<text top="845" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref183">Mills EJ, Thorlund K, Eapen S, et al. Cardiovas-</a></text>
<text top="858" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref183">cular events associated with smoking cessation phar-</a></text>
<text top="871" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref183">macotherapies: a network meta-analysis. Circulation.</a></text>
<text top="885" left="301" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref183">2014;129:28</a></text>
<text top="883" left="350" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref183">–41</a></text>
<text top="885" left="364" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref183">.</a></text>
<text top="903" left="301" width="18" height="9" font="5">184.</text>
<text top="903" left="321" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref184">Prochaska JJ, Hilton JF. Risk of cardiovascular</a></text>
<text top="917" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref184">serious adverse events associated with varenicline use</a></text>
<text top="930" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref184">for tobacco cessation: systematic review and meta-</a></text>
<text top="944" left="301" width="125" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref184">analysis. BMJ. 2012;344:e2856</a></text>
<text top="944" left="426" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref184">.</a></text>
<text top="962" left="301" width="17" height="9" font="5">185.</text>
<text top="962" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref185">Tan CE, Glantz SA. Association between smoke-</a></text>
<text top="976" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref185">free legislation and hospitalizations for cardiac, cere-</a></text>
<text top="989" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref185">brovascular, and respiratory diseases: a meta-analysis.</a></text>
<text top="1003" left="301" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref185">Circulation. 2012;126:2177</a></text>
<text top="1001" left="405" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref185">–83</a></text>
<text top="1003" left="419" width="3" height="9" font="5">.</text>
<text top="1021" left="301" width="18" height="9" font="5">186.</text>
<text top="1021" left="321" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref186">Lu L, Mackay DF, Pell JP. Association between</a></text>
<text top="1035" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref186">level of exposure to secondhand smoke and peripheral</a></text>
<text top="1048" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref186">arterial disease: cross-sectional study of 5,686 never</a></text>
<text top="1061" left="301" width="159" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref186">smokers. Atherosclerosis. 2013;229:273</a></text>
<text top="1060" left="459" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref186">–6</a></text>
<text top="1061" left="469" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref186">.</a></text>
<text top="1080" left="301" width="17" height="9" font="5">187.</text>
<text top="1080" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref187">Criqui MH, Aboyans V. Epidemiology of peripheral</a></text>
<text top="1093" left="301" width="156" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref187">artery disease. Circ Res. 2015;116:1509</a></text>
<text top="1092" left="457" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref187">–26</a></text>
<text top="1093" left="471" width="3" height="9" font="5">.</text>
<text top="143" left="538" width="18" height="9" font="5">188.</text>
<text top="143" left="559" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref188">Resnick HE, Lindsay RS, McDermott MM, et al.</a></text>
<text top="156" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref188">Relationship of high and low ankle brachial index to</a></text>
<text top="170" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref188">all-cause and cardiovascular disease mortality: the</a></text>
<text top="183" left="538" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref188">Strong Heart Study. Circulation. 2004;109:733</a></text>
<text top="182" left="726" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref188">–9</a></text>
<text top="183" left="736" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref188">.</a></text>
<text top="203" left="538" width="18" height="9" font="5">189.</text>
<text top="203" left="559" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref189">Jude EB, Oyibo SO, Chalmers N, et al. Peripheral</a></text>
<text top="216" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref189">arterial disease in diabetic and nondiabetic patients: a</a></text>
<text top="230" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref189">comparison of severity and outcome. Diabetes Care.</a></text>
<text top="243" left="538" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref189">2001;24:1433</a></text>
<text top="242" left="593" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref189">–7</a></text>
<text top="243" left="602" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref189">.</a></text>
<text top="263" left="538" width="18" height="9" font="5">190.</text>
<text top="263" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref190">American Diabetes Association. Peripheral arterial</a></text>
<text top="276" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref190">disease in people with diabetes. Diabetes Care. 2003;</a></text>
<text top="289" left="538" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref190">26:3333</a></text>
<text top="288" left="570" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref190">–41</a></text>
<text top="289" left="583" width="3" height="9" font="5">.</text>
<text top="309" left="538" width="16" height="9" font="5">191.</text>
<text top="309" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref191">Singh S, Armstrong EJ, Sherif W, et al. Association</a></text>
<text top="322" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref191">of elevated fasting glucose with lower patency and</a></text>
<text top="336" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref191">increased major adverse limb events among patients</a></text>
<text top="349" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref191">with diabetes undergoing infrapopliteal balloon an-</a></text>
<text top="363" left="538" width="136" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref191">gioplasty. Vasc Med. 2014;19:307</a></text>
<text top="361" left="674" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref191">–14</a></text>
<text top="363" left="687" width="3" height="9" font="5">.</text>
<text top="382" left="538" width="17" height="9" font="5">192.</text>
<text top="382" left="558" width="169" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref192">Takahara M, Kaneto H, Iida O, et al. The in</a></text>
<text top="381" left="727" width="29" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref192">ﬂuence</a></text>
<text top="396" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref192">of glycemic control on the prognosis of Japanese pa-</a></text>
<text top="409" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref192">tients undergoing percutaneous transluminal angio-</a></text>
<text top="422" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref192">plasty for critical limb ischemia. Diabetes Care. 2010;</a></text>
<text top="436" left="538" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref192">33:2538</a></text>
<text top="434" left="570" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref192">–42</a></text>
<text top="436" left="585" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref192">.</a></text>
<text top="455" left="538" width="17" height="9" font="5">193.</text>
<text top="455" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref193">Sarac TP, Huber TS, Back MR, et al. Warfarin im-</a></text>
<text top="469" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref193">proves the outcome of infrainguinal vein bypass</a></text>
<text top="482" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref193">grafting at high risk for failure. J Vasc Surg. 1998;28:</a></text>
<text top="496" left="538" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref193">446</a></text>
<text top="494" left="555" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref193">–57</a></text>
<text top="496" left="568" width="3" height="9" font="5">.</text>
<text top="515" left="538" width="18" height="9" font="5">194.</text>
<text top="515" left="559" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref194">Ef</a></text>
<text top="514" left="567" width="189" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref194">ﬁcacy of oral anticoagulants compared with</a></text>
<text top="529" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref194">aspirin after infrainguinal bypass surgery (The Dutch</a></text>
<text top="542" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref194">Bypass Oral Anticoagulants or Aspirin Study): a rand-</a></text>
<text top="555" left="538" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref194">omised trial. Lancet. 2000;355:346</a></text>
<text top="554" left="682" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref194">–51</a></text>
<text top="555" left="694" width="3" height="9" font="5">.</text>
<text top="575" left="538" width="17" height="9" font="5">195.</text>
<text top="575" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref195">Bedenis R, Lethaby A, Maxwell H, et al. Anti-</a></text>
<text top="588" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref195">platelet agents for preventing thrombosis after pe-</a></text>
<text top="602" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref195">ripheral arterial bypass surgery. Cochrane Database</a></text>
<text top="615" left="538" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref195">Syst Rev. 2015:CD000535</a></text>
<text top="615" left="644" width="3" height="9" font="5">.</text>
<text top="635" left="538" width="18" height="9" font="5">196.</text>
<text top="635" left="559" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">Johnson WC, Williford WO, Department of Vet-</a></text>
<text top="648" left="538" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">erans Affairs Cooperative Study #362. Bene</a></text>
<text top="647" left="741" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">ﬁts,</a></text>
<text top="662" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">morbidity, and mortality associated with long-term</a></text>
<text top="675" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">administration of oral anticoagulant therapy to pa-</a></text>
<text top="688" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">tients with peripheral arterial bypass procedures: a</a></text>
<text top="702" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">prospective randomized study. J Vasc Surg. 2002;35:</a></text>
<text top="715" left="538" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">413</a></text>
<text top="714" left="552" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">–21</a></text>
<text top="715" left="565" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref196">.</a></text>
<text top="735" left="538" width="17" height="9" font="5">197.</text>
<text top="735" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">Alonso-Coello P, Bellmunt S, McGorrian C, et al.</a></text>
<text top="748" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">Antithrombotic therapy in peripheral artery disease:</a></text>
<text top="762" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">Antithrombotic Therapy and Prevention of Thrombosis,</a></text>
<text top="775" left="538" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">9th</a></text>
<text top="775" left="561" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">ed:</a></text>
<text top="775" left="583" width="76" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">American College</a></text>
<text top="775" left="667" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">of</a></text>
<text top="775" left="684" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">Chest</a></text>
<text top="775" left="716" width="41" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">Physicians</a></text>
<text top="789" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">Evidence-Based Clinical Practice Guidelines. Chest.</a></text>
<text top="802" left="538" width="64" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">2012;141:e669S</a></text>
<text top="800" left="602" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref197">–90S</a></text>
<text top="802" left="622" width="3" height="9" font="5">.</text>
<text top="821" left="538" width="18" height="9" font="5">198.</text>
<text top="821" left="559" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref198">Anand S, Yusuf S, Xie C, et al. Oral anticoagulant</a></text>
<text top="835" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref198">and antiplatelet therapy and peripheral arterial dis-</a></text>
<text top="848" left="538" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref198">ease. N Engl J Med. 2007;357:217</a></text>
<text top="847" left="675" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref198">–27</a></text>
<text top="848" left="689" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref198">.</a></text>
<text top="868" left="538" width="18" height="9" font="5">199.</text>
<text top="868" left="559" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref199">Bedenis R, Stewart M, Cleanthis M, et al. Cil-</a></text>
<text top="881" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref199">ostazol for intermittent claudication. Cochrane Data-</a></text>
<text top="895" left="538" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref199">base Syst Rev. 2014:CD003748</a></text>
<text top="895" left="666" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref199">.</a></text>
<text top="914" left="538" width="19" height="9" font="5">200.</text>
<text top="914" left="560" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref200">Dawson DL, Cutler BS, Hiatt WR, et al.</a></text>
<text top="928" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref200">A comparison of cilostazol and pentoxifylline for</a></text>
<text top="941" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref200">treating intermittent claudication. Am J Med. 2000;</a></text>
<text top="954" left="538" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref200">109:523</a></text>
<text top="953" left="571" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref200">–30</a></text>
<text top="954" left="585" width="3" height="9" font="5">.</text>
<text top="974" left="538" width="218" height="9" font="5">201. Pletal (cilostazol). Rockville, MD: Otsuka America</text>
<text top="987" left="538" width="179" height="9" font="5">Pharmaceutical, Inc.; [Package insert]. 1999.</text>
<text top="1007" left="538" width="18" height="9" font="5">202.</text>
<text top="1007" left="559" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">Lee</a></text>
<text top="1007" left="584" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">C,</a></text>
<text top="1007" left="603" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">Nelson</a></text>
<text top="1007" left="641" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">PR.</a></text>
<text top="1007" left="665" width="24" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">Effect</a></text>
<text top="1007" left="700" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">of</a></text>
<text top="1007" left="719" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">cilostazol</a></text>
<text top="1020" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">prescribed in a pragmatic treatment program for</a></text>
<text top="1034" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">intermittent claudication. Vasc Endovascular Surg.</a></text>
<text top="1047" left="538" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">2014;48:224</a></text>
<text top="1045" left="590" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref202">–9</a></text>
<text top="1047" left="599" width="3" height="9" font="5">.</text>
<text top="1067" left="538" width="18" height="9" font="5">203.</text>
<text top="1067" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref203">Salhiyyah K, Senanayake E, Abdel-Hadi M, et al.</a></text>
<text top="1080" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref203">Pentoxifylline for intermittent claudication. Cochrane</a></text>
<text top="1093" left="538" width="152" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref203">Database Syst Rev. 2012;1:CD005262</a></text>
<text top="1093" left="690" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref203">.</a></text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="791" width="17" height="9" font="5">e113</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="19" height="9" font="5">204.</text>
<text top="143" left="130" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref204">Villarruz MV, Dans A, Tan F. Chelation therapy for</a></text>
<text top="156" left="108" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref204">atherosclerotic</a></text>
<text top="156" left="178" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref204">cardiovascular</a></text>
<text top="156" left="246" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref204">disease.</a></text>
<text top="156" left="289" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref204">Cochrane</a></text>
<text top="170" left="108" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref204">Database Syst Rev. 2002:CD002785</a></text>
<text top="170" left="255" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref204">.</a></text>
<text top="188" left="108" width="18" height="9" font="5">205.</text>
<text top="188" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref205">Lonn E, Held C, Arnold JM, et al. Rationale, design</a></text>
<text top="202" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref205">and baseline characteristics of a large, simple, ran-</a></text>
<text top="215" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref205">domized trial of combined folic acid and vitamins B6</a></text>
<text top="229" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref205">and B12 in high-risk patients: the Heart Outcomes</a></text>
<text top="242" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref205">Prevention Evaluation (HOPE)-2 trial. Can J Cardiol.</a></text>
<text top="256" left="108" width="48" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref205">2006;22:47</a></text>
<text top="254" left="155" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref205">–53</a></text>
<text top="256" left="169" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref205">.</a></text>
<text top="274" left="108" width="19" height="9" font="5">206.</text>
<text top="274" left="129" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref206">Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine</a></text>
<text top="288" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref206">lowering with folic acid and B vitamins in vascular</a></text>
<text top="301" left="108" width="156" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref206">disease. N Engl J Med. 2006;354:1567</a></text>
<text top="299" left="263" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref206">–77</a></text>
<text top="301" left="277" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref206">.</a></text>
<text top="320" left="108" width="18" height="9" font="5">207.</text>
<text top="320" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref207">Khandanpour N, Loke YK, Meyer FJ, et al. Ho-</a></text>
<text top="333" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref207">mocysteine and peripheral arterial disease: systematic</a></text>
<text top="347" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref207">review and meta-analysis. Eur J Vasc Endovasc Surg.</a></text>
<text top="360" left="108" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref207">2009;38:316</a></text>
<text top="358" left="160" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref207">–22</a></text>
<text top="360" left="173" width="3" height="9" font="5">.</text>
<text top="379" left="108" width="19" height="9" font="5">208.</text>
<text top="379" left="129" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref208">Gur</a></text>
<text top="377" left="144" width="182" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref208">ﬁnkel EP, Leon de la Fuente R, Mendiz O,</a></text>
<text top="392" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref208">et al. Flu vaccination in acute coronary syndromes and</a></text>
<text top="405" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref208">planned percutaneous coronary interventions (FLU-</a></text>
<text top="419" left="108" width="154" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref208">VACS) Study. Eur Heart J. 2004;25:25</a></text>
<text top="417" left="261" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref208">–31</a></text>
<text top="419" left="274" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref208">.</a></text>
<text top="437" left="108" width="19" height="9" font="5">209.</text>
<text top="437" left="129" width="182" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref209">Ciszewski A, Bilinska ZT, Brydak LB, et al. In</a></text>
<text top="436" left="311" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref209">ﬂu-</a></text>
<text top="451" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref209">enza vaccination in secondary prevention from coro-</a></text>
<text top="464" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref209">nary ischaemic events in coronary artery disease:</a></text>
<text top="478" left="108" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref209">FLUCAD study. Eur Heart J. 2008;29:1350</a></text>
<text top="476" left="279" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref209">–8</a></text>
<text top="478" left="289" width="3" height="9" font="5">.</text>
<text top="496" left="108" width="17" height="9" font="5">210.</text>
<text top="496" left="128" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref210">Brenner I, Parry M, Brown CA. Exercise in-</a></text>
<text top="510" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref210">terventions for patients with peripheral arterial dis-</a></text>
<text top="523" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref210">ease: a review of the literature. Phys Sportsmed. 2012;</a></text>
<text top="537" left="108" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref210">40:41</a></text>
<text top="535" left="131" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref210">–55</a></text>
<text top="537" left="144" width="3" height="9" font="5">.</text>
<text top="555" left="108" width="15" height="9" font="5">211.</text>
<text top="555" left="126" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref211">Lane R, Ellis B, Watson L, et al. Exercise for</a></text>
<text top="569" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref211">intermittent claudication. Cochrane Database Syst Rev.</a></text>
<text top="582" left="108" width="70" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref211">2014:CD000990</a></text>
<text top="582" left="177" width="3" height="9" font="5">.</text>
<text top="601" left="108" width="16" height="9" font="5">212.</text>
<text top="601" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref212">Allen JD, Stabler T, Kenjale AA, et al. Diabetes</a></text>
<text top="614" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref212">status differentiates endothelial function and plasma</a></text>
<text top="628" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref212">nitrite response to exercise stress in peripheral arterial</a></text>
<text top="641" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref212">disease following supervised training. J Diabetes</a></text>
<text top="654" left="108" width="95" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref212">Complicat. 2014;28:219</a></text>
<text top="653" left="203" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref212">–25</a></text>
<text top="654" left="217" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref212">.</a></text>
<text top="673" left="108" width="16" height="9" font="5">213.</text>
<text top="673" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref213">Gardner AW, Parker DE, Montgomery PS, et al.</a></text>
<text top="686" left="108" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref213">Ef</a></text>
<text top="685" left="116" width="210" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref213">ﬁcacy of quantiﬁed home-based exercise and su-</a></text>
<text top="700" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref213">pervised exercise in patients with intermittent claudi-</a></text>
<text top="713" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref213">cation: a randomized controlled trial. Circulation. 2011;</a></text>
<text top="727" left="108" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref213">123:491</a></text>
<text top="725" left="138" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref213">–8</a></text>
<text top="727" left="148" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref213">.</a></text>
<text top="745" left="108" width="17" height="9" font="5">214.</text>
<text top="745" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref214">Guidon M, McGee H. One-year effect of a super-</a></text>
<text top="759" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref214">vised exercise programme on functional capacity and</a></text>
<text top="772" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref214">quality of life in peripheral arterial disease. Disabil</a></text>
<text top="786" left="108" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref214">Rehabil. 2013;35:397</a></text>
<text top="784" left="192" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref214">–404</a></text>
<text top="786" left="213" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref214">.</a></text>
<text top="804" left="108" width="16" height="9" font="5">215.</text>
<text top="804" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref215">Saxton JM, Zwierska I, Blagojevic M, et al. Upper-</a></text>
<text top="818" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref215">versus lower-limb aerobic exercise training on health-</a></text>
<text top="831" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref215">related quality of life in patients with symptomatic</a></text>
<text top="845" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref215">peripheral arterial disease. J Vasc Surg. 2011;53:</a></text>
<text top="858" left="108" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref215">1265</a></text>
<text top="856" left="127" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref215">–73</a></text>
<text top="858" left="140" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref215">.</a></text>
<text top="876" left="108" width="17" height="9" font="5">216.</text>
<text top="876" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref216">Gommans LN, Fokkenrood HJ, van Dalen HC, et al.</a></text>
<text top="890" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref216">Safety of supervised exercise therapy in patients with</a></text>
<text top="903" left="108" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref216">intermittent claudication. J Vasc Surg. 2015;61:512</a></text>
<text top="902" left="311" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref216">–8</a></text>
<text top="903" left="321" width="3" height="9" font="5">.</text>
<text top="922" left="108" width="16" height="9" font="5">217.</text>
<text top="922" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref217">Mazari FA, Gulati S, Rahman MN, et al. Early</a></text>
<text top="935" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref217">outcomes from a randomized, controlled trial of su-</a></text>
<text top="949" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref217">pervised exercise, angioplasty, and combined therapy</a></text>
<text top="962" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref217">in intermittent claudication. Ann Vasc Surg. 2010;24:</a></text>
<text top="976" left="108" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref217">69</a></text>
<text top="974" left="119" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref217">–79</a></text>
<text top="976" left="133" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref217">.</a></text>
<text top="994" left="108" width="17" height="9" font="5">218.</text>
<text top="994" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref218">Fakhry F, Spronk S, van der Laan L, et al. Endo-</a></text>
<text top="1008" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref218">vascular revascularization and supervised exercise for</a></text>
<text top="1021" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref218">peripheral artery disease and intermittent claudication:</a></text>
<text top="1035" left="108" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref218">a randomized clinical trial. JAMA. 2015;314:1936</a></text>
<text top="1033" left="303" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref218">–44</a></text>
<text top="1035" left="318" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref218">.</a></text>
<text top="1053" left="108" width="17" height="9" font="5">219.</text>
<text top="1053" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref219">Langbein WE, Collins EG, Orebaugh C, et al.</a></text>
<text top="1067" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref219">Increasing exercise tolerance of persons limited by</a></text>
<text top="1080" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref219">claudication pain using polestriding. J Vasc Surg. 2002;</a></text>
<text top="1093" left="108" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref219">35:887</a></text>
<text top="1092" left="136" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref219">–93</a></text>
<text top="1093" left="150" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref219">.</a></text>
<text top="143" left="345" width="18" height="9" font="5">220.</text>
<text top="143" left="366" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref220">Walker RD, Nawaz S, Wilkinson CH, et al. In</a></text>
<text top="141" left="549" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref220">ﬂu-</a></text>
<text top="156" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref220">ence of upper- and lower-limb exercise training on</a></text>
<text top="170" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref220">cardiovascular function and walking distances in pa-</a></text>
<text top="183" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref220">tients with intermittent claudication. J Vasc Surg.</a></text>
<text top="197" left="345" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref220">2000;31:662</a></text>
<text top="195" left="398" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref220">–9</a></text>
<text top="197" left="408" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref220">.</a></text>
<text top="215" left="345" width="16" height="9" font="5">221.</text>
<text top="215" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref221">Mika P, Konik A, Januszek R, et al. Comparison of</a></text>
<text top="229" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref221">two treadmill training programs on walking ability and</a></text>
<text top="242" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref221">endothelial function in intermittent claudication. Int J</a></text>
<text top="256" left="345" width="89" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref221">Cardiol. 2013;168:838</a></text>
<text top="254" left="434" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref221">–42</a></text>
<text top="256" left="448" width="3" height="9" font="5">.</text>
<text top="274" left="345" width="17" height="9" font="5">222.</text>
<text top="274" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref222">Dorresteijn JA, Kriegsman DM, Assendelft WJ,</a></text>
<text top="288" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref222">et al. Patient education for preventing diabetic foot</a></text>
<text top="301" left="345" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref222">ulceration.</a></text>
<text top="301" left="397" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref222">Cochrane</a></text>
<text top="301" left="443" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref222">Database</a></text>
<text top="301" left="489" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref222">Syst</a></text>
<text top="301" left="514" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref222">Rev.</a></text>
<text top="301" left="541" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref222">2014:</a></text>
<text top="315" left="345" width="44" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref222">CD001488</a></text>
<text top="315" left="389" width="3" height="9" font="5">.</text>
<text top="333" left="345" width="17" height="9" font="5">223.</text>
<text top="333" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref223">Miller JD, Carter E, Shih J, et al. How to do a 3-</a></text>
<text top="347" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref223">minute diabetic foot exam. J Fam Pract. 2014;63:</a></text>
<text top="360" left="345" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref223">646</a></text>
<text top="358" left="362" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref223">–56</a></text>
<text top="360" left="376" width="3" height="9" font="5">.</text>
<text top="379" left="345" width="18" height="9" font="5">224.</text>
<text top="379" left="366" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref224">Gardner SE, Hillis SL, Frantz RA. Clinical signs of</a></text>
<text top="392" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref224">infection in diabetic foot ulcers with high microbial</a></text>
<text top="405" left="345" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref224">load. Biol Res Nurs. 2009;11:119</a></text>
<text top="404" left="475" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref224">–28</a></text>
<text top="405" left="490" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref224">.</a></text>
<text top="424" left="345" width="17" height="9" font="5">225.</text>
<text top="424" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref225">Lipsky BA, Berendt AR, Cornia PB, et al. 2012 In-</a></text>
<text top="437" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref225">fectious Diseases Society of America clinical practice</a></text>
<text top="451" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref225">guideline for the diagnosis and treatment of diabetic</a></text>
<text top="464" left="345" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref225">foot infections. Clin Infect Dis. 2012;54:e132</a></text>
<text top="463" left="524" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref225">–73</a></text>
<text top="464" left="537" width="3" height="9" font="5">.</text>
<text top="483" left="345" width="18" height="9" font="5">226.</text>
<text top="483" left="366" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref226">Pickwell K, Siersma V, Kars M, et al. Predictors of</a></text>
<text top="496" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref226">lower-extremity amputation in patients with an infec-</a></text>
<text top="510" left="345" width="206" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref226">ted diabetic foot ulcer. Diabetes Care. 2015;38:852</a></text>
<text top="508" left="552" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref226">–7</a></text>
<text top="510" left="560" width="3" height="9" font="5">.</text>
<text top="528" left="345" width="17" height="9" font="5">227.</text>
<text top="528" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref227">Dinh MT, Abad CL, Safdar N. Diagnostic accuracy</a></text>
<text top="542" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref227">of the physical examination and imaging tests for</a></text>
<text top="555" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref227">osteomyelitis underlying diabetic foot ulcers: meta-</a></text>
<text top="569" left="345" width="150" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref227">analysis. Clin Infect Dis. 2008;47:519</a></text>
<text top="567" left="496" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref227">–27</a></text>
<text top="569" left="509" width="3" height="9" font="5">.</text>
<text top="587" left="345" width="18" height="9" font="5">228.</text>
<text top="587" left="366" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref228">Prompers L, Schaper N, Apelqvist J, et al. Pre-</a></text>
<text top="601" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref228">diction of outcome in individuals with diabetic foot</a></text>
<text top="614" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref228">ulcers: focus on the differences between individuals</a></text>
<text top="628" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref228">with and without peripheral arterial disease. The</a></text>
<text top="641" left="345" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref228">EURODIALE Study. Diabetologia. 2008;51:747</a></text>
<text top="639" left="530" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref228">–55</a></text>
<text top="641" left="544" width="3" height="9" font="5">.</text>
<text top="659" left="345" width="18" height="9" font="5">229.</text>
<text top="659" left="366" width="127" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref229">Vartanian SM, Robinson KD, O</a></text>
<text top="658" left="493" width="71" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref229">ﬁli K, et al. Out-</a></text>
<text top="673" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref229">comes of neuroischemic wounds treated by a multi-</a></text>
<text top="686" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref229">disciplinary amputation prevention service. Ann Vasc</a></text>
<text top="700" left="345" width="74" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref229">Surg. 2015;29:534</a></text>
<text top="698" left="419" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref229">–42</a></text>
<text top="700" left="433" width="3" height="9" font="5">.</text>
<text top="718" left="345" width="18" height="9" font="5">230.</text>
<text top="718" left="366" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref230">Clerici G, Faglia E. Saving the limb in diabetic</a></text>
<text top="732" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref230">patients with ischemic foot lesions complicated by</a></text>
<text top="745" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref230">acute infection. Int J Low Extrem Wounds. 2014;13:</a></text>
<text top="759" left="345" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref230">273</a></text>
<text top="757" left="359" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref230">–93</a></text>
<text top="759" left="374" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref230">.</a></text>
<text top="777" left="345" width="16" height="9" font="5">231.</text>
<text top="777" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref231">Lavery LA, Peters EJ, Williams JR, et al. Reevalu-</a></text>
<text top="791" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref231">ating the way we classify the diabetic foot: restruc-</a></text>
<text top="804" left="345" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref231">turing the diabetic foot risk classi</a></text>
<text top="803" left="477" width="86" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref231">ﬁcation system of the</a></text>
<text top="818" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref231">International Working Group on the Diabetic Foot.</a></text>
<text top="831" left="345" width="111" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref231">Diabetes Care. 2008;31:154</a></text>
<text top="829" left="456" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref231">–6</a></text>
<text top="831" left="466" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref231">.</a></text>
<text top="850" left="345" width="17" height="9" font="5">232.</text>
<text top="850" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref232">Nordanstig J, Taft C, Hensäter M, et al. Improved</a></text>
<text top="863" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref232">quality of life after 1 year with an invasive versus a</a></text>
<text top="876" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref232">noninvasive treatment strategy in claudicants: one-</a></text>
<text top="890" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref232">year results of the Invasive Revascularization or Not</a></text>
<text top="903" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref232">in Intermittent Claudication (IRONIC) Trial. Circulation.</a></text>
<text top="917" left="345" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref232">2014;130:939</a></text>
<text top="915" left="401" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref232">–47</a></text>
<text top="917" left="415" width="3" height="9" font="5">.</text>
<text top="935" left="345" width="17" height="9" font="5">233.</text>
<text top="935" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref233">Malgor RD, Alahdab F, Elraiyah TA, et al.</a></text>
<text top="949" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref233">A systematic review of treatment of intermittent</a></text>
<text top="962" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref233">claudication in the lower extremities. J Vasc Surg.</a></text>
<text top="976" left="345" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref233">2015;61:54S</a></text>
<text top="974" left="394" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref233">–73S</a></text>
<text top="976" left="412" width="3" height="9" font="5">.</text>
<text top="994" left="345" width="18" height="9" font="5">234.</text>
<text top="994" left="366" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref234">Leng GC, Lee AJ, Fowkes FG, et al. Incidence,</a></text>
<text top="1008" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref234">natural history and cardiovascular events in symp-</a></text>
<text top="1021" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref234">tomatic and asymptomatic peripheral arterial disease in</a></text>
<text top="1035" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref234">the general population. Int J Epidemiol. 1996;25:</a></text>
<text top="1048" left="345" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref234">1172</a></text>
<text top="1046" left="362" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref234">–81</a></text>
<text top="1048" left="376" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref234">.</a></text>
<text top="1067" left="345" width="17" height="9" font="5">235.</text>
<text top="1067" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref235">Dormandy J, Mahir M, Ascady G, et al. Fate of the</a></text>
<text top="1080" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref235">patient with chronic leg ischaemia. A review article.</a></text>
<text top="1093" left="345" width="159" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref235">J Cardiovasc Surg (Torino). 1989;30:50</a></text>
<text top="1092" left="504" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref235">–7</a></text>
<text top="1093" left="512" width="3" height="9" font="5">.</text>
<text top="143" left="583" width="18" height="9" font="5">236.</text>
<text top="143" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref236">Jelnes R, Gaardsting O, Hougaard Jensen K, et al.</a></text>
<text top="156" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref236">Fate in intermittent claudication: outcome and risk</a></text>
<text top="170" left="583" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref236">factors. Br Med J (Clin Res Ed). 1986;293:1137</a></text>
<text top="168" left="770" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref236">–40</a></text>
<text top="170" left="786" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref236">.</a></text>
<text top="190" left="583" width="17" height="9" font="5">237.</text>
<text top="190" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref237">Bloor K. Natural history of arteriosclerosis of the</a></text>
<text top="203" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref237">lower extremities: Hunterian lecture delivered at the</a></text>
<text top="217" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref237">Royal College of Surgeons of England on 22nd April</a></text>
<text top="230" left="583" width="161" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref237">1960. Ann R Coll Surg Engl. 1961;28:36</a></text>
<text top="228" left="744" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref237">–52</a></text>
<text top="230" left="758" width="3" height="9" font="5">.</text>
<text top="250" left="583" width="18" height="9" font="5">238.</text>
<text top="250" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref238">Tetteroo E, van Engelen AD, Spithoven JH, et al.</a></text>
<text top="263" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref238">Stent placement after iliac angioplasty: comparison of</a></text>
<text top="277" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref238">hemodynamic and angiographic criteria. Dutch Iliac</a></text>
<text top="290" left="583" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref238">Stent Trial Study Group. Radiology. 1996;201:155</a></text>
<text top="289" left="782" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref238">–9</a></text>
<text top="290" left="792" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref238">.</a></text>
<text top="310" left="583" width="18" height="9" font="5">239.</text>
<text top="310" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref239">Udoff EJ, Barth KH, Harrington DP, et al. Hemo-</a></text>
<text top="323" left="583" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref239">dynamic signi</a></text>
<text top="322" left="638" width="163" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref239">ﬁcance of iliac artery stenosis: pressure</a></text>
<text top="337" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref239">measurements during angiography. Radiology. 1979;</a></text>
<text top="350" left="583" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref239">132:289</a></text>
<text top="349" left="615" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref239">–93</a></text>
<text top="350" left="629" width="3" height="9" font="5">.</text>
<text top="370" left="583" width="19" height="9" font="5">240.</text>
<text top="370" left="605" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">Spronk S, Bosch JL, den Hoed PT, et al.</a></text>
<text top="384" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">Intermittent claudication: clinical effectiveness of</a></text>
<text top="397" left="583" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">endovascular</a></text>
<text top="397" left="646" width="66" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">revascularization</a></text>
<text top="397" left="723" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">versus</a></text>
<text top="397" left="760" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">supervised</a></text>
<text top="410" left="583" width="124" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">hospital-based exercise training</a></text>
<text top="409" left="707" width="95" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">—randomized controlled</a></text>
<text top="424" left="583" width="124" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">trial. Radiology. 2009;250:586</a></text>
<text top="422" left="707" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">–95</a></text>
<text top="424" left="721" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref240">.</a></text>
<text top="444" left="583" width="17" height="9" font="5">241.</text>
<text top="444" left="603" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref241">Gelin J, Jivegård L, Taft C, et al. Treatment ef</a></text>
<text top="442" left="792" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref241">ﬁ-</a></text>
<text top="457" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref241">cacy of intermittent claudication by surgical interven-</a></text>
<text top="471" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref241">tion, supervised physical exercise training compared to</a></text>
<text top="484" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref241">no treatment in unselected randomised patients, I: one</a></text>
<text top="498" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref241">year results of functional and physiological improve-</a></text>
<text top="511" left="583" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref241">ments. Eur J Vasc Endovasc Surg. 2001;22:107</a></text>
<text top="509" left="772" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref241">–13</a></text>
<text top="511" left="784" width="3" height="9" font="5">.</text>
<text top="531" left="583" width="18" height="9" font="5">242.</text>
<text top="531" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">Greenhalgh RM, Belch JJ, Brown LC, et al. The</a></text>
<text top="544" left="583" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">adjuvant bene</a></text>
<text top="543" left="639" width="162" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">ﬁt of angioplasty in patients with mild to</a></text>
<text top="558" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">moderate intermittent claudication (MIMIC) managed</a></text>
<text top="571" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">by supervised exercise, smoking cessation advice and</a></text>
<text top="585" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">best medical therapy: results from two randomised</a></text>
<text top="598" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">trials for stenotic femoropopliteal and aortoiliac arte-</a></text>
<text top="612" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">rial disease. Eur J Vasc Endovasc Surg. 2008;36:</a></text>
<text top="625" left="583" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">680</a></text>
<text top="623" left="600" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">–8</a></text>
<text top="625" left="610" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref242">.</a></text>
<text top="645" left="583" width="18" height="9" font="5">243.</text>
<text top="645" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref243">Hobbs SD, Marshall T, Fegan C, et al. The</a></text>
<text top="658" left="583" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref243">constitutive procoagulant and hypo</a></text>
<text top="657" left="726" width="76" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref243">ﬁbrinolytic state in</a></text>
<text top="672" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref243">patients with intermittent claudication due to infrain-</a></text>
<text top="685" left="583" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref243">guinal disease signi</a></text>
<text top="683" left="666" width="135" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref243">ﬁcantly improves with percuta-</a></text>
<text top="699" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref243">neous transluminal balloon angioplasty. J Vasc Surg.</a></text>
<text top="712" left="583" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref243">2006;43:40</a></text>
<text top="710" left="632" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref243">–6</a></text>
<text top="712" left="642" width="3" height="9" font="5">.</text>
<text top="732" left="583" width="19" height="9" font="5">244.</text>
<text top="732" left="605" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref244">Mazari FA, Khan JA, Carradice D, et al. Random-</a></text>
<text top="745" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref244">ized clinical trial of percutaneous transluminal angio-</a></text>
<text top="759" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref244">plasty, supervised exercise and combined treatment</a></text>
<text top="772" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref244">for intermittent claudication due to femoropopliteal</a></text>
<text top="786" left="583" width="154" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref244">arterial disease. Br J Surg. 2012;99:39</a></text>
<text top="784" left="737" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref244">–48</a></text>
<text top="786" left="752" width="3" height="9" font="5">.</text>
<text top="805" left="583" width="18" height="9" font="5">245.</text>
<text top="805" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref245">Nordanstig J, Gelin J, Hensäter M, et al. Walking</a></text>
<text top="819" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref245">performance and health-related quality of life after</a></text>
<text top="832" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref245">surgical or endovascular invasive versus non-invasive</a></text>
<text top="846" left="583" width="158" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref245">treatment for intermittent claudication</a></text>
<text top="844" left="741" width="61" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref245">—a prospective</a></text>
<text top="859" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref245">randomised trial. Eur J Vasc Endovasc Surg. 2011;42:</a></text>
<text top="873" left="583" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref245">220</a></text>
<text top="871" left="599" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref245">–7</a></text>
<text top="873" left="607" width="3" height="9" font="5">.</text>
<text top="892" left="583" width="19" height="9" font="5">246.</text>
<text top="892" left="605" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref246">Nylaende M, Abdelnoor M, Stranden E, et al. The</a></text>
<text top="906" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref246">Oslo Balloon Angioplasty versus Conservative Treat-</a></text>
<text top="919" left="583" width="85" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref246">ment study (OBACT)</a></text>
<text top="918" left="668" width="133" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref246">—the 2-years results of a single</a></text>
<text top="933" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref246">centre, prospective, randomised study in patients with</a></text>
<text top="946" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref246">intermittent claudication. Eur J Vasc Endovasc Surg.</a></text>
<text top="960" left="583" width="41" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref246">2007;33:3</a></text>
<text top="958" left="624" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref246">–12</a></text>
<text top="960" left="637" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref246">.</a></text>
<text top="979" left="583" width="18" height="9" font="5">247.</text>
<text top="979" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref247">Perkins JM, Collin J, Creasy TS, et al. Reprinted</a></text>
<text top="993" left="583" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref247">article</a></text>
<text top="991" left="611" width="190" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref247">“Exercise training versus angioplasty for stable</a></text>
<text top="1006" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref247">claudication. Long and medium term results of a pro-</a></text>
<text top="1020" left="583" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref247">spective, randomised trial.</a></text>
<text top="1018" left="689" width="112" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref247">” Eur J Vasc Endovasc Surg.</a></text>
<text top="1033" left="583" width="79" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref247">2011;42 suppl 1:S41</a></text>
<text top="1032" left="662" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref247">–5</a></text>
<text top="1033" left="671" width="3" height="9" font="5">.</text>
<text top="1053" left="583" width="19" height="9" font="5">248.</text>
<text top="1053" left="605" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">Spronk S, Bosch JL, den Hoed PT, et al. Cost-</a></text>
<text top="1067" left="583" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">effectiveness</a></text>
<text top="1067" left="648" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">of</a></text>
<text top="1067" left="669" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">endovascular</a></text>
<text top="1067" left="734" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">revascularization</a></text>
<text top="1080" left="583" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">compared</a></text>
<text top="1080" left="632" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">to</a></text>
<text top="1080" left="649" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">supervised</a></text>
<text top="1080" left="701" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">hospital-based</a></text>
<text top="1080" left="769" width="32" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">exercise</a></text>
<text top="1093" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">training in patients with intermittent claudication: a</a></text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="18" height="9" font="5">e114</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">randomized controlled trial. J Vasc Surg. 2008;48:</a></text>
<text top="156" left="63" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">1472</a></text>
<text top="155" left="81" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">–80</a></text>
<text top="156" left="97" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref248">.</a></text>
<text top="175" left="63" width="19" height="9" font="5">249.</text>
<text top="175" left="84" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref249">Taft C, Karlsson J, Gelin J, et al. Treatment ef</a></text>
<text top="173" left="272" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref249">ﬁ-</a></text>
<text top="188" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref249">cacy of intermittent claudication by invasive therapy,</a></text>
<text top="202" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref249">supervised physical exercise training compared to no</a></text>
<text top="215" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref249">treatment in unselected randomised patients, II: one-</a></text>
<text top="229" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref249">year results of health-related quality of life. Eur J</a></text>
<text top="242" left="63" width="134" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref249">Vasc Endovasc Surg. 2001;22:114</a></text>
<text top="241" left="197" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref249">–23</a></text>
<text top="242" left="210" width="3" height="9" font="5">.</text>
<text top="261" left="63" width="18" height="9" font="5">250.</text>
<text top="261" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref250">Whyman MR, Fowkes FG, Kerracher EM, et al.</a></text>
<text top="274" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref250">Randomised controlled trial of percutaneous trans-</a></text>
<text top="288" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref250">luminal angioplasty for intermittent claudication. Eur J</a></text>
<text top="301" left="63" width="133" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref250">Vasc Endovasc Surg. 1996;12:167</a></text>
<text top="299" left="196" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref250">–72</a></text>
<text top="301" left="210" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref250">.</a></text>
<text top="320" left="63" width="16" height="9" font="5">251.</text>
<text top="320" left="82" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref251">Whyman MR, Fowkes FG, Kerracher EM, et al. Is</a></text>
<text top="333" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref251">intermittent claudication improved by percutaneous</a></text>
<text top="347" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref251">transluminal angioplasty? A randomized controlled</a></text>
<text top="360" left="63" width="122" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref251">trial. J Vasc Surg. 1997;26:551</a></text>
<text top="358" left="185" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref251">–7</a></text>
<text top="360" left="193" width="3" height="9" font="5">.</text>
<text top="379" left="63" width="17" height="9" font="5">252.</text>
<text top="379" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref252">Capek P, McLean GK, Berkowitz HD. Femo-</a></text>
<text top="392" left="63" width="138" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref252">ropopliteal angioplasty. Factors in</a></text>
<text top="390" left="201" width="80" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref252">ﬂuencing long-term</a></text>
<text top="405" left="63" width="131" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref252">success. Circulation. 1991;83:I70</a></text>
<text top="404" left="193" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref252">–80</a></text>
<text top="405" left="209" width="3" height="9" font="5">.</text>
<text top="424" left="63" width="17" height="9" font="5">253.</text>
<text top="424" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref253">Löfberg AM, Karacagil S, Ljungman C, et al.</a></text>
<text top="437" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref253">Percutaneous transluminal angioplasty of the femo-</a></text>
<text top="451" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref253">ropopliteal arteries in limbs with chronic critical lower</a></text>
<text top="464" left="63" width="161" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref253">limb ischemia. J Vasc Surg. 2001;34:114</a></text>
<text top="463" left="223" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref253">–21</a></text>
<text top="464" left="236" width="3" height="9" font="5">.</text>
<text top="483" left="63" width="18" height="9" font="5">254.</text>
<text top="483" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref254">Clark TW, Groffsky JL, Soulen MC. Predictors of</a></text>
<text top="496" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref254">long-term patency after femoropopliteal angioplasty:</a></text>
<text top="510" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref254">results from the STAR registry. J Vasc Interv Radiol.</a></text>
<text top="523" left="63" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref254">2001;12:923</a></text>
<text top="522" left="112" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref254">–33</a></text>
<text top="523" left="126" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref254">.</a></text>
<text top="542" left="63" width="17" height="9" font="5">255.</text>
<text top="542" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref255">Johnston KW, Rae M, Hogg-Johnston SA, et al. 5-</a></text>
<text top="555" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref255">year results of a prospective study of percutaneous</a></text>
<text top="569" left="63" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref255">transluminal angioplasty. Ann Surg. 1987;206:403</a></text>
<text top="567" left="266" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref255">–13</a></text>
<text top="569" left="278" width="3" height="9" font="5">.</text>
<text top="587" left="63" width="18" height="9" font="5">256.</text>
<text top="587" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref256">Schulte KL, Pilger E, Schellong S, et al. Primary</a></text>
<text top="601" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref256">self-expanding nitinol stenting vs balloon angioplasty</a></text>
<text top="614" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref256">with optional bailout stenting for the treatment of</a></text>
<text top="628" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref256">infrapopliteal artery disease in patients with severe</a></text>
<text top="641" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref256">intermittent claudication or critical limb ischemia</a></text>
<text top="654" left="63" width="194" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref256">(EXPAND Study). J Endovasc Ther. 2015;22:690</a></text>
<text top="653" left="257" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref256">–7</a></text>
<text top="654" left="266" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref256">.</a></text>
<text top="673" left="63" width="17" height="9" font="5">257.</text>
<text top="673" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref257">Rastan A, Tepe G, Krankenberg H, et al. Sirolimus-</a></text>
<text top="686" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref257">eluting stents vs. bare-metal stents for treatment of</a></text>
<text top="700" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref257">focal lesions in infrapopliteal arteries: a double-blind,</a></text>
<text top="713" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref257">multi-centre, randomized clinical trial. Eur Heart J.</a></text>
<text top="727" left="63" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref257">2011;32:2274</a></text>
<text top="725" left="116" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref257">–81</a></text>
<text top="727" left="129" width="3" height="9" font="5">.</text>
<text top="745" left="63" width="18" height="9" font="5">258.</text>
<text top="745" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref258">Siablis D, Kitrou PM, Spiliopoulos S, et al.</a></text>
<text top="759" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref258">Paclitaxel-coated balloon angioplasty versus drug-</a></text>
<text top="772" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref258">eluting stenting for the treatment of infrapopliteal</a></text>
<text top="786" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref258">long-segment arterial occlusive disease: the IDEAS</a></text>
<text top="799" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref258">randomized controlled trial. J Am Coll Cardiol Intv.</a></text>
<text top="813" left="63" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref258">2014;7:1048</a></text>
<text top="811" left="113" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref258">–56</a></text>
<text top="813" left="128" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref258">.</a></text>
<text top="831" left="63" width="18" height="9" font="5">259.</text>
<text top="831" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref259">Sachs T, Pomposelli F, Hamdan A, et al. Trends in</a></text>
<text top="845" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref259">the national outcomes and costs for claudication and</a></text>
<text top="858" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref259">limb threatening ischemia: angioplasty vs bypass graft.</a></text>
<text top="871" left="63" width="104" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref259">J Vasc Surg. 2011;54:1021</a></text>
<text top="870" left="167" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref259">–31</a></text>
<text top="871" left="179" width="3" height="9" font="5">.</text>
<text top="890" left="63" width="19" height="9" font="5">260.</text>
<text top="890" left="85" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref260">Shammas NW, Shammas GA, Dippel EJ, et al.</a></text>
<text top="903" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref260">Predictors of distal embolization in peripheral percu-</a></text>
<text top="917" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref260">taneous interventions: a report from a large peripheral</a></text>
<text top="930" left="63" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref260">vascular registry. J Invasive Cardiol. 2009;21:628</a></text>
<text top="929" left="262" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref260">–31</a></text>
<text top="930" left="275" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref260">.</a></text>
<text top="949" left="63" width="17" height="9" font="5">261.</text>
<text top="949" left="83" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">Matsi</a></text>
<text top="949" left="114" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">PJ,</a></text>
<text top="949" left="136" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">Manninen</a></text>
<text top="949" left="185" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">HI.</a></text>
<text top="949" left="207" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">Complications</a></text>
<text top="949" left="273" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">of</a></text>
<text top="962" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">lower-limb percutaneous transluminal angioplasty: a</a></text>
<text top="976" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">prospective analysis of 410 procedures on 295</a></text>
<text top="989" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">consecutive patients. Cardiovasc Intervent Radiol.</a></text>
<text top="1003" left="63" width="48" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">1998;21:361</a></text>
<text top="1001" left="111" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">–6</a></text>
<text top="1003" left="121" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref261">.</a></text>
<text top="1021" left="63" width="18" height="9" font="5">262.</text>
<text top="1021" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref262">Kannel WB, Skinner JJ, Schwartz MJ, et al.</a></text>
<text top="1035" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref262">Intermittent claudication. Incidence in the Framingham</a></text>
<text top="1048" left="63" width="126" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref262">Study. Circulation. 1970;41:875</a></text>
<text top="1046" left="189" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref262">–83</a></text>
<text top="1048" left="203" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref262">.</a></text>
<text top="1067" left="63" width="18" height="9" font="5">263.</text>
<text top="1067" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref263">AbuRahma AF, Robinson PA, Holt SM. Prospective</a></text>
<text top="1080" left="63" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref263">controlled study of polytetra</a></text>
<text top="1078" left="190" width="91" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref263">ﬂuoroethylene versus</a></text>
<text top="1093" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref263">saphenous vein in claudicant patients with bilateral</a></text>
<text top="143" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref263">above knee femoropopliteal bypasses. Surgery. 1999;</a></text>
<text top="156" left="301" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref263">126:594</a></text>
<text top="155" left="333" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref263">–602</a></text>
<text top="156" left="354" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref263">.</a></text>
<text top="176" left="301" width="19" height="9" font="5">264.</text>
<text top="176" left="322" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref264">Archie JP. Femoropopliteal bypass with either</a></text>
<text top="190" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref264">adequate ipsilateral reversed saphenous vein or</a></text>
<text top="203" left="301" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref264">obligatory polytetra</a></text>
<text top="202" left="384" width="134" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref264">ﬂuoroethylene. Ann Vasc Surg.</a></text>
<text top="217" left="301" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref264">1994;8:475</a></text>
<text top="215" left="346" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref264">–84</a></text>
<text top="217" left="362" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref264">.</a></text>
<text top="236" left="301" width="18" height="9" font="5">265.</text>
<text top="236" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref265">Eugster T, Marti R, Gurke L, et al. Ten years after</a></text>
<text top="250" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref265">arterial bypass surgery for claudication: venous bypass</a></text>
<text top="263" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref265">is the primary procedure for TASC C and D lesions.</a></text>
<text top="277" left="301" width="111" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref265">World J Surg. 2011;35:2328</a></text>
<text top="275" left="411" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref265">–31</a></text>
<text top="277" left="424" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref265">.</a></text>
<text top="297" left="301" width="19" height="9" font="5">266.</text>
<text top="297" left="322" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref266">Green RM, Abbott WM, Matsumoto T, et al.</a></text>
<text top="310" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref266">Prosthetic above-knee femoropopliteal bypass graft-</a></text>
<text top="324" left="301" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref266">ing:</a></text>
<text top="322" left="318" width="201" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref266">ﬁve-year results of a randomized trial. J Vasc Surg.</a></text>
<text top="337" left="301" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref266">2000;31:417</a></text>
<text top="335" left="351" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref266">–25</a></text>
<text top="337" left="365" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref266">.</a></text>
<text top="357" left="301" width="18" height="9" font="5">267.</text>
<text top="357" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref267">Hunink MG, Wong JB, Donaldson MC, et al.</a></text>
<text top="370" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref267">Patency results of percutaneous and surgical revascu-</a></text>
<text top="384" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref267">larization for femoropopliteal arterial disease. Med</a></text>
<text top="397" left="301" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref267">Decis Making. 1994;14:71</a></text>
<text top="396" left="402" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref267">–81</a></text>
<text top="397" left="415" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref267">.</a></text>
<text top="417" left="301" width="19" height="9" font="5">268.</text>
<text top="417" left="322" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref268">Johnson WC, Lee KK. Comparative evaluation of</a></text>
<text top="431" left="301" width="191" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref268">externally supported Dacron and polytetra</a></text>
<text top="429" left="491" width="28" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref268">ﬂuoro-</a></text>
<text top="444" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref268">ethylene prosthetic bypasses for femorofemoral and</a></text>
<text top="458" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref268">axillofemoral arterial reconstructions. Veterans Affairs</a></text>
<text top="471" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref268">Cooperative Study #141. J Vasc Surg. 1999;30:</a></text>
<text top="484" left="301" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref268">1077</a></text>
<text top="483" left="319" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref268">–83</a></text>
<text top="484" left="334" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref268">.</a></text>
<text top="504" left="301" width="19" height="9" font="5">269.</text>
<text top="504" left="322" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref269">Klinkert P, Schepers A, Burger DH, et al. Vein</a></text>
<text top="518" left="301" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref269">versus polytetra</a></text>
<text top="516" left="367" width="151" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref269">ﬂuoroethylene in above-knee femo-</a></text>
<text top="531" left="301" width="111" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref269">ropopliteal bypass grafting:</a></text>
<text top="530" left="415" width="104" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref269">ﬁve-year results of a ran-</a></text>
<text top="545" left="301" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref269">domized controlled trial. J Vasc Surg. 2003;37:149</a></text>
<text top="543" left="502" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref269">–55</a></text>
<text top="545" left="516" width="3" height="9" font="5">.</text>
<text top="564" left="301" width="18" height="9" font="5">270.</text>
<text top="564" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref270">Twine CP, McLain AD. Graft type for femoro-</a></text>
<text top="578" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref270">popliteal bypass surgery. Cochrane Database Syst</a></text>
<text top="591" left="301" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref270">Rev. 2010:CD001487</a></text>
<text top="591" left="387" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref270">.</a></text>
<text top="611" left="301" width="16" height="9" font="5">271.</text>
<text top="611" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref271">Pereira CE, Albers M, Romiti M, et al. Meta-anal-</a></text>
<text top="625" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref271">ysis of femoropopliteal bypass grafts for lower ex-</a></text>
<text top="638" left="301" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref271">tremity arterial insuf</a></text>
<text top="637" left="386" width="132" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref271">ﬁciency. J Vasc Surg. 2006;44:</a></text>
<text top="652" left="301" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref271">510</a></text>
<text top="650" left="315" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref271">–7</a></text>
<text top="652" left="324" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref271">.</a></text>
<text top="671" left="301" width="17" height="9" font="5">272.</text>
<text top="671" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref272">Johnson WC, Lee KK. A comparative evaluation of</a></text>
<text top="685" left="301" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref272">polytetra</a></text>
<text top="683" left="337" width="182" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref272">ﬂuoroethylene, umbilical vein, and saphenous</a></text>
<text top="698" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref272">vein bypass grafts for femoral-popliteal above-knee</a></text>
<text top="712" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref272">revascularization: a prospective randomized Depart-</a></text>
<text top="725" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref272">ment of Veterans Affairs cooperative study. J Vasc</a></text>
<text top="739" left="301" width="78" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref272">Surg. 2000;32:268</a></text>
<text top="737" left="378" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref272">–77</a></text>
<text top="739" left="391" width="3" height="9" font="5">.</text>
<text top="758" left="301" width="17" height="9" font="5">273.</text>
<text top="758" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref273">Jensen LP, Lepäntalo M, Fossdal JE, et al. Dacron</a></text>
<text top="772" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref273">or PTFE for above-knee femoropopliteal bypass. a</a></text>
<text top="785" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref273">multicenter randomised study. Eur J Vasc Endovasc</a></text>
<text top="799" left="301" width="71" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref273">Surg. 2007;34:44</a></text>
<text top="797" left="372" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref273">–9</a></text>
<text top="799" left="381" width="3" height="9" font="5">.</text>
<text top="819" left="301" width="18" height="9" font="5">274.</text>
<text top="819" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref274">van Det RJ, Vriens BH, van der Palen J, et al.</a></text>
<text top="832" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref274">Dacron or ePTFE for femoro-popliteal above-knee</a></text>
<text top="846" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref274">bypass grafting: short- and long-term results of a</a></text>
<text top="859" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref274">multicentre randomised trial. Eur J Vasc Endovasc</a></text>
<text top="872" left="301" width="76" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref274">Surg. 2009;37:457</a></text>
<text top="871" left="376" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref274">–63</a></text>
<text top="872" left="390" width="3" height="9" font="5">.</text>
<text top="892" left="301" width="17" height="9" font="5">275.</text>
<text top="892" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref275">Feinglass J, McCarthy WJ, Slavensky R, et al.</a></text>
<text top="906" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref275">Functional status and walking ability after lower ex-</a></text>
<text top="919" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref275">tremity bypass grafting or angioplasty for intermittent</a></text>
<text top="933" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref275">claudication: results from a prospective outcomes</a></text>
<text top="946" left="301" width="126" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref275">study. J Vasc Surg. 2000;31:93</a></text>
<text top="945" left="427" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref275">–103</a></text>
<text top="946" left="445" width="3" height="9" font="5">.</text>
<text top="966" left="301" width="18" height="9" font="5">276.</text>
<text top="966" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">Koivunen K, Lukkarinen H. One-year prospective</a></text>
<text top="979" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">health-related quality-of-life outcomes in patients</a></text>
<text top="993" left="301" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">treated</a></text>
<text top="993" left="338" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">with</a></text>
<text top="993" left="365" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">conservative</a></text>
<text top="993" left="424" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">method,</a></text>
<text top="993" left="466" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">endovascular</a></text>
<text top="1006" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">treatment or open surgery for symptomatic lower limb</a></text>
<text top="1020" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">atherosclerotic disease. Eur J Cardiovasc Nurs. 2008;7:</a></text>
<text top="1033" left="301" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">247</a></text>
<text top="1032" left="315" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">–56</a></text>
<text top="1033" left="330" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref276">.</a></text>
<text top="1053" left="301" width="17" height="9" font="5">277.</text>
<text top="1053" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref277">Mori E, Komori K, Kume M, et al. Comparison of</a></text>
<text top="1067" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref277">the long-term results between surgical and conserva-</a></text>
<text top="1080" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref277">tive treatment in patients with intermittent claudica-</a></text>
<text top="1093" left="301" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref277">tion. Surgery. 2002;131:S269</a></text>
<text top="1092" left="418" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref277">–74</a></text>
<text top="1093" left="432" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref277">.</a></text>
<text top="143" left="538" width="18" height="9" font="5">278.</text>
<text top="143" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref278">Antoniou GA, Chalmers N, Georgiadis GS, et al.</a></text>
<text top="156" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref278">A meta-analysis of endovascular versus surgical</a></text>
<text top="170" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref278">reconstruction of femoropopliteal arterial disease.</a></text>
<text top="183" left="538" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref278">J Vasc Surg. 2013;57:242</a></text>
<text top="182" left="639" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref278">–53</a></text>
<text top="183" left="653" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref278">.</a></text>
<text top="202" left="538" width="18" height="9" font="5">279.</text>
<text top="202" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref279">Fowkes F, Leng GC. Bypass surgery for chronic</a></text>
<text top="216" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref279">lower limb ischaemia. Cochrane Database Syst Rev.</a></text>
<text top="229" left="538" width="72" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref279">2008:CD002000</a></text>
<text top="229" left="610" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref279">.</a></text>
<text top="248" left="538" width="19" height="9" font="5">280.</text>
<text top="248" left="560" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref280">Aihara H, Soga Y, Mii S, et al. Comparison of long-</a></text>
<text top="262" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref280">term outcome after endovascular therapy versus</a></text>
<text top="275" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref280">bypass surgery in claudication patients with Trans-</a></text>
<text top="289" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref280">Atlantic Inter-Society Consensus-II C and D femo-</a></text>
<text top="302" left="538" width="159" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref280">ropopliteal disease. Circ J. 2014;78:457</a></text>
<text top="301" left="697" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref280">–64</a></text>
<text top="302" left="712" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref280">.</a></text>
<text top="321" left="538" width="17" height="9" font="5">281.</text>
<text top="321" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref281">Chiesa R, Marone EM, Tshomba Y, et al. Aortobi-</a></text>
<text top="335" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref281">femoral bypass grafting using expanded polytetra-</a></text>
<text top="347" left="538" width="218" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref281">ﬂuoroethylene stretch grafts in patients with occlusive</a></text>
<text top="362" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref281">atherosclerotic disease. Ann Vasc Surg. 2009;23:</a></text>
<text top="375" left="538" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref281">764</a></text>
<text top="373" left="554" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref281">–9</a></text>
<text top="375" left="563" width="3" height="9" font="5">.</text>
<text top="394" left="538" width="18" height="9" font="5">282.</text>
<text top="394" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref282">Goodney PP, Likosky DS, Cronenwett JL, et al.</a></text>
<text top="408" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref282">Predicting ambulation status one year after lower ex-</a></text>
<text top="421" left="538" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref282">tremity bypass. J Vasc Surg. 2009;49:1431</a></text>
<text top="419" left="711" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref282">–9</a></text>
<text top="421" left="721" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref282">.</a></text>
<text top="440" left="538" width="18" height="9" font="5">283.</text>
<text top="440" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref283">Lo RC, Bensley RP, Dahlberg SE, et al. Presenta-</a></text>
<text top="454" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref283">tion, treatment, and outcome differences between</a></text>
<text top="467" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref283">men and women undergoing revascularization or</a></text>
<text top="480" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref283">amputation for lower extremity peripheral arterial</a></text>
<text top="494" left="538" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref283">disease. J Vasc Surg. 2014;59:409</a></text>
<text top="492" left="677" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref283">–18</a></text>
<text top="494" left="690" width="3" height="9" font="5">.</text>
<text top="513" left="538" width="19" height="9" font="5">284.</text>
<text top="513" left="560" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref284">Nguyen BN, Amdur RL, Abugideiri M, et al.</a></text>
<text top="526" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref284">Postoperative complications after common femoral</a></text>
<text top="540" left="538" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref284">endarterectomy. J Vasc Surg. 2015;61:1489</a></text>
<text top="538" left="713" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref284">–94</a></text>
<text top="540" left="728" width="3" height="9" font="5">.</text>
<text top="559" left="538" width="18" height="9" font="5">285.</text>
<text top="559" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref285">Sachwani GR, Hans SS, Khoury MD, et al. Results</a></text>
<text top="572" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref285">of iliac stenting and aortofemoral grafting for iliac ar-</a></text>
<text top="586" left="538" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref285">tery occlusions. J Vasc Surg. 2013;57:1030</a></text>
<text top="584" left="710" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref285">–7</a></text>
<text top="586" left="719" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref285">.</a></text>
<text top="605" left="538" width="19" height="9" font="5">286.</text>
<text top="605" left="560" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref286">Siracuse JJ, Gill HL, Schneider DB, et al. Assessing</a></text>
<text top="618" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref286">the perioperative safety of common femoral endar-</a></text>
<text top="632" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref286">terectomy in the endovascular era. Vasc Endovascular</a></text>
<text top="645" left="538" width="69" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref286">Surg. 2014;48:27</a></text>
<text top="643" left="607" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref286">–33</a></text>
<text top="645" left="621" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref286">.</a></text>
<text top="664" left="538" width="18" height="9" font="5">287.</text>
<text top="664" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">Veith FJ, Gupta SK, Ascer E, et al. Six-year pro-</a></text>
<text top="678" left="538" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">spective</a></text>
<text top="678" left="581" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">multicenter</a></text>
<text top="678" left="636" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">randomized</a></text>
<text top="678" left="693" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">comparison</a></text>
<text top="678" left="748" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">of</a></text>
<text top="691" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">autologous saphenous vein and expanded polytetra-</a></text>
<text top="703" left="538" width="218" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">ﬂuoroethylene grafts in infrainguinal arterial re-</a></text>
<text top="718" left="538" width="157" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">constructions. J Vasc Surg. 1986;3:104</a></text>
<text top="716" left="695" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">–14</a></text>
<text top="718" left="708" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref287">.</a></text>
<text top="737" left="538" width="19" height="9" font="5">288.</text>
<text top="737" left="560" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref288">Schweiger H, Klein P, Lang W. Tibial bypass</a></text>
<text top="750" left="538" width="191" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref288">grafting for limb salvage with ringed polytetra</a></text>
<text top="749" left="729" width="28" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref288">ﬂuoro-</a></text>
<text top="764" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref288">ethylene prostheses: results of primary and secondary</a></text>
<text top="777" left="538" width="151" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref288">procedures. J Vasc Surg. 1993;18:867</a></text>
<text top="776" left="690" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref288">–74</a></text>
<text top="777" left="704" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref288">.</a></text>
<text top="796" left="538" width="19" height="9" font="5">289.</text>
<text top="796" left="560" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref289">Baldwin ZK, Pearce BJ, Curi MA, et al. Limb</a></text>
<text top="810" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref289">salvage after infrainguinal bypass graft failure. J Vasc</a></text>
<text top="823" left="538" width="76" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref289">Surg. 2004;39:951</a></text>
<text top="822" left="614" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref289">–7</a></text>
<text top="823" left="622" width="3" height="9" font="5">.</text>
<text top="842" left="538" width="19" height="9" font="5">290.</text>
<text top="842" left="560" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref290">Abu Dabrh AM, Steffen MW, Undavalli C, et al.</a></text>
<text top="856" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref290">The natural history of untreated severe or critical limb</a></text>
<text top="869" left="538" width="146" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref290">ischemia. J Vasc Surg. 2015;62:1642</a></text>
<text top="868" left="684" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref290">–51</a></text>
<text top="869" left="697" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref290">.</a></text>
<text top="888" left="538" width="88" height="9" font="5">291. Deleted in press.</text>
<text top="907" left="538" width="18" height="9" font="5">292.</text>
<text top="907" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref292">Adam DJ, Beard JD, Cleveland T, et al. Bypass</a></text>
<text top="921" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref292">versus angioplasty in severe ischaemia of the leg</a></text>
<text top="934" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref292">(BASIL): multicentre, randomised controlled trial.</a></text>
<text top="948" left="538" width="94" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref292">Lancet. 2005;366:1925</a></text>
<text top="946" left="632" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref292">–34</a></text>
<text top="948" left="646" width="3" height="9" font="5">.</text>
<text top="967" left="538" width="18" height="9" font="5">293.</text>
<text top="967" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">Bradbury AW, Adam DJ, Bell J, et al. Multicentre</a></text>
<text top="980" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">randomised controlled trial of the clinical and cost-</a></text>
<text top="994" left="538" width="155" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">effectiveness of a bypass-surgery-</a></text>
<text top="992" left="694" width="63" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">ﬁrst versus a</a></text>
<text top="1007" left="538" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">balloon-angioplasty-</a></text>
<text top="1005" left="622" width="135" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">ﬁrst revascularisation strategy for</a></text>
<text top="1021" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">severe limb ischaemia due to infrainguinal disease. The</a></text>
<text top="1034" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">Bypass versus Angioplasty in Severe Ischaemia of the</a></text>
<text top="1048" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">Leg (BASIL) trial. Health Technol Assess. 2010;14:</a></text>
<text top="1061" left="538" width="4" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">1</a></text>
<text top="1059" left="542" width="41" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref293">–210, iii–iv</a></text>
<text top="1061" left="583" width="3" height="9" font="5">.</text>
<text top="1080" left="538" width="19" height="9" font="5">294.</text>
<text top="1080" left="560" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref294">Panaich SS, Arora S, Patel N, et al. Intravascular</a></text>
<text top="1093" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref294">ultrasound in lower extremity peripheral vascular</a></text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="791" width="17" height="9" font="5">e115</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref294">interventions: variation in utilization and impact on in-</a></text>
<text top="156" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref294">hospital outcomes from the Nationwide Inpatient</a></text>
<text top="170" left="108" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref294">Sample (2006-2011). J Endovasc Ther. 2016;23:65</a></text>
<text top="168" left="310" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref294">–75</a></text>
<text top="170" left="323" width="3" height="9" font="5">.</text>
<text top="190" left="108" width="18" height="9" font="5">295.</text>
<text top="190" left="128" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref295">Gray BH, Laird JR, Ansel GM, et al. Complex</a></text>
<text top="203" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref295">endovascular treatment for critical limb ischemia in</a></text>
<text top="217" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref295">poor surgical candidates: a pilot study. J Endovasc</a></text>
<text top="230" left="108" width="72" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref295">Ther. 2002;9:599</a></text>
<text top="229" left="180" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref295">–604</a></text>
<text top="230" left="201" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref295">.</a></text>
<text top="250" left="108" width="19" height="9" font="5">296.</text>
<text top="250" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref296">Ryer EJ, Trocciola SM, DeRubertis B, et al. Anal-</a></text>
<text top="264" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref296">ysis of outcomes following failed endovascular treat-</a></text>
<text top="277" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref296">ment of chronic limb ischemia. Ann Vasc Surg. 2006;</a></text>
<text top="291" left="108" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref296">20:440</a></text>
<text top="289" left="138" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref296">–6</a></text>
<text top="291" left="148" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref296">.</a></text>
<text top="311" left="108" width="18" height="9" font="5">297.</text>
<text top="311" left="128" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref297">Krankenberg H, Schlüter M, Steinkamp HJ, et al.</a></text>
<text top="324" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref297">Nitinol stent implantation versus percutaneous trans-</a></text>
<text top="338" left="108" width="111" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref297">luminal angioplasty in super</a></text>
<text top="336" left="219" width="107" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref297">ﬁcial femoral artery lesions</a></text>
<text top="351" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref297">up to 10 cm in length: the Femoral Artery Stenting Trial</a></text>
<text top="364" left="108" width="135" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref297">(FAST). Circulation. 2007;116:285</a></text>
<text top="363" left="243" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref297">–92</a></text>
<text top="364" left="257" width="3" height="9" font="5">.</text>
<text top="385" left="108" width="19" height="9" font="5">298.</text>
<text top="385" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref298">Schillinger M, Sabeti S, Dick P, et al. Sustained</a></text>
<text top="398" left="108" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref298">bene</a></text>
<text top="396" left="127" width="199" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref298">ﬁt at 2 years of primary femoropopliteal stenting</a></text>
<text top="411" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref298">compared with balloon angioplasty with optional</a></text>
<text top="425" left="108" width="145" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref298">stenting. Circulation. 2007;115:2745</a></text>
<text top="423" left="253" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref298">–9</a></text>
<text top="425" left="262" width="3" height="9" font="5">.</text>
<text top="445" left="108" width="19" height="9" font="5">299.</text>
<text top="445" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref299">Liistro F, Porto I, Angioli P, et al. Drug-eluting</a></text>
<text top="458" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref299">balloon in peripheral intervention for below the knee</a></text>
<text top="472" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref299">angioplasty evaluation (DEBATE-BTK): a randomized</a></text>
<text top="485" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref299">trial in diabetic patients with critical limb ischemia.</a></text>
<text top="499" left="108" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref299">Circulation. 2013;128:615</a></text>
<text top="497" left="209" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref299">–21</a></text>
<text top="499" left="221" width="3" height="9" font="5">.</text>
<text top="519" left="108" width="19" height="9" font="5">300.</text>
<text top="519" left="130" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref300">Tepe G, Schnorr B, Albrecht T, et al. Angioplasty</a></text>
<text top="532" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref300">of femoral-popliteal arteries with drug-coated bal-</a></text>
<text top="546" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref300">loons: 5-year follow-up of the THUNDER trial. J Am</a></text>
<text top="559" left="108" width="116" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref300">Coll Cardiol Intv. 2015;8:102</a></text>
<text top="557" left="223" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref300">–8</a></text>
<text top="559" left="233" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref300">.</a></text>
<text top="579" left="108" width="17" height="9" font="5">301.</text>
<text top="579" left="128" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref301">Dake MD, Ansel GM, Jaff MR, et al. Durable</a></text>
<text top="593" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref301">clinical effectiveness with paclitaxel-eluting stents in</a></text>
<text top="606" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref301">the femoropopliteal artery: 5-year results of the</a></text>
<text top="619" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref301">Zilver PTX Randomized Trial. Circulation. 2016;133:</a></text>
<text top="633" left="108" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref301">1472</a></text>
<text top="631" left="126" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref301">–83</a></text>
<text top="633" left="140" width="3" height="9" font="5">.</text>
<text top="653" left="108" width="18" height="9" font="5">302.</text>
<text top="653" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">Liistro F, Grotti S, Porto I, et al. Drug-eluting</a></text>
<text top="666" left="108" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">balloon in peripheral intervention for the super</a></text>
<text top="665" left="307" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">ﬁcial</a></text>
<text top="680" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">femoral artery: the DEBATE-SFA randomized trial</a></text>
<text top="693" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">(drug eluting balloon in peripheral intervention for the</a></text>
<text top="707" left="108" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">super</a></text>
<text top="705" left="130" width="196" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">ﬁcial femoral artery). J Am Coll Cardiol Intv.</a></text>
<text top="720" left="108" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">2013;6:1295</a></text>
<text top="719" left="157" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">–302</a></text>
<text top="720" left="177" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref302">.</a></text>
<text top="740" left="108" width="18" height="9" font="5">303.</text>
<text top="740" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref303">Bosiers M, Scheinert D, Peeters P, et al. Ran-</a></text>
<text top="754" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref303">domized comparison of everolimus-eluting versus</a></text>
<text top="767" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref303">bare-metal stents in patients with critical limb ischemia</a></text>
<text top="781" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref303">and infrapopliteal arterial occlusive disease. J Vasc</a></text>
<text top="794" left="108" width="74" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref303">Surg. 2012;55:390</a></text>
<text top="792" left="182" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref303">–8</a></text>
<text top="794" left="192" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref303">.</a></text>
<text top="814" left="108" width="19" height="9" font="5">304.</text>
<text top="814" left="130" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref304">Katsanos K, Spiliopoulos S, Diamantopoulos A,</a></text>
<text top="827" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref304">et al. Wound healing outcomes and health-related</a></text>
<text top="841" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref304">quality-of-life changes in the ACHILLES trial: 1-year</a></text>
<text top="854" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref304">results from a prospective randomized controlled</a></text>
<text top="868" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref304">trial of infrapopliteal balloon angioplasty versus</a></text>
<text top="881" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref304">sirolimus-eluting stenting in patients with ischemic</a></text>
<text top="895" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref304">peripheral arterial disease. J Am Coll Cardiol Intv.</a></text>
<text top="908" left="108" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref304">2016;9:259</a></text>
<text top="907" left="154" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref304">–67</a></text>
<text top="908" left="168" width="3" height="9" font="5">.</text>
<text top="928" left="108" width="18" height="9" font="5">305.</text>
<text top="928" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref305">Scheinert D, Katsanos K, Zeller T, et al.</a></text>
<text top="942" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref305">A prospective randomized multicenter comparison of</a></text>
<text top="955" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref305">balloon angioplasty and infrapopliteal stenting with</a></text>
<text top="969" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref305">the sirolimus-eluting stent in patients with ischemic</a></text>
<text top="982" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref305">peripheral arterial disease: 1-year results from the</a></text>
<text top="995" left="108" width="206" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref305">ACHILLES trial. J Am Coll Cardiol. 2012;60:2290</a></text>
<text top="994" left="313" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref305">–5</a></text>
<text top="995" left="322" width="3" height="9" font="5">.</text>
<text top="1015" left="108" width="19" height="9" font="5">306.</text>
<text top="1015" left="129" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref306">Zeller T, Baumgartner I, Scheinert D, et al.</a></text>
<text top="1029" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref306">Drug-eluting balloon versus standard balloon angio-</a></text>
<text top="1042" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref306">plasty for infrapopliteal arterial revascularization in</a></text>
<text top="1056" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref306">critical limb ischemia: 12-month results from the IN.</a></text>
<text top="1069" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref306">PACT DEEP randomized trial. J Am Coll Cardiol.</a></text>
<text top="1083" left="108" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref306">2014;64:1568</a></text>
<text top="1081" left="164" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref306">–76</a></text>
<text top="1083" left="178" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref306">.</a></text>
<text top="143" left="345" width="18" height="9" font="5">307.</text>
<text top="143" left="366" width="24" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref307">Rosen</a></text>
<text top="141" left="390" width="173" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref307">ﬁeld K, Jaff MR, White CJ, et al. Trial of a</a></text>
<text top="156" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref307">paclitaxel-coated balloon for femoropopliteal artery</a></text>
<text top="170" left="345" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref307">disease. N Engl J Med. 2015;373:145</a></text>
<text top="168" left="492" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref307">–53</a></text>
<text top="170" left="506" width="3" height="9" font="5">.</text>
<text top="189" left="345" width="19" height="9" font="5">308.</text>
<text top="189" left="367" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">Scheinert D, Duda S, Zeller T, et al. The LEVANT I</a></text>
<text top="202" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">(Lutonix paclitaxel-coated balloon for the prevention</a></text>
<text top="215" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">of femoropopliteal restenosis) trial for femoropopliteal</a></text>
<text top="229" left="345" width="70" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">revascularization:</a></text>
<text top="227" left="420" width="144" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">ﬁrst-in-human randomized trial of</a></text>
<text top="242" left="345" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">low-dose</a></text>
<text top="242" left="392" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">drug-coated</a></text>
<text top="242" left="451" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">balloon</a></text>
<text top="242" left="491" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">versus</a></text>
<text top="242" left="527" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">uncoated</a></text>
<text top="256" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">balloon angioplasty. J Am Coll Cardiol Intv. 2014;7:</a></text>
<text top="269" left="345" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">10</a></text>
<text top="268" left="355" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">–9</a></text>
<text top="269" left="365" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref308">.</a></text>
<text top="288" left="345" width="19" height="9" font="5">309.</text>
<text top="288" left="367" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref309">Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-</a></text>
<text top="301" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref309">coated balloons reduce restenosis after femoro-</a></text>
<text top="315" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref309">popliteal angioplasty: evidence from the randomized</a></text>
<text top="328" left="345" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref309">PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831</a></text>
<text top="327" left="543" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref309">–40</a></text>
<text top="328" left="558" width="3" height="9" font="5">.</text>
<text top="347" left="345" width="17" height="9" font="5">310.</text>
<text top="347" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref310">Acín F, Varela C, López de Maturana I, et al. Re-</a></text>
<text top="360" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref310">sults of infrapopliteal endovascular procedures per-</a></text>
<text top="374" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref310">formed in diabetic patients with critical limb ischemia</a></text>
<text top="387" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref310">and tissue loss from the perspective of an angiosome-</a></text>
<text top="401" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref310">oriented revascularization strategy. Int J Vasc Med.</a></text>
<text top="414" left="345" width="76" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref310">2014;2014:270539</a></text>
<text top="414" left="421" width="3" height="9" font="5">.</text>
<text top="433" left="345" width="15" height="9" font="5">311.</text>
<text top="433" left="363" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref311">Alexandrescu VA, Hubermont G, Philips Y, et al.</a></text>
<text top="446" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref311">Selective primary angioplasty following an angiosome</a></text>
<text top="460" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref311">model of reperfusion in the treatment of Wagner 1-4</a></text>
<text top="473" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref311">diabetic foot lesions: practice in a multidisciplinary</a></text>
<text top="487" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref311">diabetic limb service. J Endovasc Ther. 2008;15:</a></text>
<text top="500" left="345" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref311">580</a></text>
<text top="498" left="362" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref311">–93</a></text>
<text top="500" left="376" width="3" height="9" font="5">.</text>
<text top="519" left="345" width="16" height="9" font="5">312.</text>
<text top="519" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref312">Azuma N, Uchida H, Kokubo T, et al. Factors</a></text>
<text top="532" left="345" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref312">in</a></text>
<text top="531" left="352" width="211" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref312">ﬂuencing wound healing of critical ischaemic foot</a></text>
<text top="546" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref312">after bypass surgery: is the angiosome important in</a></text>
<text top="559" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref312">selecting bypass target artery? Eur J Vasc Endovasc</a></text>
<text top="573" left="345" width="73" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref312">Surg. 2012;43:322</a></text>
<text top="571" left="418" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref312">–8</a></text>
<text top="573" left="428" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref312">.</a></text>
<text top="591" left="345" width="16" height="9" font="5">313.</text>
<text top="591" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref313">Fossaceca R, Guzzardi G, Cerini P, et al. Endo-</a></text>
<text top="605" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref313">vascular treatment of diabetic foot in a selected pop-</a></text>
<text top="618" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref313">ulation of patients with below-the-knee disease: is the</a></text>
<text top="632" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref313">angiosome model effective? Cardiovasc Intervent</a></text>
<text top="645" left="345" width="80" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref313">Radiol. 2013;36:637</a></text>
<text top="643" left="426" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref313">–44</a></text>
<text top="645" left="440" width="3" height="9" font="5">.</text>
<text top="664" left="345" width="17" height="9" font="5">314.</text>
<text top="664" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref314">Iida O, Soga Y, Hirano K, et al. Long-term results</a></text>
<text top="677" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref314">of direct and indirect endovascular revascularization</a></text>
<text top="691" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref314">based on the angiosome concept in patients with</a></text>
<text top="704" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref314">critical limb ischemia presenting with isolated below-</a></text>
<text top="718" left="345" width="173" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref314">the-knee lesions. J Vasc Surg. 2012;55:363</a></text>
<text top="716" left="518" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref314">–70</a></text>
<text top="718" left="533" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref314">.</a></text>
<text top="736" left="345" width="16" height="9" font="5">315.</text>
<text top="736" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref315">Kabra A, Suresh KR, Vivekanand V, et al. Outcomes</a></text>
<text top="750" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref315">of angiosome and non-angiosome targeted revascu-</a></text>
<text top="763" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref315">larization in critical lower limb ischemia. J Vasc Surg.</a></text>
<text top="777" left="345" width="45" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref315">2013;57:44</a></text>
<text top="775" left="390" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref315">–9</a></text>
<text top="777" left="400" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref315">.</a></text>
<text top="795" left="345" width="17" height="9" font="5">316.</text>
<text top="795" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref316">Kret MR, Cheng D, Azarbal AF, et al. Utility of</a></text>
<text top="809" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref316">direct angiosome revascularization and runoff scores in</a></text>
<text top="822" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref316">predicting outcomes in patients undergoing revascu-</a></text>
<text top="836" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref316">larization for critical limb ischemia. J Vasc Surg. 2014;</a></text>
<text top="849" left="345" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref316">59:121</a></text>
<text top="847" left="371" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref316">–8</a></text>
<text top="849" left="380" width="3" height="9" font="5">.</text>
<text top="868" left="345" width="16" height="9" font="5">317.</text>
<text top="868" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref317">Lejay A, Georg Y, Tartaglia E, et al. Long-term</a></text>
<text top="881" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref317">outcomes of direct and indirect below-the-knee open</a></text>
<text top="895" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref317">revascularization based on the angiosome concept in</a></text>
<text top="908" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref317">diabetic patients with critical limb ischemia. Ann Vasc</a></text>
<text top="921" left="345" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref317">Surg. 2014;28:983</a></text>
<text top="920" left="421" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref317">–9</a></text>
<text top="921" left="430" width="3" height="9" font="5">.</text>
<text top="940" left="345" width="17" height="9" font="5">318.</text>
<text top="940" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref318">Neville RF, Attinger CE, Bulan EJ, et al. Revascu-</a></text>
<text top="954" left="345" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref318">larization of a speci</a></text>
<text top="952" left="430" width="134" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref318">ﬁc angiosome for limb salvage:</a></text>
<text top="967" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref318">does the target artery matter? Ann Vasc Surg. 2009;</a></text>
<text top="981" left="345" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref318">23:367</a></text>
<text top="979" left="372" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref318">–73</a></text>
<text top="981" left="386" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref318">.</a></text>
<text top="999" left="345" width="17" height="9" font="5">319.</text>
<text top="999" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref319">Osawa S, Terashi H, Tsuji Y, et al. Importance of</a></text>
<text top="1013" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref319">the six angiosomes concept through arterial-arterial</a></text>
<text top="1026" left="345" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref319">connections in CLI. Int Angiol. 2013;32:375</a></text>
<text top="1024" left="518" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref319">–85</a></text>
<text top="1026" left="532" width="3" height="9" font="5">.</text>
<text top="1045" left="345" width="18" height="9" font="5">320.</text>
<text top="1045" left="366" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref320">Rashid H, Slim H, Zayed H, et al. The impact of</a></text>
<text top="1058" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref320">arterial pedal arch quality and angiosome revasculari-</a></text>
<text top="1072" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref320">zation on foot tissue loss healing and infrapopliteal</a></text>
<text top="1085" left="345" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref320">bypass outcome. J Vasc Surg. 2013;57:1219</a></text>
<text top="1083" left="520" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref320">–26</a></text>
<text top="1085" left="534" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref320">.</a></text>
<text top="143" left="583" width="16" height="9" font="5">321.</text>
<text top="143" left="602" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref321">Varela C, Acín F, de Haro J, et al. The role of foot</a></text>
<text top="156" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref321">collateral vessels on ulcer healing and limb salvage</a></text>
<text top="170" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref321">after successful endovascular and surgical distal pro-</a></text>
<text top="183" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref321">cedures according to an angiosome model. Vasc</a></text>
<text top="197" left="583" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref321">Endovascular Surg. 2010;44:654</a></text>
<text top="195" left="715" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref321">–60</a></text>
<text top="197" left="731" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref321">.</a></text>
<text top="215" left="583" width="17" height="9" font="5">322.</text>
<text top="215" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">Bosanquet DC, Glasbey JC, Williams IM, et al.</a></text>
<text top="229" left="583" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">Systematic</a></text>
<text top="229" left="636" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">review</a></text>
<text top="229" left="672" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">and</a></text>
<text top="229" left="696" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">meta-analysis</a></text>
<text top="229" left="761" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">of</a></text>
<text top="229" left="778" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">direct</a></text>
<text top="242" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">versus indirect angiosomal revascularisation of infra-</a></text>
<text top="256" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">popliteal arteries. Eur J Vasc Endovasc Surg. 2014;48:</a></text>
<text top="269" left="583" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">88</a></text>
<text top="268" left="594" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref322">–97</a></text>
<text top="269" left="608" width="3" height="9" font="5">.</text>
<text top="288" left="583" width="17" height="9" font="5">323.</text>
<text top="288" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref323">Biancari F, Juvonen T. Angiosome-targeted lower</a></text>
<text top="301" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref323">limb revascularization for ischemic foot wounds: sys-</a></text>
<text top="315" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref323">tematic review and meta-analysis. Eur J Vasc Endovasc</a></text>
<text top="328" left="583" width="72" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref323">Surg. 2014;47:517</a></text>
<text top="326" left="655" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref323">–22</a></text>
<text top="328" left="669" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref323">.</a></text>
<text top="347" left="583" width="18" height="9" font="5">324.</text>
<text top="347" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref324">Eugster T, Stierli P, Guerke L, et al. Present status</a></text>
<text top="360" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref324">of infrainguinal arterial bypass procedures following an</a></text>
<text top="373" left="583" width="89" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref324">all autogenous policy</a></text>
<text top="372" left="672" width="129" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref324">—long-term results of a single</a></text>
<text top="387" left="583" width="124" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref324">center. Swiss Surg. 2002;8:171</a></text>
<text top="385" left="707" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref324">–5</a></text>
<text top="387" left="715" width="3" height="9" font="5">.</text>
<text top="405" left="583" width="17" height="9" font="5">325.</text>
<text top="405" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref325">Reifsnyder T, Arhuidese IJ, Hicks CW, et al.</a></text>
<text top="419" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref325">Contemporary outcomes for open infrainguinal bypass</a></text>
<text top="432" left="583" width="206" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref325">in the endovascular era. Ann Vasc Surg. 2016;30:52</a></text>
<text top="431" left="789" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref325">–8</a></text>
<text top="432" left="799" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref325">.</a></text>
<text top="451" left="583" width="18" height="9" font="5">326.</text>
<text top="451" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref326">Chew DK, Conte MS, Donaldson MC, et al.</a></text>
<text top="464" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref326">Autogenous composite vein bypass graft for infrain-</a></text>
<text top="478" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref326">guinal arterial reconstruction. J Vasc Surg. 2001;33:</a></text>
<text top="491" left="583" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref326">259</a></text>
<text top="490" left="598" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref326">–64</a></text>
<text top="491" left="613" width="3" height="9" font="5">.</text>
<text top="510" left="583" width="17" height="9" font="5">327.</text>
<text top="510" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref327">Belkin M, Conte MS, Donaldson MC, et al.</a></text>
<text top="523" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref327">Preferred strategies for secondary infrainguinal bypass:</a></text>
<text top="537" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref327">lessons learned from 300 consecutive reoperations.</a></text>
<text top="550" left="583" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref327">J Vasc Surg. 1995;21:282</a></text>
<text top="548" left="684" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref327">–93</a></text>
<text top="550" left="698" width="3" height="9" font="5">.</text>
<text top="569" left="583" width="18" height="9" font="5">328.</text>
<text top="569" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref328">Fogle MA, Whittemore AD, Couch NP, et al.</a></text>
<text top="582" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref328">A comparison of in situ and reversed saphenous vein</a></text>
<text top="596" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref328">grafts for infrainguinal reconstruction. J Vasc Surg.</a></text>
<text top="609" left="583" width="41" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref328">1987;5:46</a></text>
<text top="607" left="624" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref328">–52</a></text>
<text top="609" left="637" width="3" height="9" font="5">.</text>
<text top="628" left="583" width="18" height="9" font="5">329.</text>
<text top="628" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref329">Leather RP, Karmody AM. In-situ saphenous vein</a></text>
<text top="641" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref329">arterial bypass for the treatment of limb ischemia. Adv</a></text>
<text top="654" left="583" width="72" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref329">Surg. 1986;19:175</a></text>
<text top="653" left="655" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref329">–219</a></text>
<text top="654" left="673" width="3" height="9" font="5">.</text>
<text top="673" left="583" width="18" height="9" font="5">330.</text>
<text top="673" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref330">Taylor LM, Edwards JM, Porter JM. Present status</a></text>
<text top="686" left="583" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref330">of reversed vein bypass grafting:</a></text>
<text top="685" left="718" width="83" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref330">ﬁve-year results of a</a></text>
<text top="700" left="583" width="161" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref330">modern series. J Vasc Surg. 1990;11:193</a></text>
<text top="698" left="744" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref330">–205</a></text>
<text top="700" left="764" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref330">.</a></text>
<text top="718" left="583" width="16" height="9" font="5">331.</text>
<text top="718" left="602" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref331">Nolan BW, De Martino RR, Stone DH, et al. Prior</a></text>
<text top="732" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref331">failed ipsilateral percutaneous endovascular interven-</a></text>
<text top="745" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref331">tion in patients with critical limb ischemia predicts poor</a></text>
<text top="759" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref331">outcome after lower extremity bypass. J Vasc Surg.</a></text>
<text top="772" left="583" width="49" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref331">2011;54:730</a></text>
<text top="771" left="632" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref331">–5</a></text>
<text top="772" left="641" width="3" height="9" font="5">.</text>
<text top="791" left="583" width="17" height="9" font="5">332.</text>
<text top="791" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref332">Santo VJ, Dargon P, Azarbal AF, et al. Lower ex-</a></text>
<text top="804" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref332">tremity autologous vein bypass for critical limb</a></text>
<text top="818" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref332">ischemia is not adversely affected by prior endovas-</a></text>
<text top="831" left="583" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref332">cular procedure. J Vasc Surg. 2014;60:129</a></text>
<text top="829" left="754" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref332">–35</a></text>
<text top="831" left="768" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref332">.</a></text>
<text top="850" left="583" width="17" height="9" font="5">333.</text>
<text top="850" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref333">Uhl C, Hock C, Betz T, et al. Pedal bypass surgery</a></text>
<text top="863" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref333">after crural endovascular intervention. J Vasc Surg.</a></text>
<text top="876" left="583" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref333">2014;59:1583</a></text>
<text top="875" left="638" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref333">–7</a></text>
<text top="876" left="646" width="3" height="9" font="5">.</text>
<text top="895" left="583" width="18" height="9" font="5">334.</text>
<text top="895" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref334">Nishibe T, Maruno K, Iwahori A, et al. The role of</a></text>
<text top="908" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref334">common femoral artery endarterectomy in the endo-</a></text>
<text top="922" left="583" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref334">vascular era. Ann Vasc Surg. 2015;29:1501</a></text>
<text top="920" left="753" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref334">–7</a></text>
<text top="922" left="762" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref334">.</a></text>
<text top="940" left="583" width="17" height="9" font="5">335.</text>
<text top="940" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref335">Okadome J, Matsumoto T, Aoyagi Y, et al. Long-</a></text>
<text top="954" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref335">term results of a hybrid revascularization procedure for</a></text>
<text top="967" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref335">peripheral arterial disease. Fukuoka Igaku Zasshi. 2015;</a></text>
<text top="981" left="583" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref335">106:254</a></text>
<text top="979" left="616" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref335">–61</a></text>
<text top="981" left="629" width="3" height="9" font="5">.</text>
<text top="999" left="583" width="18" height="9" font="5">336.</text>
<text top="999" left="604" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref336">Starodubtsev V, Karpenko A, Ignatenko P. Hybrid</a></text>
<text top="1013" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref336">and open surgery of Trans-Atlantic Inter-Society II type</a></text>
<text top="1026" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref336">C and D iliac occlusive disease and concomitant lesion</a></text>
<text top="1040" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref336">of common femoral artery. Int Angiol. 2016;35:</a></text>
<text top="1053" left="583" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref336">484</a></text>
<text top="1051" left="599" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref336">–91</a></text>
<text top="1053" left="613" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref336">.</a></text>
<text top="1072" left="583" width="17" height="9" font="5">337.</text>
<text top="1072" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref337">Kasemi H, Marino M, Dionisi CP, et al. Seven-year</a></text>
<text top="1085" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref337">approach evolution of the aortoiliac occlusive disease</a></text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="18" height="9" font="5">e116</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref337">endovascular treatment. Ann Vasc Surg. 2016;30:</a></text>
<text top="156" left="63" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref337">277</a></text>
<text top="155" left="77" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref337">–85</a></text>
<text top="156" left="91" width="3" height="9" font="5">.</text>
<text top="175" left="63" width="18" height="9" font="5">338.</text>
<text top="175" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref338">Bredahl K, Jensen LP, Schroeder TV, et al. Mor-</a></text>
<text top="188" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref338">tality and complications after aortic bifurcated bypass</a></text>
<text top="202" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref338">procedures for chronic aortoiliac occlusive disease.</a></text>
<text top="215" left="63" width="96" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref338">J Vasc Surg. 2015;62:75</a></text>
<text top="214" left="159" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref338">–82</a></text>
<text top="215" left="174" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref338">.</a></text>
<text top="234" left="63" width="18" height="9" font="5">339.</text>
<text top="234" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref339">Kobayashi N, Hirano K, Nakano M, et al. Prognosis</a></text>
<text top="247" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref339">of critical limb ischemia patients with tissue loss after</a></text>
<text top="261" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref339">achievement of complete wound healing by endovas-</a></text>
<text top="274" left="63" width="159" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref339">cular therapy. J Vasc Surg. 2015;61:951</a></text>
<text top="273" left="221" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref339">–9</a></text>
<text top="274" left="231" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref339">.</a></text>
<text top="293" left="63" width="19" height="9" font="5">340.</text>
<text top="293" left="85" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref340">Armstrong DG, Bharara M, White M, et al. The</a></text>
<text top="306" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref340">impact and outcomes of establishing an integrated</a></text>
<text top="320" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref340">interdisciplinary surgical team to care for the diabetic</a></text>
<text top="333" left="63" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref340">foot. Diabetes Metab Res Rev. 2012;28:514</a></text>
<text top="331" left="237" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref340">–8</a></text>
<text top="333" left="247" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref340">.</a></text>
<text top="352" left="63" width="17" height="9" font="5">341.</text>
<text top="352" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref341">Chung J, Modrall JG, Ahn C, et al. Multidisci-</a></text>
<text top="365" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref341">plinary care improves amputation-free survival in pa-</a></text>
<text top="379" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref341">tients with chronic critical limb ischemia. J Vasc Surg.</a></text>
<text top="392" left="63" width="48" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref341">2015;61:162</a></text>
<text top="390" left="111" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref341">–9</a></text>
<text top="392" left="121" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref341">.</a></text>
<text top="410" left="63" width="18" height="9" font="5">342.</text>
<text top="410" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref342">García-Morales E, Lázaro-Martínez JL, Aragón-</a></text>
<text top="424" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref342">Sánchez J, et al. Surgical complications associated with</a></text>
<text top="437" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref342">primary closure in patients with diabetic foot osteo-</a></text>
<text top="451" left="63" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref342">myelitis. Diabet Foot Ankle. 2012;3:19000</a></text>
<text top="451" left="234" width="3" height="9" font="5">.</text>
<text top="469" left="63" width="18" height="9" font="5">343.</text>
<text top="469" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref343">Berceli SA, Brown JE, Irwin PB, et al. Clinical</a></text>
<text top="483" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref343">outcomes after closed, staged, and open forefoot</a></text>
<text top="496" left="63" width="160" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref343">amputations. J Vasc Surg. 2006;44:347</a></text>
<text top="495" left="223" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref343">–51</a></text>
<text top="496" left="236" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref343">.</a></text>
<text top="515" left="63" width="19" height="9" font="5">344.</text>
<text top="515" left="85" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref344">Shaikh N, Vaughan P, Varty K, et al. Outcome of</a></text>
<text top="528" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref344">limited forefoot amputation with primary closure in</a></text>
<text top="542" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref344">patients with diabetes. Bone Joint J. 2013;95-B:</a></text>
<text top="555" left="63" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref344">1083</a></text>
<text top="554" left="83" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref344">–7</a></text>
<text top="555" left="92" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref344">.</a></text>
<text top="574" left="63" width="18" height="9" font="5">345.</text>
<text top="574" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref345">Armstrong DG, Lavery LA, Diabetic Foot Study</a></text>
<text top="587" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref345">Consortium. Negative pressure wound therapy after</a></text>
<text top="601" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref345">partial diabetic foot amputation: a multicentre, rand-</a></text>
<text top="614" left="63" width="192" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref345">omised controlled trial. Lancet. 2005;366:1704</a></text>
<text top="612" left="254" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref345">–10</a></text>
<text top="614" left="268" width="3" height="9" font="5">.</text>
<text top="633" left="63" width="19" height="9" font="5">346.</text>
<text top="633" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref346">Sepúlveda G, Espíndola M, Maureira M, et al.</a></text>
<text top="646" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref346">[Negative-pressure wound therapy versus standard</a></text>
<text top="659" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref346">wound dressing in the treatment of diabetic foot</a></text>
<text top="673" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref346">amputation. A randomised controlled trial]. Cir Esp.</a></text>
<text top="686" left="63" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref346">2009;86:171</a></text>
<text top="685" left="114" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref346">–7</a></text>
<text top="686" left="122" width="3" height="9" font="5">.</text>
<text top="705" left="63" width="18" height="9" font="5">347.</text>
<text top="705" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref347">Barshes NR, Gold B, Garcia A, et al. Minor</a></text>
<text top="718" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref347">amputation and palliative wound care as a strategy to</a></text>
<text top="732" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref347">avoid major amputation in patients with foot infections</a></text>
<text top="745" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref347">and severe peripheral arterial disease. Int J Low Extrem</a></text>
<text top="759" left="63" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref347">Wounds. 2014;13:211</a></text>
<text top="757" left="146" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref347">–9</a></text>
<text top="759" left="156" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref347">.</a></text>
<text top="777" left="63" width="19" height="9" font="5">348.</text>
<text top="777" left="84" width="108" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref348">Fikri R, Bicknell CD, Bloom</a></text>
<text top="776" left="192" width="89" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref348">ﬁeld LM, et al. Await-</a></text>
<text top="791" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref348">ing autoamputation: a primary management strategy</a></text>
<text top="804" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref348">for toe gangrene in diabetic foot disease. Diabetes</a></text>
<text top="818" left="63" width="76" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref348">Care. 2011;34:e134</a></text>
<text top="818" left="138" width="3" height="9" font="5">.</text>
<text top="836" left="63" width="218" height="9" font="5">349. Centre for Clinical practice at NICE (UK). Diabetic</text>
<text top="850" left="63" width="218" height="9" font="5">Foot Problems: Inpatient Management of Diabetic Foot</text>
<text top="863" left="63" width="218" height="9" font="5">Problems. London: National Institute for Health and</text>
<text top="876" left="63" width="186" height="9" font="5">Clinical Excellence (UK), 2011. Available at:</text>
<text top="876" left="254" width="27" height="9" font="6"><a href="http://www.ncbi.nlm.nih.gov/books/NBK82350/">http://</a></text>
<text top="890" left="63" width="167" height="9" font="6"><a href="http://www.ncbi.nlm.nih.gov/books/NBK82350/">www.ncbi.nlm.nih.gov/books/NBK82350/</a></text>
<text top="890" left="230" width="3" height="9" font="5"><a href="http://www.ncbi.nlm.nih.gov/books/NBK82350/">.</a></text>
<text top="890" left="245" width="36" height="9" font="5">Accessed</text>
<text top="903" left="63" width="84" height="9" font="5">September 25, 2016.</text>
<text top="922" left="63" width="18" height="9" font="5">350.</text>
<text top="922" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref350">Lipsky BA, Aragón-Sánchez J, Diggle M, et al.</a></text>
<text top="935" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref350">IWGDF guidance on the diagnosis and management of</a></text>
<text top="949" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref350">foot infections in persons with diabetes. Diabetes</a></text>
<text top="962" left="63" width="142" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref350">Metab Res Rev. 2016;32 suppl 1:45</a></text>
<text top="961" left="205" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref350">–74</a></text>
<text top="962" left="219" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref350">.</a></text>
<text top="981" left="63" width="16" height="9" font="5">351.</text>
<text top="981" left="82" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref351">Bus SA, van Deursen RW, Armstrong DG, et al.</a></text>
<text top="994" left="63" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref351">Footwear and of</a></text>
<text top="993" left="130" width="151" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref351">ﬂoading interventions to prevent and</a></text>
<text top="1008" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref351">heal foot ulcers and reduce plantar pressure in patients</a></text>
<text top="1021" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref351">with diabetes: a systematic review. Diabetes Metab Res</a></text>
<text top="1035" left="63" width="98" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref351">Rev. 2016;32 suppl 1:99</a></text>
<text top="1033" left="161" width="17" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref351">–118</a></text>
<text top="1035" left="178" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref351">.</a></text>
<text top="1053" left="63" width="17" height="9" font="5">352.</text>
<text top="1053" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref352">Game FL, Apelqvist J, Attinger C, et al. IWGDF</a></text>
<text top="1067" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref352">guidance on use of interventions to enhance the</a></text>
<text top="1080" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref352">healing of chronic ulcers of the foot in diabetes. Dia-</a></text>
<text top="1093" left="63" width="166" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref352">betes Metab Res Rev. 2016;32 suppl 1:75</a></text>
<text top="1092" left="229" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref352">–83</a></text>
<text top="1093" left="243" width="3" height="9" font="5">.</text>
<text top="143" left="301" width="17" height="9" font="5">353.</text>
<text top="143" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">Moran PS, Teljeur C, Harrington P, et al.</a></text>
<text top="156" left="301" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">A</a></text>
<text top="156" left="315" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">systematic</a></text>
<text top="156" left="367" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">review</a></text>
<text top="156" left="402" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">of</a></text>
<text top="156" left="420" width="48" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">intermittent</a></text>
<text top="156" left="477" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">pneumatic</a></text>
<text top="170" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">compression for critical limb ischaemia. Vasc Med.</a></text>
<text top="183" left="301" width="45" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">2015;20:41</a></text>
<text top="182" left="345" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref353">–50</a></text>
<text top="183" left="360" width="3" height="9" font="5">.</text>
<text top="202" left="301" width="18" height="9" font="5">354.</text>
<text top="202" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">Abidia A, Laden G, Kuhan G, et al. The role of</a></text>
<text top="216" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">hyperbaric oxygen therapy in ischaemic diabetic lower</a></text>
<text top="229" left="301" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">extremity</a></text>
<text top="229" left="351" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">ulcers:</a></text>
<text top="229" left="389" width="4" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">a</a></text>
<text top="229" left="405" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">double-blind</a></text>
<text top="229" left="469" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">randomised-</a></text>
<text top="243" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">controlled trial. Eur J Vasc Endovasc Surg. 2003;25:</a></text>
<text top="256" left="301" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">513</a></text>
<text top="255" left="314" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref354">–8</a></text>
<text top="256" left="323" width="3" height="9" font="5">.</text>
<text top="275" left="301" width="17" height="9" font="5">355.</text>
<text top="275" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref355">Kranke P, Bennett MH, Martyn-St James M, et al.</a></text>
<text top="289" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref355">Hyperbaric oxygen therapy for chronic wounds.</a></text>
<text top="302" left="301" width="184" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref355">Cochrane Database Syst Rev. 2012:CD004123</a></text>
<text top="302" left="484" width="3" height="9" font="5">.</text>
<text top="321" left="301" width="18" height="9" font="5">356.</text>
<text top="321" left="321" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref356">Ruffolo AJ, Romano M, Ciapponi A. Prostanoids</a></text>
<text top="335" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref356">for critical limb ischaemia. Cochrane Database Syst</a></text>
<text top="348" left="301" width="88" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref356">Rev. 2010:CD006544</a></text>
<text top="348" left="389" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref356">.</a></text>
<text top="367" left="301" width="17" height="9" font="5">357.</text>
<text top="367" left="320" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref357">Baril DT, Patel VI, Judelson DR, et al. Outcomes of</a></text>
<text top="381" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref357">lower extremity bypass performed for acute limb</a></text>
<text top="394" left="301" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref357">ischemia. J Vasc Surg. 2013;58:949</a></text>
<text top="392" left="443" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref357">–56</a></text>
<text top="394" left="458" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref357">.</a></text>
<text top="413" left="301" width="18" height="9" font="5">358.</text>
<text top="413" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref358">Londero LS, Nørgaard B, Houlind K. Patient delay</a></text>
<text top="427" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref358">is the main cause of treatment delay in acute limb</a></text>
<text top="440" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref358">ischemia: an investigation of pre- and in-hospital time</a></text>
<text top="454" left="301" width="154" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref358">delay. World J Emerg Surg. 2014;9:56</a></text>
<text top="454" left="455" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref358">.</a></text>
<text top="473" left="301" width="18" height="9" font="5">359.</text>
<text top="473" left="321" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref359">Manojlovi</a></text>
<text top="470" left="360" width="159" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref359">c V, Popovic V, Nikolic D, et al. Analysis</a></text>
<text top="486" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref359">of associated diseases in patients with acute critical</a></text>
<text top="499" left="301" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref359">lower limb ischemia. Med Pregl. 2013;66:41</a></text>
<text top="498" left="477" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref359">–5</a></text>
<text top="499" left="486" width="3" height="9" font="5">.</text>
<text top="518" left="301" width="19" height="9" font="5">360.</text>
<text top="518" left="322" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref360">Duval S, Keo HH, Oldenburg NC, et al. The impact</a></text>
<text top="532" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref360">of prolonged lower limb ischemia on amputation,</a></text>
<text top="545" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref360">mortality, and functional status: the FRIENDS registry.</a></text>
<text top="559" left="301" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref360">Am Heart J. 2014;168:577</a></text>
<text top="557" left="405" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref360">–87</a></text>
<text top="559" left="420" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref360">.</a></text>
<text top="578" left="301" width="17" height="9" font="5">361.</text>
<text top="578" left="320" width="67" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref361">Morris-Stiff G, D</a></text>
<text top="576" left="387" width="132" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref361">’Souza J, Raman S, et al. Update</a></text>
<text top="591" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref361">experience of surgery for acute limb ischaemia in a</a></text>
<text top="605" left="301" width="98" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref361">district general hospital</a></text>
<text top="603" left="399" width="120" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref361">—are we getting any better?</a></text>
<text top="618" left="301" width="142" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref361">Ann R Coll Surg Engl. 2009;91:637</a></text>
<text top="617" left="443" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref361">–40</a></text>
<text top="618" left="458" width="3" height="9" font="5">.</text>
<text top="637" left="301" width="18" height="9" font="5">362.</text>
<text top="637" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref362">Blaisdell FW. The pathophysiology of skeletal</a></text>
<text top="651" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref362">muscle ischemia and the reperfusion syndrome: a re-</a></text>
<text top="664" left="301" width="146" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref362">view. Cardiovasc Surg. 2002;10:620</a></text>
<text top="663" left="447" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref362">–30</a></text>
<text top="664" left="462" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref362">.</a></text>
<text top="683" left="301" width="18" height="9" font="5">363.</text>
<text top="683" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref363">Saarinen E, Vuorisalo S, Kauhanen P, et al. The</a></text>
<text top="697" left="301" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref363">bene</a></text>
<text top="695" left="320" width="199" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref363">ﬁt of revascularization in nonagenarians with</a></text>
<text top="710" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref363">lower limb ischemia is limited by high mortality. Eur J</a></text>
<text top="724" left="301" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref363">Vasc Endovasc Surg. 2015;49:420</a></text>
<text top="722" left="438" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref363">–5</a></text>
<text top="724" left="447" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref363">.</a></text>
<text top="743" left="301" width="19" height="9" font="5">364.</text>
<text top="743" left="322" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref364">Blaisdell FW, Steele M, Allen RE. Management of</a></text>
<text top="756" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref364">acute lower extremity arterial ischemia due to embo-</a></text>
<text top="770" left="301" width="174" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref364">lism and thrombosis. Surgery. 1978;84:822</a></text>
<text top="768" left="474" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref364">–34</a></text>
<text top="770" left="488" width="3" height="9" font="5">.</text>
<text top="789" left="301" width="18" height="9" font="5">365.</text>
<text top="789" left="321" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref365">Altoijry A, MacKenzie KS, Corriveau MM, et al.</a></text>
<text top="802" left="301" width="66" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref365">Heparin-induced</a></text>
<text top="802" left="376" width="73" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref365">thrombocytopenia</a></text>
<text top="802" left="459" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref365">causing</a></text>
<text top="802" left="499" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref365">graft</a></text>
<text top="816" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref365">thrombosis and bowel ischemia postendovascular</a></text>
<text top="829" left="301" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref365">aneurysm repair. J Vasc Surg. 2015;61:234</a></text>
<text top="827" left="471" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref365">–6</a></text>
<text top="829" left="481" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref365">.</a></text>
<text top="848" left="301" width="19" height="9" font="5">366.</text>
<text top="848" left="322" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref366">Turba UC, Bozlar U, Simsek S. Catheter-directed</a></text>
<text top="861" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref366">thrombolysis of acute lower extremity arterial throm-</a></text>
<text top="875" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref366">bosis in a patient with heparin-induced thrombocyto-</a></text>
<text top="888" left="301" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref366">penia. Catheter Cardiovasc Interv. 2007;70:1046</a></text>
<text top="887" left="497" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref366">–50</a></text>
<text top="888" left="512" width="3" height="9" font="5">.</text>
<text top="907" left="301" width="18" height="9" font="5">367.</text>
<text top="907" left="321" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref367">Comerota AJ, Weaver FA, Hosking JD, et al. Re-</a></text>
<text top="921" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref367">sults of a prospective, randomized trial of surgery</a></text>
<text top="934" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref367">versus thrombolysis for occluded lower extremity</a></text>
<text top="948" left="301" width="159" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref367">bypass grafts. Am J Surg. 1996;172:105</a></text>
<text top="946" left="460" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref367">–12</a></text>
<text top="948" left="472" width="3" height="9" font="5">.</text>
<text top="967" left="301" width="19" height="9" font="5">368.</text>
<text top="967" left="322" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref368">Dif</a></text>
<text top="965" left="334" width="185" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref368">ﬁn DC, Kandarpa K. Assessment of peripheral</a></text>
<text top="980" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref368">intraarterial thrombolysis versus surgical revasculari-</a></text>
<text top="994" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref368">zation in acute lower-limb ischemia: a review of limb-</a></text>
<text top="1007" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref368">salvage and mortality statistics. J Vasc Interv Radiol.</a></text>
<text top="1021" left="301" width="40" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref368">1996;7:57</a></text>
<text top="1019" left="340" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref368">–63</a></text>
<text top="1021" left="355" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref368">.</a></text>
<text top="1040" left="301" width="19" height="9" font="5">369.</text>
<text top="1040" left="322" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref369">Ouriel K, Veith FJ, Sasahara AA. A comparison of</a></text>
<text top="1053" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref369">recombinant urokinase with vascular surgery as initial</a></text>
<text top="1067" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref369">treatment for acute arterial occlusion of the legs.</a></text>
<text top="1080" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref369">Thrombolysis or Peripheral Arterial Surgery (TOPAS)</a></text>
<text top="1093" left="301" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref369">Investigators. N Engl J Med. 1998;338:1105</a></text>
<text top="1092" left="477" width="11" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref369">–11</a></text>
<text top="1093" left="488" width="3" height="9" font="5">.</text>
<text top="143" left="538" width="18" height="9" font="5">370.</text>
<text top="143" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref370">Results of a prospective randomized trial evalu-</a></text>
<text top="156" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref370">ating surgery versus thrombolysis for ischemia of the</a></text>
<text top="170" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref370">lower extremity. The STILE trial. Ann Surg. 1994;220:</a></text>
<text top="183" left="538" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref370">266</a></text>
<text top="182" left="554" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref370">–8</a></text>
<text top="183" left="564" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref370">.</a></text>
<text top="203" left="538" width="16" height="9" font="5">371.</text>
<text top="203" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref371">Ouriel K, Shortell CK, DeWeese JA, et al.</a></text>
<text top="216" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref371">A comparison of thrombolytic therapy with operative</a></text>
<text top="230" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref371">revascularization in the initial treatment of acute</a></text>
<text top="243" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref371">peripheral arterial ischemia. J Vasc Surg. 1994;19:</a></text>
<text top="257" left="538" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref371">1021</a></text>
<text top="255" left="557" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref371">–30</a></text>
<text top="257" left="571" width="3" height="9" font="5">.</text>
<text top="276" left="538" width="17" height="9" font="5">372.</text>
<text top="276" left="558" width="77" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref372">Eliason JL, Wake</a></text>
<text top="274" left="635" width="122" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref372">ﬁeld TW. Metabolic conse-</a></text>
<text top="289" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref372">quences of acute limb ischemia and their clinical im-</a></text>
<text top="303" left="538" width="163" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref372">plications. Semin Vasc Surg. 2009;22:29</a></text>
<text top="301" left="702" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref372">–33</a></text>
<text top="303" left="715" width="3" height="9" font="5">.</text>
<text top="322" left="538" width="17" height="9" font="5">373.</text>
<text top="322" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref373">Henke PK. Contemporary management of acute</a></text>
<text top="336" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref373">limb ischemia: factors associated with amputation and</a></text>
<text top="349" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref373">in-hospital mortality. Semin Vasc Surg. 2009;22:</a></text>
<text top="363" left="538" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref373">34</a></text>
<text top="361" left="548" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref373">–40</a></text>
<text top="363" left="564" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref373">.</a></text>
<text top="382" left="538" width="18" height="9" font="5">374.</text>
<text top="382" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">Ansel GM, Botti CF, Silver MJ. Treatment of acute</a></text>
<text top="396" left="538" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">limb</a></text>
<text top="396" left="565" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">ischemia</a></text>
<text top="396" left="608" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">with</a></text>
<text top="396" left="635" width="4" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">a</a></text>
<text top="396" left="649" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">percutaneous</a></text>
<text top="396" left="712" width="44" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">mechanical</a></text>
<text top="409" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">thrombectomy-based endovascular approach: 5-year</a></text>
<text top="422" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">limb salvage and survival results from a single center</a></text>
<text top="436" left="538" width="192" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">series. Catheter Cardiovasc Interv. 2008;72:325</a></text>
<text top="434" left="730" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">–30</a></text>
<text top="436" left="745" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref374">.</a></text>
<text top="455" left="538" width="17" height="9" font="5">375.</text>
<text top="455" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref375">Gupta R, Hennebry TA. Percutaneous isolated</a></text>
<text top="469" left="538" width="87" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref375">pharmaco-mechanical</a></text>
<text top="469" left="642" width="114" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref375">thrombolysis-thrombectomy</a></text>
<text top="482" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref375">system for the management of acute arterial limb</a></text>
<text top="496" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref375">ischemia: 30-day results from a single-center experi-</a></text>
<text top="509" left="538" width="188" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref375">ence. Catheter Cardiovasc Interv. 2012;80:636</a></text>
<text top="508" left="726" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref375">–43</a></text>
<text top="509" left="741" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref375">.</a></text>
<text top="529" left="538" width="18" height="9" font="5">376.</text>
<text top="529" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref376">Silva JA, Ramee SR, Collins TJ, et al. Rheolytic</a></text>
<text top="542" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref376">thrombectomy in the treatment of acute limb-</a></text>
<text top="555" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref376">threatening ischemia: immediate results and six-month</a></text>
<text top="569" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref376">follow-up of the multicenter AngioJet registry. Possis</a></text>
<text top="582" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref376">Peripheral AngioJet Study AngioJet Investigators.</a></text>
<text top="596" left="538" width="153" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref376">Cathet Cardiovasc Diagn. 1998;45:386</a></text>
<text top="594" left="691" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref376">–93</a></text>
<text top="596" left="706" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref376">.</a></text>
<text top="615" left="538" width="17" height="9" font="5">377.</text>
<text top="615" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref377">Taha AG, Byrne RM, Avgerinos ED, et al.</a></text>
<text top="629" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref377">Comparative effectiveness of endovascular versus</a></text>
<text top="642" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref377">surgical revascularization for acute lower extremity</a></text>
<text top="656" left="538" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref377">ischemia. J Vasc Surg. 2015;61:147</a></text>
<text top="654" left="677" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref377">–54</a></text>
<text top="656" left="692" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref377">.</a></text>
<text top="675" left="538" width="18" height="9" font="5">378.</text>
<text top="675" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref378">Leung DA, Blitz LR, Nelson T, et al. Rheolytic</a></text>
<text top="688" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref378">pharmacomechanical thrombectomy for the manage-</a></text>
<text top="702" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref378">ment of acute limb ischemia: results from the PEARL</a></text>
<text top="715" left="538" width="159" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref378">Registry. J Endovasc Ther. 2015;22:546</a></text>
<text top="714" left="698" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref378">–57</a></text>
<text top="715" left="711" width="3" height="9" font="5">.</text>
<text top="735" left="538" width="18" height="9" font="5">379.</text>
<text top="735" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref379">Zaraca F, Ponzoni A, Sbraga P, et al. Factors</a></text>
<text top="748" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref379">affecting long-term outcomes after thromboembolec-</a></text>
<text top="762" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref379">tomy for acute lower limb ischemia. Minerva Chir.</a></text>
<text top="775" left="538" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref379">2012;67:49</a></text>
<text top="774" left="584" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref379">–57</a></text>
<text top="775" left="597" width="3" height="9" font="5">.</text>
<text top="795" left="538" width="19" height="9" font="5">380.</text>
<text top="795" left="560" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref380">Ender Topal A, Nesimi Eren M, Celik Y. Manage-</a></text>
<text top="808" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref380">ment of non-traumatic acute limb ischemia and pre-</a></text>
<text top="821" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref380">dictors of outcome in 270 thrombembolectomy cases.</a></text>
<text top="835" left="538" width="93" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref380">Int Angiol. 2011;30:172</a></text>
<text top="833" left="631" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref380">–80</a></text>
<text top="835" left="647" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref380">.</a></text>
<text top="854" left="538" width="17" height="9" font="5">381.</text>
<text top="854" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref381">Fogarty TJ, Cranley JJ, Krause RJ, et al. A method</a></text>
<text top="868" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref381">for extraction of arterial emboli and thrombi. Surg</a></text>
<text top="881" left="538" width="119" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref381">Gynecol Obstet. 1963;116:241</a></text>
<text top="880" left="658" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref381">–4</a></text>
<text top="881" left="667" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref381">.</a></text>
<text top="901" left="538" width="18" height="9" font="5">382.</text>
<text top="901" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref382">Creager MA, Kaufman JA, Conte MS. Clinical</a></text>
<text top="914" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref382">practice. Acute limb ischemia. N Engl J Med. 2012;366:</a></text>
<text top="928" left="538" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref382">2198</a></text>
<text top="926" left="558" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref382">–206</a></text>
<text top="928" left="579" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref382">.</a></text>
<text top="947" left="538" width="18" height="9" font="5">383.</text>
<text top="947" left="559" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref383">O</a></text>
<text top="945" left="565" width="191" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref383">’Connell JB, Quiñones-Baldrich WJ. Proper</a></text>
<text top="960" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref383">evaluation and management of acute embolic versus</a></text>
<text top="974" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref383">thrombotic limb ischemia. Semin Vasc Surg. 2009;22:</a></text>
<text top="987" left="538" width="10" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref383">10</a></text>
<text top="986" left="548" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref383">–6</a></text>
<text top="987" left="558" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref383">.</a></text>
<text top="1007" left="538" width="19" height="9" font="5">384.</text>
<text top="1007" left="560" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref384">Schrijver AM, Reijnen MM, van Oostayen JA, et al.</a></text>
<text top="1020" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref384">Initial results of catheter-directed ultrasound-acceler-</a></text>
<text top="1034" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref384">ated thrombolysis for thromboembolic obstructions of</a></text>
<text top="1047" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref384">the aortofemoral arteries: a feasibility study. Car-</a></text>
<text top="1061" left="538" width="152" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref384">diovasc Intervent Radiol. 2012;35:279</a></text>
<text top="1059" left="690" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref384">–85</a></text>
<text top="1061" left="705" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref384">.</a></text>
<text top="1080" left="538" width="18" height="9" font="5">385.</text>
<text top="1080" left="559" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref385">Schrijver A, Vos J, Hoksbergen AW, et al. Ultra-</a></text>
<text top="1093" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref385">sound-accelerated thrombolysis for lower extremity</a></text>
<text top="54" left="63" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="54" left="663" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="69" left="63" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="157" width="19" height="10" font="7">– 1 2 6</text>
<text top="69" left="559" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="53" left="791" width="17" height="9" font="5">e117</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref385">ischemia: multicenter experience and literature review.</a></text>
<text top="156" left="108" width="160" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref385">J Cardiovasc Surg (Torino). 2011;52:467</a></text>
<text top="155" left="268" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref385">–76</a></text>
<text top="156" left="282" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref385">.</a></text>
<text top="177" left="108" width="19" height="9" font="5">386.</text>
<text top="177" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref386">Schrijver AM, Reijnen MM, van Oostayen JA, et al.</a></text>
<text top="190" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref386">Dutch randomized trial comparing standard catheter-</a></text>
<text top="203" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref386">directed thrombolysis versus ultrasound-accelerated</a></text>
<text top="217" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref386">thrombolysis for thromboembolic infrainguinal dis-</a></text>
<text top="230" left="108" width="212" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref386">ease (DUET): design and rationale. Trials. 2011;12:20</a></text>
<text top="230" left="320" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref386">.</a></text>
<text top="250" left="108" width="18" height="9" font="5">387.</text>
<text top="250" left="128" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref387">Bekwelem W, Connolly SJ, Halperin JL, et al.</a></text>
<text top="264" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref387">Extracranial systemic embolic events in patients with</a></text>
<text top="277" left="108" width="72" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref387">nonvalvular atrial</a></text>
<text top="276" left="184" width="142" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref387">ﬁbrillation: incidence, risk factors,</a></text>
<text top="291" left="108" width="164" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref387">and outcomes. Circulation. 2015;132:796</a></text>
<text top="289" left="271" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref387">–803</a></text>
<text top="291" left="292" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref387">.</a></text>
<text top="311" left="108" width="19" height="9" font="5">388.</text>
<text top="311" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref388">Baker JD, Dix DE. Variability of Doppler ankle</a></text>
<text top="324" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref388">pressures with arterial occlusive disease: an evaluation</a></text>
<text top="338" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref388">of ankle index and brachial-ankle pressure gradient.</a></text>
<text top="351" left="108" width="85" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref388">Surgery. 1981;89:134</a></text>
<text top="349" left="193" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref388">–7</a></text>
<text top="351" left="201" width="3" height="9" font="5">.</text>
<text top="371" left="108" width="19" height="9" font="5">389.</text>
<text top="371" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref389">Jongsma H, Bekken JA, van Buchem F, et al.</a></text>
<text top="385" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref389">Secondary interventions in patients with autologous</a></text>
<text top="398" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref389">infrainguinal bypass grafts strongly improve patency</a></text>
<text top="411" left="108" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref389">rates. J Vasc Surg. 2016;63:385</a></text>
<text top="410" left="236" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref389">–90</a></text>
<text top="411" left="251" width="3" height="9" font="5">.</text>
<text top="431" left="108" width="19" height="9" font="5">390.</text>
<text top="431" left="129" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref390">Carter A, Murphy MO, Halka AT, et al. The natural</a></text>
<text top="445" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref390">history of stenoses within lower limb arterial bypass</a></text>
<text top="458" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref390">grafts using a graft surveillance program. Ann Vasc</a></text>
<text top="472" left="108" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref390">Surg. 2007;21:695</a></text>
<text top="470" left="182" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref390">–703</a></text>
<text top="472" left="202" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref390">.</a></text>
<text top="492" left="108" width="17" height="9" font="5">391.</text>
<text top="492" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref391">Ihlberg L, Luther M, Albäck A, et al. Does a</a></text>
<text top="505" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref391">completely accomplished duplex-based surveillance</a></text>
<text top="519" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref391">prevent vein-graft failure? Eur J Vasc Endovasc Surg.</a></text>
<text top="532" left="108" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref391">1999;18:395</a></text>
<text top="531" left="158" width="22" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref391">–400</a></text>
<text top="532" left="179" width="3" height="9" font="5">.</text>
<text top="552" left="108" width="18" height="9" font="5">392.</text>
<text top="552" left="128" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref392">Westerband A, Mills JL, Kistler S, et al. Prospec-</a></text>
<text top="566" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref392">tive validation of threshold criteria for intervention in</a></text>
<text top="579" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref392">infrainguinal vein grafts undergoing duplex surveil-</a></text>
<text top="593" left="108" width="133" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref392">lance. Ann Vasc Surg. 1997;11:44</a></text>
<text top="591" left="240" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref392">–8</a></text>
<text top="593" left="250" width="3" height="9" font="5">.</text>
<text top="613" left="108" width="18" height="9" font="5">393.</text>
<text top="613" left="128" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref393">Lundell A, Lindblad B, Bergqvist D, et al. Femo-</a></text>
<text top="626" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref393">ropopliteal-crural graft patency is improved by an</a></text>
<text top="639" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref393">intensive surveillance program: a prospective ran-</a></text>
<text top="653" left="108" width="160" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref393">domized study. J Vasc Surg. 1995;21:26</a></text>
<text top="651" left="268" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref393">–33</a></text>
<text top="653" left="281" width="3" height="9" font="5">.</text>
<text top="673" left="108" width="19" height="9" font="5">394.</text>
<text top="673" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref394">Mills JL, Harris EJ, Taylor LM, et al. The impor-</a></text>
<text top="686" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref394">tance of routine surveillance of distal bypass grafts</a></text>
<text top="143" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref394">with duplex scanning: a study of 379 reversed vein</a></text>
<text top="156" left="345" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref394">grafts. J Vasc Surg. 1990;12:379</a></text>
<text top="155" left="476" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref394">–86</a></text>
<text top="156" left="491" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref394">.</a></text>
<text top="175" left="345" width="18" height="9" font="5">395.</text>
<text top="175" left="366" width="159" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref395">Bandyk DF, Cato RF, Towne JB. A low</a></text>
<text top="173" left="529" width="34" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref395">ﬂow ve-</a></text>
<text top="188" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref395">locity predicts failure of femoropopliteal and femo-</a></text>
<text top="202" left="345" width="178" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref395">rotibial bypass grafts. Surgery. 1985;98:799</a></text>
<text top="200" left="524" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref395">–809</a></text>
<text top="202" left="545" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref395">.</a></text>
<text top="220" left="345" width="19" height="9" font="5">396.</text>
<text top="220" left="367" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref396">Davies AH, Hawdon AJ, Sydes MR, et al. Is duplex</a></text>
<text top="234" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref396">surveillance of value after leg vein bypass grafting?</a></text>
<text top="247" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref396">Principal results of the Vein Graft Surveillance Rando-</a></text>
<text top="261" left="345" width="187" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref396">mised Trial (VGST). Circulation. 2005;112:1985</a></text>
<text top="259" left="533" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref396">–91</a></text>
<text top="261" left="546" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref396">.</a></text>
<text top="279" left="345" width="18" height="9" font="5">397.</text>
<text top="279" left="366" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref397">Back MR, Novotney M, Roth SM, et al. Utility of</a></text>
<text top="293" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref397">duplex surveillance following iliac artery angioplasty</a></text>
<text top="306" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref397">and primary stenting. J Endovasc Ther. 2001;8:</a></text>
<text top="320" left="345" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref397">629</a></text>
<text top="318" left="361" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref397">–37</a></text>
<text top="320" left="375" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref397">.</a></text>
<text top="338" left="345" width="19" height="9" font="5">398.</text>
<text top="338" left="367" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref398">Baril DT, Marone LK. Duplex evaluation following</a></text>
<text top="352" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref398">femoropopliteal angioplasty and stenting: criteria and</a></text>
<text top="365" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref398">utility of surveillance. Vasc Endovascular Surg. 2012;</a></text>
<text top="379" left="345" width="28" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref398">46:353</a></text>
<text top="377" left="373" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref398">–7</a></text>
<text top="379" left="382" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref398">.</a></text>
<text top="397" left="345" width="19" height="9" font="5">399.</text>
<text top="397" left="367" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref399">Troutman DA, Madden NJ, Dougherty MJ, et al.</a></text>
<text top="410" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref399">Duplex ultrasound diagnosis of failing stent grafts</a></text>
<text top="424" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref399">placed for occlusive disease. J Vasc Surg. 2014;60:</a></text>
<text top="437" left="345" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref399">1580</a></text>
<text top="436" left="366" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref399">–4</a></text>
<text top="437" left="375" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref399">.</a></text>
<text top="456" left="345" width="20" height="9" font="5">400.</text>
<text top="456" left="368" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref400">Connors G, Todoran TM, Engelson BA, et al.</a></text>
<text top="469" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref400">Percutaneous revascularization of long femoral artery</a></text>
<text top="483" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref400">lesions for claudication: patency over 2.5 years and</a></text>
<text top="496" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref400">impact of systematic surveillance. Catheter Cardiovasc</a></text>
<text top="510" left="345" width="81" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref400">Interv. 2011;77:1055</a></text>
<text top="508" left="427" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref400">–62</a></text>
<text top="510" left="441" width="3" height="9" font="5">.</text>
<text top="528" left="345" width="18" height="9" font="5">401.</text>
<text top="528" left="366" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref401">Brumberg RS, Back MR, Armstrong PA, et al. The</a></text>
<text top="542" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref401">relative importance of graft surveillance and warfarin</a></text>
<text top="555" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref401">therapy in infrainguinal prosthetic bypass failure.</a></text>
<text top="569" left="345" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref401">J Vasc Surg. 2007;46:1160</a></text>
<text top="567" left="454" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref401">–6</a></text>
<text top="569" left="464" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref401">.</a></text>
<text top="587" left="345" width="19" height="9" font="5">402.</text>
<text top="587" left="367" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref402">Calligaro KD, Doerr K, McAffee-Bennett S, et al.</a></text>
<text top="601" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref402">Should duplex ultrasonography be performed for</a></text>
<text top="614" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref402">surveillance of femoropopliteal and femorotibial arte-</a></text>
<text top="628" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref402">rial prosthetic bypasses? Ann Vasc Surg. 2001;15:</a></text>
<text top="641" left="345" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref402">520</a></text>
<text top="639" left="361" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref402">–4</a></text>
<text top="641" left="371" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref402">.</a></text>
<text top="659" left="345" width="19" height="9" font="5">403.</text>
<text top="659" left="367" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref403">Stone PA, Armstrong PA, Bandyk DF, et al.</a></text>
<text top="673" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref403">Duplex ultrasound criteria for femorofemoral bypass</a></text>
<text top="686" left="345" width="143" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref403">revision. J Vasc Surg. 2006;44:496</a></text>
<text top="685" left="489" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref403">–502</a></text>
<text top="686" left="508" width="3" height="9" font="5">.</text>
<text top="143" left="583" width="20" height="9" font="5">404.</text>
<text top="143" left="606" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref404">Subherwal S, Patel MR, Chiswell K, et al. Clinical</a></text>
<text top="156" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref404">trials in peripheral vascular disease: pipeline and trial</a></text>
<text top="170" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref404">designs: an evaluation of the ClinicalTrials.gov data-</a></text>
<text top="183" left="583" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref404">base. Circulation. 2014;130:1812</a></text>
<text top="182" left="713" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref404">–9</a></text>
<text top="183" left="722" width="3" height="9" font="5">.</text>
<text top="202" left="583" width="19" height="9" font="5">405.</text>
<text top="202" left="605" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref405">Darling JD, McCallum JC, Soden PA, et al. Pre-</a></text>
<text top="215" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref405">dictive ability of the Society for Vascular Surgery</a></text>
<text top="229" left="583" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref405">Wound, Ischemia, and foot Infection (WIfI) classi</a></text>
<text top="227" left="784" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref405">ﬁca-</a></text>
<text top="242" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref405">tion system following infrapopliteal endovascular in-</a></text>
<text top="256" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref405">terventions for critical limb ischemia. J Vasc Surg.</a></text>
<text top="269" left="583" width="51" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref405">2016;64:616</a></text>
<text top="268" left="634" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref405">–22</a></text>
<text top="269" left="648" width="3" height="9" font="5">.</text>
<text top="288" left="583" width="20" height="9" font="5">406.</text>
<text top="288" left="606" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref406">Causey MW, Ahmed A, Wu B, et al. Society for</a></text>
<text top="301" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref406">Vascular Surgery limb stage and patient risk correlate</a></text>
<text top="315" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref406">with outcomes in an amputation prevention program.</a></text>
<text top="328" left="583" width="107" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref406">J Vasc Surg. 2016;63:1563</a></text>
<text top="326" left="690" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref406">–73</a></text>
<text top="328" left="703" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref406">.</a></text>
<text top="347" left="583" width="19" height="9" font="5">407.</text>
<text top="347" left="605" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref407">Beropoulis E, Stavroulakis K, Schwindt A, et al.</a></text>
<text top="360" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref407">Validation of the Wound, Ischemia, foot Infection</a></text>
<text top="373" left="583" width="50" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref407">(WIfI) classi</a></text>
<text top="372" left="633" width="168" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref407">ﬁcation system in nondiabetic patients</a></text>
<text top="387" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref407">treated by endovascular means for critical limb</a></text>
<text top="400" left="583" width="138" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref407">ischemia. J Vasc Surg. 2016;64:95</a></text>
<text top="399" left="721" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref407">–103</a></text>
<text top="400" left="740" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref407">.</a></text>
<text top="419" left="583" width="20" height="9" font="5">408.</text>
<text top="419" left="606" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref408">Zhan LX, Branco BC, Armstrong DG, et al. The</a></text>
<text top="432" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref408">Society for Vascular Surgery lower extremity threat-</a></text>
<text top="446" left="583" width="71" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref408">ened limb classi</a></text>
<text top="444" left="654" width="147" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref408">ﬁcation system based on Wound,</a></text>
<text top="459" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref408">Ischemia, and foot Infection (WIfI) correlates with risk</a></text>
<text top="473" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref408">of major amputation and time to wound healing. J Vasc</a></text>
<text top="486" left="583" width="74" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref408">Surg. 2015;61:939</a></text>
<text top="485" left="657" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref408">–44</a></text>
<text top="486" left="671" width="3" height="9" font="5">.</text>
<text top="505" left="583" width="20" height="9" font="5">409.</text>
<text top="505" left="606" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref409">Mills JL, Conte MS, Armstrong DG, et al. The</a></text>
<text top="518" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref409">Society for Vascular Surgery Lower Extremity Threat-</a></text>
<text top="532" left="583" width="74" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref409">ened Limb Classi</a></text>
<text top="530" left="657" width="144" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref409">ﬁcation System: risk stratiﬁcation</a></text>
<text top="545" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref409">based on wound, ischemia, and foot infection (WIfI).</a></text>
<text top="558" left="583" width="103" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref409">J Vasc Surg. 2014;59:220</a></text>
<text top="557" left="686" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)36902-9/sref409">–34</a></text>
<text top="558" left="700" width="3" height="9" font="5">.</text>
<text top="617" left="583" width="62" height="12" font="23">KEY WORDS</text>
<text top="619" left="651" width="115" height="9" font="5">ACC/AHA Clinical Practice</text>
<text top="633" left="583" width="195" height="9" font="5">Guideline, acute limb ischemia, antiplatelet</text>
<text top="646" left="583" width="218" height="9" font="5">agents, bypass surgery, claudication, critical limb</text>
<text top="659" left="583" width="218" height="9" font="5">ischemia, endovascular procedures, limb salvage,</text>
<text top="673" left="583" width="202" height="9" font="5">peripheral artery disease, smoking cessation,</text>
<text top="686" left="583" width="87" height="9" font="5">supervised exercise</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="18" height="9" font="5">e118</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="864" width="1160">
	<fontspec id="29" size="9" family="Times" color="#e3202b"/>
	<fontspec id="30" size="7" family="Times" color="#000000"/>
	<fontspec id="31" size="7" family="Times" color="#327eb1"/>
	<fontspec id="32" size="5" family="Times" color="#000000"/>
	<fontspec id="33" size="6" family="Times" color="#000000"/>
<text top="55" left="59" width="959" height="16" font="29">APPENDIX 1. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT)—2016 AHA/ACC GUIDELINE ON THE MANAGEMENT OF PATIENTS</text>
<text top="73" left="59" width="473" height="16" font="29">WITH LOWER EXTREMITY PERIPHERAL ARTERY DISEASE (NOVEMBER 2014)</text>
<text top="120" left="59" width="50" height="9" font="30">Committee</text>
<text top="132" left="59" width="38" height="9" font="30">Member</text>
<text top="132" left="209" width="58" height="9" font="30">Employment</text>
<text top="132" left="364" width="50" height="9" font="30">Consultant</text>
<text top="120" left="463" width="42" height="9" font="30">Speakers</text>
<text top="132" left="467" width="32" height="9" font="30">Bureau</text>
<text top="108" left="540" width="53" height="9" font="30">Ownership/</text>
<text top="120" left="538" width="58" height="9" font="30">Partnership/</text>
<text top="132" left="547" width="41" height="9" font="30">Principal</text>
<text top="120" left="643" width="40" height="9" font="30">Personal</text>
<text top="132" left="643" width="42" height="9" font="30">Research</text>
<text top="108" left="755" width="60" height="9" font="30">Institutional,</text>
<text top="120" left="729" width="113" height="9" font="30">Organizational, or Other</text>
<text top="132" left="747" width="67" height="9" font="30">Financial Bene</text>
<text top="130" left="814" width="10" height="12" font="30">ﬁt</text>
<text top="120" left="873" width="31" height="9" font="30">Expert</text>
<text top="132" left="870" width="37" height="9" font="30">Witness</text>
<text top="120" left="938" width="74" height="9" font="30">Voting Recusals</text>
<text top="132" left="949" width="48" height="9" font="30">by Sectio<a href="e71.full.html#50">n</a></text>
<text top="132" left="997" width="4" height="9" font="31"><a href="e71.full.html#50">*</a></text>
<text top="148" left="59" width="74" height="9" font="30">Marie D. Gerhard-</text>
<text top="160" left="74" width="33" height="9" font="30">Herman</text>
<text top="172" left="74" width="28" height="9" font="30">(Chair)</text>
<text top="148" left="173" width="99" height="9" font="30">Harvard Medical School</text>
<text top="147" left="272" width="46" height="12" font="30">—Associate</text>
<text top="160" left="226" width="39" height="9" font="30">Professor</text>
<text top="148" left="378" width="22" height="9" font="30">None</text>
<text top="148" left="473" width="22" height="9" font="30">None</text>
<text top="148" left="556" width="22" height="9" font="30">None</text>
<text top="148" left="653" width="22" height="9" font="30">None</text>
<text top="148" left="775" width="22" height="9" font="30">None</text>
<text top="148" left="878" width="22" height="9" font="30">None</text>
<text top="148" left="965" width="22" height="9" font="30">None</text>
<text top="191" left="59" width="74" height="9" font="30">Heather L. Gornik</text>
<text top="203" left="74" width="47" height="9" font="30">(Vice Chair)</text>
<text top="191" left="186" width="119" height="9" font="30">Cleveland Clinic Foundation,</text>
<text top="203" left="176" width="100" height="9" font="30">Cardiovascular Medicine</text>
<text top="202" left="276" width="39" height="12" font="30">—Medical</text>
<text top="215" left="182" width="127" height="9" font="30">Director, Noninvasive Vascular</text>
<text top="227" left="223" width="45" height="9" font="30">Laboratory</text>
<text top="191" left="378" width="22" height="9" font="30">None</text>
<text top="191" left="473" width="22" height="9" font="30">None</text>
<text top="191" left="534" width="6" height="10" font="32">n</text>
<text top="191" left="548" width="33" height="9" font="30">Summit</text>
<text top="203" left="548" width="35" height="9" font="30">Doppler</text>
<text top="215" left="548" width="36" height="9" font="30">Systems</text>
<text top="226" left="534" width="6" height="10" font="32">n</text>
<text top="227" left="548" width="50" height="9" font="30">Zin Medical</text>
<text top="191" left="625" width="6" height="10" font="32">n</text>
<text top="191" left="640" width="54" height="9" font="30">AstraZeneca</text>
<text top="203" left="625" width="6" height="10" font="32">n</text>
<text top="203" left="640" width="44" height="9" font="30">Theravasc</text>
<text top="191" left="775" width="22" height="9" font="30">None</text>
<text top="191" left="878" width="22" height="9" font="30">None</text>
<text top="191" left="942" width="47" height="9" font="30">3.1, 3.2, 5.1</text>
<text top="190" left="989" width="19" height="12" font="30">–5.3,</text>
<text top="203" left="966" width="34" height="9" font="30">and 5.6.</text>
<text top="246" left="59" width="63" height="9" font="30">Coletta Barrett</text>
<text top="246" left="182" width="128" height="9" font="30">Our Lady of the Lake Regional</text>
<text top="258" left="181" width="63" height="9" font="30">Medical Center</text>
<text top="257" left="244" width="66" height="12" font="30">—Vice President</text>
<text top="246" left="378" width="22" height="9" font="30">None</text>
<text top="246" left="473" width="22" height="9" font="30">None</text>
<text top="246" left="556" width="22" height="9" font="30">None</text>
<text top="246" left="653" width="22" height="9" font="30">None</text>
<text top="246" left="775" width="22" height="9" font="30">None</text>
<text top="246" left="878" width="22" height="9" font="30">None</text>
<text top="246" left="965" width="22" height="9" font="30">None</text>
<text top="278" left="59" width="65" height="9" font="30">Neal R. Barshes</text>
<text top="278" left="188" width="115" height="9" font="30">Baylor College of Medicine,</text>
<text top="290" left="178" width="135" height="9" font="30">Division of Vascular Surgery and</text>
<text top="302" left="177" width="138" height="9" font="30">Endovascular Therapy Michael E.</text>
<text top="313" left="174" width="135" height="9" font="30">DeBakey Department of Surgery</text>
<text top="312" left="310" width="7" height="12" font="30">—</text>
<text top="325" left="206" width="80" height="9" font="30">Assistant Professor</text>
<text top="278" left="378" width="22" height="9" font="30">None</text>
<text top="278" left="473" width="22" height="9" font="30">None</text>
<text top="278" left="556" width="22" height="9" font="30">None</text>
<text top="278" left="653" width="22" height="9" font="30">None</text>
<text top="278" left="775" width="22" height="9" font="30">None</text>
<text top="278" left="878" width="22" height="9" font="30">None</text>
<text top="278" left="965" width="22" height="9" font="30">None</text>
<text top="345" left="59" width="49" height="9" font="30">Matthew A.</text>
<text top="357" left="74" width="33" height="9" font="30">Corriere</text>
<text top="345" left="180" width="94" height="9" font="30">University of Michigan</text>
<text top="343" left="274" width="37" height="12" font="30">—Frankel</text>
<text top="357" left="188" width="114" height="9" font="30">Professor of Cardiovascular</text>
<text top="369" left="180" width="131" height="9" font="30">Surgery, Associate Professor of</text>
<text top="381" left="230" width="32" height="9" font="30">Surgery</text>
<text top="345" left="378" width="22" height="9" font="30">None</text>
<text top="345" left="473" width="22" height="9" font="30">None</text>
<text top="345" left="556" width="22" height="9" font="30">None</text>
<text top="345" left="653" width="22" height="9" font="30">None</text>
<text top="345" left="775" width="22" height="9" font="30">None</text>
<text top="345" left="878" width="22" height="9" font="30">None</text>
<text top="345" left="965" width="22" height="9" font="30">None</text>
<text top="400" left="59" width="45" height="9" font="30">Douglas E.</text>
<text top="412" left="74" width="42" height="9" font="30">Drachman</text>
<text top="400" left="176" width="133" height="9" font="30">Massachusetts General Hospital</text>
<text top="398" left="308" width="7" height="12" font="30">—</text>
<text top="412" left="210" width="70" height="9" font="30">Training Director</text>
<text top="399" left="344" width="6" height="10" font="32">n</text>
<text top="400" left="358" width="71" height="9" font="30">Abbott Vascular</text>
<text top="411" left="344" width="6" height="10" font="32">n</text>
<text top="412" left="358" width="73" height="9" font="30">St. Jude Medical</text>
<text top="400" left="473" width="22" height="9" font="30">None</text>
<text top="400" left="556" width="22" height="9" font="30">None</text>
<text top="399" left="625" width="6" height="10" font="32">n</text>
<text top="400" left="640" width="30" height="9" font="30">Atrium</text>
<text top="412" left="640" width="34" height="9" font="30">Medical</text>
<text top="423" left="625" width="6" height="10" font="32">n</text>
<text top="424" left="640" width="20" height="9" font="30">Bard</text>
<text top="435" left="625" width="6" height="10" font="32">n</text>
<text top="436" left="640" width="33" height="9" font="30">Lutonix</text>
<text top="400" left="775" width="22" height="9" font="30">None</text>
<text top="400" left="878" width="22" height="9" font="30">None</text>
<text top="400" left="947" width="30" height="9" font="30">4, 8.1.1</text>
<text top="398" left="977" width="27" height="12" font="30">–9.1.2,</text>
<text top="412" left="960" width="46" height="9" font="30">and 10.2.2.</text>
<text top="455" left="59" width="62" height="9" font="30">Lee A. Fleisher</text>
<text top="455" left="175" width="141" height="9" font="30">University of Pennsylvania Health</text>
<text top="467" left="198" width="95" height="9" font="30">System Department of</text>
<text top="479" left="174" width="135" height="9" font="30">Anesthesiology and Critical Care</text>
<text top="477" left="310" width="7" height="12" font="30">—</text>
<text top="491" left="235" width="21" height="9" font="30">Chair</text>
<text top="455" left="378" width="22" height="9" font="30">None</text>
<text top="455" left="473" width="22" height="9" font="30">None</text>
<text top="455" left="556" width="22" height="9" font="30">None</text>
<text top="455" left="653" width="22" height="9" font="30">None</text>
<text top="455" left="775" width="22" height="9" font="30">None</text>
<text top="455" left="878" width="22" height="9" font="30">None</text>
<text top="455" left="965" width="22" height="9" font="30">None</text>
<text top="510" left="59" width="66" height="9" font="30">Francis Gerry R.</text>
<text top="522" left="74" width="31" height="9" font="30">Fowkes</text>
<text top="510" left="174" width="99" height="9" font="30">University of Edinburgh</text>
<text top="508" left="273" width="43" height="12" font="30">—Emeritus</text>
<text top="522" left="190" width="110" height="9" font="30">Professor of Epidemiology</text>
<text top="509" left="344" width="6" height="10" font="32">n</text>
<text top="510" left="358" width="54" height="9" font="30">AstraZeneca</text>
<text top="508" left="412" width="5" height="12" font="31"><a href="e71.full.html#50">†</a></text>
<text top="521" left="344" width="6" height="10" font="32">n</text>
<text top="522" left="358" width="24" height="9" font="30">Bayer</text>
<text top="533" left="344" width="6" height="10" font="32">n</text>
<text top="534" left="358" width="26" height="9" font="30">Merck</text>
<text top="510" left="473" width="22" height="9" font="30">None</text>
<text top="510" left="556" width="22" height="9" font="30">None</text>
<text top="510" left="653" width="22" height="9" font="30">None</text>
<text top="510" left="775" width="22" height="9" font="30">None</text>
<text top="510" left="878" width="22" height="9" font="30">None</text>
<text top="510" left="933" width="12" height="9" font="30">5.1</text>
<text top="508" left="945" width="73" height="12" font="30">–5.3, 5.6, 5.10, 7,</text>
<text top="522" left="966" width="34" height="9" font="30">and 9.2.</text>
<text top="553" left="59" width="40" height="9" font="30">Naomi M.</text>
<text top="565" left="74" width="38" height="9" font="30">Hamburg</text>
<text top="553" left="187" width="116" height="9" font="30">Boston University School of</text>
<text top="565" left="174" width="143" height="9" font="30">Medicine, Cardiovascular Medicine</text>
<text top="577" left="180" width="31" height="9" font="30">Section</text>
<text top="575" left="211" width="100" height="12" font="30">—Associate Professor of</text>
<text top="589" left="227" width="37" height="9" font="30">Medicine</text>
<text top="553" left="378" width="22" height="9" font="30">None</text>
<text top="553" left="473" width="22" height="9" font="30">None</text>
<text top="553" left="556" width="22" height="9" font="30">None</text>
<text top="553" left="653" width="22" height="9" font="30">None</text>
<text top="553" left="775" width="22" height="9" font="30">None</text>
<text top="553" left="878" width="22" height="9" font="30">None</text>
<text top="553" left="965" width="22" height="9" font="30">None</text>
<text top="608" left="59" width="50" height="9" font="30">Scott Kinlay</text>
<text top="608" left="180" width="125" height="9" font="30">VA Boston Healthcare System</text>
<text top="606" left="305" width="7" height="12" font="30">—</text>
<text top="620" left="189" width="114" height="9" font="30">Associate Chief, Cardiology</text>
<text top="632" left="178" width="136" height="9" font="30">Director, Cardiac Catheterization</text>
<text top="644" left="179" width="133" height="9" font="30">Laboratory &amp; Vascular Medicine</text>
<text top="608" left="378" width="22" height="9" font="30">None</text>
<text top="608" left="473" width="22" height="9" font="30">None</text>
<text top="608" left="556" width="22" height="9" font="30">None</text>
<text top="607" left="625" width="6" height="10" font="32">n</text>
<text top="608" left="640" width="44" height="9" font="30"><a href="e71.full.html#50">Medtronic</a></text>
<text top="606" left="684" width="5" height="12" font="31"><a href="e71.full.html#50">†</a></text>
<text top="619" left="625" width="6" height="10" font="32">n</text>
<text top="620" left="640" width="63" height="9" font="30">The Medicines</text>
<text top="632" left="640" width="40" height="9" font="30">Company</text>
<text top="630" left="680" width="5" height="12" font="31"><a href="e71.full.html#50">†</a></text>
<text top="608" left="775" width="22" height="9" font="30">None</text>
<text top="608" left="878" width="22" height="9" font="30">None</text>
<text top="608" left="937" width="77" height="9" font="30">4, 5.6, 8.1.1, 9.1.1,</text>
<text top="620" left="937" width="77" height="9" font="30">10.2.1, and 10.2.2.</text>
<text top="663" left="59" width="71" height="9" font="30">Robert Lookstein</text>
<text top="663" left="173" width="115" height="9" font="30">Mount Sinai Medical Center</text>
<text top="661" left="288" width="31" height="12" font="30">—Chief,</text>
<text top="675" left="172" width="146" height="9" font="30">Interventional Radiology; Professor</text>
<text top="687" left="181" width="129" height="9" font="30">of Radiology and Surgery; Vice</text>
<text top="699" left="179" width="133" height="9" font="30">Chair, Department of Radiology</text>
<text top="662" left="344" width="6" height="10" font="32">n</text>
<text top="663" left="358" width="63" height="9" font="30">Boston Scienti</text>
<text top="661" left="422" width="10" height="12" font="30">ﬁc</text>
<text top="674" left="344" width="6" height="10" font="32">n</text>
<text top="675" left="358" width="33" height="9" font="30">Medrad</text>
<text top="687" left="358" width="62" height="9" font="30">Interventional</text>
<text top="698" left="344" width="6" height="10" font="32">n</text>
<text top="699" left="358" width="27" height="9" font="30">Possis</text>
<text top="710" left="344" width="6" height="10" font="32">n</text>
<text top="711" left="358" width="63" height="9" font="30">The Medicines</text>
<text top="723" left="358" width="40" height="9" font="30">Company</text>
<text top="662" left="459" width="6" height="10" font="32">n</text>
<text top="663" left="473" width="27" height="9" font="30">Cord<a href="e71.full.html#50">is</a></text>
<text top="661" left="500" width="5" height="12" font="31"><a href="e71.full.html#50">‡</a></text>
<text top="663" left="556" width="22" height="9" font="30">None</text>
<text top="662" left="625" width="6" height="10" font="32">n</text>
<text top="663" left="640" width="48" height="9" font="30">Shockwave</text>
<text top="675" left="640" width="33" height="9" font="30">(DSMB)</text>
<text top="663" left="775" width="22" height="9" font="30">None</text>
<text top="663" left="878" width="22" height="9" font="30">None</text>
<text top="663" left="937" width="77" height="9" font="30">4, 5.6, 8.1.1, 9.1.1,</text>
<text top="675" left="937" width="77" height="9" font="30">10.2.1, and 10.2.2.</text>
<text top="744" left="59" width="52" height="9" font="30">Sanjay Misra</text>
<text top="744" left="178" width="136" height="9" font="30">Mayo Clinic, Division of Vascular</text>
<text top="756" left="182" width="121" height="9" font="30">and Interventional Radiology</text>
<text top="754" left="303" width="7" height="12" font="30">—</text>
<text top="767" left="192" width="106" height="9" font="30">Professor; Department of</text>
<text top="779" left="192" width="41" height="9" font="30">Radiology</text>
<text top="778" left="234" width="65" height="12" font="30">—Interventional</text>
<text top="791" left="222" width="46" height="9" font="30">Radiologist</text>
<text top="744" left="378" width="22" height="9" font="30">None</text>
<text top="744" left="473" width="22" height="9" font="30">None</text>
<text top="744" left="556" width="22" height="9" font="30">None</text>
<text top="743" left="625" width="6" height="10" font="32">n</text>
<text top="744" left="640" width="46" height="9" font="30">Johnson &amp;</text>
<text top="756" left="640" width="36" height="9" font="30">Johnson</text>
<text top="767" left="640" width="33" height="9" font="30">(DSMB)</text>
<text top="744" left="775" width="22" height="9" font="30">None</text>
<text top="744" left="878" width="22" height="9" font="30">None</text>
<text top="744" left="936" width="80" height="9" font="30">4, 7, 8, and 10.2.2.</text>
<text top="812" left="912" width="105" height="8" font="33">Continued on the next page</text>
<text top="57" left="1102" width="0" height="7" font="7">J</text>
<text top="63" left="1102" width="0" height="7" font="7">A</text>
<text top="69" left="1102" width="0" height="7" font="7">CC</text>
<text top="86" left="1102" width="0" height="7" font="7">VO</text>
<text top="99" left="1102" width="0" height="7" font="7">L.</text>
<text top="112" left="1102" width="0" height="7" font="7">69,</text>
<text top="131" left="1102" width="0" height="7" font="7">NO.</text>
<text top="152" left="1102" width="0" height="7" font="7">11,</text>
<text top="167" left="1102" width="0" height="7" font="7">20</text>
<text top="179" left="1102" width="0" height="7" font="7">1</text>
<text top="183" left="1102" width="0" height="7" font="7">7</text>
<text top="656" left="1100" width="0" height="9" font="13">Gerhard-Herman</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="7">MA</text>
<text top="71" left="1087" width="0" height="7" font="7">RCH</text>
<text top="94" left="1087" width="0" height="7" font="7">21,</text>
<text top="111" left="1087" width="0" height="7" font="7">2</text>
<text top="117" left="1087" width="0" height="7" font="7">0</text>
<text top="123" left="1087" width="0" height="7" font="7">1</text>
<text top="127" left="1087" width="0" height="7" font="7">7:e</text>
<text top="142" left="1087" width="0" height="7" font="7">7</text>
<text top="147" left="1087" width="0" height="12" font="7">1–</text>
<text top="157" left="1087" width="0" height="7" font="7">126</text>
<text top="552" left="1085" width="0" height="9" font="13">2016</text>
<text top="576" left="1085" width="0" height="9" font="13">AHA/ACC</text>
<text top="618" left="1085" width="0" height="9" font="13">Lower</text>
<text top="647" left="1085" width="0" height="9" font="13">Extremity</text>
<text top="690" left="1085" width="0" height="9" font="13">PAD</text>
<text top="711" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="783" left="1101" width="0" height="9" font="5">e119</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="864" width="1160">
<text top="105" left="59" width="156" height="16" font="29">APPENDIX 1. CONTINUED</text>
<text top="152" left="59" width="50" height="9" font="30">Committee</text>
<text top="164" left="59" width="38" height="9" font="30">Member</text>
<text top="164" left="209" width="58" height="9" font="30">Employment</text>
<text top="164" left="364" width="50" height="9" font="30">Consultant</text>
<text top="152" left="463" width="42" height="9" font="30">Speakers</text>
<text top="164" left="467" width="32" height="9" font="30">Bureau</text>
<text top="140" left="540" width="53" height="9" font="30">Ownership/</text>
<text top="152" left="538" width="59" height="9" font="30">Partnership/</text>
<text top="164" left="547" width="41" height="9" font="30">Principal</text>
<text top="152" left="644" width="40" height="9" font="30">Personal</text>
<text top="164" left="643" width="42" height="9" font="30">Research</text>
<text top="140" left="755" width="60" height="9" font="30">Institutional,</text>
<text top="152" left="729" width="113" height="9" font="30">Organizational, or Other</text>
<text top="164" left="747" width="67" height="9" font="30">Financial Bene</text>
<text top="162" left="814" width="10" height="12" font="30">ﬁt</text>
<text top="152" left="873" width="31" height="9" font="30">Expert</text>
<text top="164" left="870" width="37" height="9" font="30">Witness</text>
<text top="152" left="938" width="74" height="9" font="30">Voting Recusals</text>
<text top="164" left="949" width="48" height="9" font="30">by Section</text>
<text top="164" left="998" width="4" height="9" font="31"><a href="e71.full.html#50">*</a></text>
<text top="180" left="59" width="59" height="9" font="30">Leila Mureebe</text>
<text top="180" left="176" width="131" height="9" font="30">Duke University Medical Center</text>
<text top="179" left="308" width="7" height="12" font="30">—</text>
<text top="192" left="180" width="131" height="9" font="30">Associate Professor of Surgery,</text>
<text top="204" left="187" width="117" height="9" font="30">Division of Vascular Surgery</text>
<text top="180" left="378" width="22" height="9" font="30">None</text>
<text top="180" left="473" width="22" height="9" font="30">None</text>
<text top="180" left="556" width="22" height="9" font="30">None</text>
<text top="180" left="653" width="22" height="9" font="30">None</text>
<text top="180" left="775" width="22" height="9" font="30">None</text>
<text top="180" left="878" width="22" height="9" font="30">None</text>
<text top="180" left="965" width="22" height="9" font="30">None</text>
<text top="223" left="59" width="63" height="9" font="30">Jeffrey W. Olin</text>
<text top="223" left="172" width="146" height="9" font="30">Ichan School of Medicine at Mount</text>
<text top="235" left="175" width="142" height="9" font="30">Sinai, Zena and Michael A. Wiener</text>
<text top="247" left="172" width="146" height="9" font="30">Cardiovascular Institute and Marie-</text>
<text top="259" left="176" width="139" height="9" font="30">Josée and Henry R. Kravis Center</text>
<text top="271" left="189" width="106" height="9" font="30">for Cardiovascular Health</text>
<text top="269" left="295" width="7" height="12" font="30">—</text>
<text top="283" left="174" width="144" height="9" font="30">Professor of Medicine, Cardiology;</text>
<text top="295" left="189" width="114" height="9" font="30">Director, Vascular Medicine</text>
<text top="223" left="344" width="6" height="10" font="32">n</text>
<text top="223" left="358" width="54" height="9" font="30">AstraZeneca</text>
<text top="234" left="344" width="6" height="10" font="32">n</text>
<text top="235" left="358" width="26" height="9" font="30">Merck</text>
<text top="246" left="344" width="6" height="10" font="32">n</text>
<text top="247" left="358" width="37" height="9" font="30">Novartis</text>
<text top="258" left="344" width="6" height="10" font="32">n</text>
<text top="259" left="358" width="44" height="9" font="30">Plurestem</text>
<text top="223" left="473" width="22" height="9" font="30">None</text>
<text top="223" left="534" width="6" height="10" font="32">n</text>
<text top="223" left="548" width="46" height="9" font="30">Northwind</text>
<text top="222" left="595" width="5" height="12" font="31"><a href="e71.full.html#50">†</a></text>
<text top="223" left="625" width="6" height="10" font="32">n</text>
<text top="223" left="640" width="54" height="9" font="30">AstraZeneca</text>
<text top="222" left="694" width="5" height="12" font="31"><a href="e71.full.html#50">†</a></text>
<text top="223" left="775" width="22" height="9" font="30">None</text>
<text top="223" left="878" width="22" height="9" font="30">None</text>
<text top="223" left="939" width="12" height="9" font="30">5.1</text>
<text top="222" left="950" width="62" height="12" font="30">–5.3, 5.6, 5.10,</text>
<text top="235" left="968" width="30" height="9" font="30">and 12.</text>
<text top="314" left="59" width="67" height="9" font="30">Rajan A.G. Patel</text>
<text top="314" left="180" width="130" height="9" font="30">John Ochsner Heart &amp; Vascular</text>
<text top="326" left="179" width="133" height="9" font="30">Center, Ochsner Clinical School,</text>
<text top="338" left="172" width="146" height="9" font="30">University of Queensland School of</text>
<text top="350" left="192" width="37" height="9" font="30">Medicine</text>
<text top="348" left="229" width="70" height="12" font="30">—Senior Lecturer</text>
<text top="314" left="378" width="22" height="9" font="30">None</text>
<text top="314" left="473" width="22" height="9" font="30">None</text>
<text top="314" left="556" width="22" height="9" font="30">None</text>
<text top="314" left="653" width="22" height="9" font="30">None</text>
<text top="314" left="775" width="22" height="9" font="30">None</text>
<text top="314" left="878" width="22" height="9" font="30">None</text>
<text top="314" left="965" width="22" height="9" font="30">None</text>
<text top="369" left="59" width="38" height="9" font="30">Judith G.</text>
<text top="381" left="74" width="54" height="9" font="30">Regensteiner</text>
<text top="369" left="182" width="127" height="9" font="30">University of Colorado, Health</text>
<text top="381" left="188" width="115" height="9" font="30">Sciences Center, Division of</text>
<text top="393" left="173" width="45" height="9" font="30">Cardiology</text>
<text top="392" left="218" width="100" height="12" font="30">—Associate Professor of</text>
<text top="405" left="227" width="37" height="9" font="30">Medicine</text>
<text top="369" left="378" width="22" height="9" font="30">None</text>
<text top="369" left="473" width="22" height="9" font="30">None</text>
<text top="369" left="556" width="22" height="9" font="30">None</text>
<text top="369" left="653" width="22" height="9" font="30">None</text>
<text top="369" left="775" width="22" height="9" font="30">None</text>
<text top="369" left="878" width="22" height="9" font="30">None</text>
<text top="369" left="965" width="22" height="9" font="30">None</text>
<text top="424" left="59" width="69" height="9" font="30">Andres Schanzer</text>
<text top="424" left="187" width="117" height="9" font="30">University of Massachusetts</text>
<text top="436" left="185" width="63" height="9" font="30">Medical School</text>
<text top="435" left="248" width="58" height="12" font="30">—Professor of</text>
<text top="448" left="178" width="135" height="9" font="30">Surgery and Quantitative Health</text>
<text top="460" left="188" width="115" height="9" font="30">Sciences; Program Director,</text>
<text top="472" left="188" width="114" height="9" font="30">Vascular Surgery Residency</text>
<text top="424" left="344" width="6" height="10" font="32">n</text>
<text top="424" left="358" width="59" height="9" font="30">Cook Medical</text>
<text top="424" left="473" width="22" height="9" font="30">None</text>
<text top="424" left="556" width="22" height="9" font="30">None</text>
<text top="424" left="653" width="22" height="9" font="30">None</text>
<text top="424" left="775" width="22" height="9" font="30">None</text>
<text top="424" left="878" width="22" height="9" font="30">None</text>
<text top="424" left="947" width="57" height="9" font="30">4, 8.1.1, 9.1.1,</text>
<text top="436" left="960" width="47" height="9" font="30">and 10.2.2.</text>
<text top="491" left="59" width="38" height="9" font="30">Mehdi H.</text>
<text top="503" left="74" width="46" height="9" font="30">Shishehbor</text>
<text top="491" left="180" width="130" height="9" font="30">Cleveland Clinic, Interventional</text>
<text top="503" left="172" width="140" height="9" font="30">Cardiology and Vascular Medicine</text>
<text top="502" left="312" width="7" height="12" font="30">—</text>
<text top="515" left="180" width="131" height="9" font="30">Director, Endovascular Services</text>
<text top="491" left="344" width="6" height="10" font="32">n</text>
<text top="491" left="358" width="31" height="9" font="30">Boston</text>
<text top="503" left="358" width="29" height="9" font="30">Scienti</text>
<text top="502" left="388" width="10" height="12" font="30">ﬁc</text>
<text top="502" left="398" width="5" height="12" font="31"><a href="e71.full.html#50">‡</a></text>
<text top="515" left="344" width="6" height="10" font="32">n</text>
<text top="515" left="358" width="44" height="9" font="30">Medtronic</text>
<text top="514" left="403" width="5" height="12" font="31"><a href="e71.full.html#50">‡</a></text>
<text top="491" left="473" width="22" height="9" font="30">None</text>
<text top="491" left="556" width="22" height="9" font="30">None</text>
<text top="491" left="653" width="22" height="9" font="30">None</text>
<text top="491" left="728" width="6" height="10" font="32">n</text>
<text top="491" left="742" width="67" height="9" font="30">Atrium Medical</text>
<text top="503" left="728" width="6" height="10" font="32">n</text>
<text top="503" left="742" width="54" height="9" font="30">AstraZeneca</text>
<text top="502" left="796" width="5" height="12" font="31"><a href="e71.full.html#50">†</a></text>
<text top="491" left="878" width="22" height="9" font="30">None</text>
<text top="491" left="947" width="30" height="9" font="30">4, 8.1.1</text>
<text top="490" left="977" width="27" height="12" font="30">–9.1.2,</text>
<text top="503" left="960" width="47" height="9" font="30">and 10.2.2.</text>
<text top="535" left="59" width="67" height="9" font="30">Kerry J. Stewart</text>
<text top="535" left="176" width="139" height="9" font="30">Johns Hopkins University, School</text>
<text top="547" left="188" width="115" height="9" font="30">of Medicine; Johns Hopkins</text>
<text top="558" left="173" width="100" height="9" font="30">Bayview Medical Center</text>
<text top="557" left="273" width="46" height="12" font="30">—Professor</text>
<text top="570" left="175" width="142" height="9" font="30">of Medicine; Director, Clinical and</text>
<text top="582" left="184" width="122" height="9" font="30">Research Exercise Physiology</text>
<text top="535" left="378" width="22" height="9" font="30">None</text>
<text top="535" left="473" width="22" height="9" font="30">None</text>
<text top="535" left="556" width="22" height="9" font="30">None</text>
<text top="535" left="653" width="22" height="9" font="30">None</text>
<text top="535" left="775" width="22" height="9" font="30">None</text>
<text top="535" left="878" width="22" height="9" font="30">None</text>
<text top="535" left="965" width="22" height="9" font="30">None</text>
<text top="602" left="59" width="52" height="9" font="30">Diane Treat-</text>
<text top="614" left="74" width="38" height="9" font="30">Jacobson</text>
<text top="602" left="173" width="145" height="9" font="30">University of Minnesota, School of</text>
<text top="614" left="207" width="32" height="9" font="30">Nursing</text>
<text top="612" left="239" width="46" height="12" font="30">—Professor</text>
<text top="602" left="378" width="22" height="9" font="30">None</text>
<text top="602" left="473" width="22" height="9" font="30">None</text>
<text top="602" left="556" width="22" height="9" font="30">None</text>
<text top="602" left="653" width="22" height="9" font="30">None</text>
<text top="602" left="775" width="22" height="9" font="30">None</text>
<text top="602" left="878" width="22" height="9" font="30">None</text>
<text top="602" left="965" width="22" height="9" font="30">None</text>
<text top="633" left="59" width="67" height="9" font="30">M. Eileen Walsh</text>
<text top="633" left="179" width="134" height="9" font="30">University of Toledo, College of</text>
<text top="645" left="207" width="32" height="9" font="30">Nursing</text>
<text top="643" left="239" width="46" height="12" font="30">—Professor</text>
<text top="633" left="378" width="22" height="9" font="30">None</text>
<text top="633" left="473" width="22" height="9" font="30">None</text>
<text top="633" left="556" width="22" height="9" font="30">None</text>
<text top="633" left="653" width="22" height="9" font="30">None</text>
<text top="633" left="775" width="22" height="9" font="30">None</text>
<text top="633" left="878" width="22" height="9" font="30">None</text>
<text top="633" left="965" width="22" height="9" font="30">None</text>
<text top="668" left="59" width="959" height="8" font="33">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls</text>
<text top="680" left="59" width="396" height="8" font="33">of the writing committee during the document development process. The table does not necessarily re</text>
<text top="679" left="454" width="563" height="11" font="33">ﬂect relationships with industry at the time of publication. A person is deemed to have a signiﬁcant interest in a business if the interest represents</text>
<text top="692" left="59" width="50" height="8" font="33">ownership of</text>
<text top="691" left="111" width="907" height="11" font="33">$5% of the voting stock or share of the business entity, or ownership of $$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the</text>
<text top="704" left="59" width="177" height="8" font="33">previous year. Relationships that exist with no</text>
<text top="703" left="238" width="779" height="11" font="33">ﬁnancial beneﬁt are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the</text>
<text top="716" left="59" width="959" height="8" font="33">relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in</text>
<text top="728" left="59" width="470" height="8" font="33">the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person</text>
<text top="727" left="529" width="489" height="11" font="33">’s household, has a reasonable potential for ﬁnancial, professional, or other personal gain or loss as a result of the issues/content</text>
<text top="740" left="59" width="107" height="8" font="33">addressed in the document.</text>
<text top="752" left="59" width="421" height="8" font="33">*Writing committee members are required to recuse themselves from voting on sections to which their speci</text>
<text top="750" left="480" width="230" height="11" font="33">ﬁc relationships with industry and other entities may apply.</text>
<text top="762" left="59" width="94" height="11" font="33">†Signiﬁcant relationship.</text>
<text top="774" left="59" width="82" height="11" font="33">‡No ﬁnancial beneﬁt.</text>
<text top="790" left="67" width="558" height="8" font="33">ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; and VA, Veterans Affairs.</text>
<text top="100" left="1100" width="0" height="9" font="13">Gerhard-Herman</text>
<text top="173" left="1100" width="0" height="9" font="13">et</text>
<text top="184" left="1100" width="0" height="9" font="13">al</text>
<text top="192" left="1100" width="0" height="9" font="13">.</text>
<text top="667" left="1102" width="0" height="7" font="7">JAC</text>
<text top="685" left="1102" width="0" height="7" font="7">C</text>
<text top="695" left="1102" width="0" height="7" font="7">VOL.</text>
<text top="721" left="1102" width="0" height="7" font="7">69,</text>
<text top="740" left="1102" width="0" height="7" font="7">NO.</text>
<text top="761" left="1102" width="0" height="7" font="7">11,</text>
<text top="776" left="1102" width="0" height="7" font="7">2</text>
<text top="782" left="1102" width="0" height="7" font="7">0</text>
<text top="788" left="1102" width="0" height="7" font="7">17</text>
<text top="100" left="1085" width="0" height="9" font="13">2016</text>
<text top="125" left="1085" width="0" height="9" font="13">AHA/ACC</text>
<text top="167" left="1085" width="0" height="9" font="13">Lower</text>
<text top="195" left="1085" width="0" height="9" font="13">Extremity</text>
<text top="239" left="1085" width="0" height="9" font="13">PAD</text>
<text top="260" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="683" left="1087" width="0" height="7" font="7">M</text>
<text top="690" left="1087" width="0" height="7" font="7">A</text>
<text top="697" left="1087" width="0" height="7" font="7">R</text>
<text top="703" left="1087" width="0" height="7" font="7">C</text>
<text top="710" left="1087" width="0" height="7" font="7">H</text>
<text top="720" left="1087" width="0" height="7" font="7">2</text>
<text top="725" left="1087" width="0" height="7" font="7">1,</text>
<text top="737" left="1087" width="0" height="7" font="7">20</text>
<text top="748" left="1087" width="0" height="7" font="7">17:</text>
<text top="761" left="1087" width="0" height="7" font="7">e</text>
<text top="767" left="1087" width="0" height="7" font="7">71</text>
<text top="775" left="1087" width="0" height="10" font="7">–</text>
<text top="782" left="1087" width="0" height="7" font="7">126</text>
<text top="50" left="1101" width="0" height="9" font="5">e120</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="864" width="1160">
<text top="135" left="59" width="43" height="9" font="30">Reviewer</text>
<text top="135" left="162" width="71" height="9" font="30">Representation</text>
<text top="135" left="289" width="58" height="9" font="30">Employment</text>
<text top="135" left="423" width="50" height="9" font="30">Consultant</text>
<text top="123" left="530" width="42" height="9" font="30">Speakers</text>
<text top="135" left="535" width="32" height="9" font="30">Bureau</text>
<text top="111" left="608" width="53" height="9" font="30">Ownership/</text>
<text top="123" left="605" width="58" height="9" font="30">Partnership/</text>
<text top="135" left="614" width="41" height="9" font="30">Principal</text>
<text top="135" left="692" width="85" height="9" font="30">Personal Research</text>
<text top="111" left="829" width="60" height="9" font="30">Institutional,</text>
<text top="123" left="802" width="113" height="9" font="30">Organizational, or Other</text>
<text top="135" left="820" width="67" height="9" font="30">Financial Bene</text>
<text top="134" left="888" width="10" height="12" font="30">ﬁt</text>
<text top="123" left="954" width="31" height="9" font="30">Expert</text>
<text top="135" left="951" width="37" height="9" font="30">Witness</text>
<text top="154" left="59" width="67" height="9" font="30">Deepak L. Bhatt</text>
<text top="154" left="190" width="10" height="9" font="30">Of</text>
<text top="153" left="200" width="19" height="12" font="30">ﬁcial</text>
<text top="166" left="174" width="38" height="9" font="30">Reviewer</text>
<text top="165" left="212" width="24" height="12" font="30">—ACC</text>
<text top="178" left="168" width="74" height="9" font="30">Board of Trustees</text>
<text top="154" left="279" width="87" height="9" font="30">Brigham and Women</text>
<text top="153" left="366" width="6" height="12" font="30">’s</text>
<text top="166" left="261" width="34" height="9" font="30">Hospital</text>
<text top="165" left="296" width="94" height="12" font="30">—Executive Director of</text>
<text top="178" left="265" width="122" height="9" font="30">Interventional Cardiovascular</text>
<text top="190" left="269" width="113" height="9" font="30">Programs; Harvard Medical</text>
<text top="202" left="263" width="28" height="9" font="30">School</text>
<text top="201" left="291" width="98" height="12" font="30">—Professor of Medicine</text>
<text top="154" left="402" width="6" height="10" font="32">n</text>
<text top="154" left="416" width="34" height="9" font="30">Elsevier</text>
<text top="154" left="540" width="22" height="9" font="30">None</text>
<text top="154" left="623" width="22" height="9" font="30">None</text>
<text top="154" left="673" width="6" height="10" font="32">n</text>
<text top="154" left="687" width="31" height="9" font="30">Amarin</text>
<text top="154" left="718" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="166" left="673" width="6" height="10" font="32">n</text>
<text top="166" left="687" width="30" height="9" font="30">Amgen</text>
<text top="166" left="718" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="178" left="673" width="6" height="10" font="32">n</text>
<text top="178" left="687" width="54" height="9" font="30">AstraZeneca</text>
<text top="178" left="741" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="190" left="673" width="6" height="10" font="32">n</text>
<text top="190" left="687" width="92" height="9" font="30">Bristol-Myers Squibb</text>
<text top="190" left="780" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="202" left="673" width="6" height="10" font="32">n</text>
<text top="202" left="687" width="30" height="9" font="30">Cardax</text>
<text top="201" left="717" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="213" left="673" width="6" height="10" font="32">n</text>
<text top="214" left="687" width="20" height="9" font="30">Eisai</text>
<text top="214" left="707" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="225" left="673" width="6" height="10" font="32">n</text>
<text top="226" left="687" width="33" height="9" font="30"><a href="e71.full.html#55">Ethicon</a></text>
<text top="226" left="720" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="237" left="673" width="6" height="10" font="32">n</text>
<text top="238" left="687" width="32" height="9" font="30">FlowCo</text>
<text top="236" left="720" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="249" left="673" width="6" height="10" font="32">n</text>
<text top="250" left="687" width="86" height="9" font="30">Forest Laboratories</text>
<text top="250" left="773" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="261" left="673" width="6" height="10" font="32">n</text>
<text top="262" left="687" width="38" height="9" font="30">Ischemi<a href="e71.full.html#55">x</a></text>
<text top="262" left="725" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="273" left="673" width="6" height="10" font="32">n</text>
<text top="274" left="687" width="50" height="9" font="30">Mayo Clinic</text>
<text top="285" left="673" width="6" height="10" font="32">n</text>
<text top="286" left="687" width="44" height="9" font="30">Medtronic</text>
<text top="286" left="732" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="297" left="673" width="6" height="10" font="32">n</text>
<text top="298" left="687" width="26" height="9" font="30">Merck</text>
<text top="296" left="714" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="309" left="673" width="6" height="10" font="32">n</text>
<text top="310" left="687" width="5" height="9" font="30">P</text>
<text top="308" left="693" width="19" height="12" font="30">ﬁzer</text>
<text top="310" left="712" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="321" left="673" width="6" height="10" font="32">n</text>
<text top="322" left="687" width="52" height="9" font="30">PLx Pharma</text>
<text top="320" left="739" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="333" left="673" width="6" height="10" font="32">n</text>
<text top="334" left="687" width="86" height="9" font="30">Regado Biosciences</text>
<text top="332" left="774" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="345" left="673" width="6" height="10" font="32">n</text>
<text top="346" left="687" width="27" height="9" font="30">Roche</text>
<text top="346" left="714" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="357" left="673" width="6" height="10" font="32">n</text>
<text top="358" left="687" width="21" height="9" font="30">Sano</text>
<text top="356" left="708" width="41" height="12" font="30">ﬁ-aventis</text>
<text top="358" left="750" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="369" left="673" width="6" height="10" font="32">n</text>
<text top="370" left="687" width="73" height="9" font="30">St. Jude Medical</text>
<text top="381" left="673" width="6" height="10" font="32">n</text>
<text top="382" left="687" width="31" height="9" font="30">Take<a href="e71.full.html#55">da</a></text>
<text top="380" left="718" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="393" left="673" width="6" height="10" font="32">n</text>
<text top="394" left="687" width="105" height="9" font="30">The Medicines Company</text>
<text top="394" left="793" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="405" left="673" width="6" height="10" font="32">n</text>
<text top="406" left="687" width="34" height="9" font="30">WebMD</text>
<text top="406" left="721" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="154" left="802" width="6" height="10" font="32">n</text>
<text top="154" left="816" width="87" height="9" font="30">Belvoir Publications</text>
<text top="166" left="816" width="34" height="9" font="30">(Editor)</text>
<text top="166" left="850" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="178" left="802" width="6" height="10" font="32">n</text>
<text top="178" left="816" width="40" height="9" font="30">Biotronik</text>
<text top="190" left="802" width="6" height="10" font="32">n</text>
<text top="190" left="816" width="63" height="9" font="30">Boston Scienti</text>
<text top="189" left="879" width="10" height="12" font="30">ﬁc</text>
<text top="202" left="802" width="6" height="10" font="32">n</text>
<text top="202" left="816" width="82" height="9" font="30">Clinical Cardiology</text>
<text top="214" left="816" width="69" height="9" font="30">(Deputy Editor)</text>
<text top="213" left="885" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="225" left="802" width="6" height="10" font="32">n</text>
<text top="226" left="816" width="70" height="9" font="30">Harvard Clinical</text>
<text top="238" left="816" width="80" height="9" font="30">Research Institute</text>
<text top="249" left="802" width="6" height="10" font="32">n</text>
<text top="250" left="816" width="96" height="9" font="30">HMP Communications</text>
<text top="262" left="816" width="34" height="9" font="30">(Editor)</text>
<text top="262" left="850" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="273" left="802" width="6" height="10" font="32">n</text>
<text top="274" left="816" width="99" height="9" font="30">Duke Clinical Research</text>
<text top="286" left="816" width="37" height="9" font="30">Institut<a href="e71.full.html#55">e</a></text>
<text top="286" left="853" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="297" left="802" width="6" height="10" font="32">n</text>
<text top="298" left="816" width="83" height="9" font="30">Journal of Invasive</text>
<text top="310" left="816" width="84" height="9" font="30">Cardiology (Editor)</text>
<text top="310" left="900" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="321" left="802" width="6" height="10" font="32">n</text>
<text top="322" left="816" width="94" height="9" font="30">Medscape Cardiology</text>
<text top="333" left="802" width="6" height="10" font="32">n</text>
<text top="334" left="816" width="79" height="9" font="30">Slack Publications</text>
<text top="346" left="816" width="34" height="9" font="30">(Editor)</text>
<text top="346" left="850" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="357" left="802" width="6" height="10" font="32">n</text>
<text top="358" left="816" width="73" height="9" font="30">St. Jude Medical</text>
<text top="369" left="802" width="6" height="10" font="32">n</text>
<text top="370" left="816" width="63" height="9" font="30">VA Healthcare</text>
<text top="382" left="816" width="32" height="9" font="30">System</text>
<text top="380" left="848" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="154" left="958" width="22" height="9" font="30">None</text>
<text top="425" left="59" width="67" height="9" font="30">Mark A. Creager</text>
<text top="425" left="190" width="10" height="9" font="30">Of</text>
<text top="423" left="200" width="19" height="12" font="30">ﬁcial</text>
<text top="437" left="173" width="38" height="9" font="30">Reviewer</text>
<text top="435" left="211" width="25" height="12" font="30">—AHA</text>
<text top="425" left="263" width="125" height="9" font="30">Dartmouth-Hitchcock Medical</text>
<text top="437" left="292" width="27" height="9" font="30">Center</text>
<text top="435" left="319" width="40" height="12" font="30">—Director</text>
<text top="425" left="437" width="22" height="9" font="30">None</text>
<text top="425" left="540" width="22" height="9" font="30">None</text>
<text top="425" left="623" width="22" height="9" font="30">None</text>
<text top="425" left="724" width="22" height="9" font="30">None</text>
<text top="424" left="802" width="6" height="10" font="32">n</text>
<text top="425" left="816" width="93" height="9" font="30">AHA (Past President)</text>
<text top="423" left="909" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="425" left="958" width="22" height="9" font="30">None</text>
<text top="456" left="59" width="63" height="9" font="30">Philip Goodney</text>
<text top="456" left="190" width="10" height="9" font="30">Of</text>
<text top="454" left="200" width="19" height="12" font="30">ﬁcial</text>
<text top="468" left="173" width="38" height="9" font="30">Reviewer</text>
<text top="466" left="211" width="25" height="12" font="30">—AHA</text>
<text top="456" left="251" width="89" height="9" font="30">Dartmouth-Hitchcock</text>
<text top="454" left="340" width="46" height="12" font="30">—Associate</text>
<text top="468" left="264" width="123" height="9" font="30">Professor of Surgery and The</text>
<text top="480" left="266" width="120" height="9" font="30">Dartmouth Institute Director</text>
<text top="456" left="437" width="22" height="9" font="30">None</text>
<text top="456" left="540" width="22" height="9" font="30">None</text>
<text top="456" left="623" width="22" height="9" font="30">None</text>
<text top="455" left="673" width="6" height="10" font="32">n</text>
<text top="456" left="687" width="16" height="9" font="30">NIH</text>
<text top="456" left="704" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="455" left="802" width="6" height="10" font="32">n</text>
<text top="456" left="816" width="16" height="9" font="30">NIH</text>
<text top="456" left="958" width="22" height="9" font="30">None</text>
<text top="499" left="59" width="79" height="9" font="30">John S. Ikonomidis</text>
<text top="499" left="190" width="10" height="9" font="30">Of</text>
<text top="497" left="200" width="19" height="12" font="30">ﬁcial</text>
<text top="511" left="183" width="38" height="9" font="30">Reviewer</text>
<text top="509" left="221" width="7" height="12" font="30">—</text>
<text top="523" left="175" width="61" height="9" font="30">ACC/AHA Task</text>
<text top="535" left="170" width="69" height="9" font="30">Force on Clinical</text>
<text top="547" left="188" width="33" height="9" font="30">Practice</text>
<text top="559" left="184" width="43" height="9" font="30">Guidelines</text>
<text top="499" left="268" width="116" height="9" font="30">Medical University of South</text>
<text top="511" left="295" width="34" height="9" font="30">Carolina</text>
<text top="509" left="329" width="28" height="12" font="30">—Chief</text>
<text top="499" left="437" width="22" height="9" font="30">None</text>
<text top="499" left="540" width="22" height="9" font="30">None</text>
<text top="499" left="623" width="22" height="9" font="30">None</text>
<text top="499" left="724" width="22" height="9" font="30">None</text>
<text top="499" left="848" width="22" height="9" font="30">None</text>
<text top="499" left="958" width="22" height="9" font="30">None</text>
<text top="578" left="59" width="61" height="9" font="30">Amy W. Pollak</text>
<text top="578" left="190" width="10" height="9" font="30">Of</text>
<text top="576" left="200" width="19" height="12" font="30">ﬁcial</text>
<text top="590" left="173" width="38" height="9" font="30">Reviewer</text>
<text top="588" left="211" width="25" height="12" font="30">—AHA</text>
<text top="578" left="268" width="48" height="9" font="30">Mayo Clinic</text>
<text top="576" left="316" width="67" height="12" font="30">—Cardiovascular</text>
<text top="590" left="287" width="78" height="9" font="30">Medicine Physician</text>
<text top="578" left="437" width="22" height="9" font="30">None</text>
<text top="578" left="540" width="22" height="9" font="30">None</text>
<text top="578" left="623" width="22" height="9" font="30">None</text>
<text top="578" left="724" width="22" height="9" font="30">None</text>
<text top="578" left="848" width="22" height="9" font="30">None</text>
<text top="578" left="958" width="22" height="9" font="30">None</text>
<text top="609" left="59" width="71" height="9" font="30">Michael D. White</text>
<text top="609" left="190" width="10" height="9" font="30">Of</text>
<text top="607" left="200" width="19" height="12" font="30">ﬁcial</text>
<text top="621" left="174" width="38" height="9" font="30">Reviewer</text>
<text top="619" left="212" width="24" height="12" font="30">—ACC</text>
<text top="633" left="187" width="36" height="9" font="30">Board of</text>
<text top="645" left="184" width="42" height="9" font="30">Governors</text>
<text top="609" left="269" width="108" height="9" font="30">Catholic Health Initiatives</text>
<text top="607" left="376" width="7" height="12" font="30">—</text>
<text top="621" left="278" width="77" height="9" font="30">Chief Academic Of</text>
<text top="619" left="355" width="18" height="12" font="30">ﬁcer</text>
<text top="608" left="402" width="6" height="10" font="32">n</text>
<text top="609" left="416" width="35" height="9" font="30">Anthera</text>
<text top="621" left="416" width="71" height="9" font="30">Pharmaceuticals</text>
<text top="619" left="488" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="609" left="540" width="22" height="9" font="30">None</text>
<text top="609" left="623" width="22" height="9" font="30">None</text>
<text top="608" left="673" width="6" height="10" font="32">n</text>
<text top="609" left="687" width="54" height="9" font="30">AstraZeneca</text>
<text top="607" left="741" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="609" left="848" width="22" height="9" font="30">None</text>
<text top="609" left="958" width="22" height="9" font="30">None</text>
<text top="663" left="59" width="79" height="9" font="30">Ehrin J. Armstrong</text>
<text top="663" left="175" width="60" height="9" font="30">Organizational</text>
<text top="675" left="173" width="38" height="9" font="30">Reviewer</text>
<text top="673" left="211" width="25" height="12" font="30">—SVM</text>
<text top="663" left="275" width="94" height="9" font="30">University of Colorado</text>
<text top="661" left="369" width="7" height="12" font="30">—</text>
<text top="675" left="277" width="97" height="9" font="30">Director, Interventional</text>
<text top="687" left="304" width="45" height="9" font="30">Cardiology</text>
<text top="662" left="402" width="6" height="10" font="32">n</text>
<text top="663" left="416" width="30" height="9" font="30">Abbott</text>
<text top="674" left="402" width="6" height="10" font="32">n</text>
<text top="675" left="416" width="44" height="9" font="30">Medtronic</text>
<text top="686" left="402" width="6" height="10" font="32">n</text>
<text top="687" left="416" width="26" height="9" font="30">Merck</text>
<text top="698" left="402" width="6" height="10" font="32">n</text>
<text top="699" left="416" width="59" height="9" font="30">Spectranetics</text>
<text top="663" left="540" width="22" height="9" font="30">None</text>
<text top="663" left="623" width="22" height="9" font="30">None</text>
<text top="663" left="724" width="22" height="9" font="30">None</text>
<text top="663" left="848" width="22" height="9" font="30">None</text>
<text top="663" left="958" width="22" height="9" font="30">None</text>
<text top="719" left="912" width="105" height="8" font="33">Continued on the next page</text>
<text top="60" left="59" width="959" height="16" font="29">APPENDIX 2. REVIEWER RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—2016 AHA/ACC GUIDELINE ON THE MANAGEMENT OF</text>
<text top="78" left="59" width="512" height="16" font="29">PATIENTS WITH LOWER EXTREMITY PERIPHERAL ARTERY DISEASE (MARCH 2016)</text>
<text top="57" left="1102" width="0" height="7" font="7">J</text>
<text top="63" left="1102" width="0" height="7" font="7">A</text>
<text top="69" left="1102" width="0" height="7" font="7">CC</text>
<text top="86" left="1102" width="0" height="7" font="7">VO</text>
<text top="99" left="1102" width="0" height="7" font="7">L.</text>
<text top="112" left="1102" width="0" height="7" font="7">69,</text>
<text top="131" left="1102" width="0" height="7" font="7">NO.</text>
<text top="152" left="1102" width="0" height="7" font="7">11,</text>
<text top="167" left="1102" width="0" height="7" font="7">20</text>
<text top="179" left="1102" width="0" height="7" font="7">1</text>
<text top="183" left="1102" width="0" height="7" font="7">7</text>
<text top="656" left="1100" width="0" height="9" font="13">Gerhard-Herman</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="7">MA</text>
<text top="71" left="1087" width="0" height="7" font="7">RCH</text>
<text top="94" left="1087" width="0" height="7" font="7">21,</text>
<text top="111" left="1087" width="0" height="7" font="7">2</text>
<text top="117" left="1087" width="0" height="7" font="7">0</text>
<text top="123" left="1087" width="0" height="7" font="7">1</text>
<text top="127" left="1087" width="0" height="7" font="7">7:e</text>
<text top="142" left="1087" width="0" height="7" font="7">7</text>
<text top="147" left="1087" width="0" height="12" font="7">1–</text>
<text top="157" left="1087" width="0" height="7" font="7">126</text>
<text top="552" left="1085" width="0" height="9" font="13">2016</text>
<text top="576" left="1085" width="0" height="9" font="13">AHA/ACC</text>
<text top="618" left="1085" width="0" height="9" font="13">Lower</text>
<text top="647" left="1085" width="0" height="9" font="13">Extremity</text>
<text top="690" left="1085" width="0" height="9" font="13">PAD</text>
<text top="711" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="784" left="1101" width="0" height="9" font="5">e121</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="864" width="1160">
<text top="162" left="59" width="43" height="9" font="30">Reviewer</text>
<text top="162" left="162" width="71" height="9" font="30">Representation</text>
<text top="162" left="289" width="58" height="9" font="30">Employment</text>
<text top="162" left="423" width="50" height="9" font="30">Consultant</text>
<text top="150" left="530" width="42" height="9" font="30">Speakers</text>
<text top="162" left="535" width="32" height="9" font="30">Bureau</text>
<text top="138" left="608" width="53" height="9" font="30">Ownership/</text>
<text top="150" left="605" width="59" height="9" font="30">Partnership/</text>
<text top="162" left="614" width="41" height="9" font="30">Principal</text>
<text top="162" left="692" width="85" height="9" font="30">Personal Research</text>
<text top="138" left="829" width="60" height="9" font="30">Institutional,</text>
<text top="150" left="802" width="113" height="9" font="30">Organizational, or Other</text>
<text top="162" left="820" width="67" height="9" font="30">Financial Bene</text>
<text top="161" left="888" width="10" height="12" font="30">ﬁt</text>
<text top="150" left="954" width="31" height="9" font="30">Expert</text>
<text top="162" left="951" width="37" height="9" font="30">Witness</text>
<text top="181" left="59" width="83" height="9" font="30">Bernadette Aulivola</text>
<text top="181" left="175" width="60" height="9" font="30">Organizational</text>
<text top="193" left="172" width="38" height="9" font="30">Reviewer</text>
<text top="192" left="210" width="28" height="12" font="30">—VESS</text>
<text top="181" left="272" width="107" height="9" font="30">Loyola University medical</text>
<text top="193" left="274" width="103" height="9" font="30">Center, Stritch School of</text>
<text top="205" left="262" width="37" height="9" font="30">Medicine</text>
<text top="204" left="299" width="90" height="12" font="30">—Director, Division of</text>
<text top="217" left="282" width="88" height="9" font="30">Vascular Surgery and</text>
<text top="229" left="279" width="94" height="9" font="30">Endovascular Therapy;</text>
<text top="241" left="284" width="84" height="9" font="30">Associate Professor,</text>
<text top="253" left="276" width="99" height="9" font="30">Department of Surgery;</text>
<text top="265" left="269" width="112" height="9" font="30">Program Director, Vascular</text>
<text top="277" left="267" width="117" height="9" font="30">Surgery Fellowship; Medical</text>
<text top="289" left="262" width="127" height="9" font="30">Director, Vascular Noninvasive</text>
<text top="301" left="319" width="13" height="9" font="30">lab</text>
<text top="181" left="437" width="22" height="9" font="30">None</text>
<text top="181" left="540" width="22" height="9" font="30">None</text>
<text top="181" left="623" width="22" height="9" font="30">None</text>
<text top="181" left="724" width="22" height="9" font="30">None</text>
<text top="181" left="848" width="22" height="9" font="30">None</text>
<text top="181" left="958" width="22" height="9" font="30">None</text>
<text top="320" left="59" width="54" height="9" font="30">Alison Bailey</text>
<text top="320" left="175" width="60" height="9" font="30">Organizational</text>
<text top="332" left="182" width="38" height="9" font="30">Reviewer</text>
<text top="330" left="221" width="7" height="12" font="30">—</text>
<text top="344" left="188" width="34" height="9" font="30">AACVPR</text>
<text top="320" left="276" width="100" height="9" font="30">University of Tennessee</text>
<text top="332" left="271" width="53" height="9" font="30">Chattanooga</text>
<text top="330" left="324" width="56" height="12" font="30">—Cardiologist</text>
<text top="320" left="437" width="22" height="9" font="30">None</text>
<text top="320" left="540" width="22" height="9" font="30">None</text>
<text top="320" left="623" width="22" height="9" font="30">None</text>
<text top="319" left="673" width="6" height="10" font="32">n</text>
<text top="320" left="687" width="53" height="9" font="30">CSL Behring</text>
<text top="319" left="802" width="6" height="10" font="32">n</text>
<text top="320" left="816" width="36" height="9" font="30">AACVPR</text>
<text top="318" left="852" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="331" left="802" width="6" height="10" font="32">n</text>
<text top="332" left="816" width="60" height="9" font="30">ZOLL Medical</text>
<text top="320" left="958" width="22" height="9" font="30">None</text>
<text top="363" left="59" width="51" height="9" font="30">Todd Brown</text>
<text top="363" left="175" width="60" height="9" font="30">Organizational</text>
<text top="375" left="182" width="38" height="9" font="30">Reviewer</text>
<text top="374" left="221" width="7" height="12" font="30">—</text>
<text top="387" left="188" width="34" height="9" font="30">AACVPR</text>
<text top="363" left="274" width="104" height="9" font="30">University of Alabama at</text>
<text top="375" left="278" width="50" height="9" font="30">Birmingham</text>
<text top="374" left="328" width="46" height="12" font="30">—Associate</text>
<text top="387" left="306" width="39" height="9" font="30">Professor</text>
<text top="363" left="437" width="22" height="9" font="30">None</text>
<text top="363" left="540" width="22" height="9" font="30">None</text>
<text top="363" left="623" width="22" height="9" font="30">None</text>
<text top="362" left="673" width="6" height="10" font="32">n</text>
<text top="363" left="687" width="30" height="9" font="30">Amgen</text>
<text top="363" left="718" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="374" left="673" width="6" height="10" font="32">n</text>
<text top="375" left="687" width="38" height="9" font="30">Omthera</text>
<text top="374" left="725" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="386" left="673" width="6" height="10" font="32">n</text>
<text top="387" left="687" width="16" height="9" font="30">NIH</text>
<text top="387" left="704" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="363" left="848" width="22" height="9" font="30">None</text>
<text top="363" left="958" width="22" height="9" font="30">None</text>
<text top="406" left="59" width="71" height="9" font="30">Kristen Columbia</text>
<text top="406" left="175" width="60" height="9" font="30">Organizational</text>
<text top="418" left="174" width="38" height="9" font="30">Reviewer</text>
<text top="417" left="212" width="24" height="12" font="30">—SVN</text>
<text top="406" left="278" width="95" height="9" font="30">University of Maryland</text>
<text top="418" left="262" width="128" height="9" font="30">Baltimore Washington Medical</text>
<text top="430" left="271" width="110" height="9" font="30">Center, Maryland Vascular</text>
<text top="442" left="271" width="27" height="9" font="30">Center</text>
<text top="441" left="298" width="82" height="12" font="30">—Nurse practitioner</text>
<text top="406" left="437" width="22" height="9" font="30">None</text>
<text top="406" left="540" width="22" height="9" font="30">None</text>
<text top="406" left="623" width="22" height="9" font="30">None</text>
<text top="406" left="724" width="22" height="9" font="30">None</text>
<text top="406" left="848" width="22" height="9" font="30">None</text>
<text top="406" left="958" width="22" height="9" font="30">None</text>
<text top="461" left="59" width="70" height="9" font="30">Michael S. Conte</text>
<text top="461" left="175" width="60" height="9" font="30">Organizational</text>
<text top="473" left="175" width="38" height="9" font="30">Reviewer</text>
<text top="472" left="213" width="23" height="12" font="30">—SVS</text>
<text top="461" left="269" width="114" height="9" font="30">University of California San</text>
<text top="473" left="262" width="39" height="9" font="30">Francisco</text>
<text top="472" left="301" width="89" height="12" font="30">—Professor and Chief</text>
<text top="461" left="402" width="6" height="10" font="32">n</text>
<text top="461" left="416" width="59" height="9" font="30">Cook Medical</text>
<text top="473" left="402" width="6" height="10" font="32">n</text>
<text top="473" left="416" width="44" height="9" font="30">Medtronic</text>
<text top="461" left="540" width="22" height="9" font="30">None</text>
<text top="461" left="623" width="22" height="9" font="30">None</text>
<text top="461" left="673" width="6" height="10" font="32">n</text>
<text top="461" left="687" width="20" height="9" font="30">Bard</text>
<text top="461" left="802" width="6" height="10" font="32">n</text>
<text top="461" left="816" width="101" height="9" font="30">University of California</text>
<text top="473" left="816" width="101" height="9" font="30">Department of Surgery</text>
<text top="461" left="958" width="22" height="9" font="30">None</text>
<text top="493" left="59" width="45" height="9" font="30">Alik Farber</text>
<text top="493" left="175" width="60" height="9" font="30">Organizational</text>
<text top="505" left="172" width="38" height="9" font="30">Reviewer</text>
<text top="503" left="210" width="28" height="12" font="30">—SCVS</text>
<text top="493" left="263" width="95" height="9" font="30">Boston Medical Center</text>
<text top="491" left="358" width="31" height="12" font="30">—Chief,</text>
<text top="505" left="267" width="117" height="9" font="30">Division of Vascular Surgery</text>
<text top="492" left="402" width="6" height="10" font="32">n</text>
<text top="493" left="416" width="20" height="9" font="30">Bard</text>
<text top="491" left="437" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="493" left="540" width="22" height="9" font="30">None</text>
<text top="493" left="623" width="22" height="9" font="30">None</text>
<text top="493" left="724" width="22" height="9" font="30">None</text>
<text top="493" left="848" width="22" height="9" font="30">None</text>
<text top="493" left="958" width="22" height="9" font="30">None</text>
<text top="524" left="59" width="59" height="9" font="30">Robert Feezor</text>
<text top="524" left="175" width="60" height="9" font="30">Organizational</text>
<text top="536" left="172" width="38" height="9" font="30">Reviewer</text>
<text top="534" left="210" width="28" height="12" font="30">—VESS</text>
<text top="524" left="280" width="85" height="9" font="30">University of Florida</text>
<text top="522" left="365" width="7" height="12" font="30">—</text>
<text top="536" left="261" width="128" height="9" font="30">Associate Professor of Surgery,</text>
<text top="548" left="267" width="117" height="9" font="30">Division of Vascular Surgery</text>
<text top="560" left="271" width="110" height="9" font="30">and Endovascular Therapy</text>
<text top="523" left="402" width="6" height="10" font="32">n</text>
<text top="524" left="416" width="59" height="9" font="30">Cook Medical</text>
<text top="524" left="475" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="535" left="402" width="6" height="10" font="32">n</text>
<text top="536" left="416" width="44" height="9" font="30">Medtronic</text>
<text top="547" left="402" width="6" height="10" font="32">n</text>
<text top="548" left="416" width="33" height="9" font="30">Terumo</text>
<text top="524" left="540" width="22" height="9" font="30">None</text>
<text top="524" left="623" width="22" height="9" font="30">None</text>
<text top="523" left="673" width="6" height="10" font="32">n</text>
<text top="524" left="687" width="59" height="9" font="30">Cook Medical</text>
<text top="523" left="802" width="6" height="10" font="32">n</text>
<text top="524" left="816" width="59" height="9" font="30">Cook Medical</text>
<text top="535" left="802" width="6" height="10" font="32">n</text>
<text top="536" left="816" width="31" height="9" font="30">Novate</text>
<text top="523" left="921" width="6" height="10" font="32">n</text>
<text top="524" left="935" width="67" height="9" font="30">Defendant, pe-</text>
<text top="536" left="935" width="65" height="9" font="30">ripheral angio-</text>
<text top="548" left="935" width="54" height="9" font="30">plasty, 2015</text>
<text top="579" left="59" width="81" height="9" font="30">Dmitriy N. Feldman</text>
<text top="579" left="175" width="60" height="9" font="30">Organizational</text>
<text top="591" left="173" width="38" height="9" font="30">Reviewer</text>
<text top="589" left="211" width="26" height="12" font="30">—SCAI</text>
<text top="579" left="263" width="126" height="9" font="30">Weill Cornell Medical College,</text>
<text top="591" left="278" width="95" height="9" font="30">New York Presbyterian</text>
<text top="603" left="264" width="34" height="9" font="30">Hospital</text>
<text top="601" left="299" width="88" height="12" font="30">—Associate Professor</text>
<text top="615" left="301" width="49" height="9" font="30">of Medicine</text>
<text top="578" left="402" width="6" height="10" font="32">n</text>
<text top="579" left="416" width="54" height="9" font="30">AstraZeneca</text>
<text top="578" left="506" width="6" height="10" font="32">n</text>
<text top="579" left="521" width="30" height="9" font="30">Abbott</text>
<text top="590" left="506" width="6" height="10" font="32">n</text>
<text top="591" left="521" width="59" height="9" font="30">Bristol-Myers</text>
<text top="603" left="521" width="30" height="9" font="30">Squibb</text>
<text top="601" left="551" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="614" left="506" width="6" height="10" font="32">n</text>
<text top="615" left="521" width="64" height="9" font="30">Daiichi-Sankyo</text>
<text top="626" left="506" width="6" height="10" font="32">n</text>
<text top="627" left="521" width="33" height="9" font="30">Eli Lilly</text>
<text top="638" left="506" width="6" height="10" font="32">n</text>
<text top="639" left="521" width="44" height="9" font="30">Medtronic</text>
<text top="650" left="506" width="6" height="10" font="32">n</text>
<text top="651" left="521" width="5" height="9" font="30">P</text>
<text top="649" left="526" width="19" height="12" font="30">ﬁzer</text>
<text top="662" left="506" width="6" height="10" font="32">n</text>
<text top="663" left="521" width="63" height="9" font="30">The Medicines</text>
<text top="674" left="521" width="40" height="9" font="30">Company</text>
<text top="579" left="623" width="22" height="9" font="30">None</text>
<text top="579" left="724" width="22" height="9" font="30">None</text>
<text top="578" left="802" width="6" height="10" font="32">n</text>
<text top="579" left="816" width="39" height="9" font="30">Biotronic</text>
<text top="590" left="802" width="6" height="10" font="32">n</text>
<text top="591" left="816" width="63" height="9" font="30">The Medicines</text>
<text top="603" left="816" width="40" height="9" font="30">Company</text>
<text top="579" left="958" width="22" height="9" font="30">None</text>
<text top="694" left="59" width="79" height="9" font="30">Jonathan Golledge</text>
<text top="694" left="175" width="60" height="9" font="30">Organizational</text>
<text top="706" left="172" width="38" height="9" font="30">Reviewer</text>
<text top="704" left="210" width="28" height="12" font="30">—TASC</text>
<text top="694" left="275" width="94" height="9" font="30">James Cook University</text>
<text top="692" left="369" width="7" height="12" font="30">—</text>
<text top="706" left="273" width="106" height="9" font="30">Professor, Department of</text>
<text top="718" left="271" width="109" height="9" font="30">Surgery, Head of Vascular</text>
<text top="730" left="300" width="52" height="9" font="30">Biology Unit</text>
<text top="694" left="437" width="22" height="9" font="30">None</text>
<text top="694" left="540" width="22" height="9" font="30">None</text>
<text top="694" left="623" width="22" height="9" font="30">None</text>
<text top="693" left="673" width="6" height="10" font="32">n</text>
<text top="694" left="687" width="99" height="9" font="30">James Cook University</text>
<text top="694" left="787" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="694" left="848" width="22" height="9" font="30">None</text>
<text top="694" left="958" width="22" height="9" font="30">None</text>
<text top="747" left="59" width="58" height="9" font="30">Bruce H. Gray</text>
<text top="747" left="175" width="60" height="9" font="30">Organizational</text>
<text top="759" left="173" width="38" height="9" font="30">Reviewer</text>
<text top="758" left="211" width="26" height="12" font="30">—SCAI</text>
<text top="747" left="269" width="106" height="9" font="30">Greenville Health System</text>
<text top="746" left="375" width="7" height="12" font="30">—</text>
<text top="759" left="273" width="106" height="9" font="30">Director of Clinical Trials,</text>
<text top="771" left="278" width="96" height="9" font="30">Department of Surgery</text>
<text top="747" left="437" width="22" height="9" font="30">None</text>
<text top="746" left="506" width="6" height="10" font="32">n</text>
<text top="747" left="521" width="44" height="9" font="30">Medtronic</text>
<text top="746" left="565" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="747" left="623" width="22" height="9" font="30">None</text>
<text top="746" left="673" width="6" height="10" font="32">n</text>
<text top="747" left="687" width="30" height="9" font="30">Abbott</text>
<text top="746" left="718" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="758" left="673" width="6" height="10" font="32">n</text>
<text top="759" left="687" width="43" height="9" font="30">W.L. Gore</text>
<text top="758" left="731" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="746" left="802" width="6" height="10" font="32">n</text>
<text top="747" left="816" width="25" height="9" font="30">NCDR</text>
<text top="746" left="841" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="758" left="802" width="6" height="10" font="32">n</text>
<text top="759" left="816" width="18" height="9" font="30">ACC</text>
<text top="758" left="834" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="747" left="958" width="22" height="9" font="30">None</text>
<text top="792" left="912" width="105" height="8" font="33">Continued on the next page</text>
<text top="105" left="59" width="158" height="16" font="29">APPENDIX 2. CONTINUED</text>
<text top="100" left="1100" width="0" height="9" font="13">Gerhard-Herman</text>
<text top="173" left="1100" width="0" height="9" font="13">et</text>
<text top="184" left="1100" width="0" height="9" font="13">al</text>
<text top="192" left="1100" width="0" height="9" font="13">.</text>
<text top="667" left="1102" width="0" height="7" font="7">JAC</text>
<text top="685" left="1102" width="0" height="7" font="7">C</text>
<text top="695" left="1102" width="0" height="7" font="7">VOL.</text>
<text top="721" left="1102" width="0" height="7" font="7">69,</text>
<text top="740" left="1102" width="0" height="7" font="7">NO.</text>
<text top="761" left="1102" width="0" height="7" font="7">11,</text>
<text top="776" left="1102" width="0" height="7" font="7">2</text>
<text top="782" left="1102" width="0" height="7" font="7">0</text>
<text top="788" left="1102" width="0" height="7" font="7">17</text>
<text top="100" left="1085" width="0" height="9" font="13">2016</text>
<text top="125" left="1085" width="0" height="9" font="13">AHA/ACC</text>
<text top="167" left="1085" width="0" height="9" font="13">Lower</text>
<text top="195" left="1085" width="0" height="9" font="13">Extremity</text>
<text top="239" left="1085" width="0" height="9" font="13">PAD</text>
<text top="260" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="683" left="1087" width="0" height="7" font="7">M</text>
<text top="690" left="1087" width="0" height="7" font="7">A</text>
<text top="697" left="1087" width="0" height="7" font="7">R</text>
<text top="703" left="1087" width="0" height="7" font="7">C</text>
<text top="710" left="1087" width="0" height="7" font="7">H</text>
<text top="720" left="1087" width="0" height="7" font="7">2</text>
<text top="725" left="1087" width="0" height="7" font="7">1,</text>
<text top="737" left="1087" width="0" height="7" font="7">20</text>
<text top="748" left="1087" width="0" height="7" font="7">17:</text>
<text top="761" left="1087" width="0" height="7" font="7">e</text>
<text top="767" left="1087" width="0" height="7" font="7">71</text>
<text top="775" left="1087" width="0" height="10" font="7">–</text>
<text top="782" left="1087" width="0" height="7" font="7">126</text>
<text top="50" left="1101" width="0" height="9" font="5">e122</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="864" width="1160">
<text top="120" left="59" width="43" height="9" font="30">Reviewer</text>
<text top="120" left="162" width="71" height="9" font="30">Representation</text>
<text top="120" left="289" width="58" height="9" font="30">Employment</text>
<text top="120" left="423" width="50" height="9" font="30">Consultant</text>
<text top="108" left="530" width="42" height="9" font="30">Speakers</text>
<text top="120" left="535" width="32" height="9" font="30">Bureau</text>
<text top="96" left="608" width="53" height="9" font="30">Ownership/</text>
<text top="108" left="605" width="58" height="9" font="30">Partnership/</text>
<text top="120" left="614" width="41" height="9" font="30">Principal</text>
<text top="120" left="692" width="85" height="9" font="30">Personal Research</text>
<text top="96" left="829" width="60" height="9" font="30">Institutional,</text>
<text top="108" left="802" width="113" height="9" font="30">Organizational, or Other</text>
<text top="120" left="820" width="67" height="9" font="30">Financial Bene</text>
<text top="118" left="888" width="10" height="12" font="30">ﬁt</text>
<text top="108" left="954" width="31" height="9" font="30">Expert</text>
<text top="120" left="951" width="37" height="9" font="30">Witness</text>
<text top="139" left="59" width="66" height="9" font="30">William R. Hiatt</text>
<text top="139" left="175" width="60" height="9" font="30">Organizational</text>
<text top="151" left="172" width="38" height="9" font="30">Reviewer</text>
<text top="149" left="210" width="28" height="12" font="30">—TASC</text>
<text top="139" left="264" width="116" height="9" font="30">Colorado Prevention Center</text>
<text top="137" left="380" width="7" height="12" font="30">—</text>
<text top="151" left="280" width="91" height="9" font="30">Professor of Medicine</text>
<text top="139" left="437" width="22" height="9" font="30">None</text>
<text top="139" left="540" width="22" height="9" font="30">None</text>
<text top="139" left="623" width="22" height="9" font="30">None</text>
<text top="138" left="673" width="6" height="10" font="32">n</text>
<text top="139" left="687" width="54" height="9" font="30">AstraZeneca</text>
<text top="139" left="741" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="150" left="673" width="6" height="10" font="32">n</text>
<text top="151" left="687" width="24" height="9" font="30">Bayer</text>
<text top="151" left="712" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="162" left="673" width="6" height="10" font="32">n</text>
<text top="163" left="687" width="14" height="9" font="30">CSI</text>
<text top="174" left="673" width="6" height="10" font="32">n</text>
<text top="175" left="687" width="24" height="9" font="30">Kowa</text>
<text top="186" left="673" width="6" height="10" font="32">n</text>
<text top="187" left="687" width="79" height="9" font="30">Kyushu University</text>
<text top="198" left="673" width="6" height="10" font="32">n</text>
<text top="199" left="687" width="26" height="9" font="30">Merck</text>
<text top="210" left="673" width="6" height="10" font="32">n</text>
<text top="211" left="687" width="42" height="9" font="30">Pluristem</text>
<text top="211" left="729" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="222" left="673" width="6" height="10" font="32">n</text>
<text top="223" left="687" width="43" height="9" font="30">ReNeuron</text>
<text top="138" left="802" width="6" height="10" font="32">n</text>
<text top="139" left="816" width="95" height="9" font="30">CPC Clinical Research</text>
<text top="139" left="911" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="150" left="802" width="6" height="10" font="32">n</text>
<text top="151" left="816" width="16" height="9" font="30">NIH</text>
<text top="151" left="832" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="139" left="958" width="22" height="9" font="30">None</text>
<text top="242" left="59" width="52" height="9" font="30">Joseph Mills</text>
<text top="242" left="175" width="60" height="9" font="30">Organizational</text>
<text top="254" left="175" width="38" height="9" font="30">Reviewer</text>
<text top="252" left="213" width="23" height="12" font="30">—SVS</text>
<text top="242" left="266" width="113" height="9" font="30">Baylor College of Medicine</text>
<text top="240" left="379" width="7" height="12" font="30">—</text>
<text top="254" left="261" width="129" height="9" font="30">Professor and Chief, Division of</text>
<text top="266" left="282" width="87" height="9" font="30">Vascular surgery and</text>
<text top="278" left="280" width="92" height="9" font="30">Endovascular Therapy</text>
<text top="242" left="437" width="22" height="9" font="30">None</text>
<text top="242" left="540" width="22" height="9" font="30">None</text>
<text top="242" left="623" width="22" height="9" font="30">None</text>
<text top="242" left="724" width="22" height="9" font="30">None</text>
<text top="241" left="802" width="6" height="10" font="32">n</text>
<text top="242" left="816" width="27" height="9" font="30">AnGes</text>
<text top="253" left="802" width="6" height="10" font="32">n</text>
<text top="254" left="816" width="25" height="9" font="30">Bayer</text>
<text top="265" left="802" width="6" height="10" font="32">n</text>
<text top="266" left="816" width="25" height="9" font="30">Cesca</text>
<text top="242" left="958" width="22" height="9" font="30">None</text>
<text top="297" left="59" width="72" height="9" font="30">Mohammad Reza</text>
<text top="309" left="74" width="25" height="9" font="30">Rajebi</text>
<text top="297" left="175" width="60" height="9" font="30">Organizational</text>
<text top="309" left="176" width="38" height="9" font="30">Reviewer</text>
<text top="307" left="214" width="20" height="12" font="30">—SIR</text>
<text top="297" left="279" width="94" height="9" font="30">University of Colorado</text>
<text top="309" left="268" width="29" height="9" font="30">Denver</text>
<text top="307" left="297" width="86" height="12" font="30">—Assistant Professor</text>
<text top="297" left="437" width="22" height="9" font="30">None</text>
<text top="297" left="540" width="22" height="9" font="30">None</text>
<text top="297" left="623" width="22" height="9" font="30">None</text>
<text top="297" left="724" width="22" height="9" font="30">None</text>
<text top="297" left="848" width="22" height="9" font="30">None</text>
<text top="297" left="958" width="22" height="9" font="30">None</text>
<text top="328" left="59" width="70" height="9" font="30">Mitchell J. Silver</text>
<text top="328" left="175" width="60" height="9" font="30">Organizational</text>
<text top="340" left="173" width="38" height="9" font="30">Reviewer</text>
<text top="338" left="211" width="25" height="12" font="30">—SVM</text>
<text top="328" left="265" width="122" height="9" font="30">McConnell Heart Hospital for</text>
<text top="340" left="263" width="74" height="9" font="30">Critical Limb Care</text>
<text top="338" left="337" width="52" height="12" font="30">—Director of</text>
<text top="352" left="290" width="71" height="9" font="30">Vascular Imaging</text>
<text top="327" left="402" width="6" height="10" font="32">n</text>
<text top="328" left="416" width="63" height="9" font="30">Boston Scienti</text>
<text top="326" left="480" width="10" height="12" font="30">ﬁc</text>
<text top="339" left="402" width="6" height="10" font="32">n</text>
<text top="340" left="416" width="43" height="9" font="30">W.L. Gore</text>
<text top="351" left="402" width="6" height="10" font="32">n</text>
<text top="352" left="416" width="44" height="9" font="30">Medtronic</text>
<text top="327" left="506" width="6" height="10" font="32">n</text>
<text top="328" left="521" width="59" height="9" font="30">Bristol-Myers</text>
<text top="340" left="521" width="30" height="9" font="30">Squibb</text>
<text top="340" left="551" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="351" left="506" width="6" height="10" font="32">n</text>
<text top="352" left="521" width="5" height="9" font="30">P</text>
<text top="350" left="526" width="19" height="12" font="30">ﬁzer</text>
<text top="352" left="546" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="327" left="600" width="6" height="10" font="32">n</text>
<text top="328" left="615" width="37" height="9" font="30">Contego</text>
<text top="340" left="615" width="34" height="9" font="30">Medical</text>
<text top="340" left="649" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="328" left="724" width="22" height="9" font="30">None</text>
<text top="327" left="802" width="6" height="10" font="32">n</text>
<text top="328" left="816" width="43" height="9" font="30">W.L. Gore</text>
<text top="339" left="802" width="6" height="10" font="32">n</text>
<text top="340" left="816" width="44" height="9" font="30">Medtronic</text>
<text top="351" left="802" width="6" height="10" font="32">n</text>
<text top="352" left="816" width="16" height="9" font="30">NIH</text>
<text top="328" left="958" width="22" height="9" font="30">None</text>
<text top="371" left="59" width="56" height="9" font="30">Lily Thomson</text>
<text top="371" left="175" width="60" height="9" font="30">Organizational</text>
<text top="383" left="174" width="38" height="9" font="30">Reviewer</text>
<text top="381" left="212" width="24" height="12" font="30">—SVN</text>
<text top="371" left="263" width="119" height="9" font="30">Hôpital St-Boniface Hospital</text>
<text top="369" left="382" width="7" height="12" font="30">—</text>
<text top="383" left="263" width="125" height="9" font="30">Clinical Research Coordinator,</text>
<text top="395" left="276" width="100" height="9" font="30">Vascular Surgery Nurse,</text>
<text top="407" left="267" width="118" height="9" font="30">Section of Vascular Surgery,</text>
<text top="419" left="278" width="96" height="9" font="30">Health Sciences Centre</text>
<text top="371" left="437" width="22" height="9" font="30">None</text>
<text top="371" left="540" width="22" height="9" font="30">None</text>
<text top="371" left="623" width="22" height="9" font="30">None</text>
<text top="371" left="724" width="22" height="9" font="30">None</text>
<text top="371" left="848" width="22" height="9" font="30">None</text>
<text top="371" left="958" width="22" height="9" font="30">None</text>
<text top="438" left="59" width="76" height="9" font="30">Sana M. Al-Khatib</text>
<text top="438" left="188" width="33" height="9" font="30">Content</text>
<text top="450" left="183" width="38" height="9" font="30">Reviewer</text>
<text top="448" left="221" width="7" height="12" font="30">—</text>
<text top="462" left="175" width="61" height="9" font="30">ACC/AHA Task</text>
<text top="474" left="170" width="69" height="9" font="30">Force on Clinical</text>
<text top="486" left="188" width="33" height="9" font="30">Practice</text>
<text top="498" left="184" width="43" height="9" font="30">Guidelines</text>
<text top="438" left="279" width="94" height="9" font="30">Duke Clinical Research</text>
<text top="450" left="264" width="35" height="9" font="30">Institute</text>
<text top="448" left="299" width="88" height="12" font="30">—Associate Professor</text>
<text top="462" left="301" width="49" height="9" font="30">of Medicine</text>
<text top="438" left="437" width="22" height="9" font="30">None</text>
<text top="438" left="540" width="22" height="9" font="30">None</text>
<text top="438" left="623" width="22" height="9" font="30">None</text>
<text top="437" left="673" width="6" height="10" font="32">n</text>
<text top="438" left="687" width="18" height="9" font="30">FD<a href="e71.full.html#55">A</a></text>
<text top="438" left="705" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="449" left="673" width="6" height="10" font="32">n</text>
<text top="450" left="687" width="27" height="9" font="30">NHLBI</text>
<text top="450" left="715" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="461" left="673" width="6" height="10" font="32">n</text>
<text top="462" left="687" width="27" height="9" font="30">PCOR<a href="e71.full.html#55">I</a></text>
<text top="462" left="714" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="473" left="673" width="6" height="10" font="32">n</text>
<text top="474" left="687" width="48" height="9" font="30">VA (DSMB)</text>
<text top="437" left="802" width="6" height="10" font="32">n</text>
<text top="438" left="816" width="62" height="9" font="30">HRS (Board of</text>
<text top="450" left="816" width="41" height="9" font="30">Trustees)</text>
<text top="448" left="857" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="461" left="802" width="6" height="10" font="32">n</text>
<text top="462" left="816" width="34" height="9" font="30">Elsevi<a href="e71.full.html#55">er</a></text>
<text top="462" left="850" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="438" left="958" width="22" height="9" font="30">None</text>
<text top="517" left="59" width="67" height="9" font="30">Herbert Aronow</text>
<text top="517" left="188" width="33" height="9" font="30">Content</text>
<text top="529" left="174" width="38" height="9" font="30">Reviewer</text>
<text top="527" left="212" width="24" height="12" font="30">—ACC</text>
<text top="541" left="184" width="42" height="9" font="30">Peripheral</text>
<text top="553" left="170" width="69" height="9" font="30">Vascular Disease</text>
<text top="565" left="171" width="68" height="9" font="30">Member Section</text>
<text top="517" left="277" width="92" height="9" font="30">Rhode Island Hospital</text>
<text top="515" left="368" width="7" height="12" font="30">—</text>
<text top="529" left="287" width="78" height="9" font="30">Director of Cardiac</text>
<text top="541" left="267" width="118" height="9" font="30">Catheterization Laboratories</text>
<text top="517" left="437" width="22" height="9" font="30">None</text>
<text top="517" left="540" width="22" height="9" font="30">None</text>
<text top="517" left="623" width="22" height="9" font="30">None</text>
<text top="516" left="673" width="6" height="10" font="32">n</text>
<text top="517" left="687" width="78" height="9" font="30">Silk Road Medical</text>
<text top="515" left="765" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="528" left="673" width="6" height="10" font="32">n</text>
<text top="529" left="687" width="46" height="9" font="30">Saint Luke</text>
<text top="527" left="733" width="39" height="12" font="30">’s Health</text>
<text top="541" left="687" width="32" height="9" font="30">System</text>
<text top="552" left="673" width="6" height="10" font="32">n</text>
<text top="553" left="687" width="105" height="9" font="30">The Medicines Compa<a href="e71.full.html#55">ny</a></text>
<text top="551" left="792" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="516" left="802" width="6" height="10" font="32">n</text>
<text top="517" left="816" width="20" height="9" font="30">Bard</text>
<text top="528" left="802" width="6" height="10" font="32">n</text>
<text top="529" left="816" width="16" height="9" font="30">NIH</text>
<text top="540" left="802" width="6" height="10" font="32">n</text>
<text top="541" left="816" width="27" height="9" font="30">PCORI</text>
<text top="539" left="843" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="552" left="802" width="6" height="10" font="32">n</text>
<text top="553" left="816" width="19" height="9" font="30"><a href="e71.full.html#55">SVM</a></text>
<text top="551" left="835" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="564" left="802" width="6" height="10" font="32">n</text>
<text top="565" left="816" width="43" height="9" font="30">W.L. Gore</text>
<text top="584" left="59" width="81" height="9" font="30">Joshua A. Beckman</text>
<text top="584" left="168" width="74" height="9" font="30">Content Reviewer</text>
<text top="584" left="264" width="123" height="9" font="30">Vanderbilt University Medical</text>
<text top="596" left="292" width="27" height="9" font="30">Center</text>
<text top="594" left="319" width="40" height="12" font="30">—Director</text>
<text top="583" left="402" width="6" height="10" font="32">n</text>
<text top="584" left="416" width="54" height="9" font="30">AstraZeneca</text>
<text top="584" left="470" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="595" left="402" width="6" height="10" font="32">n</text>
<text top="596" left="416" width="26" height="9" font="30">Merck</text>
<text top="596" left="443" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="607" left="402" width="6" height="10" font="32">n</text>
<text top="608" left="416" width="21" height="9" font="30">Sano</text>
<text top="606" left="437" width="5" height="12" font="30">ﬁ</text>
<text top="608" left="443" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="584" left="540" width="22" height="9" font="30">None</text>
<text top="583" left="600" width="6" height="10" font="32">n</text>
<text top="584" left="615" width="20" height="9" font="30">EM<a href="e71.full.html#55">X</a></text>
<text top="582" left="634" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="595" left="600" width="6" height="10" font="32">n</text>
<text top="596" left="615" width="39" height="9" font="30">JanaCare</text>
<text top="594" left="654" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="583" left="673" width="6" height="10" font="32">n</text>
<text top="584" left="687" width="92" height="9" font="30">Bristol-Myers Squibb</text>
<text top="584" left="780" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="595" left="673" width="6" height="10" font="32">n</text>
<text top="596" left="687" width="26" height="9" font="30">Merck</text>
<text top="596" left="714" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="607" left="673" width="6" height="10" font="32">n</text>
<text top="608" left="687" width="16" height="9" font="30">NIH</text>
<text top="583" left="802" width="6" height="10" font="32">n</text>
<text top="584" left="816" width="81" height="9" font="30">Vascular Interven-</text>
<text top="596" left="816" width="70" height="9" font="30">tional Advances</text>
<text top="583" left="921" width="6" height="10" font="32">n</text>
<text top="584" left="935" width="82" height="9" font="30">Defendant, venous</text>
<text top="596" left="935" width="42" height="9" font="30">thrombo-</text>
<text top="608" left="935" width="70" height="9" font="30">embolism, 2015</text>
<text top="608" left="1005" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="626" left="59" width="90" height="9" font="30">James C. Blankenship</text>
<text top="626" left="168" width="74" height="9" font="30">Content Reviewer</text>
<text top="626" left="270" width="104" height="9" font="30">Geisinger Medical Center</text>
<text top="624" left="374" width="7" height="12" font="30">—</text>
<text top="638" left="274" width="103" height="9" font="30">Staff Physician; Director,</text>
<text top="650" left="277" width="97" height="9" font="30">Cardiac Catheterization</text>
<text top="662" left="303" width="45" height="9" font="30">Laboratory</text>
<text top="626" left="437" width="22" height="9" font="30">None</text>
<text top="626" left="540" width="22" height="9" font="30">None</text>
<text top="626" left="623" width="22" height="9" font="30">None</text>
<text top="625" left="673" width="6" height="10" font="32">n</text>
<text top="626" left="687" width="30" height="9" font="30">Abbott</text>
<text top="624" left="718" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="637" left="673" width="6" height="10" font="32">n</text>
<text top="638" left="687" width="54" height="9" font="30">AstraZeneca</text>
<text top="636" left="741" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="649" left="673" width="6" height="10" font="32">n</text>
<text top="650" left="687" width="63" height="9" font="30">Boston Scienti</text>
<text top="648" left="751" width="10" height="12" font="30">ﬁc</text>
<text top="648" left="761" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="661" left="673" width="6" height="10" font="32">n</text>
<text top="662" left="687" width="72" height="9" font="30">GlaxoSmithKline</text>
<text top="660" left="760" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="673" left="673" width="6" height="10" font="32">n</text>
<text top="674" left="687" width="72" height="9" font="30">Hamilton Health</text>
<text top="686" left="687" width="37" height="9" font="30">Science<a href="e71.full.html#55">s</a></text>
<text top="684" left="724" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="697" left="673" width="6" height="10" font="32">n</text>
<text top="698" left="687" width="55" height="9" font="30">Medinal L<a href="e71.full.html#55">TD</a></text>
<text top="696" left="742" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="709" left="673" width="6" height="10" font="32">n</text>
<text top="709" left="687" width="99" height="9" font="30">Orexigen Therapeutics</text>
<text top="708" left="786" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="721" left="673" width="6" height="10" font="32">n</text>
<text top="721" left="687" width="73" height="9" font="30">St. Jude Medical</text>
<text top="720" left="760" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="733" left="673" width="6" height="10" font="32">n</text>
<text top="733" left="687" width="33" height="9" font="30">Stentys</text>
<text top="732" left="720" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="744" left="673" width="6" height="10" font="32">n</text>
<text top="745" left="687" width="105" height="9" font="30">Takeda Pharmaceutical<a href="e71.full.html#55">s</a></text>
<text top="744" left="792" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="625" left="802" width="6" height="10" font="32">n</text>
<text top="626" left="816" width="94" height="9" font="30">SCAI (Past President)</text>
<text top="624" left="910" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="637" left="802" width="6" height="10" font="32">n</text>
<text top="638" left="816" width="20" height="9" font="30"><a href="e71.full.html#55">AMA</a></text>
<text top="636" left="836" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="626" left="958" width="22" height="9" font="30">None</text>
<text top="766" left="912" width="105" height="8" font="33">Continued on the next page</text>
<text top="60" left="59" width="158" height="16" font="29">APPENDIX 2. CONTINUED</text>
<text top="57" left="1102" width="0" height="7" font="7">J</text>
<text top="63" left="1102" width="0" height="7" font="7">A</text>
<text top="69" left="1102" width="0" height="7" font="7">CC</text>
<text top="86" left="1102" width="0" height="7" font="7">VO</text>
<text top="99" left="1102" width="0" height="7" font="7">L.</text>
<text top="112" left="1102" width="0" height="7" font="7">69,</text>
<text top="131" left="1102" width="0" height="7" font="7">NO.</text>
<text top="152" left="1102" width="0" height="7" font="7">11,</text>
<text top="167" left="1102" width="0" height="7" font="7">20</text>
<text top="179" left="1102" width="0" height="7" font="7">1</text>
<text top="183" left="1102" width="0" height="7" font="7">7</text>
<text top="656" left="1100" width="0" height="9" font="13">Gerhard-Herman</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="7">MA</text>
<text top="71" left="1087" width="0" height="7" font="7">RCH</text>
<text top="94" left="1087" width="0" height="7" font="7">21,</text>
<text top="111" left="1087" width="0" height="7" font="7">2</text>
<text top="117" left="1087" width="0" height="7" font="7">0</text>
<text top="123" left="1087" width="0" height="7" font="7">1</text>
<text top="127" left="1087" width="0" height="7" font="7">7:e</text>
<text top="142" left="1087" width="0" height="7" font="7">7</text>
<text top="147" left="1087" width="0" height="12" font="7">1–</text>
<text top="157" left="1087" width="0" height="7" font="7">126</text>
<text top="552" left="1085" width="0" height="9" font="13">2016</text>
<text top="576" left="1085" width="0" height="9" font="13">AHA/ACC</text>
<text top="618" left="1085" width="0" height="9" font="13">Lower</text>
<text top="647" left="1085" width="0" height="9" font="13">Extremity</text>
<text top="690" left="1085" width="0" height="9" font="13">PAD</text>
<text top="711" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="783" left="1101" width="0" height="9" font="5">e123</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="864" width="1160">
<text top="162" left="59" width="43" height="9" font="30">Reviewer</text>
<text top="162" left="162" width="71" height="9" font="30">Representation</text>
<text top="162" left="289" width="58" height="9" font="30">Employment</text>
<text top="162" left="423" width="50" height="9" font="30">Consultant</text>
<text top="150" left="530" width="42" height="9" font="30">Speakers</text>
<text top="162" left="535" width="32" height="9" font="30">Bureau</text>
<text top="138" left="608" width="53" height="9" font="30">Ownership/</text>
<text top="150" left="605" width="59" height="9" font="30">Partnership/</text>
<text top="162" left="614" width="41" height="9" font="30">Principal</text>
<text top="162" left="692" width="85" height="9" font="30">Personal Research</text>
<text top="138" left="829" width="60" height="9" font="30">Institutional,</text>
<text top="150" left="802" width="113" height="9" font="30">Organizational, or Other</text>
<text top="162" left="820" width="67" height="9" font="30">Financial Bene</text>
<text top="161" left="888" width="10" height="12" font="30">ﬁt</text>
<text top="150" left="954" width="31" height="9" font="30">Expert</text>
<text top="162" left="951" width="37" height="9" font="30">Witness</text>
<text top="181" left="59" width="65" height="9" font="30">Biykem Bozkurt</text>
<text top="181" left="188" width="33" height="9" font="30">Content</text>
<text top="193" left="182" width="38" height="9" font="30">Reviewer</text>
<text top="192" left="221" width="7" height="12" font="30">—</text>
<text top="205" left="175" width="61" height="9" font="30">ACC/AHA Task</text>
<text top="217" left="170" width="69" height="9" font="30">Force on Clinical</text>
<text top="229" left="188" width="33" height="9" font="30">Practice</text>
<text top="241" left="183" width="43" height="9" font="30">Guidelines</text>
<text top="181" left="261" width="129" height="9" font="30">Michael E. DeBakey VA Medical</text>
<text top="193" left="263" width="27" height="9" font="30">Center</text>
<text top="192" left="290" width="98" height="12" font="30">—The Mary and Gordon</text>
<text top="205" left="269" width="114" height="9" font="30">Cain Chair and Professor of</text>
<text top="217" left="307" width="37" height="9" font="30">Medicine</text>
<text top="181" left="437" width="22" height="9" font="30">None</text>
<text top="181" left="540" width="22" height="9" font="30">None</text>
<text top="181" left="623" width="22" height="9" font="30">None</text>
<text top="181" left="673" width="6" height="10" font="32">n</text>
<text top="181" left="687" width="36" height="9" font="30">Novartis</text>
<text top="181" left="848" width="22" height="9" font="30">None</text>
<text top="181" left="958" width="22" height="9" font="30">None</text>
<text top="260" left="59" width="81" height="9" font="30">Joaquin E. Cigarroa</text>
<text top="260" left="188" width="33" height="9" font="30">Content</text>
<text top="272" left="182" width="38" height="9" font="30">Reviewer</text>
<text top="271" left="221" width="7" height="12" font="30">—</text>
<text top="284" left="175" width="61" height="9" font="30">ACC/AHA Task</text>
<text top="296" left="170" width="69" height="9" font="30">Force on Clinical</text>
<text top="308" left="188" width="33" height="9" font="30">Practice</text>
<text top="320" left="183" width="43" height="9" font="30">Guidelines</text>
<text top="260" left="269" width="113" height="9" font="30">Oregon Health and Science</text>
<text top="272" left="265" width="42" height="9" font="30">University</text>
<text top="271" left="307" width="79" height="12" font="30">—Clinical Professor</text>
<text top="284" left="301" width="49" height="9" font="30">of Medicine</text>
<text top="260" left="437" width="22" height="9" font="30">None</text>
<text top="260" left="540" width="22" height="9" font="30">None</text>
<text top="260" left="623" width="22" height="9" font="30">None</text>
<text top="260" left="724" width="22" height="9" font="30">None</text>
<text top="260" left="802" width="6" height="10" font="32">n</text>
<text top="260" left="816" width="41" height="9" font="30">ACC/AHA</text>
<text top="259" left="857" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="272" left="802" width="6" height="10" font="32">n</text>
<text top="272" left="816" width="19" height="9" font="30">AHA</text>
<text top="271" left="835" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="283" left="802" width="6" height="10" font="32">n</text>
<text top="284" left="816" width="17" height="9" font="30">AS<a href="e71.full.html#55">A</a></text>
<text top="283" left="833" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="295" left="802" width="6" height="10" font="32">n</text>
<text top="296" left="816" width="86" height="9" font="30">Catheterization and</text>
<text top="308" left="816" width="64" height="9" font="30">Cardiovascular</text>
<text top="320" left="816" width="54" height="9" font="30">Intervention</text>
<text top="318" left="870" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="331" left="802" width="6" height="10" font="32">n</text>
<text top="332" left="816" width="90" height="9" font="30">Portland Metro Area</text>
<text top="344" left="816" width="71" height="9" font="30">AHA (President)</text>
<text top="342" left="887" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="355" left="802" width="6" height="10" font="32">n</text>
<text top="356" left="816" width="99" height="9" font="30">SCAI Quality Interven-</text>
<text top="368" left="816" width="61" height="9" font="30">tional Council</text>
<text top="366" left="877" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="379" left="802" width="6" height="10" font="32">n</text>
<text top="380" left="816" width="16" height="9" font="30">NIH</text>
<text top="260" left="958" width="22" height="9" font="30">None</text>
<text top="399" left="59" width="68" height="9" font="30">Federico Gentile</text>
<text top="399" left="188" width="33" height="9" font="30">Content</text>
<text top="411" left="182" width="38" height="9" font="30">Reviewer</text>
<text top="409" left="221" width="7" height="12" font="30">—</text>
<text top="423" left="175" width="61" height="9" font="30">ACC/AHA Task</text>
<text top="435" left="170" width="69" height="9" font="30">Force on Clinical</text>
<text top="447" left="188" width="33" height="9" font="30">Practice</text>
<text top="459" left="183" width="43" height="9" font="30">Guidelines</text>
<text top="399" left="266" width="112" height="9" font="30">Centro Medico Diagnostico</text>
<text top="397" left="379" width="7" height="12" font="30">—</text>
<text top="411" left="276" width="99" height="9" font="30">Director, Cardiovascular</text>
<text top="423" left="310" width="31" height="9" font="30">Disease</text>
<text top="399" left="437" width="22" height="9" font="30">None</text>
<text top="399" left="540" width="22" height="9" font="30">None</text>
<text top="399" left="623" width="22" height="9" font="30">None</text>
<text top="399" left="724" width="22" height="9" font="30">None</text>
<text top="399" left="848" width="22" height="9" font="30">None</text>
<text top="399" left="958" width="22" height="9" font="30">None</text>
<text top="478" left="59" width="47" height="9" font="30">Anuj Gupta</text>
<text top="478" left="188" width="33" height="9" font="30">Content</text>
<text top="490" left="174" width="38" height="9" font="30">Reviewer</text>
<text top="488" left="212" width="24" height="12" font="30">—ACC</text>
<text top="502" left="184" width="42" height="9" font="30">Peripheral</text>
<text top="514" left="170" width="69" height="9" font="30">Vascular Disease</text>
<text top="526" left="171" width="68" height="9" font="30">Member Section</text>
<text top="478" left="275" width="95" height="9" font="30">University of Maryland</text>
<text top="476" left="370" width="7" height="12" font="30">—</text>
<text top="490" left="280" width="91" height="9" font="30">Assistant Professor of</text>
<text top="502" left="307" width="37" height="9" font="30">Medicine</text>
<text top="478" left="437" width="22" height="9" font="30">None</text>
<text top="478" left="540" width="22" height="9" font="30">None</text>
<text top="478" left="623" width="22" height="9" font="30">None</text>
<text top="477" left="673" width="6" height="10" font="32">n</text>
<text top="478" left="687" width="36" height="9" font="30">Seimens</text>
<text top="478" left="723" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="489" left="673" width="6" height="10" font="32">n</text>
<text top="490" left="687" width="44" height="9" font="30">Medtronic</text>
<text top="488" left="732" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="477" left="802" width="6" height="10" font="32">n</text>
<text top="478" left="816" width="88" height="9" font="30">Direct Flow Medical</text>
<text top="476" left="904" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="489" left="802" width="6" height="10" font="32">n</text>
<text top="490" left="816" width="37" height="9" font="30">Edwards</text>
<text top="488" left="853" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="478" left="958" width="22" height="9" font="30">None</text>
<text top="545" left="59" width="69" height="9" font="30">John Jeb Hallett</text>
<text top="545" left="168" width="74" height="9" font="30">Content Reviewer</text>
<text top="545" left="268" width="116" height="9" font="30">Medical University of South</text>
<text top="557" left="264" width="34" height="9" font="30">Carolina</text>
<text top="555" left="297" width="90" height="12" font="30">—Clinical Professor of</text>
<text top="569" left="310" width="32" height="9" font="30">Surgery</text>
<text top="545" left="437" width="22" height="9" font="30">None</text>
<text top="545" left="540" width="22" height="9" font="30">None</text>
<text top="545" left="623" width="22" height="9" font="30">None</text>
<text top="545" left="724" width="22" height="9" font="30">None</text>
<text top="545" left="848" width="22" height="9" font="30">None</text>
<text top="545" left="958" width="22" height="9" font="30">None</text>
<text top="588" left="59" width="47" height="9" font="30">Alan Hirsch</text>
<text top="588" left="168" width="74" height="9" font="30">Content Reviewer</text>
<text top="588" left="276" width="100" height="9" font="30">University of Minnesota</text>
<text top="600" left="265" width="63" height="9" font="30">Medical School</text>
<text top="599" left="328" width="58" height="12" font="30">—Professor of</text>
<text top="612" left="267" width="118" height="9" font="30">Medicine, Epidemiology and</text>
<text top="624" left="276" width="99" height="9" font="30">Community Health, and</text>
<text top="636" left="270" width="111" height="9" font="30">Director Vascular Medicine</text>
<text top="648" left="308" width="35" height="9" font="30">Program</text>
<text top="587" left="402" width="6" height="10" font="32">n</text>
<text top="588" left="416" width="26" height="9" font="30">Merck</text>
<text top="588" left="443" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="599" left="402" width="6" height="10" font="32">n</text>
<text top="600" left="416" width="37" height="9" font="30">Novartis</text>
<text top="599" left="453" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="588" left="540" width="22" height="9" font="30">None</text>
<text top="588" left="623" width="22" height="9" font="30">None</text>
<text top="587" left="673" width="6" height="10" font="32">n</text>
<text top="588" left="687" width="24" height="9" font="30">Bayer</text>
<text top="588" left="712" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="599" left="673" width="6" height="10" font="32">n</text>
<text top="600" left="687" width="42" height="9" font="30">Pluristem</text>
<text top="612" left="687" width="64" height="9" font="30">(PLX-PAD trial</text>
<text top="610" left="752" width="16" height="12" font="30">–PI)</text>
<text top="610" left="768" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="623" left="673" width="6" height="10" font="32">n</text>
<text top="624" left="687" width="54" height="9" font="30">AstraZeneca</text>
<text top="636" left="687" width="57" height="9" font="30">(EUCLID trial</text>
<text top="634" left="745" width="16" height="12" font="30">–PI<a href="e71.full.html#55">)</a></text>
<text top="634" left="761" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="647" left="673" width="6" height="10" font="32">n</text>
<text top="648" left="687" width="42" height="9" font="30">Pluristem</text>
<text top="648" left="729" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="587" left="802" width="6" height="10" font="32">n</text>
<text top="588" left="816" width="19" height="9" font="30">AHA</text>
<text top="587" left="835" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="599" left="802" width="6" height="10" font="32">n</text>
<text top="600" left="816" width="66" height="9" font="30">Tactile Medical</text>
<text top="600" left="883" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="588" left="958" width="22" height="9" font="30">None</text>
<text top="666" left="59" width="62" height="9" font="30">Mark A. Hlatky</text>
<text top="666" left="188" width="33" height="9" font="30">Content</text>
<text top="678" left="182" width="38" height="9" font="30">Reviewer</text>
<text top="676" left="221" width="7" height="12" font="30">—</text>
<text top="690" left="175" width="61" height="9" font="30">ACC/AHA Task</text>
<text top="702" left="170" width="69" height="9" font="30">Force on Clinical</text>
<text top="714" left="188" width="33" height="9" font="30">Practice</text>
<text top="726" left="183" width="43" height="9" font="30">Guidelines</text>
<text top="666" left="264" width="123" height="9" font="30">Stanford University School of</text>
<text top="678" left="263" width="37" height="9" font="30">Medicine</text>
<text top="676" left="300" width="88" height="12" font="30">—Professor of Health</text>
<text top="690" left="262" width="128" height="9" font="30">Research and Policy, Professor</text>
<text top="702" left="301" width="49" height="9" font="30">of Medicine</text>
<text top="665" left="402" width="6" height="10" font="32">n</text>
<text top="666" left="416" width="35" height="9" font="30">Acumen</text>
<text top="666" left="451" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="677" left="402" width="6" height="10" font="32">n</text>
<text top="678" left="416" width="47" height="9" font="30">Genentech</text>
<text top="666" left="540" width="22" height="9" font="30">None</text>
<text top="666" left="623" width="22" height="9" font="30">None</text>
<text top="665" left="673" width="6" height="10" font="32">n</text>
<text top="666" left="687" width="100" height="9" font="30">Blue Cross/Blue Shield</text>
<text top="678" left="687" width="107" height="9" font="30">Center for Effectiveness</text>
<text top="690" left="687" width="46" height="9" font="30">Evaluation</text>
<text top="690" left="734" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="701" left="673" width="6" height="10" font="32">n</text>
<text top="702" left="687" width="72" height="9" font="30">George Institute</text>
<text top="713" left="673" width="6" height="10" font="32">n</text>
<text top="714" left="687" width="45" height="9" font="30">HeartFlow</text>
<text top="714" left="733" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="725" left="673" width="6" height="10" font="32">n</text>
<text top="726" left="687" width="27" height="9" font="30">NHLBI</text>
<text top="737" left="673" width="6" height="10" font="32">n</text>
<text top="738" left="687" width="21" height="9" font="30">Sano</text>
<text top="736" left="708" width="41" height="12" font="30">ﬁ-aventis</text>
<text top="665" left="802" width="6" height="10" font="32">n</text>
<text top="666" left="816" width="99" height="9" font="30">ACC (Associate Editor)</text>
<text top="678" left="816" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="666" left="958" width="22" height="9" font="30">None</text>
<text top="758" left="912" width="105" height="8" font="33">Continued on the next page</text>
<text top="105" left="59" width="158" height="16" font="29">APPENDIX 2. CONTINUED</text>
<text top="100" left="1100" width="0" height="9" font="13">Gerhard-Herman</text>
<text top="173" left="1100" width="0" height="9" font="13">et</text>
<text top="184" left="1100" width="0" height="9" font="13">al</text>
<text top="192" left="1100" width="0" height="9" font="13">.</text>
<text top="667" left="1102" width="0" height="7" font="7">JAC</text>
<text top="685" left="1102" width="0" height="7" font="7">C</text>
<text top="695" left="1102" width="0" height="7" font="7">VOL.</text>
<text top="721" left="1102" width="0" height="7" font="7">69,</text>
<text top="740" left="1102" width="0" height="7" font="7">NO.</text>
<text top="761" left="1102" width="0" height="7" font="7">11,</text>
<text top="776" left="1102" width="0" height="7" font="7">2</text>
<text top="782" left="1102" width="0" height="7" font="7">0</text>
<text top="788" left="1102" width="0" height="7" font="7">17</text>
<text top="100" left="1085" width="0" height="9" font="13">2016</text>
<text top="125" left="1085" width="0" height="9" font="13">AHA/ACC</text>
<text top="167" left="1085" width="0" height="9" font="13">Lower</text>
<text top="195" left="1085" width="0" height="9" font="13">Extremity</text>
<text top="239" left="1085" width="0" height="9" font="13">PAD</text>
<text top="260" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="683" left="1087" width="0" height="7" font="7">M</text>
<text top="690" left="1087" width="0" height="7" font="7">A</text>
<text top="697" left="1087" width="0" height="7" font="7">R</text>
<text top="703" left="1087" width="0" height="7" font="7">C</text>
<text top="710" left="1087" width="0" height="7" font="7">H</text>
<text top="720" left="1087" width="0" height="7" font="7">2</text>
<text top="725" left="1087" width="0" height="7" font="7">1,</text>
<text top="737" left="1087" width="0" height="7" font="7">20</text>
<text top="748" left="1087" width="0" height="7" font="7">17:</text>
<text top="761" left="1087" width="0" height="7" font="7">e</text>
<text top="767" left="1087" width="0" height="7" font="7">71</text>
<text top="775" left="1087" width="0" height="10" font="7">–</text>
<text top="782" left="1087" width="0" height="7" font="7">126</text>
<text top="50" left="1101" width="0" height="9" font="5">e124</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="864" width="1160">
	<fontspec id="34" size="6" family="Times" color="#327eb1"/>
<text top="120" left="59" width="43" height="9" font="30">Reviewer</text>
<text top="120" left="162" width="71" height="9" font="30">Representation</text>
<text top="120" left="289" width="58" height="9" font="30">Employment</text>
<text top="120" left="423" width="50" height="9" font="30">Consultant</text>
<text top="108" left="530" width="42" height="9" font="30">Speakers</text>
<text top="120" left="535" width="32" height="9" font="30">Bureau</text>
<text top="96" left="608" width="53" height="9" font="30">Ownership/</text>
<text top="108" left="605" width="59" height="9" font="30">Partnership/</text>
<text top="120" left="614" width="41" height="9" font="30">Principal</text>
<text top="120" left="692" width="85" height="9" font="30">Personal Research</text>
<text top="96" left="829" width="60" height="9" font="30">Institutional,</text>
<text top="108" left="802" width="113" height="9" font="30">Organizational, or Other</text>
<text top="120" left="820" width="67" height="9" font="30">Financial Bene</text>
<text top="118" left="888" width="10" height="12" font="30">ﬁt</text>
<text top="108" left="954" width="31" height="9" font="30">Expert</text>
<text top="120" left="951" width="37" height="9" font="30">Witness</text>
<text top="139" left="59" width="62" height="9" font="30">Michael R. Jaff</text>
<text top="139" left="160" width="74" height="9" font="30">Content Reviewer</text>
<text top="139" left="267" width="116" height="9" font="30">Newton-Wellesley Hospital;</text>
<text top="151" left="273" width="99" height="9" font="30">Harvard Medical School</text>
<text top="149" left="372" width="7" height="12" font="30">—</text>
<text top="163" left="280" width="91" height="9" font="30">Professor of Medicine</text>
<text top="138" left="402" width="6" height="10" font="32">n</text>
<text top="139" left="416" width="25" height="9" font="30">AOPA</text>
<text top="150" left="402" width="6" height="10" font="32">n</text>
<text top="151" left="416" width="68" height="9" font="30">Cardinal Health</text>
<text top="162" left="402" width="6" height="10" font="32">n</text>
<text top="163" left="416" width="37" height="9" font="30">Covidien</text>
<text top="161" left="454" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="174" left="402" width="6" height="10" font="32">n</text>
<text top="175" left="416" width="26" height="9" font="30">Micell</text>
<text top="186" left="402" width="6" height="10" font="32">n</text>
<text top="187" left="416" width="82" height="9" font="30">Vascular Therapies</text>
<text top="139" left="540" width="22" height="9" font="30">None</text>
<text top="138" left="600" width="6" height="10" font="32">n</text>
<text top="139" left="614" width="24" height="9" font="30">MC10</text>
<text top="137" left="639" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="150" left="600" width="6" height="10" font="32">n</text>
<text top="151" left="614" width="38" height="9" font="30">Janacare</text>
<text top="149" left="653" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="162" left="600" width="6" height="10" font="32">n</text>
<text top="163" left="614" width="46" height="9" font="30">Northwind</text>
<text top="174" left="600" width="6" height="10" font="32">n</text>
<text top="175" left="614" width="46" height="9" font="30">PQ Bypass</text>
<text top="186" left="600" width="6" height="10" font="32">n</text>
<text top="187" left="614" width="39" height="9" font="30">Primacea</text>
<text top="198" left="600" width="6" height="10" font="32">n</text>
<text top="199" left="614" width="27" height="9" font="30">SanoV</text>
<text top="210" left="600" width="6" height="10" font="32">n</text>
<text top="211" left="614" width="31" height="9" font="30">Valiant</text>
<text top="223" left="614" width="34" height="9" font="30">Medical</text>
<text top="138" left="673" width="6" height="10" font="32">n</text>
<text top="139" left="687" width="30" height="9" font="30">Abbott</text>
<text top="137" left="718" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="150" left="673" width="6" height="10" font="32">n</text>
<text top="151" left="687" width="63" height="9" font="30">Boston Scienti</text>
<text top="149" left="750" width="10" height="12" font="30">ﬁc</text>
<text top="149" left="761" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="162" left="673" width="6" height="10" font="32">n</text>
<text top="163" left="687" width="27" height="9" font="30">Cordis</text>
<text top="161" left="715" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="174" left="673" width="6" height="10" font="32">n</text>
<text top="175" left="687" width="49" height="9" font="30">IC Sciences</text>
<text top="186" left="673" width="6" height="10" font="32">n</text>
<text top="187" left="687" width="44" height="9" font="30">Medtronic</text>
<text top="185" left="732" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="198" left="673" width="6" height="10" font="32">n</text>
<text top="199" left="687" width="34" height="9" font="30">Novello</text>
<text top="138" left="802" width="6" height="10" font="32">n</text>
<text top="139" left="816" width="28" height="9" font="30">CBSET</text>
<text top="150" left="802" width="6" height="10" font="32">n</text>
<text top="151" left="816" width="94" height="9" font="30">Intersocietal Accredi-</text>
<text top="163" left="816" width="81" height="9" font="30">tation Commission</text>
<text top="174" left="802" width="6" height="10" font="32">n</text>
<text top="175" left="816" width="20" height="9" font="30">SCAI</text>
<text top="173" left="836" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="186" left="802" width="6" height="10" font="32">n</text>
<text top="187" left="816" width="69" height="9" font="30">VIVA Physicians</text>
<text top="199" left="816" width="26" height="9" font="30"><a href="e71.full.html#55">Group</a></text>
<text top="199" left="842" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="139" left="958" width="22" height="9" font="30">None</text>
<text top="242" left="59" width="59" height="9" font="30">José A. Joglar</text>
<text top="242" left="188" width="33" height="9" font="30">Content</text>
<text top="254" left="182" width="38" height="9" font="30">Reviewer</text>
<text top="252" left="221" width="7" height="12" font="30">—</text>
<text top="266" left="175" width="61" height="9" font="30">ACC/AHA Task</text>
<text top="278" left="170" width="69" height="9" font="30">Force on Clinical</text>
<text top="290" left="188" width="33" height="9" font="30">Practice</text>
<text top="302" left="183" width="43" height="9" font="30">Guidelines</text>
<text top="242" left="272" width="107" height="9" font="30">UT Southwestern Medical</text>
<text top="254" left="265" width="27" height="9" font="30">Center</text>
<text top="252" left="293" width="93" height="12" font="30">—Professor of Internal</text>
<text top="266" left="273" width="106" height="9" font="30">Medicine; Clinical Cardiac</text>
<text top="278" left="263" width="74" height="9" font="30">Electrophysiology</text>
<text top="276" left="337" width="51" height="12" font="30">—Fellowship</text>
<text top="290" left="290" width="72" height="9" font="30">Program Director</text>
<text top="242" left="437" width="22" height="9" font="30">None</text>
<text top="242" left="540" width="22" height="9" font="30">None</text>
<text top="242" left="623" width="22" height="9" font="30">None</text>
<text top="242" left="724" width="22" height="9" font="30">None</text>
<text top="242" left="848" width="22" height="9" font="30">None</text>
<text top="242" left="958" width="22" height="9" font="30">None</text>
<text top="321" left="59" width="67" height="9" font="30">Glenn N. Levine</text>
<text top="321" left="188" width="33" height="9" font="30">Content</text>
<text top="333" left="182" width="38" height="9" font="30">Reviewer</text>
<text top="331" left="221" width="7" height="12" font="30">—</text>
<text top="345" left="175" width="61" height="9" font="30">ACC/AHA Task</text>
<text top="357" left="170" width="69" height="9" font="30">Force on Clinical</text>
<text top="369" left="188" width="33" height="9" font="30">Practice</text>
<text top="381" left="183" width="43" height="9" font="30">Guidelines</text>
<text top="321" left="266" width="113" height="9" font="30">Baylor College of Medicine</text>
<text top="319" left="379" width="7" height="12" font="30">—</text>
<text top="333" left="279" width="94" height="9" font="30">Professor of Medicine;</text>
<text top="345" left="270" width="111" height="9" font="30">Director, Cardiac Care Unit</text>
<text top="321" left="437" width="22" height="9" font="30">None</text>
<text top="321" left="540" width="22" height="9" font="30">None</text>
<text top="321" left="623" width="22" height="9" font="30">None</text>
<text top="321" left="724" width="22" height="9" font="30">None</text>
<text top="321" left="848" width="22" height="9" font="30">None</text>
<text top="321" left="958" width="22" height="9" font="30">None</text>
<text top="400" left="59" width="59" height="9" font="30">Khusrow Niazi</text>
<text top="400" left="188" width="33" height="9" font="30">Content</text>
<text top="412" left="174" width="38" height="9" font="30">Reviewer</text>
<text top="410" left="212" width="24" height="12" font="30">—ACC</text>
<text top="424" left="184" width="42" height="9" font="30">Peripheral</text>
<text top="436" left="170" width="69" height="9" font="30">Vascular Disease</text>
<text top="448" left="171" width="68" height="9" font="30">Member Section</text>
<text top="400" left="264" width="124" height="9" font="30">Emory University Department</text>
<text top="412" left="278" width="49" height="9" font="30">of Medicine</text>
<text top="410" left="327" width="46" height="12" font="30">—Associate</text>
<text top="424" left="280" width="91" height="9" font="30">Professor of Medicine</text>
<text top="400" left="437" width="22" height="9" font="30">None</text>
<text top="399" left="506" width="6" height="10" font="32">n</text>
<text top="400" left="521" width="44" height="9" font="30">Medtronic</text>
<text top="400" left="565" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="400" left="623" width="22" height="9" font="30">None</text>
<text top="399" left="673" width="6" height="10" font="32">n</text>
<text top="400" left="687" width="20" height="9" font="30">Bard</text>
<text top="411" left="673" width="6" height="10" font="32">n</text>
<text top="412" left="687" width="31" height="9" font="30">Impeto</text>
<text top="423" left="673" width="6" height="10" font="32">n</text>
<text top="424" left="687" width="33" height="9" font="30">Terumo</text>
<text top="400" left="848" width="22" height="9" font="30">None</text>
<text top="399" left="921" width="6" height="10" font="32">n</text>
<text top="400" left="935" width="52" height="9" font="30">Plaintiff, MI</text>
<text top="412" left="935" width="81" height="9" font="30">resulting in death,</text>
<text top="424" left="935" width="21" height="9" font="30">2015</text>
<text top="424" left="957" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="467" left="59" width="61" height="9" font="30">Paul D. Varosy</text>
<text top="467" left="188" width="33" height="9" font="30">Content</text>
<text top="479" left="173" width="38" height="9" font="30">Reviewer</text>
<text top="477" left="211" width="25" height="12" font="30">—Task</text>
<text top="491" left="187" width="37" height="9" font="30">Force on</text>
<text top="503" left="178" width="53" height="9" font="30">Performance</text>
<text top="515" left="185" width="39" height="9" font="30">Measures</text>
<text top="467" left="267" width="117" height="9" font="30">VA Eastern Colorado Health</text>
<text top="479" left="277" width="52" height="9" font="30">Care System</text>
<text top="477" left="329" width="46" height="12" font="30">—Associate</text>
<text top="491" left="306" width="39" height="9" font="30">Professor</text>
<text top="467" left="437" width="22" height="9" font="30">None</text>
<text top="467" left="540" width="22" height="9" font="30">None</text>
<text top="467" left="623" width="22" height="9" font="30">None</text>
<text top="466" left="673" width="6" height="10" font="32">n</text>
<text top="467" left="687" width="83" height="9" font="30">VA Health Services</text>
<text top="479" left="687" width="102" height="9" font="30">Research and Develop-</text>
<text top="491" left="687" width="41" height="9" font="30">ment (PI)</text>
<text top="491" left="729" width="4" height="9" font="31"><a href="e71.full.html#55">*</a></text>
<text top="466" left="802" width="6" height="10" font="32">n</text>
<text top="467" left="816" width="84" height="9" font="30">AHA (Guest Edi<a href="e71.full.html#55">tor)</a></text>
<text top="465" left="900" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="467" left="958" width="22" height="9" font="30">None</text>
<text top="534" left="59" width="85" height="9" font="30">Christopher J. White</text>
<text top="534" left="168" width="74" height="9" font="30">Content Reviewer</text>
<text top="534" left="276" width="100" height="9" font="30">Ochsner Clinical School,</text>
<text top="546" left="270" width="105" height="9" font="30">University of Queensland</text>
<text top="544" left="375" width="7" height="12" font="30">—</text>
<text top="558" left="273" width="106" height="9" font="30">Chairman, Department of</text>
<text top="570" left="304" width="44" height="9" font="30">Cardiology</text>
<text top="533" left="402" width="6" height="10" font="32">n</text>
<text top="534" left="416" width="36" height="9" font="30">Neovasc</text>
<text top="534" left="540" width="22" height="9" font="30">None</text>
<text top="534" left="623" width="22" height="9" font="30">None</text>
<text top="533" left="673" width="6" height="10" font="32">n</text>
<text top="534" left="687" width="54" height="9" font="30">AstraZeneca</text>
<text top="546" left="687" width="71" height="9" font="30">Pharmaceuticals</text>
<text top="557" left="673" width="6" height="10" font="32">n</text>
<text top="558" left="687" width="16" height="9" font="30">NIH</text>
<text top="569" left="673" width="6" height="10" font="32">n</text>
<text top="570" left="687" width="36" height="9" font="30">Neovasc</text>
<text top="581" left="673" width="6" height="10" font="32">n</text>
<text top="582" left="687" width="45" height="9" font="30">Surmodics</text>
<text top="533" left="802" width="6" height="10" font="32">n</text>
<text top="534" left="816" width="62" height="9" font="30">ACE (Board of</text>
<text top="546" left="816" width="43" height="9" font="30">Director<a href="e71.full.html#55">s)</a></text>
<text top="544" left="859" width="5" height="12" font="31"><a href="e71.full.html#55">†</a></text>
<text top="534" left="958" width="22" height="9" font="30">None</text>
<text top="605" left="59" width="959" height="8" font="33">This table represents all relationships of reviewers with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not</text>
<text top="617" left="59" width="52" height="8" font="33">necessarily re</text>
<text top="616" left="111" width="906" height="11" font="33">ﬂect relationships with industry at the time of publication. A person is deemed to have a signiﬁcant interest in a business if the interest represents ownership of $5% of the voting stock or share of the business entity, or ownership</text>
<text top="629" left="59" width="8" height="8" font="33">of</text>
<text top="628" left="69" width="949" height="11" font="33">$$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no ﬁnancial beneﬁt are also included for the</text>
<text top="641" left="59" width="388" height="8" font="33">purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to</text>
<text top="641" left="449" width="411" height="8" font="34"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy</a></text>
<text top="641" left="863" width="23" height="8" font="33">for de</text>
<text top="640" left="885" width="132" height="11" font="33">ﬁnitions of disclosure categories or</text>
<text top="653" left="59" width="327" height="8" font="33">additional information about the ACC/AHA Disclosure Policy for Writing Committees.</text>
<text top="665" left="59" width="22" height="8" font="33">*Signi</text>
<text top="663" left="81" width="72" height="11" font="33">ﬁcant relationship.</text>
<text top="675" left="59" width="82" height="11" font="33">†No ﬁnancial beneﬁt.</text>
<text top="691" left="67" width="951" height="8" font="33">AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; ACC, American College of Cardiology; ACE, Accreditation for Cardiovascular Excellence; AHA, American Heart Association; AMA, American Medical Association;</text>
<text top="703" left="59" width="959" height="8" font="33">DSMB, data and safety monitoring board; EUCLID, Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease; FDA, U.S. Food and Drug Administration; HRS, Heart Rhythm Society; MI, myocardial infarction; NCDR, National</text>
<text top="715" left="59" width="959" height="8" font="33">Cardiovascular Data Registry; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; PCORI, Patient-Centered Outcomes Research Institute; PI, primary investigator; PLX-PAD, placental-derived adherent stromal cell; SCAI,</text>
<text top="727" left="59" width="959" height="8" font="33">Society for Cardiovascular Angiography and Interventions; SCVS, Society for Clinical Vascular Surgery; SIR, Society of Interventional Radiology; SVM, Society for Vascular Medicine; SVN, Society for Vascular Nursing; SVS, Society for Vascular Surgery;</text>
<text top="739" left="59" width="819" height="8" font="33">TASC, Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease; VA, Veterans Affairs; VESS, Vascular and Endovascular Surgery Society; and VIVA, Vascular Intervention Advances.</text>
<text top="60" left="59" width="158" height="16" font="29">APPENDIX 2. CONTINUED</text>
<text top="57" left="1102" width="0" height="7" font="7">J</text>
<text top="63" left="1102" width="0" height="7" font="7">A</text>
<text top="69" left="1102" width="0" height="7" font="7">CC</text>
<text top="86" left="1102" width="0" height="7" font="7">VO</text>
<text top="99" left="1102" width="0" height="7" font="7">L.</text>
<text top="112" left="1102" width="0" height="7" font="7">69,</text>
<text top="131" left="1102" width="0" height="7" font="7">NO.</text>
<text top="152" left="1102" width="0" height="7" font="7">11,</text>
<text top="167" left="1102" width="0" height="7" font="7">20</text>
<text top="179" left="1102" width="0" height="7" font="7">1</text>
<text top="183" left="1102" width="0" height="7" font="7">7</text>
<text top="656" left="1100" width="0" height="9" font="13">Gerhard-Herman</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="7">MA</text>
<text top="71" left="1087" width="0" height="7" font="7">RCH</text>
<text top="94" left="1087" width="0" height="7" font="7">21,</text>
<text top="111" left="1087" width="0" height="7" font="7">2</text>
<text top="117" left="1087" width="0" height="7" font="7">0</text>
<text top="123" left="1087" width="0" height="7" font="7">1</text>
<text top="127" left="1087" width="0" height="7" font="7">7:e</text>
<text top="142" left="1087" width="0" height="7" font="7">7</text>
<text top="147" left="1087" width="0" height="12" font="7">1–</text>
<text top="157" left="1087" width="0" height="7" font="7">126</text>
<text top="552" left="1085" width="0" height="9" font="13">2016</text>
<text top="576" left="1085" width="0" height="9" font="13">AHA/ACC</text>
<text top="618" left="1085" width="0" height="9" font="13">Lower</text>
<text top="647" left="1085" width="0" height="9" font="13">Extremity</text>
<text top="690" left="1085" width="0" height="9" font="13">PAD</text>
<text top="711" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="782" left="1101" width="0" height="9" font="5">e125</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1160" width="864">
<text top="181" left="126" width="25" height="12" font="2">AAA</text>
<text top="180" left="155" width="172" height="15" font="2">¼ abdominal aortic aneurysm</text>
<text top="204" left="126" width="20" height="12" font="2">ABI</text>
<text top="202" left="150" width="132" height="15" font="2">¼ ankle-brachial index</text>
<text top="226" left="126" width="20" height="12" font="2">ALI</text>
<text top="224" left="149" width="129" height="15" font="2">¼ acute limb ischemia</text>
<text top="249" left="126" width="25" height="12" font="2">CAD</text>
<text top="247" left="154" width="149" height="15" font="2">¼ coronary artery disease</text>
<text top="271" left="126" width="19" height="12" font="2">CLI</text>
<text top="269" left="149" width="137" height="15" font="2">¼ critical limb ischemia</text>
<text top="293" left="126" width="24" height="12" font="2">CTA</text>
<text top="292" left="154" width="221" height="15" font="2">¼ computed tomography angiography</text>
<text top="316" left="126" width="32" height="12" font="2">DAPT</text>
<text top="314" left="162" width="158" height="15" font="2">¼ dual antiplatelet therapy</text>
<text top="338" left="126" width="23" height="12" font="2">DES</text>
<text top="336" left="152" width="133" height="15" font="2">¼ drug-eluting stent(s)</text>
<text top="361" left="126" width="36" height="12" font="2">GDMT</text>
<text top="359" left="165" width="273" height="15" font="2">¼ guideline-directed management and therapy</text>
<text top="182" left="483" width="15" height="12" font="2">MI</text>
<text top="180" left="502" width="138" height="15" font="2">¼ myocardial infarction</text>
<text top="205" left="483" width="28" height="12" font="2">MRA</text>
<text top="203" left="515" width="204" height="15" font="2">¼ magnetic resonance angiography</text>
<text top="227" left="483" width="24" height="12" font="2">PAD</text>
<text top="225" left="511" width="157" height="15" font="2">¼ peripheral artery disease</text>
<text top="249" left="483" width="23" height="12" font="2">PTA</text>
<text top="248" left="510" width="240" height="15" font="2">¼ percutaneous transluminal angioplasty</text>
<text top="272" left="483" width="24" height="12" font="2">RCT</text>
<text top="270" left="511" width="173" height="15" font="2">¼ randomized controlled trial</text>
<text top="294" left="483" width="21" height="12" font="2">SPP</text>
<text top="293" left="508" width="150" height="15" font="2">¼ skin perfusion pressure</text>
<text top="317" left="483" width="20" height="12" font="2">TBI</text>
<text top="315" left="507" width="119" height="15" font="2">¼ toe-brachial index</text>
<text top="339" left="483" width="30" height="12" font="2">TcPO</text>
<text top="344" left="513" width="5" height="8" font="7">2</text>
<text top="337" left="522" width="201" height="15" font="2">¼ transcutaneous oxygen pressure</text>
<text top="362" left="483" width="23" height="12" font="2">QoL</text>
<text top="360" left="510" width="91" height="15" font="2">¼ quality of life</text>
<text top="141" left="108" width="187" height="16" font="14">APPENDIX 3. ABBREVIATIONS</text>
<text top="53" left="108" width="94" height="9" font="13">Gerhard-Herman et al.</text>
<text top="54" left="672" width="129" height="7" font="7">J A C C V O L . 6 9 , N O . 1 1 , 2 0 1 7</text>
<text top="68" left="108" width="198" height="9" font="13">2016 AHA/ACC Lower Extremity PAD Guideline</text>
<text top="69" left="688" width="92" height="7" font="7">M A R C H 2 1 , 2 0 1 7 : e 7 1</text>
<text top="67" left="782" width="19" height="10" font="7">– 1 2 6</text>
<text top="53" left="57" width="19" height="9" font="5">e126</text>
</page>
<outline>
<item page="1">2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease</item>
<outline>
<item page="2">Table of Contents</item>
<item page="3">Preamble</item>
<outline>
<item page="3">Intended Use</item>
<item page="3">Modernization</item>
<item page="3">Evidence Review</item>
<item page="3">Guideline-Directed Management and Treatment</item>
<item page="4">Class of Recommendation and Level of Evidence</item>
<item page="5">Relationships With Industry and Other Entities</item>
<item page="5">Individualizing Care in Patients With Associated Conditions and Comorbidities</item>
<item page="5">Clinical Implementation</item>
</outline>
<item page="5">1. Introduction</item>
<outline>
<item page="5">1.1. Methodology and Evidence Review</item>
<item page="6">1.2. Organization of the Writing Committee</item>
<item page="6">1.3. Document Review and Approval</item>
<item page="6">1.4. Scope of Guideline</item>
</outline>
<item page="9">flink4</item>
<outline>
<item page="9">2.1. History and Physical Examination: Recommendations</item>
</outline>
<item page="10">flink5</item>
<outline>
<item page="10">3.1. Resting ABI for Diagnosing PAD: Recommendations</item>
<item page="11">3.2. Physiological Testing: Recommendations</item>
<item page="16">3.3. Imaging for Anatomic Assessment: Recommendations</item>
</outline>
<item page="17">flink6</item>
<outline>
<item page="17">4.1. Abdominal Aortic Aneurysm: Recommendation</item>
<item page="17">4.2. Screening for Asymptomatic Atherosclerosis in Other Arterial Beds (Coronary, Carotid, and Renal Arteries)</item>
</outline>
<item page="17">flink7</item>
<outline>
<item page="18">5.1. Antiplatelet Agents: Recommendations</item>
<item page="19">5.2. Statin Agents: Recommendation</item>
<item page="19">5.3. Antihypertensive Agents: Recommendations</item>
<item page="20">5.4. Smoking Cessation: Recommendations</item>
<item page="21">5.5. Glycemic Control: Recommendations</item>
<item page="21">5.6. Oral Anticoagulation: Recommendations</item>
<item page="22">5.7. Cilostazol: Recommendation</item>
<item page="22">5.8. Pentoxifylline: Recommendation</item>
<item page="22">5.9. Chelation Therapy: Recommendation</item>
<item page="22">5.10. Homocysteine Lowering: Recommendation</item>
<item page="23">5.11. Influenza Vaccination: Recommendation</item>
</outline>
<item page="23">6. Structured Exercise Therapy: Recommendations</item>
<item page="25">flink9</item>
<item page="26">8. Revascularization for Claudication</item>
<outline>
<item page="26">8.1. Revascularization for Claudication: Recommendation</item>
<outline>
<item page="27">8.1.1. Endovascular Revascularization for Claudication: Recommendations</item>
<item page="28">8.1.2. Surgical Revascularization for Claudication: Recommendations</item>
</outline>
</outline>
<item page="29">flink11</item>
<outline>
<item page="29">9.1. Revascularization for CLI: Recommendations</item>
<outline>
<item page="30">9.1.1. Endovascular Revascularization for CLI: Recommendations</item>
<item page="31">9.1.2. Surgical Revascularization for CLI: Recommendations</item>
</outline>
<item page="32">9.2. Wound Healing Therapies for CLI: Recommendations</item>
</outline>
<item page="33">flink12</item>
<outline>
<item page="33">10.1. Clinical Presentation of ALI: Recommendations</item>
<item page="34">10.2. Medical Therapy for ALI: Recommendations</item>
<item page="35">10.3. Revascularization for ALI: Recommendations</item>
<item page="35">10.4. Diagnostic Evaluation of the Cause of ALI: Recommendations</item>
</outline>
<item page="36">11. Longitudinal Follow-Up: Recommendations</item>
<item page="38">12. Evidence Gaps and Future Research Directions</item>
<item page="38">13. Advocacy Priorities</item>
<item page="39">Presidents and Staff</item>
<item page="39">References</item>
</outline>
</outline>
</pdf2xml>
